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Abstract 
Deubiquitinating enzymes (DUBs) constitute a diverse family of regulators of ubiquitin 
signalling. Aberrations in this can underlie pathologies including osteoarthritis, cancers, 
inflammatory diseases, and even ageing. Understanding the biology of ubiquitin 
signalling components and how they regulate cell signalling pathways is therefore a 
widening area of research. The aim of this thesis was to further understanding on the 
function of the DUB, ubiquitin-specific protease 4 (USP4), and the mechanism of Usp4 
regulation by its post-translational modification (PTM) at two serine residues, focusing 
on the nuclear factor of κB (NF-κB) pathway. 
Initial observations in Usp4 null (-/-) mice suggested a role for Usp4 in regulating 
circulating levels of specific inflammatory cytokines and, perhaps consequentially, a role 
in viral infection clearance. Thus, in vitro, the role of USP4 in IL-1- and TNFα-mediated 
NF-κB signalling was examined. Overexpression of Usp4 significantly increased NF-κB 
signalling, and using an RNAi approach to deplete USP4 resulted in suppressed NF-κB 
activity and significantly reduced expression of NF-κB-regulated genes (MMP13, IL-6 
and IL-8). Depletion of USP4 also significantly reduced ubiquitination and degradation 
of IκBα, and phosphorylation of p65 and IKK. Together, data were indicative of USP4 as 
a positive regulator of NF-κB signalling by functioning upstream of the IKK complex. 
Importantly, aspects of these findings were confirmed in mouse embryonic fibroblasts 
(MEFs) isolated from the Usp4-/- mice. Further, identification of potential USP4 
substrates were assessed. Reductions in K48- and K63-linked polyubiquitination were 
observed with depletion of USP4. 
To further understanding of the regulation of USP4, the PTM at serines 675 and 680 was 
examined. Lentiviral-mediated delivery of Usp4 phosphorylation variants revealed that a 
complex mechanism of phosphorylation/dephosphorylation of USP4 may regulate its 
function in NF-κB signalling. 
In conclusion, this thesis identifies USP4 as a positive regulator of IL-1-induced NF-κB 
signalling, potentially regulating itself through its PTM. 
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Chapter 1 : Introduction 
 Ubiquitin signalling 
Ubiquitin signalling is key in the regulation of many diverse cellular processes. The 
conjugation of the highly conserved, 76 residue, ubiquitin protein to a substrate is a key 
post-translational modification (PTM) event able to control the function, stability or 
localisation of many proteins. Previously, ubiquitin signalling was primarily known for 
targeting proteins for degradation by the ubiquitin-proteasome system (UPS) to control 
the turnover of cellular proteins and to degrade short-lived and abnormal proteins. 
Intracellular proteolysis is necessary in many cellular processes and is critical for cell 
survival, but additionally ubiquitin signalling is fast becoming recognised as crucial in 
regulating events independently of the proteasome. Rather than acting as a target for 
degradation, the conjugation of ubiquitin can serve to recruit other proteins via ubiquitin-
binding domains (UBDs) and in this way regulate events including membrane trafficking, 
signal transduction, DNA damage repair and gene expression (Chen and Sun, 2009, Yao 
and Ndoja, 2012). Progress in the knowledge of the molecular mechanisms of 
ubiquitination in signalling pathways has led to increased understanding that aberrations 
in both proteolytic and non-proteolytic ubiquitin signalling underlie many pathologies 
including neurodegeneration, osteoarthritis, cancers and inflammatory diseases. Further 
understanding the biology of the components involved in ubiquitin signalling could 
provide key insight into these pathologies which could be exploited for new therapies 
(Popovic et al., 2014). 
 Ubiquitin conjugation 
Ubiquitin conjugation has been widely investigated and occurs in three steps involving 
ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin 
ligases (E3) which act together in an enzymatic cascade to covalently attach ubiquitin to 
a specific substrate protein. Firstly, E1 activates ubiquitin by the ATP-dependent 
formation of a thioester bond between the C-terminal of ubiquitin and an E1 catalytic 
cysteine. Secondly, the activated ubiquitin is transferred from the E1 cysteine to a cysteine 
residue of an E2 enzyme to form an E2-ubiquitin thioester intermediate. Thirdly, an E3 
ligase catalyses the transfer of ubiquitin to the -amino group of a lysine (Lys) residue in 
the target protein substrate in a substrate-specific manner. This results in an isopeptide 
linkage via the ubiquitin C-terminal glycine (Gly) (Pickart and Eddins, 2004). Proteins 
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can remain conjugated to one ubiquitin (monoubiquitinated) or single ubiquitin moieties 
can link together via an isopeptide bond between the glycine on one ubiquitin moiety C-
terminal and a lysine residue on the previous ubiquitin moiety to form a polyubiquitin 
chain. It is the ubiquitin-binding enzyme (E4), along with enzymes E1, E2 and E3, that 
in some cases is responsible for ubiquitin chain elongation (Koegl et al., 1999) (Figure 
1.1). 
 
Figure 1.1. Schematic of ubiquitin conjugation. In an ATP-dependent reaction, E1 activates ubiquitin 
by forming a thioester with the ubiquitin C-terminal. The activated ubiquitin is then transferred to 
E2 before catalysis of the transfer to the target substrate protein by E3. Orange circles represent 
ubiquitin. Yellow stars represent deubiquitinating enzymes (DUBs).   
ATP +
E1 E1
E2 E2
E3
Substrate Substrate
Substrate
E4
DUB
DUB
DUB
AMP
U
U
U
U
U
U
U
U
U
U
26S 
Proteasome
U
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 E3 ligases 
As with phosphorylation, a well-known PTM in the regulation of proteins carried out by 
a vast array of kinases, ubiquitination is carried out by a vast array of different families 
of ubiquitin enzymes. There are over 600 E3 ligases which target a broad array of 
substrates, confer specificity and diversify the ubiquitination of proteins (Li et al., 2008). 
Depending on their structural domains, E3 ligases can be categorised into different protein 
families. The vast majority of E3 ligases belong to the really interesting new gene (RING) 
and homologous to E6-AP C terminus (HECT) families. Different E3 ligase families 
adopt different mechanisms of ubiquitin transfer: RING domains act as a scaffold by 
binding directly to E2 enzymes to catalyse the transfer of ubiquitin to the target substrate, 
whereas HECT E3 ligases form a thioester intermediate with ubiquitin and the cysteine 
of the active site of the E3 (Berndsen and Wolberger, 2014). These RING and HECT 
domains generate a large number of E3 ligases which can dictate the spatial, temporal and 
substrate specificity of ubiquitin conjugation.  
1.1.2.1  Polyubiquitin chain topology  
Ubiquitin has seven intrinsic, internal lysines, all of which contribute to the linkages 
between ubiquitin moieties for the formation of polyubiquitin chains depending on which 
lysine (K) residue ubiquitin is accepted by: K6, K11, K27, K29, K33, K48 and K63 (Xu 
et al., 2009c). Polyubiquitin chains can be assembled from more than one linkage type 
(branched chains) or a single linkage type. These different topologies of ubiquitin 
moieties in a polyubiquitin chain can influence ubiquitin signalling, with physiological 
roles for each of them still emerging. The first two types of linkages to be characterised 
were the well-established K48- and K63-linked chains. It is generally thought that K48 
polyubiquitin chains signal the targeting of substrates to the proteasome for degradation; 
whereas K63 polyubiquitin chains signal for a variety of non-proteolytic processes 
including kinase activation and signal transduction (Trempe, 2011). In addition to 
linkages involving the internal lysines of ubiquitin, linear ubiquitin chains can form when 
an isopeptide bond forms between the glycine of one ubiquitin moiety C-terminal and a 
methionine residue of the previous ubiquitin moiety N-terminal (Kirisako et al., 2006). 
Unusually, linear chains are catalysed by a specific E3 ligase complex made up of three 
proteins; Heme-oxidised IRP2 ubiquitin ligase1 (HOIL-1), HOIL-1 interacting protein 
(HOIP) and SHARPIN. These form the linear ubiquitin assembly complex (LUBAC), 
and play a role in IL-1- and TNFα-mediated signalling pathways (Walczak et al., 2012).  
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As well as ubiquitin chain topology, the length of the polyubiquitin chain also influences 
ubiquitin signalling. For proteasomal degradation the target protein needs to be 
sufficiently polyubiquitinated (a chain of at least four ubiquitins) (Pitrowski et al., 1997). 
Alternatively, ubiquitination can proceed with a single ubiquitin (monoubiquitination). 
This conjugation to a single lysine residue has been implicated in many non-proteolytic 
cellular processes including membrane trafficking, transcriptional regulation by histone 
modification and signal transduction pathways (Hicke, 2001, Sun and Allis, 2002, Wada 
et al., 2009). Ubiquitin chains are diverse structures with chains of different lysine linkage 
topology and lengths determining the fate of the substrate protein. The specificity of the 
lysine residue and the decision between mono- or polyubiquitination of the substrate 
protein occurs at the level of E3 ligases, explaining why there are such large and 
mechanistically different families of E3s, and making ligases attractive therapeutic targets 
(David et al., 2011).  
 Deubiquitinating enzymes 
An additional level in the regulation of ubiquitin signalling is provided by a diverse family 
of key proteins: deubiquitinating enzymes (DUBs). The E3-mediated conjugation of 
ubiquitin to a substrate protein is a reversible process due to the enzymatic activity of 
DUBs which can attack the carbonyl group and thus cleave the isopeptide bond linking 
ubiquitin-substrate, ubiquitin-ubiquitin lysines, or N-terminals (Figure 1.1) (Komander et 
al., 2009, Reyes-Turcu et al., 2009). DUBs are less well understood than E3 ligases but 
may be as functionally important. In many cases E3 ligases and DUBs associate with the 
same complexes thereby highly regulating the ubiquitination/deubiquitination of the 
substrate as well as regulating the available pool of free ubiquitin to maintain ubiquitin 
homeostasis (Ventii and Wilkinson, 2008). This counter-regulation is a crucial 
mechanism in ubiquitin signalling and allows several functional roles of DUBs including 
cleaving ubiquitin precursor proteins, recycling ubiquitin, preventing proteins from 
degradation (e.g. by the removal of K48-linked chains), or modulating signalling through 
the editing or removal of ubiquitin chains (Figure 1.2) (Komander et al., 2009, Reyes-
Turcu et al., 2009). 
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Figure 1.2. General functions of DUBs. A) Cleavage of ubiquitin precursors. B) Removal of 
degradative ubiquitin (most commonly K48-linked chains) to prevent degradation by the 
proteasome. C) Recycling of ubiquitin. D) Editing of non-degradative chains (e.g. K63-linked chains) 
in signal transduction pathways. The orange circles represent ubiquitin. Yellow stars represents 
DUBs. Adapted from Komander et al. (2009). 
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1.1.3.1  DUB families 
There are five families of DUBs categorised by their catalytic domain architecture: one 
metalloprotease JAB1/MPN/Mov34 (JAMM) family, and four cysteine proteases: the 
ubiquitin C-terminal hydroxylase (UCH), Ovarian Tumour protease (OTU), Machade-
Joseph disease protease (MJD), and ubiquitin-specific protease (USP) families. The 
papain-like cysteine protease families are characterised by a catalytic triad: usually an 
aspartic acid, histidine and cysteine residue. In most cases, the aspartic acid polarises the 
histidine which lowers the pKa of the catalytic cysteine facilitating a nucleophilic attack 
on the carbonyl group for the hydrolysation of the isopeptide bond between ubiquitins or 
ubiquitin-substrate (Komander et al., 2009). In contrast to this, the JAMM family are a 
group of zinc metalloproteases in which a catalytic zinc atom is attached to two histidine, 
one aspartate and one polarised water molecule for activity in carrying out a nucleophilic 
attack on the isopeptide bond (Ambroggio et al., 2004). 
1.1.3.2  The USP family and their regulation 
DUBs play a key role in diversifying ubiquitin signalling by displaying selectivity for 
substrates and types of ubiquitin chains. As such, DUBs themselves use multiple 
mechanisms for the regulation of their specificity and activity. 
The USPs are the largest family of DUBs, with over 60 USPs identified. These are 
characterised by the conserved catalytic core containing cysteine and histidine (Cys and 
His) boxes necessary for the enzymatic activity of USPs. Besides the catalytic domain, 
DUBs contain a unique modular combination of other internal domains which vary 
between DUBs and may regulate their activity. Out of all DUBs, USPs contain the biggest 
array of additional domains that frequently include: ubiquitin-binding domains (UBDs); 
ubiquitin-like (UBL) domains, which are involved in recruitment to the proteasome and 
both inhibition and activation of USP catalysis; domain present in USPs (DUSPs), which 
contribute to substrate recognition; and zinc-finger (ZnF) domains, which can regulate 
USP catalytic activity (Faesen et al., 2012, Bonnet et al., 2008, Clague et al., 2013).  
Although the cysteine protease families of DUBs share a mechanism for catalytic activity, 
individual DUBs within these families may require rearrangement of the catalytic site, 
action of other DUB domains, or interactions with non-substrate proteins to become fully 
active. USP7 (also known as herpesvirus-associated USP, HAUSP) has several identified 
substrates involved in tumour suppression, DNA damage and immune responses. For the 
hydrolysis of the isopeptide bond between ubiquitin and the substrates of USP7, the 
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residues in the catalytic site triad must first be realigned upon ubiquitin binding (Hu et 
al., 2002). This conformational change is achieved through USP7 C-terminal UBL 
domains (HUBLs). In its active state, USP7 UBLs  interact with the catalytic domain to 
promote affinity for ubiquitin binding and increase activity (Faesen et al., 2011). 
However, not all USPs possess inactive conformations; they generally feature accessible 
and active catalytic sites and are regulated by other mechanisms.  
Another mechanism of regulation for USP DUBs can be through protein-protein 
interactions. USP1, a DUB involved in the deubiquitination of monoubiquitinated 
enzymes in the DNA damage response, directly associates with the WD40-containing 
protein, USP1 associated factor 1 (UAF1). UAF1 forms a complex with USP1 which is 
essential for the catalytic activity of USP1 and additionally functions to maintain its 
stability (Cohn et al., 2007). UAF1 and other WD40-containing proteins have also been 
documented to interact with many other USPs, likely to represent a mechanism for their 
regulation (Villamil et al., 2013).  
Like a wide number of proteins, the function of DUBs can also be regulated by PTMs. 
Monoubiquitination, sumoylation, phosphorylation, methylation and acetylation can all 
be involved in the regulation of proteins. The phosphorylation of USP1 on serine (Ser) 
313 allows the interaction of UAF1 with USP1 for the stimulation of its catalytic activity 
(Villamil et al., 2012). Conversely, USP25 is sumoylated with small ubiquitin-related 
modifiers 2/3 (SUMO2/3) within its ubiquitin interaction motifs (UIMs) to inhibit the 
affinity of USP25 for binding to ubiquitin and subsequently its activity, demonstrating 
that PTMs can impair or enhance the activity of USPs (Meulmeester et al., 2008). 
The regulation of USP DUB activity has been characterised in multiple studies, a fraction 
of which have been touched upon as examples here. It appears that USPs can be regulated 
through their subset of domains, protein-protein interactions and PTMs (or through a 
combination of PTMs), though these have been ascertained for only a few well-studied 
DUBs. The mechanism of regulation for the majority of DUBs still has a fairly limited 
understanding and the full spectrum of DUB substrates remain unidentified. However, it 
is clear the regulation of these proteins is extensive and there is most likely cross-talk 
between the different mechanisms to keep the tight regulation necessary for ubiquitin 
signalling.  
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1.1.3.3  Specificity of DUBs 
There are many levels to the specificity of DUBs which allow them to recognise 
substrates and individual polyubiquitin chain types. 
One feature that is shared between all DUBs is the binding of ubiquitin and the cleavage 
of the isopeptide bond by the DUBs catalytic site. DUBs are able to cleave ubiquitin 
chains from the proximal or distal ends of the chain, or in the middle. They work by 
binding ubiquitin to their ubiquitin-binding sites and it is the conserved ubiquitin C-
terminal sequence, Leu-Arg-Leu-Arg-Gly-Gly, which DUBs are able to recognise and 
distinguish from molecules that are ubiquitin-like, including SUMO. (Drag et al., 2008).  
The versatility of ubiquitin’s ability to form topologically different polyubiquitin chains 
via its different lysines suggests DUBs assume specificity in recognising these different 
polyubiquitin chains. Studies have profiled DUB specificity for polyubiquitin chain 
topology and have identified that most DUBs can discriminate particular linkages. 
Although some show broad specificity for recognising different polyubiquitin linkages, 
others show high specificity preferences for certain types of linkages (McGouran et al., 
2013). DUBs are also able to cleave ubiquitin from monoubiquitinated substrates and 
cleave unanchored ubiquitin chains. USP5 is able to disassemble unanchored ubiquitin 
chains by cleavage of one ubiquitin at a time from the proximal end. It works through 
recognition of a C-terminal Gly-Gly motif of the unanchored ubiquitin chains by its ZnF-
UBP domain as part of maintaining ubiquitin pools (Reyes-Turcu et al., 2006).  DUBs 
also show specificity towards specific protein substrates and may exert their specificity 
in part by acting at distinct subcellular locations (Komander et al., 2009). 
 The importance of proteolytic and non-proteolytic ubiquitin 
signalling in disease 
The specificity, diversity and tight regulation in ubiquitin signalling mean that any 
aberrations or dysregulation of ubiquitin signalling, or the vast array of proteins involved 
in ubiquitin signalling, can be highly detrimental to cellular functioning and is 
consequently implicated in the development of many diseases and pathologies (Kessler, 
2013, Popovic et al., 2014). 
1.1.4.1  Ubiquitin signalling in neurodegenerative diseases 
Ubiquitination was initially discovered as targeting proteins for degradation by the 
proteasome. Although it is now known that ubiquitination is also involved in many non-
Chapter 1: Introduction 
 
9 
 
proteolytic processes, its role in the degradation of proteins is still significant. The UPS 
controls the degradation and turnover of abnormal or short-lived proteins and changes in 
its function can lead to the accumulation of protein aggregates, a characteristic of 
neurodegenerative diseases including Huntington’s (HD), Parkinson’s (PD) and 
Alzheimer’s diseases (AD), which can disrupt homeostasis within the cells and the 
function of neurons (Sherman and Goldberg, 2001). For example, HD is a polyglutamine 
disorder which feature an expanded polyglutamine tract in the HTT gene leading to 
aggregation of misfolded proteins forming inclusion bodies which result in the 
progressive pathogenesis of HD. As the UPS is responsible for the removal of misfolded 
proteins, aggregation of these as in HD suggest UPS impairment and disruption of 
ubiquitin homeostasis (Ortega and Lucas, 2014). 
1.1.4.2  Ubiquitin signalling in cancer 
Additionally, aberrations within the UPS can underlie the pathology of many cancers 
through changes in the turnover of oncoproteins or tumour suppressors (Satija et al., 
2013). Many oncoproteins and tumour suppressors can be subject to ubiquitination by E3 
ligases to alter their stability. This can be emphasised using the example of the tumour 
suppressor p53, mutations of which are common in many cancers. UPS-mediated p53 
regulation includes several E3 ligases: the first E3 identified to directly ubiquitinate p53 
and promote its subsequent degradation was the RING finger protein Mdm2 (Haupt et 
al., 1997). In counterplay with this, USP7 deubiquitinates p53, preventing Mdm2-
mediated degradation and stabilising the protein, crucial for its tumour suppressing 
functions on apoptosis and inhibition of cell proliferation (Li et al., 2002). Imbalance in 
this regulation can lead to the progression of tumour development with overexpression of 
Mdm2 reported in many cancers. 
Non-proteolytic functions of ubiquitin conjugation can also become aberrant leading to 
the disruption of many cellular functions including abnormal activation and inactivation 
of cell signalling pathways (Satija et al., 2013). Pathways which are oncogenic or tumour 
suppressing can both be regulated by ubiquitin signalling. The nuclear factor κB (NF-κB) 
signalling pathway is predominantly associated with inflammation but the transcription 
factor NF-κB not only induces many inflammatory genes but also many pro-survival and 
pro-proliferative genes all of which can contribute to the development of tumours. 
Constitutive activation of NF-κB can lead to chronic inflammation and drive the 
expression of these NF-κB target genes to promote the progression of tumours (Pal et al., 
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2014). Ubiquitination in NF-κB signalling has been the subject of many studies as it plays 
a crucial part in its activation (Napetschnig and Wu, 2013, Chen, 2012). In addition to 
altering the stability of proteins involved in signalling, polyubiquitination is key in 
recruiting proteins at various stages of the NF-κB signalling cascade (Iwai, 2014). As 
with proteolytic ubiquitination, the interplay between E3 ligases and DUBs in this 
pathway play a critical part in its tight regulation and disruption to this may lead to 
development of cancers. Amongst others, members of the TNF receptor-associated factor 
(TRAF) family, which have an E3 ligase RING domain, are involved in NF-κB signalling 
and mutations in at least two of these (which cause constitutive activation of the NF-κB 
pathway) have been identified in multiple myeloma, an example highlighting the 
importance of ubiquitin signalling in the NF-κB pathway in the pathogenesis of cancer 
(Keats et al., 2007).  
The examples given here emphasise the tight regulation involved in ubiquitin signalling 
and the critical importance of this in maintaining cellular homeostasis to avoid aberrations 
preceding many disease pathologies. Although components of ubiquitin signalling, 
particularly many E3 ligases and DUBs, have become increasingly studied in recent years 
full knowledge of the regulation and function of these enzymes has not yet been 
established. Further understanding into the molecular mechanisms of ubiquitin signalling 
could provide openings for potential therapies for these diseases.  
 Ubiquitin-specific protease 4 (USP4) 
 Discovery of USP4 
The DUB USP4 was first identified during a survey of mouse genes and, due to detection 
of a protein product in fractioned nuclei and a putative nuclear localisation signal (NLS), 
it was originally designated ubiquitous nuclear protein (Unp). It was described as a proto-
oncogene with similarities to the human oncogene tre-2/TRE17 (USP6) and localised to 
mouse chromosome 9 (Gupta et al., 1993, Gupta et al., 1994). USP4 has been shown to 
have oncogenic properties as consistently elevated expression levels of the human USP4 
were observed in primary lung tumour cell lines and lung adenocarcinomas (Gray et al., 
1995). Later, reduced USP4 expression was reported, however this was in small cell lung 
carcinoma cells (Frederick et al., 1998). Further, the human USP4 gene was mapped to 
chromosome 3p21.3, a locus previously implicated in lung cancer, and associations of 
USP4 with the retinoblastoma protein (pRb), a tumour suppressor central in cell cycle 
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regulation, were established (Blanchette et al., 2001, Desalle et al., 2001). Later, 
transcriptional profiling studies found increased USP4 expression in adrenocortical 
carcinomas, further implicating USP4 in cancers (Velázquez-Fernández et al., 2005, 
Laurell et al., 2009). 
 Structure and localisation of USP4 
USP4 is a cysteine protease USP containing the characteristic Cys and His residues within 
the catalytic domain essential for its deubiquitinating activity. Additionally, a number of 
other functional domains within USP4 have been delineated as depicted in Figure 1.3. 
USP4 contains two UBL domains, one N-terminal to and one within the catalytic domain. 
The function of the catalytic UBL domain is incompletely defined but the N-terminal 
UBL domain binds to the S9 subunit of the proteasome meaning this domain can be 
involved in mediating the interactions of USP4 (Zhao et al., 2012a). This UBL domain is 
found juxtaposed with the DUSP domain and is essential for the catalytic activity of 
USP4. Through binding to the catalytic site, DUSP-UBL enhances ubiquitin dissociation, 
preventing retention of ubiquitin after hydrolysis of the isopeptide bond with the substrate 
and thus allowing full catalytic turnover of USP4 (Clerici et al., 2014). The most closely 
related USP to USP4 is USP15, the DUSP-UBL domain tandem of which is conserved 
between both of these USPs (Harper et al., 2011). In addition, the USP4 DUSP domain 
has been implicated in substrate interactions.  It is required for direct interaction with 
Sart3, a recycling factor of components of the spliceosome (Song et al., 2010). Although 
the function of the domains of USP4 are not well understood they are likely involved in 
mediating protein interactions, as with S9 and Sart3, and in regulating the activity of 
USP4, as appears to be the case in the novel method of DUSP-UBL-mediated catalytic 
activity.  
 
Figure 1.3. Domain structure of USP4. Schematic of the Cys and His domains comprising the catalytic 
core and DUSP and UBL domains. Also shown are nuclear import and export signals, NLS and NES 
respectively. Figure adapted from Gray, unpublished. 
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Although originally designated a nuclear protein, USP4 was also found located to the 
cytoplasm (Frederick et al., 1998). Later, nuclear export and nuclear import signals (NES 
and NLS, respectively) were identified and it was demonstrated to exhibit 
nucleocytoplasmic shuttling properties (Frederick et al., 1998, Soboleva et al., 2005). The 
equilibrium between nuclear and cytoplasmic USP4 appears to differ depending on the 
level of expression and also between cell types, possibly explaining why initial findings 
identified nuclear USP4 and later identified USP4 localised cytoplasmically. Shuttling 
between the nucleus and cytoplasm is essential for the correct and efficient functioning 
of many proteins. It is a highly regulated process requiring the active transport of proteins 
through the nuclear envelope aided by interactions with the karyopherin-β family of 
transporters: importins recognise specific NLSs for nuclear import and exportins 
recognise specific NESs for nuclear export (Sorokin et al., 2007). The physiological 
relevance of USP4 subcellular localisation is not fully understood but the 
nucleocytoplasmic shuttling of USP4 may be central to its function and studies have 
identified instances for which this appears to be the case. Protein interactions can 
influence relocation within the cell and it has been documented that complex formation 
of USP4 with Sart3 is sufficient to trigger the translocation of USP4 from the cytoplasm 
to the nucleus where it can deubiquitinate Prp3, a component of the spliceosomal U4 
small nuclear ribonucleoprotein (snRNP) (Song et al., 2010).  
 Substrates of USP4 
The discovery of USP4 and its potential link to some cancers led to increased interest in 
the enzyme and reports identifying substrates for USP4 and of USP4 acting in multiple 
cellular systems have since emerged. Through its catalytic activity USP4 deubiquitinates 
many of its substrates, but for some the catalytic activity is not involved and their 
interaction must have other functions. Amongst its substrates are the spliceosome U4 
component Prp3 which is deubiquitinated by USP4 to regulate the spliceosome by 
controlling the stability of spliceosome components, snRNPs U4/U6.5, upon complex 
formation with Sart3 (as discussed above) (Song et al., 2010); the G protein-coupled 
receptor A2A adenosine receptor which becomes enhanced at the cell surface after 
deubiquitination by USP4 (Milojević et al., 2006); phosphoinositide-dependent kinase 1 
(PDK1) whose monoubiquitination is modulated by USP4 (Uras et al., 2012); and the 
S9/Rpn6 subunit of the proteasome, potentially to regulate protein turnover or the stability 
or function of the proteasome (Zhao et al., 2012a). 
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Interestingly, as well as deubiquitinating some of the substrates mentioned above, USP4 
has also been reported to deubiquitinate itself. Wada and Kamitani (2006b) reported 
ubiquitination, possibly monoubiquitination, of USP4 by the autoantigen E3 ligase Ro52 
which is reversed by deubiquitination of itself. Conversely, Ro52 can ubiquitinate itself 
which can be reversed by deubiquitination by USP4 (Wada and Kamitani, 2006a, Wada 
et al., 2006). The functional consequence of this auto-ubiquitinating/deubiquitnating 
complex is not clear but many E3 ligases and DUBs are found in complexes, presumably 
for a higher level of regulation, and so this heterodimeric complex may be involved in the 
ubiquitination/deubiquitination of other substrates. 
Recently, a study has explored the role of ubiquitination, particularly USPs, involved in 
neuronal morphogenesis and connectivity in the brain. This is an area for which regulation 
by ubiquitin signalling mechanisms is only just beginning to be elucidated. Using an 
USP4 RNAi plasmid generated using short hairpin RNA (shRNA), this study determined 
an interesting role for USP4 in granule neuron axon and dendrite development: USP4 
promoted growth of axons whilst the growth of dendrites was restricted. An in vivo RNAi 
approach revealed that indeed USP4 is involved in proper granule neuron dendrite 
development in the cerebellum. Although a role for USP4 in neuronal morphogenesis has 
been described, this is one of the first studies exploring USPs in this field and as such the 
mechanism of action or possible substrate targets for USP4 have not yet been ascertained 
(Anckar and Bonni, 2015).  
 Specificity of USP4  
Ubiquitin is synthesised as a fusion protein, either to other ubiquitins in a polyubiquitin 
chain or the N-terminus of one of two ribosomal proteins. It is encoded by four genes: 
UBC and UBB, encoding polyubiquitin precursors; UBA52, encoding a fusion protein of 
ubiquitin and ribosomal protein L40; UBA80, encoding a fusion protein of ubiquitin and 
ribosomal protein S27a (Shabek and Ciechanover, 2010). A key function of DUBs is the 
post-translational cleavage of these precursor proteins to process them for the generation 
of free ubiquitin to allow conjugation to substrate proteins or ubiquitin (Komander et al., 
2009). Biological techniques have utilised ubiquitin fusion proteins as it allows the 
synthesis of a protein with any residue at its N-terminus. USP4 is able to cleave ubiquitin-
proline fusions, a fusion which is usually inefficiently cleaved and does not occur 
naturally.  This gives rise to the possibility that USP4 may be able to cleave ubiquitin 
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precursors or ubiquitin-like proteins and suggests some flexibility in the USP4 catalytic 
domain, consistent with its broad cleavage activity (Gilchrist et al., 1997). 
Many DUBs show a broad specificity for recognising different ubiquitin linkage 
topologies whereas others have a greater affinity for specific linkages. In a profiling study 
to examine DUB selectivity for recognising different ubiquitin linkage Di-ubiquitin 
probes were engineered to mimic linkages for all seven lysines and for linear 
ubiquitination. USP4 was a DUB identified by mass spectrometry from 
immunoprecipitates of cell lysates labelled with Di-ubiquitin probes. It was found to show 
reactivity for all seven types of ubiquitin linkage, most notably for the linear linkage of 
which 20% of total USP4 bound to out of all the different linkage topologies (McGouran 
et al., 2013). The most studied ubiquitin linkages topologies are for K48 and K63 
linkages. Through incubation of USP4 with K48 and K63 polyubiquitin chains it has been 
shown that USP4 can hydrolyse both types of these linkages with equal efficiency. This 
may be important for its functions in cell signalling pathways where these types of 
linkages are commonly found to regulate pathways by affecting the stability and 
recruitment of proteins (Zhao et al., 2009).  
 Cell signalling pathways 
USP4 has been reported to have substrates in many cell signalling pathways including the 
p53 pathway, Wnt/β-catenin pathway, transforming growth factor-β (TGF-β) pathway, 
retinoic acid-inducible gene I (RIG-I) pathway and NF-κB pathway, all of which will be 
discussed further in this section (Zhang et al., 2011, Zhao et al., 2009, Fan et al., 2011b, 
Zhang et al., 2012, Wang et al., 2013).  
 The p53 pathway 
The transcription factor p53 is critical in cellular regulation; activation in response to 
stress induces the expression of genes that prevent cell proliferation or induce DNA 
repair, senescence or apoptosis. Mutations in the p53 tumour suppressor gene, and its 
regulatory genes which inactivate p53, are widely found in human cancers (Toledo and 
Wahl, 2006). p53 is modulated by a number of PTMs to regulate its stability, subcellular 
localisation or transcriptional regulation and ubiquitination plays a large part in this 
mechanism of p53 control. Under normal conditions, p53 is subject to constant 
proteasomal degradation to keep the tumour suppressor at low levels but constitutively 
expressed. Under stressed conditions, this is inhibited and p53 is stabilised. Many E3 
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ligases are associated with the regulation of p53 through its proteasomal degradation 
including Mdm2, ARF-binding protein 1 (ARF-BP1), COP1 and Pirh2 (Chao, 2015). The 
predominant E3 ligase and the first to be identified is the RING finger E3 ligase, Mdm2, 
which directly ubiquitinates p53 for nuclear export and subsequent degradation (Haupt et 
al., 1997, Lohrum et al., 2001). Mdm2 is also a transcriptional target of p53, establishing 
a feedback loop in the negative regulation of p53 function (Barak et al., 1993). The 
degradation of p53 can be reversed by a number of DUBs including USP7 which directly 
deubiquitinates p53, preventing degradation and stabilising the protein (Li et al., 2002). 
Further, USP7 also interacts with and deubiquitinates Mdm2 resulting in an interesting 
feedback loop. Under normal conditions, USP7 has a higher affinity for and stabilises 
Mdm2, but under stressed conditions the DNA damage-induced ATM-mediated 
phosphorylation of Mdm2 causes an affinity switch. The result of this is the 
destabilisation of Mdm2 and therefore stabilisation of p53 which enables p53-mediated 
apoptosis, inhibition of cell proliferation or DNA repair (Li et al., 2004, Meulmeester et 
al., 2005).  
Other DUBs can also regulate p53 activity directly by interacting with p53, or indirectly 
without any direct interaction or deubiquitination of p53. USP4 is an important regulator 
of p53 through interactions with the HECT domain-containing p53 E3 ligase, ARF-BP1 
(Zhang et al., 2011). ARF-BP1 is a critical mediator in tumour suppression: it directly 
induces the ubiquitination of p53 but its ubiquitin ligase activity can be inhibited by the 
binding of the ARF tumour suppressor to ARF-BP1 thereby stabilising p53 (Chen et al., 
2005). USP4 deubiquitinates ARF-BP1 thereby stabilising the ligase and consequently 
leading to the ubiquitination and degradation of p53 (Figure 1.4). Moreover, mouse 
embryonic fibroblasts (MEFs) from Usp4 null mice exhibit enhanced apoptosis as well 
as a reduced cell growth and enhanced premature senescence, consistent with increased 
levels of p53 (Zhang et al., 2011).  
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Figure 1.4. A model of USP4 inhibition of p53 via interaction with ARF-BP1. USP4 deubiquitinates 
ARF-BP1 leading to its stabilisation and subsequent ubiquitination and proteasomal degradation of 
p53. 
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 The Wnt/β-catenin pathway 
The Wnt signalling pathway is involved in embryonic developmental processes and tissue 
homeostasis and dysregulation of this pathway has been linked to diseases including 
osteoporosis and cancers (MacDonald et al., 2009). Members of the Wnt family are 
capable of activating non-canonical and canonical Wnt signalling pathways and it is the 
latter, the Wnt/β-catenin pathway, which is the most studied and which USP4 is reported 
to regulate (Zhao et al., 2009).  
Wnt can bind to the seven transmembrane cell surface receptors known as Frizzled 
proteins. This, and interactions with the co-receptor, low density lipoprotein receptor 
related protein 5 or 6 (LRP5/6), can induce the canonical Wnt/β-catenin signalling 
pathway (He et al., 2004). Upon binding of a ligand to a Wnt receptor, the central player 
in the canonical pathway, β-catenin, accumulates and translocates to the nucleus to exert 
transcriptional effects through various interactions. There are many components of the 
Wnt cascade which regulate the stability of this central player: components which form 
the destruction complex are able to cause the degradation of β-catenin. The tumour 
suppressor adenomatous polyposis coli (APC), the scaffolding protein Axin, and two 
Ser/threonine (Thr) kinases: casein kinase 1 (CK1) and glycogen kinase 3 (GSK3) all 
comprise the destruction complex. In the absence of a ligand bound to Wnt receptors, 
APC and Axin adhere to both β-catenin and CK1 and GSK3β of the destruction complex 
(Kim et al., 2013). These kinases promote the phosphorylation of specific Ser/Thr 
residues at the N-terminus of β-catenin allowing recognition by the E3 ligase complex 
known as Skp1, Cullin1, F-box containing complex, β-transducin repeat containing 
protein (SCFβ-TrCP) (Latres et al., 1999). Consequently, β-catenin is polyubiquitinated by 
SCFβ-TrCP and targeted for proteasomal degradation (Figure 1.5) (Aberle et al., 1997).  
Induction of the Wnt signalling pathway through binding of a ligand induces CK1 and 
GSKβ-mediated phosphorylation of the co-receptor LRP6. This recruits Axin to the 
LRP5/6 receptor complex thereby disassembling the destruction complex and causing its 
dissociation from β-catenin. Subsequently, this leads to the accumulation of β-catenin and 
its translocation to the nucleus to enable binding to transcription factors, including T-cell 
factor (TCF) and lymphoid enhancer factor (LEF), to trigger transcriptional activation of 
an array of Wnt target genes (Kim et al., 2013). Additional factors are involved in this 
signalling pathway to keep β-catenin highly regulated, including the MAP kinase-related 
Nemo-like kinase (Nlk) which acts as a negative regulator of canonical Wnt signalling. 
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Nlk interacts with a TCF/LEF complex bound to β-catenin to suppress transcriptional 
activity through Nlk-mediated phosphorylation of Ser/Thr residues on the TCF/LEF 
complex (Figure 1.5) (Ishitani et al., 2003).  
Although ubiquitin signalling has not been widely studied in terms of the Wnt signalling 
pathway, it does play an important role in the control of β-catenin which, as well as being 
targeted for degradation, can be ubiquitinated by K11 or K29 polyubiquitin chains for the 
promotion of nuclear localisation and the upregulation of β-catenin levels (Hay-Koren et 
al., 2011). USP4 has been reported to be a negative regulator of canonical Wnt signalling 
(Zhao et al., 2009). Downstream of the destruction complex, USP4 interacts with Nlk and 
translocates to the nucleus to allow USP4 interaction with, and deubiquitination of, the 
predominantly nuclear transcription factor TCF4. Overall, loss of USP4 results in an 
increase in Wnt signalling but the consequences of TCF4 ubiquitination/deubiquitination 
and how USP4 may regulate Wnt signalling in this way are not clear. TCF4 can be 
subjected to ubiquitin-mediated degradation, but USP4 does not affect TCF4 stability and 
prevention of the ubiquitin-mediated degradation of TCF4 would be expected to enhance 
Wnt target gene activation, not consistent with downregulation of Wnt by USP4. USP4 
may deubiquitinate non-degradative polyubiquitin chains on TCF but there are currently 
no studies to determine this (Zhao et al., 2009). 
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Figure 1.5. The Wnt/β-catenin pathway. With absence of Wnt (left): Axin, APC, CK1 and GSK3 
form the destruction complex which binds to and phosphorylates β-catenin for ubiquitination and 
degradation. Binding of Wnt to the Frizzled receptor (right) initiates the dissociation of the 
destruction complex. β-catenin is then free to translocate to the nucleus where it accumulates and 
binds to transcription factors TCF and LEF for the transcription of target genes. Nlk inhibits this 
transcription and recruits USP4 (highlighted in pink) for deubiquitination of TCF4. Grey circles 
represent phosphorylation. Orange circles represent ubiquitin.  
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 The TGF-β pathway 
The TGF-β signalling pathway regulates biological processes including proliferation, 
differentiation, apoptosis, and migration, invasion and metastasis in cancers (Katz et al., 
2013). The TGF-β pathway involves type I and type II transmembrane receptors (TβR-I 
and TβR-II) which exist as homodimers on the cell surface but form heterotetramers upon 
binding of TGF-β. Both receptors have an N-terminal domain which binds the ligand and 
a C-terminal Ser/Thr kinase domain. Additionally, TβR-Is have a Gly/Ser-rich (GS) 
domain which becomes phosphorylated by the constitutively active TβR-II Ser/Thr kinase 
activity to activate the type I receptors (Wrana et al., 1994). A family of Smad proteins 
mediate TGF-β signalling. Upon TβR-I activation receptor-regulated Smads (R-Smads) 
including Smads 1, 2, 3, 5 and 8, themselves become activated by phosphorylation. The 
phosphorylated R-Smads dissociate from the receptor complex and form a hetero-
oligomer complex with a common partner for all R-Smads, Smad4 (Co-Smad) (Feng and 
Derynck, 2005). This allows translocation of the complex and accumulation in the 
nucleus for the regulation of the transcription of an array of target genes (Figure 1.6). 
Factors induced by TGF-β-activated transcriptional regulation include Smad6 and Smad7 
(I-Smads) which are inhibitory in TGF-β signalling (Imamura et al., 2013). 
Like many cell signalling pathways, TGF-β signalling is also under tight regulation by 
ubiquitination. Smad ubiquitin regulatory factor 1 and 2 (Smurf1 and 2) are HECT E3 
ligases involved in TGF-β signalling. Smurf1 and Smurf2 interact with I-Smads to induce 
their nuclear export to the TGF-β receptors. This targets the receptors and I-Smads for 
ubiquitin-dependent proteasomal degradation. In addition, Smurf1 and Smurf2 
ubiquitinate R-Smads to mediate their proteasomal degradation. The phosphorylation of 
R-Smads allows recognition of Smad1 and Smad5 by Smurf1 and Smad1 and Smad2 by 
Smurf2 for their polyubiquitination (Zhang et al., 2001). Non-degradative ubiquitination 
is also implicated in TGF-β regulation. Smad4 is monoubiquitinated by the E3 ligase 
Ectodermin/Tif1γ, preventing complex formation with Smad2 and thereby inhibiting the 
TGF-β pathway (Dupont et al., 2009).  
Equally, deubiquitination also regulates TGF-β signalling and some of the DUBs 
involved in this have been identified. It was actually the discovery of the FAM/USP9x as 
a DUB able to deubiquitinate Smad4 in TGF-β signalling which led to the knowledge that 
Smad4 monoubiquitination occurs in the control of the pathway (Dupont et al., 2009). 
USP15, a DUB sharing significant sequence similarity with USP4, regulates TGF-β 
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signalling through deubiquitination of both monoubiquitinated and Smurf1-induced 
polyubiquitinated R-Smads; Smad1 and Smad3. USP15 plays some role in regulating the 
stability of R-Smads but mainly enhances TGF-β signalling through the suppression of 
R-Smad monoubiquitination to enable R-Smad DNA-binding and promoter recognition 
required for full transcriptional activity in TGF-β signalling (Inui et al., 2011). 
Additionally, USP15 is recruited to the TβR-I complex by binding to Smad7 of the 
Smad7-Smurf2 complex. This allows USP15 to remove the Smurf2-mediated 
ubiquitination of TβR-I, thereby stabilising the receptor and resulting in enhanced 
phosphorylation and activation of R-Smads. At low concentrations of TGF-β stimulation 
USP15 counteracts the Smurf2-mediated degradation of TβR-I, but at higher TGF-β 
stimulation USP15 dissociates from Smad7 and therefore TβR-I, indicating there is a 
balance between USP15 and Smurf2 in regulating TGF-β signalling (Eichhorn et al., 
2012). The stability of the TβR-I is also regulated by USP4 in the TGF-β signalling 
pathway, although it does this through utilisation of a different mechanism to USP15 
(Aggarwal and Massagué, 2012). USP4 increases activation of TGF-β, Smad2 
phosphorylation and Smad2-Smad4 complex formation. It directly interacts with the 
TβR-I intracellular domain to deubiquitinate and stabilise the receptor at the membrane, 
unlike USP15 which required interactions with Smad7 (Figure 1.6) (Zhang et al., 2012).  
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Figure 1.6. The TGF-β signalling pathway. Diagram of the cascade of events in the TGF-β pathway. 
Upon activation of the TβR-I, R-Smads (Smads 1, 2, 3, 5 and 8) are recruited and phosphorylated to 
trigger dissociation from the receptor complex allowing recruitment of Smad4 and translocation to 
the nucleus for the transcription of target genes, including I-Smads (Smad6 and Smad 7). For the 
negative regulation of the pathway, R-Smads are subject to K48-linked polyubiquitination by Smurf1 
and Smurf 2 (Smurf) for degradation by the proteasome. Smurf also binds to I-Smads in the nucleus 
for transportation to the plasma membrane and the K48-linked polyubiquitination and subsequent 
degradation of TβR-I. This is reversed by USP4 (highlighted in pink). Grey circles represent 
phosphorylation. Orange circles represent ubiquitin. 
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 The RIG-I pathway 
Viral infection triggers the activation of innate immunity signalling pathways critical in 
the immune response. RIG-I-like receptors (RLRs) detect viral RNA in viral infection 
and initiate downstream signalling events to induce expression of cytokines and type I 
interferons (IFNs): IFN-α and IFN-β. RIG-I is a member of the RLR family, with domains 
including two N-terminal caspase recruitment domains (CARDs), a C-terminal domain 
(CTD) and a central DExD/H-box RNA helicase domain (Yoneyama et al., 2004). Upon 
detection of viral RNA by the receptor, such as Sendai virus (SeV) and vesicular 
stomatitis virus (VSV), the ATP-dependent conformational change of the CTD allows 
CARDs to interact with the adaptor protein mitochondrial antiviral signalling protein 
(MAVS or also known as IPS-I) (Yoneyama et al., 2015). The RING-finger E3 ligase 
tripartite motif 25 (TRIM25) catalyses the K63-linked polyubiquitination of RIG-I 
CARDs which is crucial in mediating the recruitment of MAVS and inducing RIG-I 
antiviral signal transduction (Gack et al., 2007). Interaction of MAVS with CARDs 
recruits signalling components including TANK-binding kinase 1 (TBK1) which results 
in the phosphorylation and dimerisation of the transcription factor IFN regulatory factor 
3 (IRF3) (Seth et al., 2005). This leads to nuclear translocation of IRF3 for the 
transcriptional activation of IRF3-target genes including IFN-β and possibly matrix 
metalloproteinase 13 (MMP13) (Figure 1.7) (Radwan et al., 2013). Inhibitor of κB (IκB) 
kinase (IKK) complex components are also recruited to MAVS. The IKK complex is 
required for the activation of the transcription factor NF-κB and so in this way RIG-I 
activation can also lead to the activation of NF-κB target genes including many 
inflammatory cytokines (Figure 1.7) (Yoneyama et al., 2015, Seth et al., 2005). Ubiquitin 
signalling events are an important aspect in the tight regulation of RIG-I. As well as the 
K63-linked polyubiquitination of CARDs by TRIM25 to induce RIG-1 activation, 
TRIM25 is itself regulated by K48-linked polyubiquitination to mediate its degradation 
to inhibit RIG-I activation. This can be reversed by USP15 (Pauli et al., 2014). RIG-I is 
also ubiquitinated with K48-linked polyubiquitin chains to mediate its proteasomal 
degradation in the negative regulation of this pathway. The RING-finger E3 ligase 
RNF125 interacts with RIG-I and, together with the E2 conjugating enzyme UbcH5c, 
catalyses its K48-linked polyubiquitination for the degradation of RIG-I and downstream 
suppression of IRF3 and NF-κB (Arimoto et al., 2007). This K48-linked 
polyubiquitination of RIG-I can be reversed by the deubiquitinating activity of USP4 
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indicating that USP4 acts as a positive regulator of RIG-I signalling by stabilising RIG-I 
and enhancing RIG-I signalling (Wang et al., 2013).  
 
Figure 1.7. The RIG-I pathway. Detection of viral RNA by RIG-I leads to the TRIM25-mediated 
K63-linked polyubiquitination of RIG-I CARD domains and the recruitment of MAVS for the 
cascade of events leading downstream translocation of IRF3 and NF-κB and the transcription of 
target genes. For the negative regulation of RIG-I signalling, RIG-I is polyubiquitinated with K48-
linked chains to mediate its proteasomal degradation. USP4 is highlighted in pink. The 
phosphorylation of proteins is represented by grey circles. Ubiquitination of proteins is represented 
by orange circles. 
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 The NF-κB pathway 
The NF-κB pathway is immensely critical in inflammation, cell proliferation and 
apoptosis. Inappropriate activation of the NF-κB signalling pathway is implicated in the 
pathogenesis of cancers and chronic inflammation (Pal et al., 2014). In unstimulated cells, 
IκB proteins bind to a Rel-related transcription factor dimer of NF-κB and sequester it to 
the cytoplasm by masking its NLS. Induction of NF-κB leads to a cascade of events 
resulting in the phosphorylation, ubiquitination and degradation of IκB. This exposes the 
NLS of NF-κB and facilitates its translocation to the nucleus where the activation of NF-
κB induces the expression of a number of target genes including pro-survival and 
proinflammatory genes. Many adaptor proteins are involved in NF-κB signalling which 
can interact to ensure tight regulation is maintained (Karin and Ben-Neriah, 2000). 
Ubiquitin signalling also plays a key part in this tight regulation: the determining step in 
NF-κB activation is the phosphorylation of IκB which is a prerequisite for its K48-linked 
polyubiquitination and degradation. This was the first ubiquitin-dependent proteolysis to 
be shown as an integral step in signal transduction but ubiquitination is prevalent 
throughout the pathway and non-proteolytic ubiquitination is important in the activation 
and recruitment of multiple NF-κB adaptor proteins (Iwai, 2014). 
1.3.5.1  The NF-κB transcription factor 
The highly conserved NF-κB family of proteins share an N-terminal region Rel homology 
domain (RHD) and can form homo- or heterodimers of subunits p50, p52, p65 (also 
known as RelA), c-Rel or RelB. Both p50 and p52 are synthesised as precursor proteins, 
p105 and p100, which are proteolytically processed to p50 and p52, respectively (Karin 
and Ben-Neriah, 2000, Ghosh et al., 1998). Typically, non-canonical NF-κB activation is 
mediated by RelB/p52 heterodimers and canonical NF-κB activation, which will be the 
focus of this section, is mediated by p65/p50 heterodimers (Hayden and Ghosh, 2008). 
IκBs, including IκBα, IκBβ and IκBγ, are inhibitors of NF-κB which bind to NF-κB 
dimers to retain them in the cytoplasm. IκBs contain ankyrin repeats which interact with 
the RHD of NF-κB to mask the NLS and prevent nuclear translocation in unstimulated 
cells (Karin and Ben-Neriah, 2000).    
Induction of canonical NF-κB activation can be achieved by a wide variety of stimuli 
including cytokines tumour necrosis factor α (TNFα), interleukin-1 (IL-1) or bacterial 
lipopolysaccharide (LPS) leading to a cascade of events involving the recruitment of 
numerous adaptor proteins (Ghosh et al., 1998). The different stimuli may lead to a 
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differing cascade of events but the key step in all canonical NF-κB activation is the 
liberation of the NF-κB dimer from its inhibitory proteins through the IKK-mediated 
phosphorylation and consequent ubiquitination and degradation of IκB.  
1.3.5.2  TNFα-mediated NF-κB activation 
TNFα can bind to and activate TNF receptor 1 (TNFR1) or TNFR2 to mediate effects on 
proliferation, inflammation and apoptosis. The activation of NF-κB mediated by TNFα is 
primarily through TNFR1, with TNFR2 potentially suppressing NF-κB activation 
(Puimège et al., 2014). The binding of TNFα to the TNFR1 promotes specific interaction 
with the adaptor protein TNF receptor-associated protein with a death domain (TRADD) 
which interacts with the death domain of TNFR1 to induce two distinct signalling 
cascades for either apoptosis or NF-κB activation (Hsu et al., 1995). The recruitment of 
TRAF2 by TRADD then signals the cascade leading to NF-κB activation rather than 
leading to apoptosis (Hsu et al., 1996b). In addition to TRAF2, the binding of TRADD to 
the TNFR1 also promotes the simultaneous recruitment of another death domain protein: 
the Ser/Thr kinase receptor-interacting protein 1 (RIP1) (Hsu et al., 1996a). TRAF2 forms 
complexes with cellular inhibitor of apoptosis protein 1 and 2 (cIAP1/2) thereby also 
recruiting them to the TNFR1 signalling complex. Many of the proteins within this 
TNFR1 complex possess ubiquitin ligase activity including the RING domain-containing 
cIAP1/2 which directly ubiquitinate RIP1 with K63 polyubiquitin chains, crucial for 
TNFα-induced NF-κB activation  (Varfolomeev et al., 2008). TRAF2 also possesses an 
E3 ligase RING domain and was initially assumed to be the ligase responsible for the 
K63-linked polyubiquitination of RIP1, however there is a lack of evidence that TRAF2 
directly catalyses RIP1 ubiquitination. Moreover, TRAF2 lacks key amino acid residues 
in its RING domain required for binding Ubc13, part of the E2 complex specific for K63-
linked polyubiquitination (Yin et al., 2009). It has been suggested that the E3 ligase 
activity of TRAF2 may be initiated by the pro-survival lipid mediator, sphingosine-1-
phosphate (S1P), but the exact role of TRAF2 is still unclear and TRAF2 may only act as 
an aid in cIAP1/2-mediated RIP1 K63-linked polyubiquitination (Alvarez et al., 2010).  
Throughout the NF-κB pathway, K63 polyubiquitin chains and other polyubiquitin 
chains, including K11 and linear chains, have crucial functions in serving as a platform 
for recruiting the UBD-containing proteins required for the activation of NF-κB (Husnjak 
and Dikic, 2012, Wertz, 2014). The cIAP1/2-mediated RIP1 (and also TRAF2) K63-
linked polyubiquitination mediates the recruitment and activation of the transforming 
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growth factor-β-activated kinase 1 (TAK1) through interactions with TAK1 binding 
protein (TAB) 2 and 3. TAB2 and TAB3 act as adaptors by binding ubiquitin through 
their C-terminal Npl4 zinc-finger domains (NZFs) which specifically recognise the Ile 44 
hydrophobic patch on ubiquitin in K63 polyubiquitin chains (Sato et al., 2009). This 
recruitment of TAK1 is significant in the NF-κB signalling cascade as TAK1 is a key 
modulator of NF-κB activation. It is a member of the mitogen-activation protein kinase 
(MAPK) kinase kinase (MAPKKK) family essential in the activation of not only NF-κB 
but also JNK and p38 MAPK pathways (Ajibade et al., 2013). The activation of TAK1 
through the TAB2- and TAB3-mediated binding to polyubiquitinated RIP1 leads to its 
own K63 polyubiquitination and consequently the recruitment of the IKK complex via 
the binding of the NF-κB essential modifier (NEMO) subunit (also known as IKKγ) to 
the polyubiquitinated TAK1 (Fan et al., 2010). In addition to K63 polyubiquitination, 
RIP1 is also subjected to K11 polyubiquitination by cIAP1/2 and linear polyubiqutination 
by the LUBAC complex which is recruited to RIP1 by cIAP1/2 (Haas et al., 2009, Dynek 
et al., 2010, Gerlach et al., 2011). The NEMO subunit has a high affinity for specifically 
recognising and binding to linear ubiqutin chains through its ubiquitin binding in ABIN 
and NEMO (UBAN) motif and, as well as K63 polyubiquitin and K11 chains, linear 
ubiquitin chains are important in the recruitment of the IKK complex (Rahighi et al., 
2009, Hadian et al., 2011). Additionally, NEMO is itself linearly ubiqutinated through 
recognition of NEMO by the NZF1 domain of HOIP of the LUBAC complex, which 
enhances interactions of the TNFR1 complex with the IKK complex (Fujita et al., 2014).   
The IKK complex is another key modulator required in NF-κB activation as it is 
responsible for the most crucial regulatory event in the activation of NF-κB: the 
phosphorylation and subsequent degradation of IκB (Hinz and Scheidereit, 2014). RIP1 
serves as a docking platform for the recruitment of the IKK complex, particularly the 
NEMO subunit which can bind to the many ubiquitin chains topologies attached to RIP1. 
This ubiquitin-dependent concomitant recruitment of the IKK complex via RIP1 and 
TRAF2 brings TAK1 into close proximity with the IKK complex to allow the 
phosphorylation of IKK neccessary for its activation (Wertz, 2014).   
Along with the regulatory subunit NEMO, the IKK complex is made up of two other 
subunits: kinases IKKα and IKKβ (Zandi et al., 1997). IKKβ is the major IKK subunit for 
TNFα-induced NF-κB activation and its phosphorylation at Ser177 and Ser181 in the 
IKKβ activation loop is required for the activation of the IKK complex. There is much 
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evidence to indicate that TAK1 is essential in the direct phosphorylation and activation 
of the IKK complex and it was recently proposed that activated TAK1 phosphorylates 
IKKβ at Ser177 which then enables the sequential autophosphorylation of IKKβ at Ser 
181 for the activation of IKKβ (Zhang et al., 2014). Once activated, IKKβ in turn 
phosphorylates IκB, specifically Ser32 and Ser36 of IκBα, which creates a specific 
phosphodegron motif to be recognised by the E3 ligase SCFβ-TrCP (Spencer et al., 1999). 
Similarly to the recognition of phosphorylated β-catenin, SCFβ-TrCP only recognises the 
phosphorylated form of IκBα. The F-box component of SCFβ-TrCP, β-TrCP, is responsible 
for this recognition whilst Skp1 and Cul1 act as scaffolds and the RING domain acts as 
an E2 adaptor. Together this complex recognises phosphorylated IκBα and catalyses its 
K48-linked polyubiquitination to tag it for degradation by the 26S proteasome (Spencer 
et al., 1999). Degradation of IκBα releases dimeric NF-κB, exposing the NLS of the p65 
subunit of the dimer and allowing its translocation to the nucleus for the transcription of 
an array of NF-κB target genes (Figure 1.8). 
1.3.5.3  IL-1-mediated NF-κB activation 
Similarly to TNFα-induced NF-κB activation, IL-1-induced NF-κB activation requires 
the recruitment of a series of adaptor proteins leading to the activation of the IKK complex 
for the phosphorylation, ubiquitination and degradation of IκBα. The adaptor proteins 
required for this differ to those involved in TNFα induction upstream of the IKK complex, 
but again this cascade of events is ubiquitin-dependent. 
The IL-1 receptor (IL-1R), aided by the IL-1 receptor accessory protein (IL-1R AcP), can 
bind IL-1α or IL-β to activate the NF-κB signalling pathway (Martin and Wesche, 2002). 
Upon binding of IL-1 to IL-1R, the adaptor protein death domain-containing adaptor 
myeloid differentiation factor (MyD88) is recruited to the receptor through interactions 
with its Toll/IL-1 receptor (TIR) domain, a domain which also shares homology with 
Toll-like receptors (TLRs). This in turn leads to the recruitment of members of the IL-
1R-associated kinase (IRAK) family including IRAK1, IRAK2 and IRAK4 to the IL-1R 
complex. MyD88 and IRAK1 both possess death domains which are able to interact with 
each other. The parallel recruitment of IRAK4 to the receptor complex scaffold allows it 
to phosphorylate IRAK1 on Thr209 and Thr387 which subsequently initiates the 
hyperphosphorylation of IRAK1, potentially through further autophosphorylation 
(Martin and Wesche, 2002, Verstrepen et al., 2008). 
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The phosphorylation of IRAK1 enables the recruitment of TRAF6 to the receptor 
complex and is thought to cause dissociation of IRAK1 and TRAF6 from the receptor 
complex (Cao et al., 1996). The self-ubiquitination of TRAF6 with K63-polyubiquitin 
chains and the formation of TRAF6-catalysed unanchored K63-polyubiquitin chains, 
together with E2 ubiquitin conjugating complex Ubc13/Uev1A or Ubc5, then leads to the 
recruitment of TAK1 through TAB2 and TAB3 interactions (Xia et al., 2009). The RING 
domain-containing TRAF6 also ubiquitinates IRAK1 with K63-linked polyubiquitin 
chains and in this way, as well as acting as an adaptor in the recruitment of TAK1, recruits 
the IKK complex through the binding of NEMO to K63 polyubiquitinated IRAK1 (Conze 
et al., 2008).  
As with TNFα-induced NF-κB signalling, IL-1 induces the formation of linear ubiquitin 
chains by LUBAC. It has been reported that the formation of K63-linked chains in 
response to IL-1 stimulation is a prerequisite for the formation of linear ubiquitin chains 
by the LUBAC complex which, through interactions of HOIP with K63-linked chains, 
covalently attach to the IRAK1 K63-linked polyubiquitin chains leading to both the 
recruitment of TAK1 through TAB2 binding of K63-linked chains required for IKK 
phosphorylation and activation and also to the recruitment of IKK itself through NEMO 
binding to linear chains (Emmerich et al., 2013). Again, linear and K63 polyubiquitin 
chains serve as a platform for recruiting TAK1 and IKK, essential for NF-κB activation. 
This recruitment leads to autophosphorylation of TAK1 and direct activation of the kinase 
to induce the TAK1-mediated phosphorylation of IKKβ, as in TNFα-induced signalling.  
As well as K63-linked polyubiquitination and linear ubiquitination, IRAK1 later 
undergoes K48-linked polyubiquitination. The E3 ligase SCFβ-TrCP recognises IRAK1 and 
eventually targets the protein for degradation allowing the TRAF6-TAK1 complex to 
dissociate from the membrane complex where it can activate IKK (Cui et al., 2012). A 
model for the ubiquitination of IRAK1 could involve initial K63-linked 
polyubiquitination of IRAK1 for the recruitment of IKK, later followed by removal of 
these chains and the addition of K48-linked polyubiquitination to for its degradation and 
to allow TAK1 to dissociate from the membrane to activate IKK in the cytosol (Figure 
1.8).  
1.3.5.4  Overview of ubiquitination in TNFα- and IL-1-induced NF-κB activation 
In addition to the key integral step in NF-κB activation of the phosphorylation and 
subsequent K48-linked polyubiquitination for the degradation of IκBα, other ubiquitin 
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chain topologies are required for the activation of the IKK complex which leads to this 
IκBα degradation in both TNFα- and Il-1α-induced NF-κB signalling. TNFα stimulation 
causes the linear, K11- and K63-linked polyubiquitination of RIP1 which serves to recruit 
ubiquitin-binding proteins TAB2 and NEMO, which act as regulators of TAK1 and the 
IKK complex, respectively (Wertz, 2014). IL-1 stimulation also promotes linear and K63-
linked polyubiquitination, possibly of TRAF6 and/or IRAK1, for the recruitment of 
TAK1 and the IKK complex (Verstrepen et al., 2008). This ubiquitin-dependent 
recruitment mechanism of these proteins initiates the activation of TAK1 and may be 
required to co-localise TAK1 and the IKK complex for the TAK1-mediated 
phosphorylation of IKKβ (Figure 1.8). 
1.3.5.5  p65 activation 
The release of NF-κB from its inhibitory proteins unmasks the NLS on NF-κB of the most 
abundant and ubiquitously expressed NF-κB dimer, p65/p50, allowing its nuclear 
translocation and the expression of many NF-κB target genes. The mechanism of efficient 
transactivation of NF-κB is itself regulated, for example the p65 NF-κB subunit 
undergoes phosphorylations to regulate its activity. The family of NF-κB proteins all 
share a RHD which is responsible for dimerisation and DNA binding activity. p65 is 
phosphorylated at Ser276 of its N-terminal RHD by protein kinase A (PKA) which 
promotes interactions with transcriptional activator CREB-binding protein (CBP)/p300, 
critical for p65 activation and NF-κB-dependent transcription (Zhong et al., 1998). The 
p65 subunit of NF-κB, but not the p50 subunit, also contains a transactivation domain 
(TAD) within its C-terminal domain which regulates the transcriptional activity of the 
prototypical p65/p50 complex (Diamant and Dikstein, 2013). Besides its phosphorylation 
at Ser276, p65 is also phosphorylated at Ser 536 within the TAD domain. Both TNFα and 
IL-1 induce p65 Ser536 phosphorylation by IKKβ, and possibly a range of other kinases 
including IKKα, to regulate the transcriptional activity of p65 (Sakurai et al., 2003). Other 
sites for p65 phosphorylation, including Ser311 and Ser539, and other PTMs, including 
acetylation and ubiquitination, have been identified that serve as a mechanism of 
regulation in NF-κB signalling downstream of the IKK complex (Schmitz et al., 2004).  
These multiple sites are thought to be involved in the recruitment of proteins and 
promoters required for the transcriptional activity of NF-κB and the expression of NF-κB 
target genes or are involved in the stability of p65. 
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1.3.5.6  The role of DUBs in NF-κB signalling 
The NF-κB signalling pathway is under tight regulation to maintain homeostasis and 
prevent dysregulation of the pathway which can lead to the pathogenesis of many diseases 
including chronic inflammation and cancers (Pal et al., 2014). For this purpose inhibitors 
are required to balance out ubiquitination events in the pathway and many DUBs have 
been identified which act to provide this balance (Harhaj and Dixit, 2011). 
A20 
A20 is a well established OTU domain-containing DUB which acts as a negative regulator 
of NF-κB activation. Overexpression of A20 inhibits TNFα- and IL-1-induced NF-κB 
activation and A20-deficient mice show severe inflammation and hypersensitivity to 
treatment with LPS and TNFα resulting in premature death. Additionally, TNFα-
stimulated A20-deficient cells exhibit persistent NF-κB activation, clearly indicating that 
A20 is critical in the negative regulation of NF-kB (Jaattela et al., 1996, Lee et al., 2000). 
A20 also has 7 C-terminal ZnF domains, one of which, ZnF4, displays intrinsic ubiquitin 
ligase activity meaning that, unusually, A20 is a novel ubiquitin-editing enzyme able to 
exhibit both deubiquitinase and E3 ligase properties. A likely model for the function of 
A20 in ubiquitin editing in TNFα-induced NF-κB signalling is the initial suppression of 
NF-κB through cleavage of K63-linked polyubiquitin chains on RIP1 by the OTU domain 
of A20 which is a prerequisite for the polyubiquitination of RIP1 with K48-linked 
polyubiquitin chains by the A20 ZnF4 domain for the targeting of RIP1 for proteasomal 
degradation to further downregulate NF-κB activation (Wertz et al., 2004). A20 is also 
able to inhibit IL-1-induced NF-κB activation through interactions with TRAF6, resulting 
in the deubiquitination of K63-linked TRAF6 polyubiquitin chains, however it does not 
mediate its degradation through the catlaysis of K48-linked polyubiquitin chains as with 
RIP1 (Heyninck and Beyart, 1999, Boone et al., 2004).  
Cylindromatosis tumour supressor 
The cylindromatosis (CYLD) gene encodes a tumour suppressor, mutations of which have 
been linked to familial cylindromatosis, a genetic predisposition to multiple neoplasms 
of the skin appendages known as cylindromas (Bignell et al., 2000). CYLD-deficient 
mice have uncovered functions of CYLD in various biological processes including T-cell 
development and, in addition, CYLD-deficient mice are more susceptible to induced 
inflammation and tumourigenesis in a colitis-associated cancer model and exhibit 
enhanced NF-κB and JNK activity (Reiley et al., 2006, Zhang et al., 2006).  CYLD is a 
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NEMO-interacting enzyme able to deubiquitinate K63 polyubiquitinated substrates 
including TRAF2, RIP1 and TRAF6 and in this way downregulate NF-κB activity 
(Brummelkamp et al., 2003, Kovalenko et al., 2003, Wright et al., 2007, Trompouki et 
al., 2003).  
USP4 
Whereas most reports to date have identified roles for DUBs in TNFα-induced NF-κB 
signalling in particular, reports for a role of USP4 in TNFα-, IL-1- and LPS-induced NF-
κB signalling have also emerged. Initially, Fan et al. (2011b) reported that USP4 
downregulates TAK1-induced NF-κB activity. It was reported that TNFα induces 
association of USP4 with TAK1 via its C-terminal USP domain and this consequently 
leads to reduced ubiquitination of TAK1. Furthermore, USP4 was also reported to inhibit 
IL-1β- and LPS-induced NF-κB activity and IKK phosphorylation. In addition to 
identifying TAK1 as a substrate for USP4 in the downregulation of NF-κB, it was also 
suggested that TRAF2 and TRAF6 may be substrates of USP4 due to the reduction in 
NF-κB activity with overexpression of USP4 in TRAF2- and TRAF6-induced cells (Fan 
et al., 2011b). This observation was supported in another study which reported 
interactions of USP4 with both TRAF2 and TRAF6 targeting them for deubiquitination 
(Xiao et al., 2012). The interaction with TRAF6 occurs between the C-terminal USP 
domain of USP4 and the TRAF domain of TRAF6. USP4 was reported to inhibit TRAF2-
, TRAF6-, TNFα- and IL-1β-induced NF-κB activity by deubiquitinating the non-
degradative K63-linked polyubiquitination of TRAF2 and TRAF6. Similarly, Zhou et al. 
(2012) supported the role of USP4 as a negative regulator of NF-kB signalling in line 
with these studies, with more focus on IL-1- and LPS-induced effects. As with the other 
studies, it was reported that USP4 suppresses IL-1-induced NF-κB activity and affects 
the expression levels of NF-κB target genes, including TNFα, IL-1β and IL-6 in response 
to IL-1 or LPS stimulation. Together these studies implicate USP4 as a negative regulator 
of NF-κB activation through deubiquitination of mediators TRAF2, TRAF6 and TAK1 
with TNFα- and IL-1-induced pathways (Figure 1.8) (Fan et al., 2011b, Xiao et al., 2012, 
Zhou et al., 2012). 
Other USPs involved in the regulation of NF-kB 
USP21 downregulates TNFα-induced NF-κB activity by interacting with and directly 
deubiquitinating RIP1 (Xu et al., 2010). In addition, USP2a inhibits TNFα-induced NF-
κB activity through association and deubiquitination of K63-linked polyubiquitination of 
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RIP1 and TRAF2 and also K48-linked polyubiquitination of RIP1. By deubiquitinating 
the K63 polyubiquitin chains of RIP1, USP2a represses NF-κB activation and potentially 
causes conversion to the apoptotic pathway mediated by the TNFR1 pro-apoptotic 
complex II to mediate cell death (Mahul-Mellier et al., 2012). 
Most negative regulators in the NF-κB signalling pathway act upstream of the IKK 
complex but others act downstream of this. The key integral step in canonical NF-κB 
activation is the ubiquitination and subsequent proteasomal degradation of IκB. USP11 
is able to reverse this by specific association and direct deubiquitination of IκBα, thereby 
negatively regulating TNFα-induced NF-κB activation by acting at an essential step in 
the signalling pathway and controlling the stability of IκBα (Sun et al., 2010).  
All the DUBs discussed so far act as negative regulators in the NF-κB pathway but, 
additionally, DUBs can upregulate NF-κB signalling. Ye et al. (2010) identified USP6 
(also known as TRE17) as the first DUB to activate NF-κB via an unusual mechanism. 
USP6 does not affect the phosphorylation or degradation of IκBα but instead activates 
NF-κB through stimulation of the nuclear accumulation of IκBα-free p65 and the 
phosphorylation of p65 at Ser536 through associations with and activation of the IKK 
complex. IKKα, IKKβ and NEMO are all required for this NF-κB activation, unusual as 
IKKα is considered essential in non-canonical rather than canonical NF-kB signalling 
(Pringle et al., 2012). Moreover, USP6 overexpression contributes to tumour 
pathogenesis in aneurysmal bone cysts, likely by the USP6-induced transcription of 
MMP9 and MMP13 via activation of NF-κB (Ye et al., 2010).  
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Figure 1.8. The NF-κB signalling pathway.  Diagram of the cascade of events in TNFα- and IL-1-
induced NF-κB activation. Ubiquitin-mediated recruitment of proteins, via K63-, K11- and linear 
polyubiquitin chains, results in the activation and K63-linked polyubiquitination of TAK1 which 
phosphorylates the IKK complex for subsequent IκB phosphorylation, K48-linked 
polyubiquitination and degradation. Free from its inhibitory proteins, this allows the translocation 
of the NF-κB dimer, p65/p50, to the nucleus for the transcriptional activation of a wide array of 
NF-κB target genes. Ubiquitination of proteins is represented by orange circles. The 
phosphorylation of proteins is represented by grey circles. Many known DUBs are listed at their 
target substrates. USP4 is highlighted in pink.  
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1.3.5.7  Non-canonical NF-κB signalling 
The canonical (also called classical) NF-κB signalling pathway is initiated by signals 
through receptors including TNFRs, IL-1Rs and TLRs and mainly leads to the IKKβ-
dependent phosphorylation of IκBα for the nuclear translocation and activation of NF-
κB, usually p65/p50 heterodimers. The NEMO subunit of IKK is also required for this 
response, whereas the IKKα subunit may be redundant. Alternatively, NF-κB can be 
activated through the less well studied non-canonical (also called alternative) pathway 
(Figure 1.9). The non-canonical pathway can be induced by ligands through members of 
the TNF family receptors; CD40 ligand (CD40L), B-cell activating factor belonging to 
the TNF family (BAFF) and lymphotoxin-β (LT-β) receptor (Coope et al., 2002, Claudio 
et al., 2002, Dejardin et al., 2002). This pathway is dependent on IKKα which 
phosphorylates p100 of a p100/RelB dimer to mediate its partial processing by 
ubiquitination and proteasomal degradation to yield NF-κB subunit p52, resulting in the 
nuclear translocation of p52/RelB dimers for transcriptional activation (Bonizzi and 
Karin, 2004). Upstream of the IKK complex, the non-canonical pathway also differs to 
the canonical pathway in terms of the signalling cascade leading to the activation of IKK. 
A key component essential in the non-canonical pathway is the NF-κB-inducing kinase 
(NIK), a Ser/Thr kinase in the MAPKKK family which, when activated, phosphorylates 
IKKα for downstream activation of NF-κB (Ling et al., 1998). NIK is kept under strict 
regulation by ubiquitination to prevent uncontrolled activation of the pathway which can 
lead to disorders including inflammation and autoimmune disorders. This regulation 
requires the proteasomal degradation of NIK by a complex of TRAF2, TRAF3 and 
cIAP1/2. In unstimulated cells, TRAF2 recruits E3 ligases cIAP1/2 to TRAF3-bound NIK 
which binds to an IAP binding motif (IBM) on NIK and mediates its ubiquitination for 
degradation (Zarnegar et al., 2008, Varfolomeev et al., 2007). This results in suppression 
of p100 processing and reduced expression of NF-κB target genes. When the non-
canonical pathway is induced, this complex is dissociated and TRAF2 and TRAF3 are 
degraded, resulting in the stabilisation and activation of NIK, and consequently the 
downstream NIK-mediated phosphorylation of IKKα and processing of p100 required for 
NF-κB activation (Lee et al., 2014). 
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Figure 1.9. The non-canonical NF-κB signalling pathway. Diagram of the cascade of events in non-
canonical NF-κB activation. Ubiquitin-mediated proteasomal degradation of the TRAF2-TRAF3-
cIAP1/2 complex allows the phosphorylation of IKKα by NIK which in turn phosphorylates p100 for 
its subsequent proteasome-mediated processing to p52. The NF-κB dimer p52/RelB can then 
translocate to the nucleus for the transcriptional activation of NF-κB target genes. Ubiquitination of 
proteins is represented by orange circles. The phosphorylation of proteins is represented by grey 
circles.  
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The many NF-κB-inducing stimuli activating the canonical or non-canonical pathway, 
the array of NF-κB target genes involved in different biological processes including 
immune and inflammatory responses, and the disorders and diseases linked to NF-κB 
activity dysregulation all highlight the diversity of NF-κB responses and the need for tight 
regulation through multiple levels of positive and negative regulators. Furthermore, there 
is crosstalk between NF-κB and parallel signalling pathways to regulate its response 
(Oeckinghaus et al., 2011). As discussed, RLRs can activate NF-κB transcription 
initiation as well as IRF3 activation for IFN-β production (Yoneyama et al., 2015). The 
gatekeeper for NF-κB signalling is the IKK complex as this mediates the phosphorylation 
of IκB for its ubiquitination, degradation and release of NF-κB. The IKK complex is 
activated by RIG-I signalling for downstream activation of NF-κB but many proteins 
upstream of the IKK complex, such as TAK1, are also critical in other signalling 
pathways including MAPK pathways (Ajibade et al., 2013).  
 The MAPK pathways 
MAPKs are Ser/Thr kinases that mediate signalling pathways involved in diverse 
biological processes including inflammation, proliferation, differentiation, survival and 
apoptosis. The MAPK pathways are activated by stimuli such as cytokines, peptide 
growth factors and cellular stresses to induce a cascade of phosphorylation events leading 
to the activation of transcription factors, for instance AP-1 and NF-κB, for the expression 
of a wide array of genes (Kim and Choi, 2010). The MAPK family comprises 
extracellular signal-related kinase 1/2 (ERK1/2), p38α/β/γ/δ and c-Jun NH2-terminal 
kinases (JNKs) which form three distinct MAPK signalling cascades. All of these involve 
a MAPKKK which phosphorylates and activates a MAPK kinase (MAPKK) which can 
then phosphorylate and activate MAPK for the downstream signalling and 
phosphorylation of further components of the MAPK pathway (Figure 1.10). These 
signalling cascades rely on a series of scaffolding proteins for the formation of complexes 
required for transduction of the signal. Dysregulation in the MAPK signalling pathways 
has been implicated in the pathogenesis of diseases including cancers and 
neurodegenerative diseases (Kim and Choi, 2010). 
1.3.6.1  The ERK pathway 
Stimulation of the ERK MAPK pathway activates Ras GTPase which activates the 
MAPKKK Raf (A-Raf, B-Raf or Raf-1). This in turn phosphorylates and activates the 
MAPKK MEK1/2 which phosphorylates and activates ERK1/2.  
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1.3.6.2  The JNK pathway 
Stimulation of the JNK MAPK pathway activates MAPKKKs, including apoptosis 
signal-regulating kinase 1 (ASK1), MAP and ERK kinase kinase (MEKK1) or TAK1; 
which in turn phosphorylate MAPKKs, including MKK4 or MKK7; which phosphorylate 
and activate JNK. 
1.3.6.3  The p38 pathway 
Stimulation of the p38 pathway activates the same MAPKKKs as in the JNK pathway; 
ASK1, MEKK1 or TAK1, which phosphorylate and activate MAPKKs, MKK3 or 
MKK6, to phosphorylate and activate p38.  
 
Figure 1.10. The MAPK pathways. Upon stimulation of the pathway, a MAPKKK phosphorylates 
and activates a MAPKK which in turn phosphorylates and activates a MAPK leading to the 
activation of transcription factors, such as AP-1, Elk-1/SRF and NF-κB.  
  
Raf ASK1 MEKK1
MEK MKK4 MKK7
ERK JNK p38
MAPKKK
MAPKK
MAPK
TAK1
MKK3 MKK6
NUCLEUS
AP-1
Elk-1/SRF
NF-κB Target genes
Chapter 1: Introduction 
 
39 
 
 Implications of USP4 functions in cell signalling pathways on 
disease pathogenesis 
Due to the wide functioning of ubiquitin signalling in a variety of cellular processes 
including protein degradation, cell signalling, DNA damage repair and gene expression, 
dysregulation may have damaging consequences to the cell. It may lead to accumulation 
of proteins, improper activation or deactivation of cell signalling pathways or inefficient 
DNA repair which can all contribute to the pathogenesis of diseases such as autoimmune 
and neurodegenerative disorders and cancers (Popovic et al., 2014). 
1.3.7.1  USP4 in cancer pathogenesis 
As previously discussed, early studies documented elevated expression of USP4 in human 
lung cancers and primary cell lines, although in contrast, others reported reduced 
expression in small cell lung carcinoma cell lines (Gray et al., 1995, Frederick et al., 
1998). More recently, evidence suggests that USP4 acts to regulate ubiquitination in 
multiple cellular pathways including both tumour-suppressing and tumour-promoting 
pathways which have been discussed in this chapter. In the p53 pathway USP4 stabilises 
ARF-BP1, a p53 E3 ligase which ubiquitinates p53 for proteasomal degradation thereby 
reducing levels of the p53 tumour suppressor (Zhang et al., 2011). Consistent with the 
potential oncogenic properties of USP4, the same study also reported overexpression of 
USP4 in human cancer samples, particularly in urinary bladder and prostate cancer 
samples and elevated levels of p53 in Usp4 null MEFs with premature senescence and 
increased apoptosis of these cells. Together these data suggest that through regulation of 
p53 USP4 displays oncogenic properties. Moreover, USP4 enhances TGF-β signalling by 
deubiquitinating and maintaining the stability of TβR-I at the plasma membrane (Zhang 
et al., 2012). TGF-β is a known inducer of epithelial-to-mesenchymal transition (EMT), 
a highly regulated process in normal embryo development and also implicated in cancer 
progression and metastasis (Xu et al., 2009a). TGF-β production is increased in cancer 
cells which induces EMT through the function of TβR-I and causes invasion of cells. The 
mechanism of TGF-β-induced EMT can involve many of the Smad proteins or can occur 
through non-Smad activation of MAPKs, Rho GTPases and the PI3 kinase/Akt pathway, 
which all can contribute to the transcriptional activation of genes which suppress 
epithelial marker gene expression and activate mesenchymal gene expression that defines 
EMT (Deckers et al., 2006, Xu et al., 2009a). USP4 increases expression of EMT marker 
genes with TGF-β induction and increases TβR-I-dependent invasion in a zebrafish 
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embryo xenograft invasion-metastasis model, indicating that TGF-β-induced cancer 
invasion and metastasis is enhanced by USP4 (Zhang et al., 2012). This again supports 
an oncogenic function for USP4. 
Besides p53 and TGF-β signalling, USP4 is also functions in TNFα- and IL-1-mediated 
NF-κB signalling. Although predominantly recognised for its role in inflammation and 
immunity, NF-κB signalling is also linked to the progression of cancers (Popovic et al., 
2014, Ben-Neriah and Karin, 2011). Activation of the NF-κB pathway activates 
proinflammatory cytokines and chemokines as well as many other genes including those 
involved in cell survival, proliferation, migration and invasion. Dysregulation of the NF-
κB pathway or persistent activation can lead to chronic inflammation and eventually 
promotion of cancer development and progression through NF-κB-mediated gene 
expression. In fact, many cancers have constitutively active NF-κB (Pal et al., 2014). 
TNFα signalling is linked to many cancers, including increasing migration of breast 
cancer cells (Wu et al., 2009). USP4 is reportedly a negative regulator of NF-κB 
signalling with substrates including TAK1, TRAF2 and TRAF6. Further, depletion of 
USP4 promotes TNFα-induced migration in a human lung adenocarcinoma cell line, 
indicating USP4 may display tumour suppressor properties in the context of TNFα 
signalling, potentially though regulation of NF-κB (Xiao et al., 2012). Additionally, USP4 
acts as a negative regulator of the Wnt signalling pathway. Dysregulation of the Wnt 
pathway can lead to tumourigenesis and so USP4 may act as a tumour suppressor through 
its actions in suppressing this pathway (Zhao et al., 2009). These contrasting reports on 
the function of USP4 in the pathogenesis of cancers suggest USP4 may possess oncogenic 
and tumour suppressor properties depending on the substrate and in a context-dependent 
manner. 
1.3.7.2  USP4 in inflammation and the immune response 
The NF-κB pathway is critical in inflammation and the immune response, the activation 
of which induces the expression of a variety of proinflammatory cytokines and 
chemokines. As such, aberrations in this signalling pathway have been linked to chronic 
inflammation and multiple immunological disorders (Makarov, 2000). USP4 is reported 
to act as a negative regulator by deubiquitinating components TAK1, TRAF2 and TRAF6 
thus attenuating the TNFα- and IL-1-induced NF-κB signal and proinflammatory 
response. Furthermore, usp4-depleted zebrafish embryos are more susceptible to LPS-
mediated endotoxin challenge and express higher levels of proinflammatory cytokines 
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indicating that USP4 is essential in negatively regulating the IL-1-mediated immune 
response and in preventing chronic inflammation (Fan et al., 2011b, Zhou et al., 2012, 
Xiao et al., 2012).  
USP4 is also implicated in the RIG-I immune signalling pathway which activates 
immunes cells to produce type I IFNs and proinflammatory cytokines in response to viral 
infection (Yoneyama et al., 2015). In this context, USP4 is reported to deubiquitinate and 
stabilise RIG-I to enhance RIG-I signalling and IFN-β, a critical factor in innate immune 
responses. Moreover, overexpression of USP4 decreased viral replication in cells infected 
with VSV, a virus recognised by RIG-I, and siRNA-mediated depletion of USP4 
increased viral replication in VSV infected cells (Wang et al., 2013). As well as 
controlling immune homeostasis through the negative regulation of NF-κB, USP4 
potentially plays an important role in the antiviral immune response through positive 
regulation of RIG-I-mediated IFN-β signalling.  
Reports to date have identified roles of USP4 in cell signalling pathways which may 
potentially be important in the pathogenesis of cancers and inflammation. However, the 
physiological substrates, how USP4 itself is regulated and how dysregulation of USP4 
may lead to pathologies in these pathways are incompletely defined. Understanding the 
mechanistic actions of USP4 in tightly regulating inflammatory, cell proliferation and 
apoptotic pathways may provide targets for therapies of inflammatory diseases and 
cancers.   
 Post-translational modifications (PTMs) 
The function of a wide number of proteins can be regulated by PTMs: ubiquitination, 
sumoylation, phosphorylation, methylation and acetylation can all control the activity of 
proteins in a dynamic and reversible way. PTMs can influence the activity of enzymes, 
protein-protein interactions, protein stability and the subcellular localisation of proteins 
(Kessler and Edelmann, 2011). The function of ubiquitination within cell signalling 
pathways is apparent and, similarly, other PTMs are crucial in the regulation of cell 
signalling pathways and other biological processes underlining the significance of this 
mechanism in regulating the activity of proteins. Proteins can undergo more than one 
modification and there is much crosstalk between the different types of PTMs. Recently 
it has been reported that ubiquitin itself can be subjected to phosphorylation to alter its 
structure, ubiquitin chain assembly and the hydrolysis of ubiquitin chains; thus adding 
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further complexity to ubiquitin signalling and the regulation of proteins by PTMs (Wauer 
et al., 2014). 
 Importance of PTMs in cell signalling pathways 
As well as ubiquitination of proteins in cell signalling pathways, phosphorylation also 
plays a critical role in their co-ordination. In fact there is much crosstalk between 
ubiquitination and phosphorylation to mediate the tight regulation of these pathways 
(Karin and Ben-Neriah, 2000). This can be highlighted by the integral step in NF-κB 
signalling in which the initial phosphorylation of IκB is required for the ubiquitination 
and subsequent degradation of IκB, catalysed by the E3 ligase SCFβ-TrCP. SCFβ-TrCP only 
recognises the phosphorylated form of IκB and so phosphorylation mediates interactions 
between IκB and this E3 ligase. This ensures it is only degraded when the pathway is 
activated and upstream events lead to the IKK-mediated phosphorylation of IκB, thereby 
adding an extra level of control in the activation of NF-κB (Spencer et al., 1999). As well 
as creating a phosphodegron for the recognition of E3 ligases, phosphorylation can 
crosstalk with ubiquitination by altering the subcellular localisation of ubiquitin 
signalling components to allow them to function at the correct location within the cell 
(Yuan et al., 2010). Conversely, ubiquitination can crosstalk with phosphorylation 
through the degradation of protein kinases or the activation of protein kinases, as occurs 
when TAK1 becomes polyubiquitinated within the NF-κB pathway (Fan et al., 2010).  
The most studied PTMs are phosphorylation and ubiquitination, however, other PTMs 
exist which also provide another level of regulation within signalling pathways. As 
mentioned, the phosphorylation of p65 at Ser276 by PKA promotes its interaction with 
CBP/p300 for p65 activation. This in turn leads to the acetylation of p65 at Lys310 to 
facilitate the recruitment of factors required for transcriptional activity (Diamant and 
Dikstein, 2013).  
 Regulation of DUBs by PTMs 
DUBs are vital regulators in cell signalling pathways and many other diverse cellular 
processes and are themselves modulated by ubiquitin binding, binding of scaffold and 
adaptor proteins, and also PTMs to regulate their activity and function (Kessler and 
Edelmann, 2011). PTMs can regulate DUB protein interactions as already discussed using 
the example of USP1 for which its phosphorylation at Ser313 mediates its interaction 
with UAF1 (Villamil et al., 2012). PTMs can also enhance or reduce the activity of DUBs. 
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Under normal conditions, CYLD deubiquitinates TRAF2 to downregulate NF-κB 
activation but its TNFα-mediated phosphorylation suppresses the ability of CYLD to 
deubiquitinate TRAF2 thus leading to downstream activation of NF-κB (Reiley et al., 
2005). Conversely, the phosphorylation of A20 by IKKβ enhances the ability of A20 to 
suppress NF-κB activation (Hutti et al., 2007). Additionally, PTMs can regulate the 
subcellular localisation of DUBs. In unstressed cells, USP10 stabilises p53 in the 
cytoplasm, but after induced DNA damage ATM-mediated phosphorylation of USP10 
translocates it to the nucleus for the stabilisation of nuclear p53 (Yuan et al., 2010). 
 USP4 PTMs 
Given the mechanism of regulation of other DUBs by their PTMs, it is likely that USP4 
is subjected to PTMs for its regulation. One mechanism of regulation for USP4 in the 
TGF-β signalling pathway is through its phosphorylation at Ser445 by AKT. TGF-β-
induced AKT activation leads to the translocation of USP4 from the nucleus to the 
cytoplasm and plasma membrane where USP4 stabilises TβR-I and enhances TGF-β 
signalling (Zhang et al., 2012). In Wnt signalling, USP4 interacts with the kinase Nlk 
which promotes its nuclear translocation. Although not examined in this study, Nlk may 
regulate the subcellular localisation of USP4 by phosphorylation, similarly to Akt-
mediated phosphorylation in TGF-β signalling (Zhao et al., 2009). 
In addition to phosphorylation, USP4 is also subjected to ubiquitination by the E3 ligase 
Ro52 (Wada and Kamitani, 2006b). Although this ubiquitination does not appear to affect 
the stability of USP4, other ways in which it may regulate USP4 have not been explored.  
Further to these, and many other studies, which have identified examples of PTMs in the 
regulation of DUBs, several proteomic and high-throughput studies have mapped 
multiple other residues which are modified by PTMs. The mechanism of how these PTMs 
regulate DUBs is only just beginning to be revealed but the potential for the regulation of 
DUBs by these is extensive and may provide insight into the biological significance of 
these proteins. In addition to its phosphorylation at Ser445, studies have identified a 
multitude of phosphorylation and ubiquitination sites which may play a part in the 
function of USP4 (PhosphoSitePlusTM: www.phosphosite.org). Since many DUBs, 
including USP4, have been implicated in many diseases, knowledge on the PTM-
mediated regulation of these DUBs may provide further therapeutic targets.  
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 Aims 
When this study first began the role of USP4 in any single cell signalling pathway had 
not been well studied. Ubiquitin signalling is key to the tight regulation of many cell 
signalling pathways in maintaining homeostasis and preventing pathological diseases and 
so the initial aim of this thesis will be to examine whether USP4 functions in any of these 
key pathways and what its role may be. As reports have emerged implicating USP4 in the 
regulation of NF-κB signalling, more focus will be given to the mechanism by which 
USP4 acts in this pathway and immune responses. An RNAi approach to deplete USP4 
and overexpression of Usp4 will be utilised to examine effects on NF-κB signalling. Also, 
Usp4 null mouse embryonic fibroblasts, established from Usp4 null mice, which are 
phenotypically normal, will also be utilised for examining effects on the loss of Usp4 in 
NF-κB signalling. In addition, establishing the effect of the phosphorylation of Usp4 
through generation of a series of Usp4 phosphorylation mutants, particularly effects on 
NF-κB signalling, will also be examined.  Therefore the main aims of this thesis will be: 
 Determine the cell signalling pathways that Usp4 may regulate 
 Examine the function of USP4 in the IL-1- and TNFα-induced NF-κB cell signalling 
pathway 
 Identify potential target substrates of USP4 in the NF-κB signalling pathway 
 Examine the regulation of Usp4 by the PTM at serines 675 and 680, with particular 
focus on effects on the NF-κB signalling pathway 
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Chapter 2 : Materials and Methods 
 Materials 
 Antibodies 
All primary antibodies used are listed in Table 2.1. Polyclonal goat anti-mouse and anti-
rabbit immunoglobulins/HRP were purchased from Dako (Cambridgeshire, UK).  
Table 2.1. Antibodies used for immunoblotting and immunoprecipitation experiments. All antibodies 
were purchased from either Cell Signaling Technology (Beverly, MA, USA), Santa Cruz 
Biotechnology (CA, USA), Sigma-Aldrich (Poole, UK), Millipore (Watford, UK), Abcam 
(Cambridge, UK) or Caltag Medsystems Ltd. (Buckingham, UK) as stated.  
Antibody Species Monoclonal
/Polyclonal 
Purchased 
from 
Catalogue 
number 
Dilution  
(Immunoblotting) 
IκBα Mouse Monoclonal Cell Signaling 
Technology  
#4814 1:1000 
Phospho-IκBα 
(Ser32)  
Rabbit Monoclonal Cell Signaling 
Technology 
#2859 1:1000 
NF-κB p65 Rabbit Monoclonal Cell Signaling 
Technology  
#8242 1:1000 
NF-κB phosho-p65 
(Ser536) 
Rabbit Monoclonal Cell Signaling 
Technology  
#3033 1:1000 
IKKα Rabbit Polyclonal Cell Signaling 
Technology  
#2682 1:1000 
IKKβ Rabbit Monoclonal Cell Signaling 
Technology  
#2370 1:1000 
Phospho-IKKα/β 
(Ser176/180) 
Rabbit Monoclonal Cell Signaling 
Technology  
#2697 1:1000 
Phospho-p38 MAPK 
(Thr180/Tyr182) 
Rabbit Polyclonal Cell Signaling 
Technology  
#9211 1:1000 
p44/42 MAPK 
(ERK1/2) 
Rabbit Polyclonal Cell Signaling 
Technology  
#9102 1:1000 
Phospho-p44/42 
MAPK (ERK1/2) 
(Thr202/Tyr204) 
Rabbit Polyclonal Cell Signaling 
Technology  
#9101 1:1000 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
Rabbit Polyclonal Cell Signaling 
Technology  
#9251 1:1000 
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TRAF6 Rabbit Monoclonal Cell Signaling 
Technology 
#8028 1:1000 
TRAF2  Rabbit Polyclonal Cell Signaling 
Technology 
#4724 1:1000 
TAK1 Rabbit Polyclonal Caltag 
Medsystems 
PSI-3385 1:1000 
NIK Rabbit Polyclonal Caltag 
Medsystems 
PSI-1129 1:1000 
IRAK Rabbit Polyclonal Caltag 
Medsystems 
PSI-1007 1:1000 
USP4 Rabbit Polyclonal Cell Signaling 
Technology 
#2651 1:1000 
GFP Rabbit Polyclonal Santa Cruz 
Biotechnology 
sc-8334 1:1000 
Anti-FLAG M2 Mouse Monoclonal Sigma-Aldrich F1804 1:1000 
Anti-phosphoserine  Rabbit Polyclonal Millipore AB1603 1:500 
Anti-glyceraldehyde-
3-phosphate 
dehydrogenase 
(GAPDH) 
Mouse Monoclonal Millipore MAB374 1:40 000 
Anti-HA tag (HA C5) Mouse Monoclonal Abcam ab18181 1:1000 
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 Immunoblotting reagents 
Ammonium persulphate (APS), β-mercaptoethanol, bovine serum albumin (BSA), 
polyoxyethylene sorbitan (Tween-20), N,N,N’,N’-Tetramethylethylenediamine 
(TEMED), Triton X-100 and Kodak high-speed X-ray film were all purchased from 
Sigma-Aldrich (Poole, UK). A standard stock solution of BSA was purchased from Pierce 
& Warriner (Chester, UK). BradfordUltra reagent was purchased from Expedeon 
(Cambridge, UK). A 37.5:1 mix of acrylamide/bis-acrylamide was purchased from 
Severn Biotech Ltd. (Worcestershire, UK). PageRuler™ pre-stained protein ladder was 
purchased from Thermo Scientific (Leicestershire, UK). Immobilon-P polyvinylidene 
difluoride (PVDF) 0.45µM membrane and Immobilon western chemiluminescent HRP 
substrate were purchased from Millipore (Watford, UK). Enhanced chemiluminescence 
(ECL) and ECL-advanced western blotting detection reagents were purchased from GE 
Healthcare Life Sciences (Buckinghamshire, UK). Marvel non-fat dry milk powder was 
purchased from Premier Foods (St. Albans, UK).  
 Cell lines 
2.1.3.1 SW1353 
SW1353 cells were purchased from the American Type Culture Collection (ATCC) 
(HTB-94) and cultured in Dulbecco’s Modified Eagle’s Medium: Nutrient Mixture F-12 
(DMEM/F-12) culture medium as described in section 2.2.1. This cell line initiated from 
a primary grade II chondrosarcoma in the right humerus of a 72 year old Caucasian female 
in 1977, full details of which can be found on the ATCC website (www.atcc.org).  
2.1.3.2 HeLa 
The HeLa cell line initiated from the cervical adenocarcinoma of a 31 year old female 
and were cultured in DMEM as described in section 2.2.1. Full details can be found on 
the ATCC website (www.atcc.org).  
2.1.3.3 HEK 293T 
HEK 293T cells were purchased from the ATCC and cultured in DMEM as described in 
section 2.2.1. This cell line initiated in the human embryonic kidney cells of a foetus, full 
details of which can be found on the ATCC website (www.atcc.org).   
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2.1.3.4 Usp4+/+ and Usp4-/- mouse embryonic fibroblasts (MEFs) 
MEFs were obtained from wild-type (Usp4+/+) and Usp4 null (Usp4-/-) mouse embryos 
and prepared and cultured as described in section 2.2.1.1. 
2.1.3.5 U2OS 
U2OS cells were obtained from the ATCC (HTB-96) and cultured in DMEM as described 
in section 2.2.1. This cell line initiated from osteosarcoma in the bone of a 15 year old 
Caucasian female, full details of which can be found on the ATCC website 
(www.atcc.org).  
2.1.3.6 NIH3T3 
NIH3T3 cells were purchased from the ATCC and cultured in DMEM as described in 
section 2.2.1. This cell line initiated from mouse fibroblasts, full details of which can be 
found on the ATCC website (www.atcc.org).  
 Cell culture reagents 
DMEM/F-12 and DMEM culture media were both purchased from Gibco, Life 
Technologies Ltd. (Paisley, UK). Foetal bovine serum (FBS), Dulbecco’s phosphate 
buffered saline (PBS), trypsin-EDTA (derived from porcine pancreas), L-glutamine, 
penicillin-streptomycin, and dimethyl sulphoxide (DMSO), were purchased from Sigma-
Aldrich (Poole, UK).  
 Transfection reagents 
DharmaFECT Transfection Reagent 1 was used for transfection of cells with siGENOME 
SMARTpool small interfering RNAs (siRNAs) or siGENOME Non-targeting Pool #2 
(siControl), all purchased from Dharmacon (Leicestershire, UK). For transient 
transfections with plasmid DNA, Attractene transfection reagent purchased from 
QIAGEN (West Sussex, UK), GeneJuice transfection reagent purchased from Merck 
Millipore (Watford, UK) or FuGENE HD transfection reagent purchased from Promega 
(Southampton, UK) were used.   
 Plasmids 
pCMV6-AN-mGFP was purchased from OriGene Technologies (MD, USA) and used as 
the backbone for all Usp4 mutant plasmids.  The following plasmids were obtained from 
Addgene: FLAG-TRAF6-wt (21624) and p-EBG-TRAF2 (GST) (21586) both deposited 
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by John Kyriasis, pRK5 Myc-RIP1 (44159) and pcDNA3 TAK1/F (44161) both 
deposited by Xin Lin, psPAX2 (12260) deposited by Didier Trono, pCMV-VSV-G 
(8454) deposited by Bob Weinberg, pRK5-HA-Ubiquitin-WT (17608), pRK-HA-
Ubiquitin-K48 (17605) and pRK5-HA-Ubiquitin-K63 (17606) all deposited by Ted 
Danson and pHAGE NF-κB-TA-LUC-UBC-GFP-W (49343) deposited by Darrell 
Kotton. NF-κB firefly luciferase reporter and pRL-TK Renilla expression vectors were a 
gift from Dr Matt Barter (Newcastle University, Newcastle, UK). pCDH-EF1-MCS-
IRES-GFP lentiviral expression vector was purchased from System Biosciences 
(Cambridge, UK). pLVX-Tet-ON Advanced, pLVX-Tight-Puro and Lenti-X HTX 
Packaging Mix were all purchased from Clontech (Paris, France).  
 Cytokines and other stimuli 
Tumour necrosis factor α (TNFα) was purchased from Sigma-Aldrich (Poole, UK) and 
stored at -20oC in sterile filtered PBS. Doxycycline hyclate was also purchased from 
Sigma-Aldrich (Poole, UK). Recombinant human interleukin-1α (IL-1α) was a gift from 
GlaxoSmithKline (Stevenage, UK).   
 Inhibitors 
MG132 (carbobenzoxy-Leu-Leu-leucinal) proteasome inhibitor and N-ethylmaleimide 
(NEM) deubiquitinase inhibitor were purchased from Sigma-Aldrich (Poole, UK). NEM 
was reconstituted in ethanol as per the manufacturer’s instructions.  
 Immunohistochemistry reagents and antibodies 
The Vectastain® Elite® ABC kit used for immunohistochemical staining was purchased 
from Vector Laboratories (Peterborough, UK). VSV primary antibody was a gift from the 
laboratory of Dr John Bell (Ottawa Hospital Research Institute, Ottawa University, 
Ottawa, Canada). D.P.X. mounting medium was purchased from Sigma-Aldrich (Poole, 
UK). 
 General molecular biology reagents 
Ampicillin and Luria-Broth (LB) EZMixTM powder were purchased from Sigma-Aldrich 
(Poole, UK). Bacto Agar was purchased from Scientific Laboratory Supplies 
(Nottingham, UK). Molecular biology grade agarose was purchased from Severn Biotech 
Ltd. (Worcestershire, UK). S.O.C medium and Subcloning Efficiency™ DH5α™ 
Competent Cells were purchased from Invitrogen, Life Technologies Ltd. (Paisley, UK). 
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GeneRulerTM 100bp and 1kb DNA ladders, Rapid DNA Ligation kit and FastDigest® 
restriction enzymes and FastDigest® Green buffer were purchased from Fermentas, 
Thermo Fisher Scientific (Leicestershire, UK). Cells-to-cDNA II lysis buffer was 
purchased from Ambion, Ambion (Europe) Ltd. (Huntingdon, UK).  Random hexamers 
p(dN)6 were synthesised by Integrated DNA Technologies (IDT) (Leuven, Belgium).  
Deoxyribonucleotide triphosphate (dNTP) mix was purchased from Bioline (London, 
UK). RNase-, DNase-free water and all real-time reverse transcriptase quantitiative 
polymerase chain reaction (real-time qRT-PCR) primers and probes and regular desalted 
oligonucleotides were purchased from Sigma-Aldrich (Poole, UK). Probe library probes 
were purchased from Roche, Roche Diagnostics Ltd. (West Sussex, UK). Moloney 
Murine Leukaemia Virus (M-MLV) reverse transcriptase, 5X First Strand Buffer and 
100mM DTT were all purchased from Invitrogen, Life Technologies Ltd. (Paisley, UK) 
and TaqMan® gene expression master mix was purchased from Applied Biosystems, Life 
Technologies Ltd. (Paisley, UK). Protein G PLUS-Agarose was purchased from Santa 
Cruz Biotechnology (CA, USA). Phire Reaction Buffer and Phire Hot Start II DNA 
Polymerase were purchased from Thermo Scientific (Leicestershire, UK). Stellar 
Competent Cells were purchased from Takara Bio Europe/Clontech (Paris, France). 
Vectorshield® Mounting Medium for Fluorescence was purchased from Vector 
Laboratories (Peterborough, UK). 
All standard laboratory chemicals and reagents were commercially available from Sigma-
Aldrich, Thermo Scientific or Invitrogen, Life Technologies unless otherwise indicated.  
 Commercially available kits 
Rapid DNA ligation kit was purchased from Fermentas, Thermo Fisher Scientific 
(Leicestershire, UK). Cignal Finder Reporter Array and QIAquick Gel Extraction kits 
were purchased from QIAGEN (West Sussex, UK). QuikChange II XL Site-directed 
Mutagenesis Kit was purchased from Agilent Technologies (Santa Clara, CA, USA). 
PureYieldTM Plasmid Mini/Maxiprep, Dual-Luciferase® Reporter Assay and Dual-Glo® 
Luciferase Reporter Assay Systems were purchased from Promega (Southampton, UK). 
Mouse ProInflammatory 7-Plex Ultra-Sensitive Kit was purchased from Meso Scale 
Discovery®, Meso Scale Diagnostics (Gaithersburg, MD, USA). Mouse IL-6 Quantikine 
ELISA and Mouse CXCL1 Quantikine ELISA kits were purchased from R&D Systems® 
(Abingdon, UK).  Extract-N-AmpTM Tissue PCR Kit was purchased from Sigma-Aldrich 
(Poole, UK). In-Fusion® HD Cloning kit and Lenti-X™ qRT-PCR Titration kit were 
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purchased from Takara Bio Europe/Clontech (Paris, France). NucleoSpin® Gel & PCR 
Clean-up kit was purchased from Machery-Nagel (Düren, Germany). 
 Culture vessels 
Tissue culture plates (96-, 48-, 24-, 12- and 6-well), 75cm2 and 162cm2 vented cell culture 
flasks were purchased from Corning/Costar (Sunderland, UK). Flat-bottomed non-sterile 
96-well plates and 30ml universals were purchased from Greiner Bio-One (Stonehouse, 
UK). Falcon tubes (15ml and 50ml), scrapers and 10cm cell culture dishes were purchased 
from Cellstar (Leicestershire, UK). Eppendorf-equivalent tubes (0.6ml and 1.5ml) were 
purchased from Starlab (Milton Keynes, UK).  
 Methods 
 Cell culture 
Reagents 
 HEK 293T, HeLa, U2OS, NIH3T3 and MEF culture medium: DMEM containing 
2mM L-glutamine, 100U/ml penicillin, 100µg/ml streptomycin and 10% (v/v) FBS 
 SW1353 culture medium: DMEM/F12 containing 2mM L-glutamine, 100U/ml 
penicillin, 100µg/ml streptomycin and 10% (v/v) FBS 
 Freezing medium: 90% (v/v) FBS and 10% (v/v) DMSO  
Method 
Cells were plated into vented T75cm2 flasks and cultured at 37°C with 5% CO2 (v/v) in a 
humidified incubator until they reached approximately 80% confluence. Cells were 
washed with PBS and detached by incubation with trypsin-EDTA to be passaged into 
further T75cm2 flasks for continuation of the line every 2-3 days, or into the appropriate 
culture vessel for experimentation. For long-term storage in liquid nitrogen, cells were 
resuspended in freezing medium, transferred to cryovials, and frozen slowly at -80°C 
overnight before being transferred for storage in liquid nitrogen.  
2.2.1.1 Usp4 +/+ and Usp4 -/- MEF preparation 
Mice containing an inactivating retroviral provirus in the Usp4 gene (strain TF 2497) 
(Figure 2.1) were purchased from Taconic Laboratories (Hudson, New York, USA). 
Crosses were performed between mice previously determine by PCR-based genotyping 
to be heterozygous (details of the genotyping are provided in section 2.2.9). 
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Pregnant female mice were sacrificed between day E13.5 and E15.5. Under sterile 
conditions the embryos were removed from the uterus, individual embryo sacs were cut 
and rinsed in PBS. After removing each embryo from its yolk sac, the head and internal 
organs of the embryos were removed and the remaining tissue was incubated in trypsin-
EDTA at 37°C for 10 minutes before pipetting up and down to homogenise. To allow 
genotyping of the embryos, as described in section 2.2.9, a small piece of tail was cut and 
stored at -20°C until required. Next, 5ml of MEF culture medium (DMEM) was added 
and the cell suspension was centrifuged at 300 x g for 5 minutes. Medium was aspirated 
and cells resuspended in fresh DMEM before being plated into 10cm dishes at 37°C with 
5% CO2 (v/v) in a low oxygen (3%) (v/v) incubator until approximately 80% confluent. 
The cell culture was then continued, transferred to the relevant culture vessel for 
experimentation, or stored in liquid nitrogen as described in section 2.2.1. 
 
Figure 2.1. Schematic of the retroviral insertion in the Usp4 gene. 
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 Generation and use of expression vectors 
Usp4 and mutant versions of Usp4 were transiently transfected into cells to study effects 
of Usp4 overexpression in NF-κB signalling. First, a range of Usp4 mutant constructs 
were designed to incorporate Usp4 within a pCMV-AN-mGFP vector (OriGene 
Technologies, MD, USA). Wild-type Usp4 and a catalytically inactive version of Usp4 
(C311A), a gift from Dr Doug Gray (Ottawa Hospital Research Institute, Ottawa, 
Canada), were cloned into the pCMV6-AN-mGFP vector (section 2.2.2.1). Other 
versions of Usp4 were then created by mutagenesis of the phosphorylation sites: serines 
675 and 680 of the wild-type pCMV-AN-Usp4-mGFP vector (section 2.2.2.2).  
2.2.2.1 Cloning 
For cloning, all restriction enzymes used were FastDigest® enzymes in combination with 
10X FastDigest® Green buffer and ligation was performed using the Rapid DNA ligation 
kit (Fermentas, Thermo Scientific, Leicestershire, UK). 
Method 
To subclone the catalytically inactive version of Usp4 (for which a cysteine at the 
catalytic site has been substituted for an alanine: C311A) into the correct vector, Xba I 
and Cla I restriction enzymes were used in a double digest reaction following the 
manufacturer’s protocol. Briefly, reactions were prepared of 2µl 10X buffer, 1µl 
restriction enzymes and either donor or recipient vector made up to 20µl total in nuclease-
free water. After mixing, reactions were incubated at 37°C for 10 minutes before heat 
killing at 80°C for 20 minutes to stop restriction endonuclease activity. Reactions were 
loaded onto a 0.8% (w/v) agarose gel as described in section 2.2.2.5.  
Next, bands of the expected size on the gel were extracted using a QIAquick Gel 
Extraction kit according to the manufacturer’s protocol.  DNA was eluted in 50µl and the 
insert cut from the donor vector was ligated into the recipient vector by a reaction with 
insert and vector at a 3:1 ratio using the Rapid DNA Ligation kit, following the 
manufacturer’s instructions. 1µl of the ligation was then used in bacterial transformation 
as described in section 2.2.2.3. 
2.2.2.2 Site-directed mutagenesis 
To examine the function of Usp4 phosphorylation, two phosphorylation sites at serines 
675 and 680 were mutated by site-directed mutagenesis. Mutagenesis of the pCMV6-AN-
Usp4-mGFP vector was performed using the QuikChange II XL kit (Agilent 
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Technologies, Santa Clara, CA, USA) following the manufacturer’s protocol. Primers 
were designed approximately 16 base pairs (bp) either side of the region to be mutated 
(Table 2.2). 
Method 
For the mutagenesis, a reaction mix was prepared of 5µl 10X reaction buffer, 50ng 
double-stranded DNA (dsDNA) template, 1.25ng forward and reverse mutant primers, 
0.01M dNTP mix, 3µl QuikSolution reagent and made up to 50µl with distilled H2O 
(dH2O) followed by the addition of 2.5U PfuUltra HF DNA polymerase. The reaction 
was cycled following the parameters: 95°C for 2 minutes followed by 18 cycles of 95°C 
for 1 minute, 60°C for 1 minute, 68°C for 1 minute per kb of plasmid length, and a final 
step at 68°C for 7 minutes. Next, 10U Dpn I restriction endonuclease was added to the 
reaction and incubated at 37°C for 1 hour to digest the parental methylated, supercoiled 
dsDNA.  
After mutagenesis, the new mutated plasmid was then transformed into XL10-Gold 
ultracompetent cells following the manufacturer’s protocol. The plasmid sample was 
added to ice-cold XL10-Gold cells with XL10-Gold β-mercaptoethanol mix (β-ME) and 
incubated on ice for 30 minutes. Following a 30 second heat-shock at 42°C, pre-heated 
(42°C) S.O.C. medium was added to the sample and incubated at 37°C with shaking at 
225rpm. After 1 hour’s incubation, the sample was spread onto LB-agar plates 
supplemented with ampicillin, and the mutated plasmids expanded as described in 
sections 2.2.2.3 and 2.2.2.4. 
  
  
 
5
5
 
Table 2.2. Sequences of primers used for the generation of Usp4 mutants by site-directed mutagenesis and the sequencing primer used to verify the presence of the correct 
mutation in plasmids generated by site-directed mutagenesis and In-Fusion cloning. 
Mutant Template Primer Primer sequence Amino acid sequence 
S675A/S680S pCMV-AN-
Usp4-GFP 
Forward 
Reverse 
5’-AGGAAAAGAGCAGCTTGCGGAAGTGGAAGGCAGT-3’ 
5’-ACTGCCTTCCACTTCCGCAAGCTGCTCTTTTCCT-3’ 
GKEQLAEVEGS 
S675S/S680A pCMV-AN-
Usp4-GFP 
Forward 
Reverse 
5’-TTCCGAAGTGGAAGGCGCGGGTGAGGACGATCGG-3’ 
5’-CTGATCGTCCTCACCCGCGCCTTCCACTTCGGAA-3’ 
SEVEGAGEDDQ 
S675D/S680S pCMV-AN-
Usp4-GFP 
Forward 
Reverse 
5’-AGGAAAAGAGCAGCTTGACGAAGTGGAAGGCAGT-3’ 
5’-ACTGCCTTCCACTTCGTCAAGCTGCTCTTTTCCT-3’ 
GKEQLDEVEGS 
S675S/S680D pCMV-AN-
Usp4-GFP 
Forward 
Reverse 
5’-TTCCGAAGTGGAAGGCGATGGTGAGGACGATCAG-3’ 
5’-CTGATCGTCCTCACCATCGCCTTCCACTTCGGAA-3’ 
SEVEGDGEDDQ 
S675D/S680D S675S/S680D Forward 
Reverse 
5’-AGGAAAAGAGCAGCTTGACGAAGTGGAAGGCAGT-3’ 
5’-ACTGCCTTCCACTTCGTCAAGCTGCTCTTTTCCT-3’ 
GKEQLDEVEGD 
S675A/S680D S675S/S680D Forward 
Reverse 
5’-AGGAAAAGAGCAAGCTTGCGGAAGTGGAAGGCGAT-3’ 
5’-ATCGCCTTCCACTTCCGCAAGCTGCTCTTTTCCT-3’ 
GKEQLAEVEGD 
S675D/S680A S675D/S680S Forward 
Reverse 
5’-TGACGAAGTGGAAGGCGCGGGTGAGGACGATCAG-3’ 
5’-CTGATCGTCCTCACCCGCGCCTTCCACTTCGTCA-3’ 
GKEQLDEVEGA 
Method Sequencing primers 
Site-directed mutagenesis  5’-GCTGTTTGTGATCGTATCAG-3’ 
In-Fusion Cloning EF1: 
                  IRES:  
5’-CTCCACGCTTTGCCTGACC-3’ 
5’-CCTCACATTGCCAAAAGACG-3’ 
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2.2.2.3 Transformation 
Reagents 
 LB (EZMix (Sigma-Aldrich, Poole, UK) in dH2O, autoclaved) 
 LB-agar with ampicillin-resistance (LB, Bacto Agar and ampicillin (100µg/ml) in 
dH2O, autoclaved) 
Method 
Plasmid DNA was added to Subcloning Efficiency DH5α Competent Cells and incubated 
on ice for 20 minutes before a 30 second heat-shock at 42°C. S.O.C medium was added 
to the cells and incubated at 37°C with shaking for 1 hour. Next, the transformation 
mixture was spread onto LB-agar plates and incubated at 37°C overnight. The following 
day individual colonies were selected and incubated in 5ml of LB supplemented with 
ampicillin (100µg/ml) at 37°C with shaking at 225rpm. For minipreps, bacteria were 
cultured overnight. For maxipreps, the 5ml bacteria was cultured for approximately 4 
hours before transferring to 250ml of LB supplemented with ampicillin and cultured 
overnight.  
2.2.2.4 Minipreps/maxipreps 
Minipreps/maxipreps were performed using the PureYieldTM plasmid mini/maxiprep 
system (Promega, Southampton, UK) following the manufacturer’s protocol. Plasmid 
DNA was eluted in 30µl or 1ml nuclease-free water for minipreps and maxipreps, 
respectively. DNA concentration was determined using the NanoDrop ND-1000 
spectrophotometer. Plasmids were electrophoresed on a 1% Tris-acetate-ethylenediamine 
tetraacetic acid (TAE) agarose gel as outlined in section 2.2.2.5 and sequenced by Sanger 
sequencing (Source BioScience Life Sciences, Nottingham, UK) to verify correct identity 
and confirm the presence of the correct mutation in the case of the Usp4 mutant 
constructs. The sequencing primer used for this verification is listed in Table 2.2. 
2.2.2.5 Agarose gel electrophoresis 
Reagents 
 TAE buffer (0.04M Tris (pH 8), 5.7% (v/v) glacial acetic acid and 0.001M 
ethylenediaminetetraacetic acid (EDTA)) 
 Loading buffer (Tris 0.125M (pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol and 0.001% 
(w/v) bromophenol blue)  
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Method 
Agarose gels were prepared at 1% (w/v) in TAE with the addition of 0.2µg/ml ethidium 
bromide solution (EtBr). After restriction digest, the required amount of DNA was 
electrophoresed on the gel in loading buffer and bands visualised on a ChemiGenius II 
BioImager (Syngene, Cambridge, UK) using a GeneRulerTM 100bp or 1kb DNA ladder 
to determine DNA band size.  
2.2.2.6 Transient transfection 
To investigate effects of overexpression on NF-κB signalling cell lines were transfected 
with Usp4 wild-type and mutant constructs. For luciferase reporter assays, cells were 
transfected with NF-κB reporter gene and Renilla luciferase vectors. For 
immunoprecipitation (IP) experiments, cells were transfected with vectors to express the 
relevant tagged proteins.  
Method 
SW1353 or HeLa cells were seeded into the appropriate culture vessel, depending on 
experiment, at a density of 1.5 x 104 cells/cm2. The following day, cells were transfected 
with DNA and FuGENE HD transfection reagent at an optimised 3:1 FuGENE:DNA 
ratio, according to manufacturer’s instructions. Briefly, DNA was added to serum-free 
DMEM and incubated at room temperature for 5 minutes. FuGENE HD was then added 
to the DNA/DMEM mix and incubated at room temperature for 15 minutes to allow 
formation of transfection reagent/DNA complexes. After complex formation the 
transfection mix was added to the cell culture medium and incubated at 37°C with 5% 
(v/v) CO2 for 24 hours. For stimulation of cells, overnight serum starvation took place as 
is described in section 2.2.2.7. 
HEK 293T cells were seeded at a density of 4.5 x 104 cells/cm2 in 10cm dishes and 
transfected with 5µg plasmid DNA at a 4:1 FuGENE:DNA ratio, optimised for 
transfection efficiency, as outlined above.  
NIH3T3 cells were seeded at a density of 1.5 x 104 cell/cm2 in 4-well glass chamber slides. 
The following day, cells were transfected with DNA and GeneJuice transfection reagent 
at an optimised 3:1 GeneJuice:DNA ratio, according to manufacturer’s instructions. After 
transfection, cells were incubated at 37ºC with 5% (v/v) CO2 for 24 hours. 
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2.2.2.7 Cell stimulations 
At 24 hours post-transfection, cells were washed in PBS and serum-containing culture 
media was replaced with serum-free culture media for 16-20 hours. Cells were then 
stimulated for the appropriate time point(s). For time course stimulations cells were 
stimulated ensuring cells for all time points were lysed at the same time.  
 Immunofluorescence 
For subcellular localisation experiments, NIH3T3 cells were transfected as described in 
section 2.2.2.6. After the transfection period, cells were fixed in paraformaldehyde (PFA) 
for 2 minutes, washed with PBS and stained using Vectashield® Mounting Medium for 
Fluorescence with 4’-6 diamidino-2-phenylindole (DAPI). Mounted slides were 
incubated for a minimum of one hour at 4ºC. A Zeiss Cell Observer Spinning Disk 
Microscope with a 63x objective lens was used to observe cells by confocal fluorescent 
microscopy. Images were scanned on two channels, blue for DAPI fluorescence and green 
for GFP expression, and analysed using Leica Application Suite Advanced Fluorescence 
imaging software. Results from the analysis were scored as predominantly nuclear, 
nuclear and cytoplasmic or predominantly cytoplasmic.  
 RNA interference (RNAi) 
2.2.4.1 Small interfering RNAs (siRNAs) 
Standard siGENOME SMARTpool siRNAs were purchased from Dharmacon 
(Leicestershire, UK). SMARTpool siRNAs contain 4 siRNAs that target different regions 
of the target gene to maximise potency and specificity; the sequences of which can be 
found in Table 2.3. 
Table 2.3. The 4 sequences which make up the siGENOME SMARTpool siRNAs for USP4 and the 
non-targeting siRNA pool #2. 
siRNA SMARTpool Target Sequences 
siGENOME USP4 siRNA  siGENOME Non-Targeting siRNA Pool #2 
GAUCUGAACCGGGUAAAGA UAAGGCUAUGAAGAGAUAC 
GAAUUGGACUAUGUAUUGG AUGUAUUGGCCUGUAUUAG 
GGAAUAAACUACUAAACUG AUGAACGUGAAUUGCUCAA 
CCAAAUGGAUGAAGGUUUA UGGUUUACAUGUCGACUAA 
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2.2.4.2 siRNA Transfection 
Method 
SW1353 or HeLa cells were seeded in a 96- or 12-well plate at a density of 1.5 x 104 
cells/cm2. The following day, at around 50% cell confluency, cells were transfected with 
50nM siRNA targeting USP4 (siUSP4) or non-targeting control siRNA pool #2 (siCon) 
using DharmaFECT transfection reagent 1 (DF1). In two separate tubes, the siRNA and 
DF1 were diluted in the appropriate volume of serum-free, antibiotic-free DMEM and 
incubated at room temperature for 5 minutes. Both tubes were then combined and 
incubated at room temperature for a further 20 minutes. After incubation, the transfection 
mix was added to an appropriate volume of serum-containing DMEM, culture medium 
was aspirated off the cells in each well and replaced with the transfection mix. Cells were 
then incubated at 37°C in 5% (v/v) CO2 for the required time period as determined in 
section 2.2.4.3. 
The optimal concentration of siGENOME siRNAs has generally been found to be 50nM 
and as such was the concentration all siRNAs were used at in this thesis (thesis of Dr. 
Matthew Barter, Newcastle University, Newcastle upon Tyne, UK).  
2.2.4.3 Optimisation of siRNA transfection time 
To determine the optimal transfection time with siUSP4 for USP4 depletion, siRNA 
transfection was performed as described in section 2.2.4.2 but for a range of transfection 
time periods: SW1353 cells were transfected with siUSP4 or siCon for 16, 24, 48 or 72 
hours before cell lysis and immunoblotting were performed as described in section 2.2.6. 
Blots were probed with an anti-USP4 antibody (Table 2.1) and the optimal transfection 
time was visually determined. Figure 2.2 indicates that 24 hours of siRNA transfection is 
the best minimum duration for depletion of USP4 protein levels and as such was the 
chosen siRNA transfection time for experiments in this thesis.  
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Figure 2.2. Optimisation of siRNA transfection time. SW1353 cells were transfected with non-
targeting control siRNA (siCon) or siRNA targeting USP4 (siUSP4) at 50nM concentration for 16, 
24, 48 or 72 hours (h). Cells were lysed and total protein extracted, resolved by SDS-PAGE and 
immunoblotted with an anti-USP4 antibody. GAPDH was used as a loading control. Figure is of one 
experiment but USP4 depletion was subsequently, routinely verified. 
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 Luciferase reporter assays 
2.2.5.1 NF-κB reporter gene assay 
Method 
An NF-κB reporter gene assay was conducted using the Dual-Luciferase Reporter Assay 
System (Promega, Southampton, UK) according to the manufacturer’s protocol. Briefly, 
cells were seeded into 48-well plates and the next day transfected with 50ng NF-κB firefly 
luciferase reporter and 3ng Renilla expression vectors as outlined in section 2.2.2.6. 
Following transient transfection of the expression vectors for appropriate times, cells 
were washed in PBS and lysed (if stimulation was required cells were serum-starved and 
stimulated as described in section 2.2.2.7 before lysis). Next, cell lysate was added to a 
cross-talk-free, white walled 96-well plate (PerkinElmer, Wellesley, MA, USA), 
luciferase assay reagent was injected to initiate the firefly luciferase reaction and 
luminescence was measured, both using a Glomax-Multi+ Detection System (Promega, 
Southampton, UK). After reading, a second reagent was injected to stop the reaction and 
luminescence for Renilla luciferase was also measured.  
For experiments in which USP4 was depleted, cells were first transfected with NF-κB 
reporter and Renilla expression vectors for a period of 6-8 hours before washing with 
PBS and transfecting with the relevant siRNAs for a further 24 hours, as described in 
section 2.2.4.2, before continuation of the reporter assay as described in this section.  
For experiments in which Usp4 was overexpressed, cells were co-transfected with Usp4, 
NF-κB reporter and Renilla expression vectors at a total DNA concentration of 
250ng/well in a 48 well plate for 24 hours before continuation of reporter assay as 
described in this section.  
2.2.5.2 Cignal Finder multi-pathway reporter array 
The multi-pathway reporter array consists of 10 dual-luciferase reporter assays for 
studying the gene activity of 10 signalling pathways in one experiment, listed in Table 
2.4. The system employs a reverse transcription format in which cells are seeded onto 
transfection complexes present on the plate. 
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Table 2.4. Pathways included in the Cancer 10-pathway Reporter Array. 
Pathway Transcription Factor 
Wnt TCF/LEF 
Notch RBP-Jκ 
p53/DNA damage p53 
TGFβ SMAD2/3/4 
Cell cycle/pRb-E2F E2F/DP1 
NF-κB NF-κB 
Myc/Max Myc/Max 
Hypoxia HIF1A 
MAPK/ERK Elk-1/SRF 
MAPK/JNK AP-1 
 
Method 
The reporter array was performed using a Cignal Finder reporter array kit (QIAGEN, 
West Sussex, UK) following the manufacturer’s protocol. Briefly, reporter assay 
constructs on the plate were resuspended in DMEM and incubated at room temperature 
for 5 minutes. After incubation, Attractene transfection reagent diluted at a 3:1 
Attractene:DNA ratio in DMEM was added to the wells, mixed and incubated at room 
temperature for a further 20 minutes to allow transfection reagent/DNA complex 
formation. Next, the appropriate density of U2OS cells was added to the plate and mixed 
by gentle rocking. Cells were then incubated at 37°C with 5% CO2 (v/v) in a humidified 
incubator for 24 hours. A luciferase assay was performed using the Dual-Glo Luciferase 
Assay System following manufacturer’s instructions and luminescence measured on a 
luminometer as in section 2.2.5.1. 
2.2.5.3 Optimisation of stimulation concentration and time  
Method 
SW1353 cells were seeded into a 48-well plate at a density of 1.5 x 104 cells/cm2. The 
following day cells were transfected with both the NF-κB firefly reporter gene and Renilla 
expression vectors as described in section 2.2.2.6. After the experimental period, cells 
were stimulated with varying concentrations of either IL-1α or TNFα for 6 hours before 
lysis. Figure 2.3A and Figure 2.3B show luminescence measured, indicating that 0.5ng/ml 
IL-1α and 10ng/ml TNFα were the optimum concentrations for inducing NF-κB activity. 
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Next the experiment was repeated but altering stimulation times before lysis. Figure 2.3C 
and Figure 2.3D show the optimum stimulation time for inducing NF-κB activity was 6 
hours for both IL-1α and TNFα. Accordingly, stimulations in this thesis were performed 
using 0.5ng/ml and 10ng/ml for IL-1α and TNFα, both for a period of 6 hours. 
 
Figure 2.3. Optimisation of stimulation concentration and time on luciferase activity. SW1353 cells 
were transfected with NF-κB firefly reporter gene and Renilla expression vectors. At 24h post-
transfection cells were stimulated at varying concentrations or time points before cell lysis and 
measurement of luminescence. A) Cells were stimulated with 0.1, 0.5, 1 and 2ng/ml IL-1α or left 
unstimulated (0). B) Cells were stimulated with 1, 5, 10, 20 and 50 ng/ml TNFα or left unstimulated 
(0). C) Cells were stimulated with IL-1α (0.5ng/ml) for 3, 6 and 24h or left unstimulated (0). D) Cells 
were stimulated with TNFα (10ng/ml) for 3, 6 and 24h or left unstimulated (0). Values were 
normalised to Renilla and displayed as relative light units (RLU) as mean ±SD (n=3/experiment).   
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 Protein analysis 
2.2.6.1 Whole cell lysis 
Reagents 
 Lysis buffer (50mM Tris, pH 7.4, 10% glycerol (v/v), 1mM EDTA, 1mM EGTA, 
1mM Na3VO4, 5mM NaF, 10mM β-glycerol phosphate, 5mM Na4P2O7, 1% Triton 
(v/v) X-100, 1μM microcystin-LF and 1 Complete protease inhibitor Mini tablet 
(Roche Diagnostics, West Sussex, UK) for 50ml of buffer)  
Method 
Cells were seeded in 12-well or 6-well plates at a density of 1.5 x 105 cells/cm2.  After the 
appropriate experimental period, culture medium was removed and cells were washed 
with ice-cold PBS. Ice-cold lysis buffer (containing 0.01% (v/v) β-mercaptoethanol) was 
added at 75µl/well or 100µl/well for 12- or 6-well plates, respectively. Cells were scraped 
and the cell suspension transferred to a cooled Eppendorf for a 20 minute incubation on 
ice. Following incubation the lysates were centrifuged at 4°C for 3 minutes at 10 000 x g. 
Supernatants were removed and immediately either stored at -80°C or a Bradford protein 
assay was performed.  
2.2.6.2 Bradford protein assay 
Method 
Bradford protein assays were used to determine protein concentration in the lysates. A 
standard stock solution of BSA (2mg/ml) was diluted to 0.4mg/ml in dH2O. A series of 
standards between 0-4mg/ml (at increments of 0.4mg/ml) and equal quantities of cell 
lysate samples and cell lysis buffer (as a control) were added to a flat-bottomed 96-well 
plate. BradfordUltra reagent was then added to the wells according to the manufacturer’s 
protocol, followed by 5 minutes incubation at room temperature. Absorbance was read at 
595nm using a Tecan Sunrise microplate absorbance reader and protein concentrations in 
the samples were calculated from this and equalised before sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis.  
2.2.6.3 Immunoblotting 
Reagents 
 Separating gel solution: 4X lower gel buffer (LGB) (1.5M Tris Base pH8.8, 0.4% 
SDS (w/v)), 37.5:1 acrylamide/bis-acrylamide 40%, APS and TEMED 
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 Stacking gel solution: 4X upper gel buffer (UGB) (0.5M Tris-HCl pH6.8, 0.4% (w/v) 
SDS), APS, TEMED 
 5X Laemmli sample buffer (0.1M Tris-HCl, pH6.8, 0.35M SDS, 20% (v/v) glycerol, 
0.01% bromophenol blue and 10% (v/v) β-mercaptoethanol) 
 10X Running buffer (250mM Tris Base, 2M Glycine and 10% (w/v) SDS) 
 Transfer buffer (20mM Tris Base, 0.6M glycine and 20% (v/v) methanol) 
 Tris buffered saline (TBS)-Tween (TBS-T) (150mM NaCl, 10mM Tris Base pH7.4, 
0.1% (v/v) Tween-20) 
 5X Stripping buffer (500mM glycine, pH2) 
Methods 
Cell lysate samples were thawed on ice and Laemmli sample buffer added to the samples 
at a 5:1 ratio of total volume. Samples were then heated to 100°C for 5 minutes, cooled 
on ice and electrophoresed on 10% SDS-polyacrylamide gels.  For the separating gel, 
acrylamide/bis-acrylamide 40% solution was diluted with 4X LGB and water at the 
correct volumes to give a 10% gel. TEMED and APS 0.2% (w/v) were added to the gel 
solution for polymerisation and the gel poured into 1.0mm Bio-Rad separator plates (Bio-
Rad Laboratories, Hemel Hempstead, UK). Stacking solution made up of 4.5% 
acrylamide/bis-acrylamide and polymerised with TEMED and APS was added on top of 
the separating solution once set, with combs inserted. The SDS-PAGE gels were 
electrophoresed at 100-180V using the Bio-Rad mini-PROTEAN gel vertical 
electrophoresis system (Bio-Rad Laboratories, Hemel Hempstead, UK) in which the gel 
plates are inserted into a sealed casting frame and placed into a tank filled with 1X 
Running buffer. PageRuler™ pre-stained protein ladder was loaded onto the gel alongside 
the protein samples.  
After electrophoresis, proteins were transferred from the gel to a PVDF membrane by 
electroblotting in transfer buffer using a Scie-Plas V20-SDB 20 x 20cm semi-dry blotter 
at 1mA/cm2 for 1.5 hours. Membranes were blocked for 1 hour in TBS-T, 5% (w/v) non-
fat dry milk powder or 1% BSA (according to antibody manufacturer’s instructions). 
After thorough washing in TBS-T (3 times for 5 minutes each with gentle agitation) 
membranes were incubated overnight with gentle agitation at 4°C with primary antibody, 
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diluted according to manufacturer’s instructions in primary antibody dilution buffer 
(TBS-T, 5% BSA/milk).  
Following overnight incubation membranes were washed (3 x 5 minutes) before 
incubation with horseradish peroxidase (HRP)-conjugated secondary antibody (diluted 
1:3000 in TBS-T, 5% milk) for one hour at room temperature with gentle agitation. 
Membranes were again washed for 3 x 5 minutes and then visualised on high-speed X-
ray film using ECL detection reagents.  
To allow probing with a different antibody, membranes were stripped. 1X Stripping 
buffer was heated to boiling and cooled to around 60°C before incubation with 
membranes for 2 x 45 minutes with gentle agitation. After washing with TBS-T for 3 x 5 
minutes, membranes were then incubated with the desired primary antibody overnight as 
described above. An anti-GAPDH antibody was used to ensure equal loading.  
 Immunoprecipitation (IP) 
Method 
HEK 293T cells were seeded into 10cm dishes at a density of 4.5 x 104 cells/cm2. The 
following day cells were transfected with the appropriate tagged protein for 24 hours as 
outlined in section 2.2.2.6. For experiments investigating effects of USP4 depletion, cells 
were transfected with siRNA 24 hours preceding plasmid transfection as outlined in 
section 2.2.4.2. Whole cell lysis was performed as in section 2.2.6.1 and cell lysate protein 
was quantified by Bradford assay as described in section 2.2.6.2. For IP experiments to 
investigate the polyubiquitination of proteins, 20mM NEM and 10µM MG132 were 
added to the extracts during lysis to inhibit deubiquitinase and proteasome activity, 
respectively. For IP experiments to investigate the phosphorylation of proteins 1mM 
Na3VO4 was added to all buffers to inhibit phosphatases. 
First, the lysate was pre-cleared by adding 3µg of irrelevant antibody (IgG mouse/rabbit 
according to IP primary antibody species) to 300µg of protein sample (1µg/µl). Samples 
were incubated on ice for one hour followed by a 30 minute incubation at 4°C with end-
to-end rotation with added Protein G PLUS-agarose conjugate suspension. After a 10 
minute centrifugation at 14000 x g at 4°C, supernatants were removed for IP. 
On ice, 3µg of the IP antibody was added to the pre-cleared lysate and incubated overnight 
with end-to-end rotation at 4°C. The following day Protein G PLUS-agarose conjugate 
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suspension was added to the samples and incubated for 3 hours with end-to-end rotation 
at 4°C. The bead pellet was collected by centrifugation at 10 000 x g for 5 minutes at 4°C 
and the supernatant discarded. The bead pellet was then washed 3 times with PBS, each 
time centrifuged at 10 000 x g for 1 minute at 4°C. After the last PBS wash was discarded, 
the bead pellet was resuspended in 2X Laemmli sample buffer and heated to 100°C for 5 
minutes. Supernatant was collected and electrophoresis was performed as described in 
section 2.2.6.3. 
2.2.7.1 Optimisation of the transfection of FLAG-tagged proteins 
Method 
SW1353 and HEK 293T cells were seeded into 10cm dishes at a density of 1.5 x 104 
cells/cm2 and 4.5 x 10
4 cells/cm2, respectively. The following day cells were transfected 
with 1µg/ml of FLAG-TRAF6-wt plasmid DNA at FuGENE:DNA ratios of 1:1, 2:1, 3:1 
and 4:1 or with 0.5µg/ml of plasmid DNA at a FuGENE:DNA ratio of 3:1 as previously 
described in section 2.2.2.6. After 24 hours, whole cell lysis and immunoblotting were 
performed as described in section 2.2.6.3. Blots were probed with anti-FLAG antibody. 
It can be seen in Figure 2.4 that at long exposure FLAG was detected in both SW1353 
and HEK 293T cells. FLAG was detected at a higher level in HEK 293Ts indicating that 
these cells have higher transfection efficiency than the SW1353s. A ratio of 4:1 
FuGENE:DNA (1µg/ml plasmid DNA) in HEK 293Ts was determined to be optimal for 
the transfection of plasmids, as such HEK 293Ts were chosen for use in IP experiments 
(Figure 2.4).  
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Figure 2.4. Optimisation of the transfection of FLAG-tagged proteins. SW1353 and HEK 293Ts were 
transfected with varying concentrations of plasmid DNA and varying transfection reagent:DNA 
ratios. At 24h post-transfection cells were lysed, immunoblotted and probed with anti-FLAG 
antibody. 1) 1:1, 2) 2:1, 3) 3:1, 4) 4:1, 5) 3:1 (0.5µg/ml). Ratios are shown as FuGENE HD transfection 
reagent:plasmid DNA. Plasmid DNA was transfected at a concentration of 1µg/ml unless otherwise 
stated. Figure is from one experiment. GAPDH was used as a loading control. Long exposure shows 
FLAG is present in SW1353s but at lower levels than in HEK 293Ts. 
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2.2.7.2 Optimisation of IP conditions with FLAG-tagged proteins 
Method 
Immunoprecipitation was performed as described previously in this section. To optimise 
IP conditions, lysates were incubated with varying concentrations of anti-FLAG 
antibody: 3µg of antibody was added to 300µg protein for a 1:100 antibody:protein ratio. 
Other concentrations of antibody were tested at ratios of 1:50 and 1:200. Conditions also 
included pre-cleared compared to not pre-cleared and washing with lysis buffer compared 
to washing with PBS. Pre-clearing the lysate and incubating with a 1:100 ratio of 
antibody:protein was optimal (Figure 2.5A). Washing in PBS rather than lysis buffer 
appeared to have no effect and so PBS was used to wash in all future 
immunoprecipitations (Figure 2.5B and E).  
 
Figure 2.5. Optimisation of IP conditions. SW1353 cells were transfected for 24 hours with FLAG-
TRAF6 plasmid before cell lysis and immunoprecipitation with anti-FLAG antibody under varying 
conditions. Immunoprecipitates were immunoblotted with anti-FLAG antibody. A) Pre-cleared, 
antibody ratio 1:100. B) Antibody ratio 1:100. C) Antibody ratio 1:50. D) Antibody ratio 1:200. E) 
Antibody ratio 1:100, washed with lysis buffer. No lysates were pre-cleared and all were washed in 
PBS unless otherwise stated. Figure is from one experiment.  
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 RNA analysis 
2.2.8.1 Cell lysis 
Cells-to-cDNA II lysis buffer yields cell lysates for reverse transcription in a single step 
to lyse cells and inactivate RNases, removing the process of isolating RNA. 
Method 
Cell lysis was performed using Cells-to-cDNA II lysis buffer following the 
manufacturer’s protocol. After siRNA transfection and the appropriate experimental time 
period as described in section 2.2.4.2, cell culture medium was removed and cells were 
washed in ice-cold PBS. Next, cells were lysed in 30µl ice-cold Cells-to-cDNA II lysis 
buffer per well, transferred to a 96-well PCR plate and heated to 75°C for 15 minutes to 
ensure RNase inactivation. Lysates were then stored at -80°C or reverse transcription was 
performed immediately.  
2.2.8.2 Reverse transcription 
Method 
For reverse transcription, 8µl of the lysate was transferred to a new PCR plate to which 
final concentrations of 0.375mM dNTPs and 0.2µg random hexamers p(dN)6 were added 
to each well and heated to 70°C for 5 minutes. The samples were then placed on ice and 
5X First Strand Buffer, final concentration of 10mM DTT and M-MLV reverse 
transcriptase were added. The reaction was made up to 20µl total per well with H2O, 
incubated at 37°C for 50 minutes followed by incubation at 75°C for 15 minutes. The 
stable cDNA was then diluted by addition of 30µl dH2O for target gene quantification 
and diluted a further 1:50 for housekeeping gene (18S) quantification. The cDNA was 
stored at -20°C prior to analysis or quantified immediately by real-time qRT-PCR. 
2.2.8.3 Primers for real-time qRT-PCR 
Both forward and reverse primers for TaqMan® probe-based real-time qRT-PCR were 
designed using the Universal ProbeLibrary Assay Design Center (Roche Diagnostics, 
West Sussex, UK) and are shown in Table 2.5. Mouse 18S was an ABI assay on demand 
(Applied Biosystems, Life Technologies Ltd., Paisley, UK). The 18S ribosomal RNA 
gene was used as the housekeeping gene as an endogenous control for normalisation and 
to allow analysis of the relative expression of the gene of interest. To prevent 
amplification of any contaminating genomic DNA, all primers were designed to span an 
intron-exon boundary. 
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2.2.8.4 TaqMan® Probe-based real-time qRT-PCR 
Method 
For quantification of target genes, a subtotal 6µl reaction of 2X TaqMan gene expression 
master mix, 200nM of each forward and reverse primers, 150nM probe and made up with 
H2O was prepared and added to each well of a 96-well qRT-PCR plate. Similarly, for 
quantification of the housekeeping gene a subtotal 5µl reaction of 2X TaqMan gene 
expression master mix, 300nM of each forward and reverse primers and 75nM probe was 
prepared. Next, 4µl of diluted cDNA or 5µl diluted cDNA, for target or housekeeping 
gene quantification respectively, was added to each well to give a total 10µl reaction. 
Real-time qRT-PCR was performed using the ABI Prism 7900HT PCR System (Applied 
Biosystems, Life Technologies Ltd., Paisley, UK). Thermocycling parameters were: 
95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. 
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Table 2.5. Sequences of primers used for real-time qRT-PCR. 
Gene Primer Primer Sequence Probe 
Human IL6 Forward 
Reverse 
5’-CAGGAGCCCAGCTATGAACT-3’ 
5’-GAAGGCAGCAGGCAACAC-3’ 
Probe library #45 
 
Human IL8 Forward 
Reverse 
5’-AGACAGCAGAGCACACAAGC-3’ 
5’-AGGAAGGCTGCCAAGAGAG-3’ 
Probe library #72 
Human MMP13 Forward 
Reverse 
5’-AAATTATGGAGGAGATGCCCATT-3’ 
5’-TCCTTGGAGTGGTCAAGACCTAA-3’ 
5’-CTACAACTTGTTTCTTGTTGCTGCGCATGA-3’ 
Human USP4 Forward 
Reverse 
5’-GATCGAGTTATGGAGGTTTTCCT-3’ 
5’-CGGCACAGTCACACGGTA-3’ 
Probe library #18 
Human IκBα  Forward 
Reverse 
5’-GTCAAGGAGCTGCAGGAGAT-3’ 
5’-ATGGCCAAGTGCAGGAAC-3’ 
Probe library #38 
Human 18S Forward 
Reverse 
5’-CGAATGGCTCATTAAATCAGTTATGG-3’ 
5’-TATTAGCTCTAGAATTACCACAGTTATCC-3’ 
5’-TCCTTTGGTCGCTCGCTCCTCTCC-3’ 
Mouse IL6 Forward 
Reverse 
5’-TGATGGATGCTACCAAACTGG-3’ 
5’-TTCATGTACTCCAGGTAGCTATGG-3’ 
Probe library #6 
Mouse CXCL1 Forward 
Reverse 
5’-GACTCCAGCCACACTCCAAC-3’ 
5’-TGACAGCGCAGCTCATTG-3’ 
Probe library #83 
Mouse MMP13 Forward 
Reverse 
5’-CAGTCTCCGAGGAGAAACTATGA-3’ 
5’-GGACTTTGTCAAAAAGAGCTCAG-3’ 
Probe library #62 
Mouse USP4 Forward 
Reverse 
5’-GCTGAATTGGTATGGCTGTG-3’ 
5’-AGGCCATGCTCCACAACTT-3’ 
Probe library #66 
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 Genotyping mice 
Genotypes of the mice/MEFs used in experiments were determined using the Extract-N-
AmpTM Tissue PCR Kit (Sigma-Aldrich, Poole, UK).  
Method 
Extraction was performed following the manufacturer’s protocol.  Briefly, a small piece 
of ear or tail tissue was obtained from the mice and incubated in a 100µl mix of Extraction 
Solution and Tissue Preparation Solution for 10 minutes at room temperature. Next tissue 
extracts were incubated at 95°C for 3 minutes before the addition of 100µl of 
Neutralization Solution B. Samples were stored at 4°C or PCR was performed 
immediately.  
All PCR reactions were prepared at room temperature as the JumpStart Taq antibody in 
the Extract-N-Amp PCR reaction mix is specific for hot start amplification. Added to a 
thin-walled PCR tube was 10µl Extract-N-Amp PCR reaction mix, 0.5µM of each of 3 
primers (see Table 2.6) and 4µl tissue extract, made up with dH2O to give a 20µl total 
reaction. Thermocycling parameters were: 94°C for 3 minutes followed by 32 cycles of 
94°C for 30 seconds, 50°C for 30 seconds, 72°C for 1 minute and a final step of 72°C for 
10 minutes. The amplified DNA was then loaded onto a 1% agarose gel, as described in 
section 2.2.2.5, to allow determination of genotype as shown in Figure 2.6. Mice were 
born at expected Mendelian ratios. 
Table 2.6. Sequences of primers used for genotyping mice. 
Primer Primer Sequence 
Ex3-F 5’-CCAGCAGCCTATTGTCAGAA-3’ 
 
In3-R 5’-TCAGTACTTAGGGATCTCTGA-3’ 
Neo-R 5’-AACCTGCGTGCAATCCATCT-3’ 
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Figure 2.6. Usp4 mouse genotypes. Extractions were performed using the ear or tail of mice before 
performing PCR using genotyping primers listed in Table 2.6 and loading onto a 1% agarose gel. 
Figure shows Usp4-/- (-/-), Usp4+/- (+/-) and Usp4+/+ (+/+) mice. 
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 Cytokine array 
A Meso Scale Discovery (MSD) cytokine array (Meso Scale Diagnostics, Gaithersburg, 
MD, USA) was performed using a Mouse ProInflammatory 7-Plex Ultra-Sensitive Kit. 
The principle of the assay is to allow measurement of levels of a number of cytokines and 
chemokines from one sample by use of antibodies pre-coated on a single well. The 
proinflammatory kit provides antibodies for IL-1β, IL-12p70, IFN-γ, IL-6, KC/GRO, IL-
10 and TNF-α in an immunoassay format. Electrochemiluminescent compounds are used 
to allow quantitative analysis of these cytokines and chemokines present in the sample by 
measuring light emitted.  
Method 
The MSD cytokine array was performed according to the manufacturer’s protocol. First, 
blood samples were collected from wild-type (Usp4+/+), heterozygous (Usp4+/-) or Usp4 
null (+/-) mice intravenously. Samples were left to clot for a minimum of 10 minutes at 
room temperature before centrifugation for 20 minutes at 4°C to remove clotted materials 
and obtain the mouse serum.  Next, antibodies on the plate were reconstituted in buffer 
by vigorous shaking on a plate shaker (300-1000rpm) for 30 minutes. A range of 
calibrator standards or sample (25µl volume) were added to each well and subjected to 
vigorous shaking on a plate shaker (300-1000rpm) for 2 hours at room temperature. The 
plate was then washed in PBS (x3) and samples were incubated on a plate shaker (300-
1000rpm) for 2 hours at room temperature with a detection antibody solution. After 
thorough washing in PBS (x3) read buffer was added to all wells and the plate was read 
on an MSD SECTOR Imager.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Enzyme-linked immunosorbent assay (ELISA) 
To measure levels of IL-6 and CXCL1 levels in mouse serum, Mouse IL-6 and CXCL1 
Quantikine kits (R&D Systems®, Abingdon, UK) were used. These immunoassays use 
antibodies raised against IL-6 and CXCL1 to quantitate levels of these cytokines.  
Method 
The serum of mice was obtained as described in section 2.2.10 and were sampled 
according to the manufacturer’s protocol. Serum was diluted to a 1:2 concentration and 
50µl of each sample was used. Briefly, standards, sample or control were added to wells 
containing a pre-coated antibody and incubated at room temperature for 2 hours. Wells 
were then washed 5 times to remove unbound substances and incubated with a HRP-
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conjugated antibody at room temperature for a further 2 hours. After repeating the 
washing steps, a substrate solution to initiate an enzyme reaction followed by a stop 
solution were added to the wells and absorbance measured at 450nm on a Tecan 
SunriseTM microplate absorbance reader (Tecan, Theale, UK). Standard curves for each 
ELISA were generated using a range of standards and are shown in Figure 2.7. Two 
standard curves are shown for CXCL1 as two separate experiments with two cohorts of 
mice were performed. 
 
Figure 2.7. Standard curves for ELISAs to measure concentration of A) IL-6, B) CXCL1 and C) 
CXCL1 (second mouse cohort). A range of standards were prepared between 0-500pg/ml of either a 
mouse IL-6 standard or a mouse CXCL1 standard. Standards were added to wells containing a pre-
coated antibody and the ELISA performed alongside samples. Absorbance was measured at 450nm.  
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  Immunohistochemistry 
2.2.12.1  Mouse infection 
To compare viral replication in Usp4-/- and Usp4+/+  mice to determine any effect on 
the immune response, immunohistochemical analysis on mouse brain sections infected 
with vesicular stomatitis virus (VSV) was performed. Mice were infected intranasally 
with 4 x 106 pfu VSV per mouse. The brains of these mice were harvested 48 hours later 
and fixed in formalin. In total 7 brains from Usp4+/+ and 8 mouse brains from Usp4-/- 
mice were harvested.  
2.2.12.2 Histology 
Method 
Mouse brains were embedded in paraffin blocks and cut into 5µm sections using a Leica 
RM2235 rotary microtome (Leica, Milton Keynes, UK) and placed on Superfrost Plus 
slides (Cellpath Ltd, Powys, UK). 
2.2.12.3  Immunohistochemistry 
Method 
Sections were deparaffinised in 2 changes of xylene for 5 minutes each and rehydrated 
through graded concentrations of ethanol for 5 minutes each: 100% (x2), 95%, 70% and 
50%, with a final wash in dH2O. For heat-induced epitope retrieval the sections were 
placed in sodium citrate buffer pH 6.0 and microwaved for 2 x 5 minutes. The endogenous 
peroxidase activity was quenched by incubating the slides in 0.3% (v/v) H2O2 in dH2O 
for 30 minutes. Sections were then blocked in 2% (v/v) normal horse blocking serum for 
30 minutes before 30 minutes incubation with a 1:3000 dilution of primary antibody 
(diluted in PBS with 2% (v/v) normal horse blocking serum). Slides were then incubated 
with Biotin-conjugated secondary antibody for 30 minutes followed by a further 30 
minutes incubation with Avidin/Biotin Complex (ABC). Peroxidase substrate 3,3’-
diaminobenzidine (DAB) demonstrated peroxidase activity. Sections were washed in 
running tap water for 5 minutes and were counterstained with haematoxylin followed by 
dehydration through graded concentrations of ethanol for 5 minutes each: 50%, 70%, 95% 
(x2) and 100% (x2) with a final 5 minutes in xylene (x2). All incubation steps were carried 
out at room temperature and sections were washed thoroughly in between each step; all 
washing steps used PBS for 2 x 5 minutes unless otherwise stated. Slides were mounted 
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with D.P.X. mounting medium and covered with glass coverslips for visualisation under 
a Leica DM4000B microscope (Leica, Milton Keynes, UK).  
Experimental work described in sections 2.2.12.1 and 2.2.12.2 was carried out by staff in 
the laboratory of Dr Doug Gray (Ottawa Hospital Research Institute, Ottawa, Canada). 
Experimental work in section 2.2.12.3 was carried out by Sharon Watson, 
Musculoskeletal Research Group (Institute of Cellular Medicine, Newcastle University, 
Newcastle, UK) with my assistance throughout. 
2.2.12.4  Image analysis 
All images were taken using a Leica SCN 400 slide scanner and viewed with the Slide 
Path software (Leica, Milton Keynes, UK). 
Method 
The percentage of area of mouse brain stained positive for VSV was calculated using 
FRamework for Image Dataset Analysis (FrIDA) software (Cornish et al., 2008). This 
software facilitated the use of image masks, enabling inclusion and exclusion of areas of 
the image or pixels of specific colours. For each image, only the brain area was selected 
and a pixel threshold for hue, saturation and brightness was set to identify only the brown 
stained pixels (VSV positive). The pixel threshold was the same for all images analysed, 
allowing a percentage of positive staining to be quantified in each brain area selected. All 
images were analysed blind to eliminate bias. 
  Lentivirus: inducible expression system 
Lentiviral expression vectors are a powerful and effective tool for the delivery of a gene 
of interest into cells which can be difficult to transfect. Primary cell lines, such as MEFs, 
are notoriously difficult to transfect and so a lentiviral system was used to introduce an 
NF-κB reporter vector for the study of NF-κB activity and mutant Usp4 overexpression 
vectors for the examination of Usp4 phosphorylation in SW1353 cells and/or Usp4+/+  
and Usp4-/- MEFs.  
Two methods were used for producing lentiviral supernatants, the first utilised the Lenti-
X™ Tet-On® Advanced Inducible Expression System (Clontech, Paris, France). 
2.2.13.1  Cloning 
For lentiviral introduction of mutant Usp4 into cells, the GFP-tagged Usp4 constructs 
were cloned into a response vector, pLVX-Tight-Puro, which contains an inducible 
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promoter, PTight, that controls expression of the Usp4 gene. These response vectors were 
generated for wild-type, catalytically inactive Usp4 and all phosphorylation mutants of 
Usp4 generated in section 2.2.2.2. For cloning, all restriction enzymes used were 
FastDigest® enzymes in combination with 10X FastDigest® Green buffer and ligation 
was performed using the Rapid DNA ligation kit (Fermentas, Thermo Scientific, 
Leicestershire, UK). 
Method 
To clone the Usp4 vectors into the multiple cloning site (MCS) of the reponse vector, all 
vectors were double digested with MluI and BamHI restriction enzymes. Briefly, 
reactions were prepared of 2µl 10X buffer, 1µl of each restriction enzyme, 1µg DNA and 
made up to total 20µl with nuclease-free water. After mixing, reactions were incubated 
for 10 minutes at 37ºC before loading onto a 0.8% (w/v) agarose gel as described in 
section 2.2.2.5.  
Next, bands of the expected size on the gel were extracted using a QIAquick Gel 
Extraction kit, according to the manufacturer’s protocol. DNA was eluted in 50µl and the 
insert cut from the Usp4 vector was ligated into the response vector by a reaction with 
insert and vector at a 5:1 ratio using the Rapid DNA Ligation kit, following the 
manufacturer’s instructions. 1µl of the ligation was then used in bacterial transformation 
as described in section 2.2.2.3. 
2.2.13.2  Lentivirus generation 
To produce lentivirus, the lentiviral vectors constructed in the previous section were 
packaged into viral particles along with Lenti-X HTX Packaging mix which contains 
lentiviral vectors and envelope vectors. A second lentiviral supernatant was produced 
with a regulator vector, pLVX-Tet-On-Advanced, which contains a tetracycline-
controlled transactivator, rtTA-Advanced, along with the Lenti-X HTX Packaging mix. 
Transduction of both lentiviral supernatants and treatment with doxycycline should 
induce expression of the Usp4 gene. 
Method 
HEK 293T cells were seeded into 10cm dishes at a density of 8 x 104 cells/cm
2. The next 
day media was replaced with DMEM (with 10% (v/v) FBS) and cells were transfected 
with the lentiviral response or regulator vector and packaging mix as in section 2.2.2.6. 
At 24 hours post-transfection, medium was replaced with DMEM (with 10% (v/v) FBS) 
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and incubated for a further 48 hours to allow viral production. Lentiviral supernatants 
were then harvested by centrifugation of the medium at 500 x I for 10 minutes to remove 
cellular debris and stored in 0.5ml aliquots at 4ºC for short-term or -80ºC for long-term 
storage. 
2.2.13.3  Transduction 
Transduction into target cells first needed to be optimised. This was tried in SW1353 cells 
using the lentiviral supernatant for wild-type Usp4. 
Method 
Target cells were seeded into 24-well plates at a density of 1.5 x 104 cells/cm2. The 
following day, media was replaced with a transduction mix containing the appropriate 
amount of virus, DMEM (with 10% FBS), varying amounts of doxycycline and 8µg/ml 
polybrene. Different ratios of response and regulator lentiviral supernatants were used 
(1:1, 1:4 or 4:1) and different concentrations of doxycycline were added to different wells 
(0. 125ng/ml, 250ng/ml, 500ng/ml, 1µg/ml or 2µg/ml). For control, some wells contained 
polybrene only. Cells were incubated at 37ºC with 5% (v/v) CO2 for 24 hours. After 24 
hours, cell culture media was replaced with DMEM (with 10% (v/v) FBS) and 
doxycycline and cells were incubated for a further 24 hours. After the experimental 
period, cells were visualised on a fluorescent microscope for examination of GFP 
expression. No fluorescence was observed with any of the conditions so it was decided 
that a different lentiviral expression system would be approached. 
 Lentivirus: second generation expression system 
The second lentiviral system utilised was a second generation lentiviral expression 
system. 
2.2.14.1  Cloning 
For lentiviral introduction of mutant Usp4 into cells, In-Fusion cloning (Takara Bio 
Europe/Clontech, Paris, France) enabled cloning of all mutant Usp4 overexpression 
vectors into the lentiviral expression vector pCDH-EF1-MCS-IRES-GFP, which contains 
the essential machinery for packaging, transduction and stable integration of the gene into 
the cells genomic DNA. Lentiviral expression vectors for wild-type, catalytically inactive 
Usp4 and all phosphorylation mutants of Usp4 generated in section 2.2.2.2 were produced 
by In-Fusion cloning using the In-Fusion® HD Cloning kit (Takara Bio Europe/Clontech, 
Paris, France). 
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Method 
Before Usp4 could be fused into the lentiviral vector, primers were designed to isolate 
and linearise Usp4 from the pCMV6-AN-mGFP vector by PCR. Primers were designed 
to incorporate a KOZAK consensus sequence immediately prior to the start codon for 
efficient initiation of translation as well as 15 bases at the 5’ end of the primers 
homologous to the vector (Kozak, 1987) (Table 2.7).  
Table 2.7. Sequences of primers for infusion cloning. 
Primer Primer Sequence 
mUSP4 Inf 1 F 5’-tagagctagcgaattGCCACCATGGCGGAAGGCCGGGGCAGCC-3’ 
 
mUSP4 Inf 1 R 5’-atttaaattcgaatttCAGTTGGTGTCCATGTTGTAAGCCT-3’ 
 
 
A PCR reaction was prepared of 4µl 5X Phire Reaction Buffer, 2.5mM dNTPs, 0.5µM 
forward and reverse infusion primers, 0.4µl Phire Hot Start II DNA Polymerase, 5ng 
plasmid DNA (pCMV-AN-Usp4-mGFP) and made up to 20µl with dH2O. The reaction 
was cycled following the parameters: initial step of 98ºC for 30 seconds followed by 35 
cycles of 98ºC for 5 seconds, 68ºC for 5 seconds, 72ºC for 1 minute 15 seconds (10-15 
seconds per kb of plasmid length), and a final step at 72ºC for 2 minutes. After cycling, 
the PCR reaction was purified using the NucleoSpin® Gel and PCR Clean-up kit 
(Machery-Nagel, Düren, Germany) following manufacturer’s protocol and was eluted in 
25µl Buffer NE. This PCR reaction was performed for wild-type and all phosphorylation 
mutants of Usp4. 
To linearise the lentiviral expression vector, pCDH-EF1-MCS-IRES-GFP, 5µg of 
plasmid DNA was digested with EcoRI in a total 25µl reaction, at 37ºC for one hour 
followed by a 15 minute heat-inactivation of EcoRI at 65ºC. 
Next, the In-Fusion Cloning reaction was prepared of 2µl In-Fusion HD enzyme premix, 
50ng linearised lentiviral vector, 50ng PCR reaction insert and made up to 10µl total with 
dH2O. The cloning reaction was then incubated for 15 minutes at 50ºC before being 
placed on ice, ready for transformation. 
Transformation of the cloning reaction mix was done using Stellar Competent Cells 
according to the manufacturer’s protocol. On ice, cloning reaction mix was added to 
Stellar Competent Cells and incubated for 30 minutes. Following a 45 second heat shock 
Chapter 2: Materials and Methods 
 
82 
 
at 42ºC, cells were returned to ice for 1-2 minutes before the addition of pre-warmed 
S.O.C. medium and a one hour incubation at 37ºC with shaking at 200rpm. After 
incubation, the transformation mixes were spread onto LB-agar plates with ampicillin 
resistance and cultured as described in sections 2.2.2.3 and 2.2.2.4. Plasmids were 
sequenced by Sanger sequencing for verification: primer sequences can be found in Table 
2.2. 
2.2.14.2  Lentivirus generation 
To produce lentivirus, the lentiviral vectors constructed in the previous section were 
packaged into viral particles using a second generation lentiviral system in which HEK 
293T cells were transfected with two other plasmids along with each lentiviral vector: 
psPAX2 packaging vector and pCMV-VSV-G envelope vector. Lentivirus using the 
empty pCDH-EF1-MCS-IRES-GFP vector, as a control, was also produced. 
Method 
HEK 293T cells were seeded into 10cm dishes at a density of 8 x 104 cells/cm
2. The next 
day media was replaced with DMEM (with 10% (v/v) heat-inactivated FBS) and cells 
were transfected with the lentiviral vector, packaging vector and envelope vector as in 
section 2.2.2.6. At 24 hours post-transfection, medium was replaced with DMEM (with 
10% (v/v) heat-inactivated FBS) and incubated for a further 48 hours to allow viral 
production. Lentiviral supernatants were then harvested by centrifugation of the medium 
at 500 x g for 10 minutes to remove cellular debris and stored in 0.5ml aliquots at 4ºC for 
short-term or -80ºC for long-term storage. 
2.2.14.3  Virus titre 
To determine the viral RNA genome content in the lentivirus supernatants produced, 
titration was performed using the Lenti-X™ qRT-PCR Titration kit (Takara Bio 
Europe/Clontech, Paris, France). 
Method 
For each of the lentiviral supernatant stocks produced, 150µl viral RNA was purified 
using the NucleoSpin RNA virus kit (part of the Lenti-X™ qRT-PCR Titration kit) 
following the manufacturer’s protocol. RNA was eluted in 50µl RNase-free water. 
Residual plasmid DNA was removed in a DNase reaction with DNase I Buffer and DNase 
I enzyme, incubated at 37ºC for 30 minutes, followed by incubation at 70ºC for 5 minutes. 
Lentiviral genomic RNA was then amplified by qRT-PCR. Both Lenti-X RNA control 
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template and sample viral RNA were diluted in a series of 10-fold dilutions and reactions 
of 12.5µl 2X Quant-X Buffer, 0.4µM of each Lenti-X forward and reverse primers, ROX 
Reference Dye LMP, 0.5µl Quant-X enzyme, 0.5µl RT enzyme mix were made up to 
25µl with RNase-free water. The enzyme reaction mix was added to the qRT-PCR plate 
and 2µl of either Lenti-X control, sample or a no-template control were added to the mix 
in duplicate. Thermocycling parameters were: 42ºC for 5 minutes, 95ºC for 10 seconds 
followed by 40 cycles of 95ºC for 5 seconds, 60ºC for 30 seconds and a final dissociation 
curve cycle at 95ºC for 15 seconds, 60ºC for 30 seconds and 60-95ºC. 
A standard curve was generated using average Ct values from the control dilution 
duplicates plotted against copy number (log scale) for the calculation of the quantity of 
viral RNA. Once an average Ct value for each sample was determined and a 
corresponding value from the standard curve read, the copy number of sample viral RNA 
per ml was then calculated from the following equation: 
Copies/ml= (copy number from Cts)(1000µl/ml)(2x DNase)(50µl RNA elution) 
   (150µl sample)(2µl added to well) 
 
The lentiviral supernatants produced were for a number of Usp4 mutants, wild-type Usp4 
and for the control empty vector. For experimental procedures using the lentiviral 
supernatants, the values obtained from the above equation were used to transduce target 
cells with equal amounts of viral RNA/particles. 
2.2.14.4  Transduction of Usp4 wild-type and phosphorylation mutants 
Method 
Target cells were seeded into 48- or 6-well plates at a density of 1.5 x 104 cells/cm2. The 
following day, media was replaced with a transduction mix containing the appropriate 
amount of virus, DMEM (with 10% heat-inactivated FBS) and 8µg/ml polybrene. Cells 
were incubated at 37ºC with 5% (v/v) CO2 for 24 hours. After 24 hours, cell culture media 
was replaced with DMEM (with 10% (v/v) heat-inactivated FBS) or serum-free DMEM 
(if cells were to be stimulated) and cells were incubated for a further 24 hours. After the 
experimental period, cells were either lysed immediately (for western blots to examine 
overexpression) or stimulated before lysis (for NF-κB luciferase reporter assays).  
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 Computational modelling 
A computational model was constructed to incorporate USP4 in NF-κB signalling. An 
initial model was constructed in collaboration with Dr Carole Proctor (Newcastle 
University, Newcastle, UK) and included key molecular mechanisms of NF-κB signalling 
and assumptions based on results from work in this thesis. The model was encoded in the 
Systems Biology Markup Language (SBML) (Hucka et al., 2003). The model was 
constructed and stochastic simulations performed using a Complex Pathway Simulator 
(COPASI) (Hoops et al., 2006). 
  Statistical analysis 
Luminescence values were normalised against Renilla values and combined experiment 
values were given as mean ± standard error of the mean (SEM).  
The relative levels of gene expression were calculated using appropriate standard curves, 
from Ct values which are inversely proportional to the expression of the gene. Data were 
normalised against the basal levels (or a set time point for time course stimulations) of 
the housekeeping gene 18S. Data were then plotted as gene of interest relative to 18S. 
Data from at least 2 experimental repeats were combined and values given as mean ± 
standard error of the mean (SEM).  
Statistical significance of differences between protein levels was determined using 
densitometry for which the relative density of each band was plotted at each stimulation 
time point. Data from at least 3 experimental repeats were combined and values given as 
mean ± SEM. 
An unpaired Student’s t-test was performed to compare the means and determine any 
statistical significance between two independent sample groups. One-way analysis of 
variance (one-way ANOVA) was performed to compare the means of more than two 
samples, with a post-hoc Tukey comparison test, or two-way ANOVA was performed, 
with a post-hoc Bonferroni comparison test. Statistical significance is shown as *p≤0.05, 
**p≤0.01 and ***p≤0.001. 
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Chapter 3 : USP4 in Inflammatory and Immune Pathways 
 Introduction 
Multiple cell signalling pathways regulate the expression of a wide number of 
immunoregulatory genes to mediate the immune response. Ligand induction of pathways, 
including those mediated by IL-1Rs, can lead to the activation of transcription factors 
NF-κB and AP-1 which control the expression of many proinflammatory cytokines such 
as TNFα, IL-6, IL-1β and IL-8, which in turn amplify inflammatory signalling cascades 
and facilitate an immune response. Besides these proinflammatory cytokines, viral 
recognition by immune cell pattern-recognition receptors (PRRs), including RLRs, 
activates signal transduction to activate the transcription factor IRF3 and produce type I 
IFNs, such as IFN-β, to mediate an antiviral response (Yoneyama et al., 2015).  
Sustaining tight regulation of these pathways is crucial in mediating the correct 
inflammatory and immune responses and maintaining immune homeostasis. When 
beginning this thesis, there were few reports on USP4 in cell signalling pathways. Since 
then, new findings have been published which have reported USP4 to play a regulatory 
role in pathways including the NF-κB and RIG-I signalling pathways, and as such may 
be important in inflammatory and immune responses (Zhou et al., 2012, Wang et al., 
2013). It has been suggested that USP4 negatively regulates TNFα, IL-1 and LPS-induced 
NF-κB activation in HEK 293T and HeLa cell lines, through interaction and 
deubiquitination of substrates including TAK1, TRAF2 and TRAF6 (Fan et al., 2011b, 
Xiao et al., 2012, Zhou et al., 2012). In support of this, expression of many 
proinflammatory cytokines regulated by NF-kB were increased with siRNA-mediated 
depletion of USP4 and in Usp4 null mouse embryonic fibroblasts (MEFs) in these 
published studies.  
USP4 has also been reported to positively regulate RIG-I signalling: it stabilises RIG-I to 
enhance RIG-I activation, and consequently downstream production of IFN-β in response 
to viral infection. Additionally, USP4 influences viral replication in HEK 293T cells 
infected with the VSV virus. RLRs recognise viral RNA, including VSV, to trigger an 
antiviral innate immune response indicating that USP4 is potentially involved in the RIG-
I-mediated response to viral infection (Wang et al., 2013). The study examined the effect 
of USP4 on viral replication in a human embryonic kidney cell line, no in vivo 
examination has been performed.  
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There is some crosstalk between the RIG-I and NF-κB pathways: detection of viral RNA 
by RLRs initiates a downstream signal to activate the transcription factor IRF3 through 
TBK1, and also to activate the NF-κB transcription factor through the IKK complex. This 
leads to induction of IFN-β and proinflammatory cytokines, respectively, to mediate 
antiviral and inflammatory responses (Yoneyama et al., 2015). Given that USP4 has been 
reported to regulate RIG-I and NF-κB pathways, USP4 may play important roles in 
facilitating antiviral and inflammatory immune responses. 
When this project was initiated, the role of USP4 in cell signalling pathways was only 
just beginning to emerge and was still poorly defined in any single pathway. Therefore 
the first step was to identify whether USP4 may play a role in cell signalling pathways. 
To determine whether USP4 affects cell signalling pathways, the effects of 
overexpression of Usp4 on the activity of an array of pathways was first examined, as 
listed in Table 2.4. As the activation of these pathways leads to the production of a number 
of genes, including inflammatory cytokines and genes involved in the immune response, 
the wider effect USP4 may have on inflammatory and immune responses was also 
examined. Experiments were performed using wild-type (Usp4+/+), heterozygous 
(Usp4+/-) and Usp4 null mice (Usp4-/-), and MEFs derived from these mice, to explore 
the potential impact Usp4 may have on cytokine production and viral replication in vivo 
and in vitro.  
 Aims 
 Determine whether Usp4 is involved in regulating cell signalling pathways 
associated with cancer  
 Examine the levels of key cytokines in the serum of Usp4+/+, Usp4+/- and Usp4-
/- mice 
 Examine viral replication in MEFs derived from Usp4+/+ and Usp4-/- mice 
 Identify whether viral replication is affected in the brains of Usp4+/+ and Usp4-/- 
mice  
Chapter 3: USP4 in Inflammatory and Immune Pathways 
 
87 
 
 Results 
 Usp4 overexpression affects cells signalling pathways  
To explore the potential role of USP4 in cell signalling pathways, an initial experiment 
to examine the effect of USP4 using a multi-pathway reporter array, which examines the 
gene activity of 10 signalling pathways in one experiment, was performed. Human 
osteosarcoma U2OS cells were used as this cell line has wild-type p53, which is a key 
player in one of the pathways examined in this array. Cells were seeded onto the reporter 
array containing constructs for 10 pathways (listed in Table 2.4) with either wild-type 
Usp4, a catalytically inactive version of Usp4 (C311A) or a control vector (p-CMV6-AN-
mGFP) and a luciferase assay was performed as described in section 2.2.5.2. The 
expression plasmid used was for mouse Usp4 which shares 94% homology with human 
USP4. The reporter array determined that overexpression of Usp4 particularly affected 
the basal activity of p53, NF-κB, MAPK/ERK and MAPK/JNK pathways (Figure 3.1). 
Overexpression of wild-type Usp4 significantly reduced p53 activity compared to the 
control, but not overexpression of catalytically inactive Usp4. MAPK/ERK activity was 
significantly increased with overexpression of wild-type Usp4 but not with 
overexpression of catalytically inactive Usp4. Most notably, overexpression of wild-type 
Usp4 significantly increased both NF-κB activity and MAPK/JNK activity, whereas 
overexpression of catalytically inactive Usp4 significantly reduced NF-κB activity and 
MAPK/JNK activity compared to wild-type Usp4 (Figure 3.1).   
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Figure 3.1. Overexpression of Usp4 affected the activity of cell signalling pathways. A Renilla 
reporter vector and either p-CMV6-AN-mGFP control vector (Control), wild-type Usp4 expression 
plasmid (WT) or catalytically inactive Usp4 expression plasmid (C311A) were added to wells of a 
multi-pathway reporter array plate containing reporter constructs for 10 different pathways. After 
transfection reagent/DNA complex formation, U2OS cells were seeded onto the plates. At 24 hours 
post-transfection a luciferase assay was performed. Data were normalised to Renilla and to positive 
control values and are displayed as normalised relative light units (RLU). Figure is from one 
experiment and plotted as mean ±SEM (n=4/experiment). For statistical analysis, one way ANOVA 
with a post-hoc Tukey comparison test was performed on data from each pathway separately. * 
p≤0.05, **p≤0.01, *** p≤0.001.  
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 Cytokine levels in Usp4+/+, Usp4+/- and Usp4-/- mice 
3.3.2.1 The effect of Usp4 on cytokine levels in mice 
Overexpressing Usp4, but not catalytically inactive Usp4, affected the activity of some 
cell signalling pathways under basal conditions: NF-κB activity and MAPK/ERK or JNK 
activity were significantly increased with Usp4 overexpression (Figure 3.1). As these 
pathways regulate the expression of a number of target genes, including many 
inflammatory cytokines, the effect of USP4 on the levels of multiple cytokines was next 
examined. 
A Usp4 deficient mouse line was produced from gene-trap embryonic stem cells and a 
colony established. Usp4 null (Usp4-/-) mice were viable and were used to detect any 
differences in some key cytokines with loss of Usp4. Serum was obtained from Usp4 
wild-type (Usp4+/+), heterozygous (Usp4+/-) and Usp4-/- mice and an MSD cytokine 
array was performed to measure the levels of a number of cytokines and chemokines in 
one experiment, as described in section 2.2.10. These preliminary data indicated there 
may be alterations in the levels of some cytokines when Usp4 was absent, particularly Il-
6 and C-X-C motif ligand 1(Cxcl1) which were reduced in the serum of Usp4-/- mice 
compared to Usp4+/+ mice (Figure 3.2). The highest levels of Cxcl1 were observed in 
Usp4+/+ mouse serum, with lower levels in Usp4+/- mouse serum and the lowest levels 
in Usp4-/- mouse serum. Il-6 levels were also observed to be at the highest in Usp4+/+ 
mouse serum, with lower levels observed in Usp4-/- mouse serum but levels of Il-6 in the 
serum of Usp4+/- mice were the most reduced (Figure 3.2). 
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Figure 3.2. Cytokine levels in Usp4+/+ (+/+), Usp4+/- (+/-) and Usp4-/- (-/-) mouse serum. A MSD 
cytokine array was performed to measure levels of proinflammatory cytokines in the serum of 
Usp4+/+, Usp4+/- and Usp4-/- mice. Serum samples were added to wells pre-coated with antibodies 
for Il-1β, Il-12p70, Ifn-γ, Il-6, Cxcl1, Il-10 and Tnfα, and levels were detected. All mice were male 
(n=4/genotype). For statistical analysis, one way ANOVA with post-hoc Tukey comparison test was 
performed for each cytokine. * p≤0.05.  
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3.3.2.2 Levels of cytokines Il-6 and Cxcl1 in Usp4-/- mice 
To further examine the potential effect of Usp4 on the levels of cytokines Il-6 and Cxcl1 
in the serum of mice, ELISAs were performed which use antibodies raised against Il-6 
and Cxcl1 to specifically detect levels in the serum of Usp4+/+, Usp4+/- and Usp4-/- 
mice as described in section 2.2.11. In contrast to Figure 3.2 where Il-6 and Cxcl1 were 
detected at lower levels in Usp4-/- compared to the wild-type, no definitive differences 
were observed between the different genotypes of either Il-6 or Cxcl1 and stratifying for 
male/female mice demonstrated no differences between gender (Figure 3.3). 
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Figure 3.3. Levels of Il-6 and Cxcl1 in the serum of mice. ELISAs were performed using serum from 
Usp4+/+ (+/+), Usp4+/- (+/-) and Usp4-/- mice (-/-). A) Il-6. Figure is of one experiment where total 
n=83. B) Cxcl1. Figure is of one experiment where total n=61, respectively. C) Cxcl1. Figure is of one 
experiment where total n=25. Male and female numbers for each genotype are displayed in tables (M 
and F, respectively).  Dots represent outliers.  
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 Viral replication in Usp4-/- mouse embryonic fibroblasts 
Usp4 has a role in the NF-κB signalling pathway, as demonstrated in this chapter by the 
increase observed in NF-κB activity with Usp4 overexpression (Figure 3.1), along with 
potential alterations in cytokine levels with loss of Usp4 (Figure 3.2). USP4 also has a 
reported role in the antiviral RIG-I signalling pathway, which can activate IRF3 and also 
NF-κB transcription factors (Wang et al., 2013). These indicated that USP4 may affect 
immune and inflammatory responses, which if compromised in any way can affect the 
ability for clearing viral infection and lead to changes in viral replication. As a preliminary 
experiment prior to examining VSV replication in rodent brains, the laboratories of Dr 
John Bell and Dr Doug Gray, Ottawa Hospital Research Institute, Ottawa, Canada, used 
a model to determine whether Usp4 affects viral replication in Usp4-/- MEFs. Usp4-/- 
and Usp4+/+ MEFs were infected at various multiplicities of infection (MOIs) with a 
GFP-tagged VSV construct (WT VSV) or a GFP-tagged recombinant 51 VSV virus 
(51 VSV), for which a deletion of methionine 51 affects the interferon response (Stojdl 
et al., 2003). MEFs were visualised under the microscope and supernatants were collected 
for titrering at various time points. All work in this section (3.3.3) was performed by 
Dominic Roy in the Dr John Bell laboratory, Ottawa. Viral replication was increased in 
Usp4-/- MEFs compared the Usp4+/+ MEFs when infected with WT VSV, as observed 
by fluorescent imaging (Figure 3.4). This was apparent at all MOIs and timepoints and 
was also confirmed by viral titre. Additionally, viral replication was increased in Usp4-/- 
MEFs compared to Usp4+/+ MEFs infected with 51 VSV (data not shown). 
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Figure 3.4. VSV viral replication in Usp4-/- MEFs. Usp4-/- and Usp4+/+ MEFs were infected with 
WT VSV at MOI 10 for 16 hours before visualisation for GFP under the microscope. Supernatants 
were also collected for titrering. A) Usp4-/- MEFs B) Usp4+/+ MEFs C) GFP fluorescence of Usp4-/- 
MEFs D) GFP fluorescence of Usp4+/+ MEFs. Bars represent 1000µm.  
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 Viral replication in the brains of Usp4-/- mice 
Given that VSV viral replication was increased in Usp4-/- MEFs, the effect of Usp4 loss 
on viral replication in vivo was next explored. Mice were infected intranasally, through 
the left side, with the virus VSV and immunohistochemical analysis using an antibody 
raised against VSV was performed to determine viral replication in both hemispheres of 
the brains of Usp4-/- and Usp4+/+ mice. Image analysis revealed that the percentage of 
VSV staining was higher in the left hemisphere than in the right hemisphere for both 
groups of mice (Figure 3.5A). Additionally, percentage of VSV staining was higher in 
the brain sections from Usp4-/- mice compared to the brain sections from Usp4+/+ mice. 
This difference was statistically significant in the right hemisphere of the brain sections, 
indicating that viral replication in the right side of the mouse brain was increased in Usp4-
/- mice (Figure 3.5A, Figure 3.5B and Figure 3.5C).  
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Figure 3.5. VSV viral replication in the brains of mice. Usp4+/+ and Usp4-/- mice were infected with 
4 x 106 pfu VSV intranasally (left side) and their brains were harvested and fixed in formalin 48 hours 
post-infection before immunohistochemistry using a VSV antibody and image analysis were 
performed. A) Percentage of VSV staining in Usp4+/+ (+/+) and Usp4-/- (-/-) brain sections in the 
right hemisphere (right) and left hemisphere (left).* p≤0.05. B) Usp4+/+ brain section stained for 
VSV. Bar represents 1mm. C) Usp4-/- brain section stained for VSV. Bar represents 1mm. D) Brain 
section magnified to 40X. Bar represents 50µm. E) Usp4-/- brain section with no primary antibody. 
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 Discussion 
When beginning this thesis, the role of USP4 in any single pathway was not well studied. 
Therefore this chapter aimed to determine the effect of overexpression of Usp4 on key 
cell signalling pathways. Multiple cell signalling pathways regulate the expression of an 
array of genes which are crucial for cellular processes and responses. Many of these genes 
include immunoregulatory cytokines which mediate the immune response. The effect of 
USP4 on many of these cytokines and responses was also examined to further investigate 
the role of USP4 in some cell signalling pathways.  
 Usp4 overexpression affected the activity of cell signalling 
pathways 
An initial experiment to determine whether USP4 affects some key cell signalling 
pathways identified significant differences with Usp4 overexpression in p53, NF-κB, 
MAPK/ERK and MAPK/JNK pathways.  
Zhang et al. (2011) identified USP4 as an inhibitor of the tumour suppressor p53 through 
stabilisation of the p53 E3 ligase, ARF-BP1. Overexpression of USP4, but not 
catalytically inactive USP4 for which the critical Cys 311 residue was mutated to an 
alanine (Ala) residue, reduced reporter activities controlled by the p53-targeting promoter 
p21 in DNA damage-induced human osteosarcoma U2OS cells. This suggests that USP4 
acts as a negative regulator of p53 through its deubiquitinase activity. Using the same cell 
line, in this chapter it was demonstrated that overexpression of Usp4, but again not a 
catalytically inactive Usp4 (C311A), significantly reduced p53 activity in a reporter array, 
in line with the study by Zhang et al. (2011). The catalytically inactive Usp4 used here 
also had a mutation of the Cys of the catalytic site to an Ala. This mutation has been 
shown previously to reduce the DUB activity of human USP4 (Zhang et al., 2011).  
The reporter array also identified USP4 as a potential regulator of the NF-κB pathway, a 
signalling pathway critical in inflammation. Overexpression of wild-type Usp4 
significantly increased NF-κB activity compared to the control. Additionally, 
overexpression of catalytically inactive Usp4 significantly reduced NF-κB activity 
compared to wild-type Usp4, indicating that the catalytic activity of USP4 may positively 
regulate NF-κB. Recently, reports have emerged identifying USP4 as a regulator in the 
NF-κB signalling pathway, although contrary to these data it has been suggested that 
USP4 acts as a negative regulator in downregulating NF-κB signalling (Fan et al., 2011b, 
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Xiao et al., 2012). These studies in human embryonic kidney 293T cells and using NF-
κB-dependent luciferase reporter gene assays proposed that wild-type USP4, but not 
catalytically inactive USP4 C311A or C311S, suppressed TAK1-, TRAF2-, TRAF6-, 
TNFα-, IL-1β- and LPS-induced NF-κB activity. TAK1, TRAF2 and TRAF6 are adaptor 
proteins involved in TNFα- and/or IL-1β-mediated NF-κB signalling which are subject 
to K63-linked polyubiquitination for the recruitment and activation of downstream 
adaptors to mediate the signal and activation of NF-κB. Fan et al. (2011b) reported that 
USP4 negatively regulates NF-κB activation through TNFα-induced TAK1 
deubiquitination and Xiao et al. (2012) further identified TRAF2 and TRAF6 as targets 
of USP4 deubiquitination for TNFα- and IL-1β-induced negative regulation of NF-κB. 
The data herein this chapter indicated that, conversely to these studies, USP4 positively 
regulated NF-κB activity in U2OS cells.  
The contrast in data could be due to a number of reasons. Both published studies were 
conducted in HEK 293T cells whereas the multi-pathway reporter array here was 
performed in U2OS cells meaning there could be differences in how USP4 functions 
between different cell lines. Additionally, the reporter array employed in this chapter was 
performed as a preliminary experiment to determine any signalling pathways Usp4 may 
affect, and as such was performed only at basal levels. The published studies reporting 
USP4 as a negative regulator either overexpressed components of the NF-κB signalling 
pathway, such as TAK1, TRAF2 or TRAF6, or used known stimuli of the NF-κB 
pathway, such as TNFα or IL-1β, to induce NF-κB activation. The mechanism of function 
of USP4 may differ upon activation of the pathway. NF-κB is under tight regulation to 
ensure control of the pathway is maintained and prevent chronic inflammation. It is 
possible that upon stimulation of the NF-κB signalling pathway, USP4 interaction with 
TAK1, TRAF2 and TRAF6 is induced to deubiquitinate their polyubiquitin chains and 
downregulate the signal to prevent uncontrolled activation of the pathway. Under basal 
conditions, USP4 may interact with other proteins to upregulate rather than downregulate 
the pathway. Fan et al. (2011b) did not examine differences between NF-κB activity at 
basal levels with USP4 overexpression and although data from Xiao et al. (2012) did 
show NF-κB basal levels with overexpression of wild-type and catalytically inactive 
USP4, differences were not clear and were not discussed in that study. 
As the reporter array performed in this chapter used 10 different constructs for 10 
different pathways on one plate, it would have been difficult to induce all the pathways, 
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however, it would have been interesting to determine effects of Usp4 overexpression 
when the pathways were induced. The activity of some of these pathways was clearly 
detectable without stimulation although this could be due to low levels of cytokines 
present in the serum added to the media in which the cells were cultured. Further 
examination of the function of USP4 in the NF-κB signalling pathway was needed to 
determine how it may positively regulate NF-κB activation. The next chapter will focus 
on this and further examine TNFα- and IL-1-mediated NF-κB signalling. 
The MAPK pathways are also involved in inflammation as well as proliferation, 
differentiation and apoptosis and signal through a three-tiered cascade of phosphorylation 
events involving a series of Ser/Thr kinases to activate transcription factors, including 
AP-1 and NF-κB (Kim and Choi, 2010). There are three distinct MAPK signalling 
cascades for ERK, JNK and p38, all of which are phosphorylated by a MAPKK which 
itself has been phosphorylated by a MAPKKK upon activation of the pathway. Data from 
the multi-reporter array used transcription factors Elk-1/SRF and AP-1 to examine the 
activity of MAPKs ERK and JNK, respectively. The activity of the ERK pathway was 
significantly increased with overexpression of Usp4, but not with overexpression of 
catalytically inactive Usp4. In addition to affecting the activity of ERK, JNK activity was 
significantly increased with overexpression of Usp4. JNK activity was also significantly 
reduced with the catalytically inactive Usp4 compared to wild-type Usp4, suggesting that 
the deubiquitinase activity of Usp4 may play a role in these MAPK pathways.  
To date there are no known reports to indicate USP4 functions directly within the MAPK 
pathways. Like other cell signalling pathways, MAPK signalling is under tight regulation 
to maintain control and mediate the correct transcriptional response. Many parallel cell 
signalling pathways crosstalk to co-ordinate and shape this transcriptional response 
leading to complex systems that interact at various steps within the signalling pathways. 
As critical in a variety of biological processes and cellular responses, NF-κB and MAPK 
signalling pathways can crosstalk through the activation of a number of proteins including 
TAK1 and members of the TRAF family (Oeckinghaus et al., 2011). Further examination 
of the effects of USP4 on these key pathway adaptor proteins was needed to understand 
the function of USP4 in these pathways and will be the focus of the following chapters in 
this thesis. 
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 Usp4 may affect cytokine levels 
Cell signalling pathways regulate the expression of many genes; NF-κB and MAPK 
pathways are involved in inflammation and as such regulate the expression of many 
cytokines. Given that Usp4 overexpression increased activity of these pathways, the 
effect of Usp4 on cytokine levels was examined. This chapter demonstrated potential 
differences in the levels of cytokines with loss of Usp4 by examination of serum cytokine 
levels in Usp4+/+, Usp4+/-, and Usp4-/- mice. A preliminary cytokine array identified 
lower levels of some cytokines including Il-6 and Cxcl1 in Usp4-/- mouse serum 
compared to Usp4+/+ mouse serum. The chemokine Cxcl1 is a murine homologue of IL-
8 and a key mediator of inflammation. CXCL1 is overexpressed in breast, colon and 
ovarian cancers and is induced through NF-κB and MAPK signalling pathways (Son et 
al., 2007, Lo et al., 2014). Another major inflammatory cytokine, IL-6, can also be 
induced through NF-κB and MAPK pathways (Shimizu et al., 1990, Yang et al., 2008). 
Therefore, the reduction in Il-6 and Cxcl1 levels with loss of Usp4 was supportive of the 
increase in NF-κB and MAPK activity with Usp4 overexpression also observed in this 
chapter.  
Recently, a study challenged usp4-depleted zebrafish larvae with LPS, to stimulate 
TLR/IL-1R signalling, and reported higher levels of expression of proinflammatory 
cytokines, including TNFα and IL-1β, with loss of usp4 (Zhou et al., 2012). This is not in 
line with data from the multiplex cytokine array which indicated that cytokine levels, 
including TNFα and IL-1β were lower with loss of Usp4. However, further examination 
of the levels of Cxcl1 and Il-6 cytokines, by performing ELISAs, identified no obvious 
differences between any of the mouse genotypes, suggesting no effect on these with loss 
of Usp4. Although a larger cohort of mice was used in the ELISAs than in the multiplex 
cytokine array, a limitation of the ELISA was that there were far fewer wild-type mice 
available for examination than Usp4+/- or Usp4-/- mice which may have reduced the 
reliability of these data.  
Another difference between these two types of experiments was that only the serum taken 
from male mice was used in the multiplex cytokine array, whereas both male and female 
serum was examined in the ELISAs. To determine whether this was responsible for the 
differing results, data from the ELISAs were stratified by gender, however no differences 
in cytokine levels between genotypes was observed in either male or female mouse serum.  
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Differences between these data may also be due to different sensitivities of the two 
experiments. Concentrations detected in the MSD cytokine array were generally higher 
than for the ELISAs suggesting that the MSD cytokine array may be more sensitive than 
the ELISAs. All assays were within the standard curves.  
These cytokine levels were measured at basal levels in the serum of these mice. As they 
are inflammatory mediators, it would have been interesting to use a model in which the 
mice were first challenged to induce an inflammatory response. As it has been 
demonstrated herein this chapter that Usp4 has potential involvement in NF-κB and 
MAPK pathways, challenging the mice with LPS could induce an inflammatory response 
through these pathways, perhaps making any differences in cytokine levels with loss of 
Usp4 more evident. It would have been interesting to utilise an inflammatory model such 
as this, however, this was not an available possibility for this thesis. The potential role of 
USP4 in the NF-κB signalling pathway will be addressed further in the next chapter and 
the expression levels of NF-κB regulated genes, including cytokines IL-6 and IL-8 will 
be examined in cell lines stimulated to induce the NF-κB pathway. As no model for 
examining an LPS-induced inflammatory response in Usp4-/- mice was available, a 
model for which mice were induced with VSV to examine effects on viral replication was 
instead adopted.  
 Increased viral replication in Usp4-/- mice 
USP4 has reported roles in inflammatory and immune pathways RIG-I and NF-κB (Wang 
et al., 2013, Fan et al., 2011b, Xiao et al., 2012). In this chapter, overexpression of Usp4 
affected the activity of pathways associated with inflammation and immune responses 
and loss of Usp4 had possible effects on the levels of inflammatory cytokines, further 
indicating that Usp4 may be involved in the inflammatory and immune responses. These 
responses are crucial in detecting viral infection and initiating signalling events to induce 
inflammatory mediators for the clearance of viruses. Given this, the laboratory of Dr John 
Bell used a model for examining the effect of Usp4 loss on immune responses in MEFs.  
Imaging revealed there was more of the VSV virus in the Usp4-/- MEFs than in the 
Usp4+/- MEFs, also confirmed by viral titre of the cell supernatants. This demonstrated 
more viral replication with loss of Usp4 indicating that the inflammatory or immune 
responses within these MEFs were compromised, potentially due the involvement of 
Usp4 in cell signalling pathways.  
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A recent study identified USP4 as a positive regulator of RIG-I signalling, an important 
pathway in the antiviral immune response (Wang et al., 2013). It was reported that USP4 
stabilises RIG-I to enhance RIG-I activation and consequently downstream production of 
IFN-β, a key mediator of antiviral activity, in response to viral infection. In vitro studies 
revealed that viral replication in HEK 293 cells infected with VSV increased viral 
replication with siRNA-mediated loss of USP4. This corresponds with data in this chapter 
for which viral replication was increased in Usp4-/- MEFs.  
Additionally, in vivo examination here (aided by myself) demonstrated an increase in 
viral replication in the brains of Usp4-/- mice infected with VSV virus. Overall, there was 
increased VSV staining in the left hemisphere compared to the right hemisphere of the 
mouse brain, possibly due to the mice being intranasally infected through the left side. 
The difference in VSV between the Usp4-/- mice and Usp4+/+ mice was only statistically 
significant when comparing staining in the right hemispheres, maybe due to a larger 
amount of virus infecting the left side of the brain and maximising antiviral pathways and 
meaning any differences with loss of Usp4 are not as evident. The increased VSV in 
Usp4-/- mouse brains is again supportive of the in vitro data and indicates that Usp4 is 
potentially involved in the innate immune response against viral infection.  
Further to activating the transcription factor IRF3 for the production of type I IFNs, RIG-
I activation is also known to activate the NF-κB transcription factor for the production of 
many inflammatory cytokines through recruitment of the IKK complex. Viral infection 
triggers the innate immune response, where receptors including Toll-like receptors 
(TLRs), IL-1Rs, and RLRs mediate signal transduction to activate transcription factors 
such as AP-1, NF-κB and IRF3 to induce the production of inflammatory cytokines and 
type I IFNs. These inflammatory mediators induce inflammatory responses subsequently 
leading to the immune response to eradicate the viral infection (Negrate, 2012). Taken 
together, data herein this chapter suggest a role for USP4 in inflammatory and immune 
responses, potentially mediated through cell signalling pathways such as NF-κB. As Usp4 
increased NF-κB activity and potentially altered cytokine levels associated with NF-κB 
signalling, the role of USP4 within the NF-κB signalling pathway will be explored in 
more detail in the next chapter. The effect of USP4 on levels of adaptor proteins in the 
pathway and expression of NF-κB-regulated genes will be examined with induction of 
the pathway to examine where and how USP4 may function as a positive regulator for 
the NF-κB signalling pathway. 
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Chapter 4 : The Effect of USP4 Depletion on NF-κB 
Signalling 
 Introduction 
USP4 regulates aspects of many different cell signalling pathways including p53, Wnt/β-
catenin, TGF-β and NF-κB pathways (Zhang et al., 2011, Zhao et al., 2009, Zhang et al., 
2012, Zhou et al., 2012, Fan et al., 2011b, Xiao et al., 2012). The previous chapter 
discussed potential involvement of USP4 in NF-κB signalling: the multi-pathway reporter 
assay performed demonstrated an increase in NF-κB activity when overexpressing wild-
type USP4, but not when overexpressing catalytically inactive USP4 (C311A mutant), 
signifying USP4 was upregulating NF-κB signalling.  
Ubiquitination of proteins involved in NF-κB signalling play vital roles in the regulation 
of the pathway and many DUBs have been identified which act to facilitate this. Amongst 
these are A20 and CYLD which downregulate NF-κB signalling through deubiquitination 
of K63-linked RIP1 polyubiquitin chains and TRAF2, TRAF6, NEMO, TAK1 and RIP1 
polyubiquitin chains, respectively (Wertz et al., 2004, Kovalenko et al., 2003, 
Brummelkamp et al., 2003, Reiley et al., 2007). Additionally, DUBs can upregulate NF-
κB signalling: USP6 induces NF-κB activation through association and activation of the 
IKK complex. Unusually, USP6 did not affect the phosphorylation or degradation of IκBα 
but instead acted in an atypical manner by activating IKK for the phosphorylation of 
nuclear p65 at Ser536 (Pringle et al., 2012). 
There are also reports of a role for USP4 in immune activation and NF-κB signalling: Fan 
et al. (2011b) identified USP4 as a deubiquitinase for TAK1, acting as a downregulator 
of TAK1-mediated NF-κB activation. In agreement with USP4 downregulating NF-κB, 
Xiao et al. (2012) identified USP4 as a deubiquitinase for two members of the TRAF 
family; TRAF2 and TRAF6. Reports on the downregulation of this pathway through 
USP4 indicated that overexpression of USP4 inhibits TNFα-, IL-1β- and LPS-induced 
NF-κB activity, but not overexpression of catalytically inactive versions of USP4 (Fan et 
al., 2011b, Xiao et al., 2012, Zhou et al., 2012). Corresponding with this, these studies 
also observed an increase in TNFα- IL-1β- and LPS-induced NF-κB activity with USP4 
depletion. A role for USP4 in regulating NF-κB activation through upregulation of the 
pathway has not yet been elucidated. A more detailed understanding of the function of 
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USP4 was required in order to examine the mechanism by which it may upregulate NF-
κB activation. 
One role of the NF-κB family is in the immune system: NF-κB can act as a transcriptional 
regulator for many genes including proinflammatory cytokines (Hayden et al., 2006). The 
previous chapter also discussed involvement of USP4 in the immune system; the 
preliminary data suggested levels of some cytokines were reduced in the serum of Usp4 
null mice compared to wild-type, suggesting a dampening down of the immune system. 
In conflict with this, Zhou et al. (2012) reported higher expression levels of 
proinflammatory cytokines in Usp4 null MEFs and usp4-depleted zebrafish larvae.  
To corroborate the involvement of USP4 in immune pathways, a more comprehensive 
examination of the effects of USP4 may enable identification of a mechanism for which 
USP4 upregulates stimulus-induced NF-κB activation and provide a link between effects 
of USP4 in the immune system and NF-κB signalling. This chapter used RNAi to 
knockdown USP4 and examine the functional consequences on various aspects of the 
NF-κB pathway. 
 Aims 
 Determine the effect of siRNA-mediated USP4 depletion on IL-1- and TNFα-
induced NF-κB activation in SW1353 cells 
 Examine IL-1- and TNFα-induced NF-κB activity in Usp4-/- MEFs 
 Identify whether IL-1- and TNFα-induced NF-κB-regulated gene expression is 
affected in siRNA-mediated USP4 depleted SW1353 cells 
 Examine IL-1- and TNFα-induced NF-κB regulated gene expression in Usp4-/- 
MEFs 
 Establish the role of USP4 within the NF-κB signalling pathway through 
examination of siRNA-mediated USP4 depletion on the stability, phosphorylation 
and ubiquitination of key NF-κB adaptor proteins 
 Determine whether the role of USP4 in the activation of NF-κB may involve other 
signalling pathways 
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 Results 
 Depletion of USP4 gene expression and USP4 protein levels by 
targeted siRNA 
To determine whether siRNA targeting USP4 (siUSP4) depletes USP4 expression levels 
and protein levels, two parallel experiments were carried out in different cell lines for 
which USP4 depletion experiments were to be performed. Human SW1353 
chondrosarcoma cells, human HeLa cervical adenocarcinoma cells and human embryonic 
kidney 293T cells were cultured, plated and transfected with siUSP4 or non-targeting 
control siRNA (siControl) as previously described in section 2.2.4.2. To ensure that 
transfection with siCon does not affect USP4 expression, an initial experiment in SW1353 
cells was performed including an additional control where cells were treated with only 
DharmaFECT transfection reagent (DF1) and no siRNA. At 24 hour post-siRNA 
transfection (or DharmaFECT treatment only) cells were lysed and USP4 gene expression 
or USP4 protein levels in whole cell lysates were determined either by real-time qRT-
PCR or by immunoblotting with anti-USP4 antibody, respectively. There was no 
significant difference in USP4 expression between SW1353 cells treated with only DF1 
compared to those also transfected with the control siRNA (Figure 4.1A). Transfection 
of siUSP4 resulted in significant depletion of USP4 mRNA levels in SW1353 cells: USP4 
was more than 90% depleted compared to the control (Figure 4.1A). This reduction in 
USP4 was also reflected in USP4 protein levels in SW1353, HeLa and HEK 293T cells 
(Figure 4.1A, Figure 4.1B and Figure 4.1C).  
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Figure 4.1. USP4 protein levels and USP4 gene expression were reduced following transfection with 
a USP4-targeting siRNA. A) Relative gene expression analysis and protein expression analysis of 
USP4 in SW1353 cells transfected with either a non-targeting siRNA (siCon) or a USP4-targeting 
siRNA (siUSP4) or treated with DF1 but no siRNA (DharmaFECT only) for 24 hours. Gene 
expression data were normalised to 18S and are relative to siCon=100%. Data are plotted as mean 
±SEM (n=6). Student’s t-test (unpaired) was performed as statistical analysis. ** p≤0.01. B) Protein 
expression analysis of USP4 in HEK 293T cells transfected with either siCon or siUSP4 for 24 hours. 
C) Protein expression analysis of USP4 in HeLa cells transfected with siCon or siUSP4 for 24 hours. 
Protein analysis for all cell lines was performed on whole cell lysates, GAPDH was used as a loading 
control.  
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 The effect of USP4 depletion on TNFα- and IL-1-induced NF-κB 
activity 
To clarify the impact of USP4 depletion on the activation of the NF-κB pathway, a 
luciferase reporter assay was performed. SW1353 cells were transfected with responsive 
NF-κB firefly luciferase reporter and Renilla expression vectors before depletion of USP4 
by RNAi. After stimulation with either tumour necrosis factor α (TNFα) or interleukin-1 
(IL-1), luciferase activity was measured and normalised to Renilla. Optimal stimulation 
conditions were previously determined in section 2.2.5.3. The reporter assay determined 
that depleting USP4 significantly reduced both IL-1- and TNFα-induced NF-κB activity 
compared to the control (Figure 4.2A and Figure 4.2B). 
 
Figure 4.2. Depletion of USP4 significantly reduced NF-κB activity. NF-κB-dependent firefly 
luciferase and Renilla reporter vectors were transfected into SW1353 cells followed by USP4 
depletion by transfection with siCon or siUSP4 after 6-8 hours. At 24 hours post-siRNA transfection 
cells were serum-starved overnight before a 6 hour stimulation, cell lysis and measurement of 
luciferase activity. Data were normalised to Renilla and are relative to siCon=100%. Data are 
displayed in normalised relative light units (RLU). A) SW1353 cells were stimulated with IL-1α 
(0.5ng/ml) or remained unstimulated (Unstim). Figure is of 4 combined independent experiments 
±SEM (n=4/experiment). ** p≤0.01. B) SW1353 cells were stimulated with TNFα (10ng/ml) or 
remained unstimulated (Unstim). Figure is of 3 combined independent experiments and plotted as 
mean ±SEM (n=4/experiment). **p≤0.01, *** p≤0.001. Student’s t-test (unpaired) was performed for 
statistical analysis. 
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 The effect of USP4 depletion on TNFα- and IL-1-induced 
expression of NF-κB-regulated genes 
Activation of the NF-κB transcription factor through pathway activation by a variety of 
stimuli, such as IL-1 and TNFα, induces the expression of numerous genes including 
many proinflammatory cytokines. As depleting USP4 significantly reduced NF-κB 
activity, the next stage was to examine whether there was any effect upon NF-κB-
regulated genes. Therefore, interleukins IL-6, IL-8 and matrix metalloproteinase 13 
(MMP13) were analysed. SW1353 cells were transfected and stimulated, as described in 
section 2.2.4.2, and IL-6, IL-8 and MMP-13 gene expression measured by real-time qRT-
PCR. This quantitative analysis revealed that both IL-1 and TNFα-induced IL-6 and 
MMP13 relative gene expression were significantly reduced in USP4 depleted cells 
compared to the control (Figure 4.3A, Figure 4.3C, Figure 4.4A and Figure 4.4C). 
Although, IL-1- and TNFα-induced relative IL-8 gene expression appeared reduced in 
USP4 depleted cells compared to the control this did not reach statistical significance 
(Figure 4.3B and Figure 4.4B). USP4 expression was determined in each experiment and 
was significantly depleted in all experiments, with no change in expression with either 
IL-1 or TNFα stimulation (Figure 4.3D and Figure 4.4D). 
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Figure 4.3. USP4 regulated IL-1-induced NF-κB-regulated gene expression. SW1353 cells were 
transfected with siCon or siUSP4 for 24 hours and stimulated with IL-1α (0.5ng/ml) for 6 hours or 
left unstimulated (Unstim) after overnight serum-starvation. Total RNA was extracted, reverse 
transcribed to cDNA and analysed by real-time qRT-PCR. Relative gene expression of IL-1α-induced 
A) IL-6, B) IL-8, C) MMP13 and D) USP4 were measured. Data were normalised to 18S and are 
shown as relative to siCon=100%. Data are combined from at least 2 independent experiments 
(n=6/experiment) and plotted as mean ± SEM. ** p<0.01, *** p<0.001. Student’s t-test (unpaired) 
was performed for statistical analysis. 
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Figure 4.4. USP4 regulated TNFα-induced NF-κB-regulated gene expression. SW1353 cells were 
transfected with siCon or siUSP4 for 24 hours and stimulated with TNFα (10ng/ml) for 6 hours or 
left unstimulated (Unstim) after overnight serum-starvation. Total RNA was extracted, reverse 
transcribed to cDNA and analysed by real-time qRT-PCR. Relative gene expression of TNFα-
induced A) IL-6, B) IL-8, C) MMP13 and D) USP4 were measured. Data were normalised to 18S and 
are shown as relative to siCon=100%. Data are combined from at least 2 independent experiments 
(n=6/experiment) and are plotted as mean ± SEM. ** p<0.01, *** p<0.001. Student’s t-test (unpaired) 
was performed for statistical analysis. 
  
si
C
on
si
U
SP
4
0
50
100
150
Unstim
TNF
***
IL-6
IL
6
/1
8
S
si
C
on
si
U
SP
4
0
50
100
150
Unstim
TNF
IL-8
IL
8
/1
8
S
si
C
on
si
U
SP
4
0
50
100
150
Unstim
TNF
***
MMP13
M
M
P
1
3
/1
8
S
si
C
on
si
U
S
P
4
0
50
100
150
Unstim
USP4
TNF
*** ***U
S
P
4
/1
8
S
A B
C D
Chapter 4: The Effect of USP4 Depletion on NF-κB Signalling 
 
111 
 
4.2.3.1  USP4 and the regulation of IL-1-induced NF-κB-regulated gene 
expression over a stimulation time course  
To further confirm the effect of USP4 depletion on NF-κB-regulated genes, cells were 
treated with IL-1 over a time course. Total RNAs were extracted from USP4 depleted and 
control SW1353 cells (treated with IL-1 for the time points indicated) and real-time qRT-
PCR was performed. Both IL-6 and IL-8 gene expression increased after stimulation 
before declining after 6 hours IL-1 stimulation (Figure 4.5A and Figure 4.5B). MMP13 
gene expression increased after IL-1 stimulation and continued to increase at each time 
point over the 24 hour stimulation period (Figure 4.5C). As in Figure 4.3A, relative IL-6 
gene expression was reduced in USP4 depleted cells in comparison to the control, 
significantly so at 6 hours after stimulation (Figure 4.5A). Similarly, relative IL-8 
expression was reduced in USP4 depleted cells, significantly so at 3 hours after 
stimulation (Figure 4.5B). Relative MMP13 expression was significantly reduced in 
USP4 depleted cells at 1, 3, 6 and 24 hours IL-1 stimulation (Figure 4.5C). From these 
data, depletion of USP4 reduced NF-κB-regulated expression of IL-6, IL-8 and MMP13 
genes after stimulation with IL-1 at different time points within a 24 hour period.  
To confirm USP4 depletion in these experiments, the relative gene expression levels of 
USP4 were analysed by the same method. Figure 4.5D shows that levels of USP4 were 
depleted in the cDNA of cells transfected with siUSP4 and that the levels did not change 
significantly with IL-1 stimulation in control cells.
  
1
1
2
 
 
Figure 4.5. USP4 regulated IL-1α-induced NF-κB-regulated gene expression. SW1353 cells were transfected with siCon or siUSP4 for 24 hours and, after a period of serum-
starvation, were stimulated with IL-1α (0.5ng/ml) for 0, 1, 3, 6 and 24 hours (h). Total RNA was extracted, reverse transcribed to cDNA, and analysed by real-time qRT-
PCR. Relative gene expression of A) IL-6, B) IL-8, C) MMP13 and D) USP4 were measured. Data are normalised to 18S and show as relative to siCon 24h = 100%. Data are 
combined from at least 2 independent experiments (n=6/experiment). Student’s t-test (unpaired) were performed as statistical analysis. Data are plotted as mean ±SEM. * 
p<0.05, ** p<0.01, *** p<0.001.
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4.2.3.2  USP4 and the regulation of TNFα-induced NF-κB-regulated gene 
expression over a stimulation time course 
In addition to IL-1, TNFα stimulation after 6 hours resulted in less NF-κB-regulated gene 
expression in USP4 depleted cells in comparison to the control (Figure 4.4), therefore 
relative gene expression after TNFα stimulation over a time course was also examined. 
Unlike previously where the relative IL-6 expression was reduced in USP4 depleted cells 
after 6 hours stimulation (Figure 4.4A), USP4 depletion resulted in significantly increased 
relative IL-6 expression after 3, 6, and 24 hours TNFα stimulation (Figure 4.6A).  
Similarly, relative IL-8 expression appeared increased in USP4 depleted cells compared 
to the control, although this was only significant after 3 hours stimulation (Figure 4.6B). 
As with IL-1 stimulation, TNFα-induced relative MMP13 expression was significantly 
reduced in USP4 depleted cells compared to the control, specifically after 6 and 24 hours 
stimulation (Figure 4.6C).  
To confirm the depletion of USP4 in these experiments, USP4 gene expression was also 
measured. Transfection with siRNA against USP4 resulted in significantly lower levels 
of relative USP4 expression compared to the control. This expression did not change 
significantly with TNFα stimulation (Figure 4.6D).   
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Figure 4.6. USP4 regulated TNFα-induced NF-κB-regulated gene expression. SW1353 cells were transfected with siCon or siUSP4 for 24 hours and, after a period of serum-
starvation, were stimulated with TNFα (10ng/ml) for 0, 1, 3, 6 and 24 hours (h). Total RNA was extracted, reverse transcribed  to cDNA and analysed by real-time qRT-
PCR. Relative gene expression of A) IL-6, B) IL-8, C) MMP13 and D) USP4 were measured. Data are normalised to 18S and relative to siCon 24h = 100%. Data are combined 
from at least 2 independent experiments (n=6/experiment). Student’s t-test (unpaired) were performed as statistical analysis. Data are plotted as mean ±SEM. * p<0.05, ** 
p<0.01, *** p<0.001.
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 The effect of USP4 depletion on levels of key NF-κB signalling 
pathway adaptor proteins 
Evidence from the data so far indicates that NF-κB activation was reduced by the 
depletion of USP4 and, in addition, the IL-1-induced expression of genes which are 
regulated by NF-κB were also reduced. This suggests USP4 plays a role in the regulation 
of NF-κB signalling so further analysis was performed to try and uncover the function of 
USP4 in NF-κB signalling. There are many key adaptor proteins important for the 
activation of NF-κB and so the effect of USP4 depletion on the levels of some of these 
key proteins were next explored to identify whether their stability or phosphorylation, 
generally a marker of their level of activation, are regulated by USP4. USP4 was depleted 
in SW1353 cells before treatment with IL-1 for the indicated time points. Cells were then 
lysed, total protein extracted, resolved by electrophoresis and immunoblotted with the 
relevant antibody. In addition to visually examining protein levels, differences were 
verified by quantification of the protein bands through densitometry. 
4.2.4.1 The effect of USP4 depletion on the IL-1-induced degradation of IκBα 
The liberation of the NF-κB dimer from its inhibitory proteins is an integral step in the 
NF-κB signalling pathway. This occurs after the phosphorylation of IκBα by IKK which 
allows recognition by the E3 ligase, SCFβ-TrCP, thus triggering the K48-linked 
polyubiquitination and subsequent degradation of IκBα (Spencer et al., 1999). As such a 
crucial event in the activation of NF-κB, the levels of IκBα with USP4 depletion were 
first examined. 
Upon depletion of USP4, there were higher levels of IκBα compared to the control (Figure 
4.7A). This was particularly evident after 5 and 15 minutes stimulation with IL-1 which 
densitometric analyses confirmed were statistically significant differences (Figure 4.7B). 
Higher IκBα levels indicate either increased stability of IκBα or increased expression 
when USP4 is depleted, consistent with downregulation of the pathway. As 
phosphorylation of IκBα occurs prior to IκBα ubiquitination, levels of phosphorylated 
IκBα were also examined. The phosphorylation of IκBα appeared to be induced in a 
biphasic manner with levels increasing after 5 and then 15 minutes of IL-1 stimulation, 
then decreasing at 30 minutes before another increase at 60 minutes (Figure 4.7A). This 
was the same for both control and USP4 depleted cells. There was less phosphorylation 
of IκBα in USP4 depleted cells but densitometry analysis determined that this difference 
was not statistically significant (Figure 4.7B). 
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4.2.4.2  The effect of USP4 depletion on IL-1-induced IκBα gene expression 
As the loss of USP4 resulted in a significant change in IκBα protein levels, the effect on 
its gene expression was then examined. As when examining the effect on the expression 
of other NF-κB-regulated genes, USP4 depleted SW1353 cells were stimulated with IL-
1 over a time course before the extraction of total RNA and analysis by real-time qRT-
PCR. 
Figure 4.7C illustrates a reduction in IκBα gene expression in USP4 depleted cells 
compared to the control, further suggesting downregulation of NF-κB signalling with 
USP4 depletion, and suggesting the mechanism that leads to altered IκBα following USP4 
depletion is not due to an increase in IκBα expression.  
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Figure 4.7. USP4 depletion affected IκBα protein levels and IκBα gene expression. SW1353 cells were 
transfected with siCon or siUSP4 for 24 hours, serum-starved and treated with IL-1α (0.5ng/ml) for 
the indicated times (minutes). A) Total protein was extracted, resolved by SDS-PAGE and 
immunoblotted with anti-IκBα and anti-phospho-IκBα (P-IκBα) antibodies. GAPDH was used as a 
loading control. Figure is representative of 5 independent experiments. B) Quantification of IκBα 
and P-IκBα protein levels. IκBα: Data are plotted as mean ± SEM *p<0.05, **p<0.01. Data are 
combined from 5 independent experiments for IκBα and standardised to siCon 0=1. P-IκBα: data 
are plotted as mean ±SEM. Data are combined from 4 independent experiments for P-IκBα and 
standardised to siCon 15=1. C) Total RNA was extracted, reverse transcribed to cDNA and analysed 
by real-time qRT-PCR. Relative IκBα gene expression was measured and normalised to 18S. Data 
are combined from 3 experiments (n=6/experiment) and plotted as mean ±SEM. *p<0.05, **p<0.01, 
*** p<0.001. Student’s t-test (unpaired) were performed as statistical analysis.   
0 5 15 30 600 5 15 30 60
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
siUSP4
siCon*
**
IB
IL-1  stimulation time (mins)
R
e
la
ti
v
e
 d
e
n
s
it
y
20 40 60
0
1
2
3
4
siCon
siUSP4
P-IB
IL-1  stimulation time (mins)
R
e
la
ti
v
e
 d
e
n
s
it
y
IB
0 20 40 60 80 10
0
12
0
0
50
100
150
siCon
siUSP4
*
**
***
IL-1  stimulation time (mins)
I 
B

/1
8
S
siCon siUSP4
IκBα
P-IκBα
GAPDH
IL-1α (0.5ng/ml):
A
B
C
:min
Chapter 4: The Effect of USP4 Depletion on NF-κB Signalling 
 
  
118 
  
4.2.4.3  The effect of USP4 depletion on the IL-1-induced polyubiquitination of 
IκBα 
For degradation of IκBα to occur, it first becomes ubiquitinated with K48-linked 
polyubiquitin chains by the E3 ligase SCFβ-TrCP (Spencer et al., 1999). Figure 4.7 indicates 
that USP4 depletion resulted in increased stability of IκBα. This would suggest there may 
be a difference in the ubiquitination of IκBα which leads to this change in its degradation 
kinetics; therefore the ubiquitination of IκBα was next examined.  
An initial experiment determined whether inhibiting USPs in general resulted in a change 
in the ubiquitination levels of IκBα. SW1353 cells were stimulated with IL-1 for the 
indicated time points and treated with either ethanol as a control/vehicle or the DUB 
inhibitor, N-ethylmaleimide (NEM). Additionally, either DMSO (again as a 
control/vehicle) or proteasome inhibitor MG132 (carbobenzoxy-Leu-Leu-leucinal), to 
prevent degradation of IκBα, were also added to additional cells. Cells treated with 
MG132 showed smeared bands at high exposure (indicative of polyubiquitination), 
particularly after 30 and 60 minutes treatment. However, treatment with NEM had no 
effect. IκBα appeared to become increasingly ubiquitinated after stimulation with IL-1 as 
would be expected but treatment with NEM did not alter the amount of IκBα 
ubiquitination (Figure 4.8A).  
Next, rather than inhibiting DUBs in general, the effect of specifically targeting USP4 
depletion on the ubiquitination of IκBα was examined. USP4 was depleted in SW1353 
cells as previously, and again stimulated with IL-1 for the indicated time points. 
Additionally, cells were treated with MG132 at the time of stimulation to prevent 
degradation of IκBα and allow visualisation of ubiquitinated IκBα. Analysis by 
immunoblotting with an anti-IκBα antibody and a longer exposure time when developing 
revealed a stronger smeared band at 60 minutes IL-1 stimulation in the control than in the 
USP4 depleted cells, indicating that IκBα does become more ubiquitinated and is 
therefore degraded more rapidly in the control cells than in the USP4 depleted cells 
(Figure 4.8B). MG132 severely inhibited the degradation of IκBα, but even with this, the 
effect of USP4 loss on the degradation that did occur was evident.  
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Figure 4.8. IκBα ubiquitination. A) MG132 inhibits proteasome. SW1353 cells were stimulated with 
IL-1α (0.5ng/ml) for 0, 30 and 60 minutes and treated with MG132 (5µM) and/or NEM (2mM) or 
DMSO and/or ethanol controls as indicated. Total protein was extracted, resolved by SDS-PAGE 
and immunoblotted with an anti-IκBα antibody. B) Reduced IκBα ubiquitination with USP4 
depletion. SW1353 cells were transfected with siCon or siUSP4, serum-starved and treated with IL-
1α (0.5ng/ml) and MG132 (5µM) for 0, 5, 15, 30 and 60 minutes before lysis and immunoblotting with 
an anti-IκBα antibody. GAPDH was used as a loading control. Figure is representative of 2 
independent experiments. 
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4.2.4.4  The effect of USP4 depletion on IL-1-induced phosphorylation of p65 
Consistent with downregulation of the NF-κB pathway, USP4 depletion increased the 
ubiquitination of IκBα and decreased the degradation of IκBα with IL-1 stimulation 
(Figure 4.7A and Figure 4.8B). The phosphorylation, ubiquitination and subsequent 
degradation of IκBα to release bound dimers of NF-κB exposes the NF-κB nuclear 
localisation site (NLS), allowing its translocation to the nucleus where it activates the 
transcription of many genes. In canonical NF-κB signalling, NF-κB exists as mostly p65 
heterodimers with p50, which becomes phosphorylated as part of the regulation in the 
activation of NF-κB; the phosphorylation of p65 occurs in accordance with the 
phosphorylation of IκBα (Sakurai et al., 2003). As USP4 depletion affected levels of 
IκBα, the levels of p65 and P-p65 further downstream in the pathway were examined. 
Figure 4.9A indicates the levels of p65 were equal; there was no change when stimulated 
with IL-1 or between USP4 depleted and control cells implying that USP4 does not affect 
the stability of p65. The phosphorylation of p65 increased with IL-1 stimulation in both 
USP4 depleted and control. P-p65 was reduced following USP4 depletion, however, this 
reduction was not fully reproducible and therefore failed to reach statistical significance 
when quantified (Figure 4.9B).  
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Figure 4.9. USP4 depletion and the effect on the levels of phosphorylation of NF-κB subunit, p65. 
SW1353 cells were transfected with siCon or siUSP4, serum-starved and treated with IL-1α 
(0.5ng/ml) for the indicated times (minutes). A) Total protein was extracted, resolved by SDS-PAGE 
and immunoblotted with anti-p65 and anti-P-p65 antibodies. GAPDH was used as a loading control. 
Figure is representative of 5 independent experiments. B) Quantification of protein levels. Data are 
plotted as mean ± SEM. Student’s t-tests (unpaired) were performed as statistical analysis. Data are 
combined from 5 independent experiments. 
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4.2.4.5  The effect of USP4 depletion on IL-1-induced phosphorylation levels of 
IKKα/β   
Further upstream of p65 and IκBα, the IKK complex is involved in the phosphorylation 
of IκBα. As such, the protein levels of IKKα, IKKβ and the phosphorylated form, P-
IKKα/β, were examined following USP4 depletion and IL-1 stimulation. 
The levels of total IKKα and IKKβ remained unchanged with IL-1 stimulation in both 
control and USP4 depleted cells indicating their stability was not affected by the loss of 
USP4 (Figure 4.10A). Upon activation of the NF-κB pathway, IKK subunits become 
phosphorylated to allow IκBα phosphorylation. Measurement of levels of phosphorylated 
IKKα/β revealed a reproducible reduction in IL-1-stimulated phosphorylation of IKKα/β 
in USP4 depleted cells compared to the control (Figure 4.10A). Quantification confirmed 
the significance of this reduction after 15, 30 and 60 minutes (phospho-protein levels at 
time points earlier than 15 minutes were unquantifiable) (Figure 4.10B). 
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Figure 4.10. USP4 depletion and the effect on IKKα, IKKβ and phosphorylated IKKα/β protein 
levels. SW1353 cells were transfected with siCon or siUSP4, serum-starved and treated with IL-1α 
for the indicated times (minutes). A) Total protein was extracted, resolved by SDS-PAGE and 
immunoblotted with anti-IKKα, anti-IKKβ and anti-P-IKKα/β antibodies. GAPDH was used as a 
loading control. Figure is representative of 4 independent experiments. B) Quantification of protein 
levels. Data are plotted as mean ± SEM. ***≤0.001. Student’s t-tests (unpaired) were performed as 
statistical analysis. Data are combined from 4 independent experiments and standardised to 
siCon15=1. 
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4.2.4.6  The effect of USP4 depletion on the phosphorylation levels of JNK 
The IKKβ subunit of the IKK complex is phosphorylated by TAK1, an essential step in 
the activation of NF-κB. TAK1 is a MAPKKK, also essential in the activation of JNK 
and p38. As depleting USP4 clearly had an effect on the levels of phosphorylated IKKα/β, 
levels of phosphorylated p38, ERK and JNK were also examined through 
immunoblotting. 
Depleting USP4 had no effect on IL-1-induced phosphorylation of p38 (Figure 4.11A). 
Basal levels of P-p38 appeared higher following USP4 depletion, although this was not 
reproducible. Additionally, USP4 depletion had no effect on the phosphorylation of ERK, 
but as ERK phosphorylation was not increased with IL-1 stimulation in either control or 
USP4 depleted cells, the ERK pathway may not have been activated by IL-1 (Figure 
4.11A). However, there was a striking reduction in the phosphorylation of JNK in USP4 
depleted cells compared to the control (Figure 4.11A). Quantification of the 
phosphorylation at Thr183 and Tyr183 of two isoforms of JNK, JNK1 and JNK2, which 
both have two different splicing forms, 54kDa (the prominent splicing form of JNK2) and 
46 kDa (the prominent splicing form of JNK1) identified a significant difference in the 
phosphorylation of the larger JNK (54kDa) after 15, 30 and 60 minutes stimulation with 
IL-1 (Figure 4.11B). There also appeared to be a reduction in the phosphorylation of the 
smaller JNK (46kDa) after 5, 15, 30 and 60 minutes stimulation with IL-1 although this 
was not statistically significant with the densitometry method used (Figure 4.11). Protein 
levels at stimulation time points lower than those mentioned were unquantifiable by this 
technique.  
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Figure 4.11. USP4 depletion and the effect on MAPK protein levels. SW1353 cells were transfected 
with siCon or siUSP4, serum-starved and treated with IL-1α for the indicated times (minutes). A) 
Total protein was extracted, resolved by SDS-PAGE and immunoblotted with anti-P-p38, anti-P-
ERK and anti-P-JNK antibodies. GAPDH was used as a loading control. Figure is representative of 
3 independent experiments. B) Quantification of P-JNK protein levels (54 kDa band). C) 
Quantification of P-JNK protein levels (46 kDa band). Data are plotted as mean ± SEM. * p≤0.05, 
*** p≤0.001. Student’s t-tests (unpaired) were performed as statistical analysis. Data are combined 
from 3 experiments and standardised to siCon15=1.  
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4.2.4.7  The effect of USP4 depletion on TNFα-induced levels of key NF-κB 
adaptor proteins 
NF-κB activation occurs via a number of stimuli, in addition to IL-1 the pathway can be 
induced by TNFα via TNFRs. To further investigate the effect of USP4 on NF-κB 
signalling, SW1353 cells were stimulated with TNFα after USP4 depletion before lysis 
and western blot analysis. Immunoblotting was performed using antibodies for those key 
proteins found to be of interest with USP4 depletion in IL-1-induced cells (sections 
4.2.4.1, 4.2.4.4, 4.2.4.5 and 4.2.4.6).  
IL-1-induced IκBα levels were higher in USP4 depleted cells (Figure 4.7) and with TNFα 
induction there was an increase in IκBα levels at basal levels and after 5 and 15 minutes 
induction in USP4 depleted cells compared to the control (Figure 4.12). Additionally, 
phosphorylated p65 was moderately reduced in USP4 depleted cells and phosphorylated 
IKKα/β after 30 minutes induction with TNFα appeared to be lower in USP4 depleted 
cells than the control. Overall, any differences between the levels of these key NF-κB 
adaptor proteins with and without USP4 depletion were not as definitive in TNFα-induced 
SW1353 cells as in IL-1-induced SW1353 cells. 
 
Figure 4.12. USP4 depletion and the effect on TNFα-induced NF-κB adaptor protein levels. SW1353 
cells were transfected with siCon or siUSP4, serum-starved and treated with TNFα (10ng/ml) for the 
indicated times (minutes). A) Total protein was extracted, resolved by SDS-PAGE and 
immunoblotted with anti-IκBα, anti-P-p65, anti-P-IKKα/β, anti-P-JNK and anti-USP4 antibodies. 
GAPDH was used as a loading control. Figure is representative of 3 independent experiments. 
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4.2.4.8  The effect of USP4 depletion on IL-1- and TNFα-induced levels of key NF-
κB adaptor proteins in HeLa cells 
To verify the findings in this chapter on the effect of USP4 depletion on levels of proteins 
involved in NF-κB signalling and to establish if this was due to cell-specific effects, levels 
of key NF-κB adaptor proteins were examined in cervical adenocarcinoma HeLa cells. 
Depletion of USP4 protein levels in HeLa cells with transfection of siUSP4 was 
confirmed in section 4.2.1. As with SW1353 cells, USP4 was depleted before treatment 
with IL-1 or TNFα for the indicated time points. Cells were then lysed, total protein 
extracted, resolved by electrophoresis and immunoblotted with the relevant antibody. As 
with TNFα induction in SW1353 cells, only the key NF-κB adaptor proteins of interest, 
for which differences in levels with USP4 depletion were previously identified, were 
examined.   
Similarly to IL-1-induction in SW1353 cells, levels of phosphorylated p65 were reduced 
when USP4 was depleted, particularly after 15, 30 and 60 minutes of stimulation (Figure 
4.13A). Again there was a dramatic reduction in the phosphorylation of both IKKα/β and 
JNK in SW1353 cells, as observed in Figure 4.10 and Figure 4.11. Surprisingly, there did 
not appear to be any IκBα degradation in either the control or USP4 depleted cells, known 
to be a key step in NF-κB activation. Considering there were changes in the levels of both 
phosphorylated IKKα/β and p65 which are upstream and downstream of IκBα, 
respectively, IL-1 was evidently inducing the pathway. Rather than loss of IκBα 
degradation, it is possible that resynthesis of IκBα was balancing its degradation: 
following stimulation, as much IκBα was being synthesised as degraded which would 
explain why levels of IκBα were unchanged. 
Contrary to IL-1 stimulation, TNFα stimulation induced clear degradation of IκBα 
(Figure 4.13B). Furthermore, levels of IκBα were higher in USP4 depleted cells compared 
to the control, particularly evident at basal levels and after 5 and 60 minutes TNFα 
stimulation. This suggests less or slower degradation of IκBα in USP4 depleted cells, 
consistent with the effects of USP4 depletion on IκBα degradation in SW1353 cells, or 
increased expression of USP4 as IκBα was induced after 5 minutes stimulation with 
TNFα. Again, dramatic reductions in the phosphorylation of both IKKα/β and JNK were 
observed in USP4 depleted cells. Overall, effects of USP4 depletion with IL-1 and TNFα 
induction on NF-κB adaptor proteins in HeLa cells were consistent with effects observed 
in SW1353 cells, although the effect in HeLas appeared to be more pronounced with 
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TNFα induction than in SW1353s and more representative of observations with IL-1α 
induction. There was also no apparent degradation of IκBα in IL-1-induced HeLa cells.  
 
Figure 4.13. USP4 depletion and the effect on NF-κB adaptor protein levels in stimulated HeLa cells. 
HeLa cells were transfected with siCon or siUSP4, serum-starved and stimulated for the indicated 
times (minutes). Total protein was extracted, resolved by SDS-PAGE and immunoblotted with anti-
IκBα, anti-P-p65, anti-P-IKKα/β, anti-P-JNK and anti-USP4 antibodies. GAPDH was used as a 
loading control. A) Cells were stimulated with IL-1α (0.5ng/ml). Figure is taken from 2 experiments. 
B) Cells were stimulated with TNFα (10ng/ml). Figure is representative of one experiment. 
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 NF-κB signalling in Usp4-/- mouse embryonic fibroblasts 
Mouse embryonic fibroblast (MEF) cell lines were established from wild-type and Usp4-
/- mouse embryos (described in section 2.2.1.1). MEFs can be used as a powerful model 
to address protein function and cell signalling (Lovas et al., 2012, Zhang et al., 2011). As 
data has shown in this chapter, depleting USP4 in SW1353 and HeLa cells significantly 
affected NF-κB signalling therefore MEFs were next used for validating these results. 
4.2.5.1  IL-1-induced NF-κB activity in Usp4+/+ and Usp4 -/- MEFs 
USP4 depletion reduced NF-κB activity in SW1353 cells in section 4.2.2 and so the first 
step was to examine IL-1-induced NF-κB activity in MEFs from Usp4-/- mouse embryos 
(Usp4 -/-) and MEFs from wild-type mouse embryos (Usp4 +/+). Initially, MEFs were 
transfected with a NF-κB responsive firefly luciferase reporter and a constitutive Renilla 
expression vector. After a period of serum-starvation cells were stimulated with IL-1 
before relative luciferase activity was measured. Data showed light units only detectable 
at background levels indicating no transfection of NF-κB firefly luciferase reporter or 
Renilla expression vectors (data not shown). Primary cell lines, such as MEFs, are 
notoriously difficult to transfect and so the next approach was to transduce a lentiviral 
NF-κB reporter vector, pHAGE-NFκB-TA-LUC-UBC-GFP-W, into the MEFs.  
Lentiviral supernatant was produced by transfection of lentiviral expression vector, 
pHAGE-NFκB-TA-LUC-UBC-GFP-W, and viral packaging plasmids into HEK 293T 
cells (section 2.2.14.2). Viral supernatant was collected and the MEFs were transduced 
with the supernatant before overnight serum starvation and stimulation with IL-1. MEFs 
were then lysed and luminescence measured. To verify successful introduction of the 
lentiviral expression vector into cells, a preliminary experiment in SW1353 cells was 
performed. Cells were either infected with lentiviral preparations with/without IL-1 
stimulation or treated with polybrene only. Infection with lentiviral preparations 
increased light units compared to the control, which was increased more than 500 fold 
with IL-1 stimulation, indicating that transduction was successful (Figure 4.14).  
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Figure 4.14. IL-1-induced NF-κB activity in SW1353 cells. Lentiviral supernatant for a NF-κB-
dependent firefly luciferase expression vector (pHAGE-NFκB-TA-LUC-UBC-GFP-W) was 
transduced into cells. SW1353 cells were infected with lentiviral preparations with IL-1α stimulation 
(0.5ng/ml) for 6 hours (Lenti-NF-κB + IL-1α), without IL-1α (Lenti-NF-κB) or with polybrene only 
(Control). Luminescence was measure after cell lysis. One way ANOVA with a post-hoc Tukey 
comparison test was performed as statistical analysis. Data are plotted as mean ± SEM 
(n=4/experiment). *** p≤0.001. 
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Next, both Usp4-/- and Usp4+/+ MEFs were infected with lentiviral preparations for the 
NF-κB luciferase reporter vector and the reporter assay performed as described above. 
IL-1-induction increased NF-κB activity by over 300 fold and 200 fold in Usp4 +/+ and 
Usp4-/- MEFs, respectively. When induced with IL-1, NF-κB activity was significantly 
reduced in Usp4-/- MEFs compared with Usp4 +/+ MEFs by over 35% (Figure 4.15).   
 
Figure 4.15. IL-1-induced NF-κB activity in MEFs. Lentiviral preparations were transduced into 
wild-type (+/+) and Usp4 null (-/-) MEFs for 24 hours before overnight serum starvation. Cells were 
stimulated with IL-1α (0.5ng/ml) for 6 hours, or left unstimulated (Unstim), before lysis and 
measurement of luminescence. Data are shown relative to IL-1α-induced +/+ = 100%. Student’s t-
tests (unpaired) were performed as statistical analysis. Data are combined from 2 independent 
experiments and plotted as mean ± SEM (n=4/experiment). *** p≤0.001. 
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4.2.5.2  IL-1-induced expression of NF-κB-regulated genes in Usp4-/- MEFs  
As with SW1353 cells, expression of NF-κB-regulated genes was measured in the MEFs. 
The day after cells were seeded, the MEFs were subjected to overnight serum-starvation. 
After stimulation with IL-1 (0.5ng/ml) total RNAs were extracted from Usp4-/- and 
Usp4+/+ MEFs and real-time qRT-PCR was performed.  
Relative Usp4 gene expression was essentially undetectable in Usp4-/- compared to 
Usp4+/+ MEFs with and without IL-1 stimulation (Figure 4.16D). In Usp4+/+ MEFs 
there was a significant increase in relative Usp4 gene expression after stimulation with 
IL-1α, not previously observed in SW1353 cells (section 4.2.3). As expected, IL-1α 
stimulation significantly increased expression of Il-6, Cxcl1 (the mouse homologue of IL-
8) and Mmp13 (Figure 4.16A to Figure 4.16C). IL-1-induced relative Il-6 and Mmp13 
gene expression were significantly reduced in the Usp4-/- MEFs (Figure 4.16A and 
Figure 4.16C). IL-1-induced relative Cxcl1 expression was not significantly reduced in 
Usp4-/- compared to Usp4+/+ (Figure 4.16B). These data concur with IL-1-induced 
expression of NF-κB-regulated genes in SW1353 cells, supporting the previous evidence 
that absence of USP4 downregulates inflammatory gene expression, presumably by 
regulation of the NF-κB pathway. 
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Figure 4.16. USP4 regulated IL-1-induced NF-κB-regulated gene expression in MEFs. Wild-type 
(+/+) and Usp4 null (-/-) MEFs were stimulated with IL-1α (0.5ng/ml) for 6 hours after overnight 
serum-starvation. Total RNA was extracted, reverse transcribed to cDNA and analysed by real-time 
qRT-PCR. Relative gene expression of IL-1α-induced A) Il-6, B) Cxcl1, C) Mmp13 and D) Usp4 were 
measured. Data were normalised to 18S and shown as relative to IL-1α-induced +/+ =100%. Data are 
combined from at least 2 experiments (n=6/experiment). Student’s t-test (unpaired) were performed 
as statistical analysis. Data are plotted as mean ± SEM. *p<0.05, ** p<0.01, *** p<0.001.  
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 Discussion 
Data from a multi-pathway reporter assay in the previous chapter alluded to a potential 
role for USP4 as a positive regulator of NF-κB signalling, something not previously seen. 
Therefore this chapter further examined USP4 by using RNAi as a molecular biological 
tool to deplete USP4 in cells. Following this, work was replicated in MEFs isolated from 
Usp4-/- mice and their wild-type littermates.  Effects were examined using a combination 
of approaches to study proteins and genes involved in NF-κB signalling in the hope of 
identifying a previously unfound role for USP4 in upregulating NF-κB activation.  
USP4 has actually been reported as a negative regulator of the NF-κB signalling pathway 
(Fan et al., 2011b, Zhou et al., 2012, Xiao et al., 2012). Results in this thesis chapter 
ultimately indicated that depleting USP4 downregulates IL-1-, and possibly less 
pronounced, TNFα-induced NF-κB signalling, suggesting USP4 upregulates NF-κB 
signalling, in stark contrast with the literature.  
It was first established that NF-κB activity was significantly reduced when cells with 
USP4 depletion were induced with both IL-1 and TNFα; consistent with data in the 
previous chapter for which overexpression of wild-type, but not catalytically inactive, 
Usp4 increased NF-κB activity. This is conflicting with published data which reported an 
increase in TNFα- and IL-1β-induced NF-κB activity with USP4 depletion and a 
reduction in TNFα- and IL-1-induced NF-κB activity with overexpression of wild-type, 
but not catalytically inactive, USP4 (Fan et al., 2011b, Zhou et al., 2012, Xiao et al., 
2012). To begin to elucidate the mechanism for USP4 in enhancing NF-κB activity, and 
why data might be conflicting with published data, more studies were performed. 
 IL-1- and TNFα-induced NF-κB-regulated gene expression 
NF-κB is an important transcription factor responsible for the regulation of many genes 
involved in the immune and inflammatory response, and any changes in the activation of 
NF-κB may be reflected in the expression levels of these target genes. IL-6 and IL-8 are 
cytokines which function as major mediators in inflammation. The activation of IL-6 and 
IL-8 gene expression can be mediated through NF-κB by inducers including IL-1 and 
TNFα (Shimizu et al., 1990, Kunsch and Rosen, 1993). It was demonstrated in this 
chapter that USP4 enhanced IL-1-induced expression of proinflammatory cytokines: after 
stimulation with IL-1 at certain time points over a 24 hour period there was a significant 
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decrease in IL-6 and IL-8 gene expression with USP4 depletion. This is again in contrast 
to literature which reported enhanced expression of IL-1-induced NF-κB-regulated gene 
expression, including IL-6 (Zhou et al., 2012). Whereas in this chapter it was 
demonstrated that IL-1-induced expression of IL-6 was reduced with siRNA-mediated 
depletion of USP4 in SW1353 cells after stimulation for 6 hours or after stimulation over 
a 24 hour time course, Zhou et al. (2012) reported that IL-1-induced expression of IL-6 
was enhanced with lentivirus shRNA-mediated USP4 knockdown in MEFs after 
stimulation for 4 hours. Differences could therefore be due to variations in cell lines or 
species utilised or method of USP4 depletion. Even though the IL-1 stimulation times 
varies slightly between published data and data in this chapter, at no time point was IL-6 
expression enhanced here. All IL-1-induced gene expression experiments herein were 
performed at least twice and the depletion of USP4 was consistently confirmed for each 
experiment. No known study has reported effects of USP4 depletion on IL-1-induced 
expression of IL-8 although other IL-1-induced NF-κB-regulated genes were measured 
which were also reported to be enhanced with USP4 depletion.  
With TNFα-induced expression of proinflammatory cytokines, the data were less clear. 
Initially, experiments demonstrated a reduction in IL-6 with USP4 depletion after 6 hours 
stimulation with TNFα, but over a time course of stimulations IL-6 appeared to increase 
with USP4 depletion. The latter is more in line with other studies in which TNFα 
induction enhanced expression of NF-κB-regulated genes including IL-6 and IL-8 with 
the knockdown of USP4 (Fan et al., 2011b, Xiao et al., 2012). Fan et al. (2011b) reported 
that TNFα-induced expression of IL-6 was enhanced in stable USP4 knockdown HeLa 
cells, and Xiao et al. (2012) reported that TNFα-induced expression of IL-6 and IL-8 were 
enhanced in siRNA-mediated USP4 depleted lung adenocarcinoma epithelial A549 cells, 
whereas the expression of IL-6 and IL-8 herein was measured in SW1353 cells with 
siRNA-mediated USP4 depletion, therefore differences could be cell-specific. The period 
of TNFα stimulation in published data (30-120 minutes) was also much shorter than here 
(1-24 hours) and it was reported that the expression of IL-6 peaked after 60 minutes of 
stimulation before decreasing whereas it was observed here that IL-6 was consistently 
increased over the 24 hour period. The reduction in TNFα-induced IL-6 expression with 
USP4 depletion after 6 hours stimulation could therefore be due to longer stimulation 
times.  
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The cascade of proteins and their activation as part of NF-κB activation does differ 
between IL-1 induction through the IL-1R and TNFα stimulation through the TNFR 
which may account for the differences in the alterations in gene expression levels 
depending on where USP4 functions in the pathway. However, this would not account 
for differences between the data observed with a 6 hour TNFα stimulation and the data 
collected at various TNFα stimulation times (including 6 hours) and so the reason for 
these observations remain unclear. Experimental procedure was the same when cells were 
stimulated for 6 hours and cells were stimulated over a time course: all experiments were 
performed in 96-well plates with the same density of cells, the same protocol was 
followed and cells were stimulated with the same concentration of TNFα (10ng/ml). The 
only difference was that cells were serum-starved for a longer period when stimulations 
were performed over a time course to allow cells stimulated for different lengths of time 
to be lysed at the same time. All gene expression experiments were replicated at least 
twice to validate results.  
In addition to proinflammatory cytokines, NF-κB is involved in the regulation of many 
other important genes. MMP13 has been majorly implicated in osteoarthritis and 
rheumatoid arthritis as a mediator of cartilage degradation when overexpressed. The 
regulation of MMP13 is complex and can be expressed by induction with TNFα, IL-1 and 
through TLRs, largely induced via AP-1, composed of c-Jun and c-Fos proteins, and NF-
κB transcription factors, both of which can often be induced by the same stimulus e.g. IL-
1 (Mengshol et al., 2000, Otero et al., 2012, Schmucker et al., 2012). In USP4 depleted 
cells, MMP13 expression was reduced with both IL-1 and TNFα induction across a 24 
hour period, indicating that USP4 is involved in IL-1- and TNFα-induced pathway(s) 
which regulate the expression of MMP13. No other studies examined the effect of USP4 
depletion on MMP13 but this is in line with data for the reduced IL-1-induced IL-6 and 
IL-8 expression also observed in this chapter.  
 Depletion of USP4 altered IL-1α-induced NF-κB adaptor protein 
levels 
Although some gene expression data appeared to be contrasting, it did suggest USP4 
affected NF-κB-regulated genes. As IL-1 stimulation proved to give the most consistent 
and profound differences on NF-κB-regulated gene expression with USP4 depletion, 
focus was given to IL-1-induced effects on NF-κB adaptor proteins. 
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For NF-κB to become activated, it relies on a cascade of events involving the recruitment 
and phosphorylation of many adaptor proteins. With both TNFα and IL-1 stimulus, the 
transactivation of NF-κB can occur through phosphorylation of Ser-536 on the p65 
subunit of NF-κB after its translocation to the nucleus to induce expression of its target 
genes by binding to consensus sequence, GGGATTTCC (Sakurai et al., 1999, Sakurai et 
al., 2003, Buss et al., 2004). Data in this chapter demonstrated a potential reduction in IL-
1-induced p65 phosphorylation when USP4 was depleted, suggesting decreased NF-κB 
activation in accordance with decreased target gene expression. Studies have shown 
dynamic translocation of NF-κB. Oscillations in NF-κB translocation arise from a 
negative feedback loop involving IκBα: degradation of IκBα allows NF-κB translocation 
to the nucleus for the transcriptional activation of NF-κB target genes, including IκBα 
which then binds to NF-κB to aid the nuclear export of NF-κB (Nelson et al., 2004, 
Hoffmann et al., 2002a). It would therefore have been interesting to study the effects of 
USP4 depletion on p65 translocation to and from the nucleus. 
Prior to p65 phosphorylation, NF-κB translocation to the nucleus occurs after the K48-
linked polyubiquitination and degradation of IκBα so it is no longer sequestered in the 
cytoplasm. Consistent with reduced phosphorylation of p65, signifying reduced NF-κB 
activation, IL-1-induced IκBα degradation was also reduced with USP4 depletion. The 
IκB family includes other members IκBβ, IκBγ, IκB which can regulate NF-κB, possibly 
through more complex regulation (Napetschnig and Wu, 2013).  Although the effect of 
USP4 depletion on these other isoforms could have been studied, the best characterised 
is IκBα with knowledge on how its degradation is key in IL-1-induced NF-κB activation 
and as such was studied here. 
As IκBα is degraded by the proteasome after K48-linked polyubiquitination, changes in 
its degradation suggest changes in its ubiquitination; therefore IκBα ubiquitination was 
examined. As many DUBs, including USPs, regulate NF-κB activation, the effect of 
inhibiting USPs using NEM, which acts by blocking DUB active sites, and the 
proteasome inhibitor MG132, was first examined. MG132 is a peptide aldehyde which 
inhibits the proteolytic activity of the 26S proteasome, leading to accumulation of K48-
linked polyubiquitinated proteins. At longer exposures, higher molecular weight IκBα 
‘smears’, which were attributed to K48-linked polyubiquitination of IκBα, were visible 
with MG132 treatment. There was no obvious difference in IκBα ubiquitination with 
DUB inhibition. This could be due to the low dose of NEM used: higher doses were toxic 
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to cells but the dose used may not have been high enough for successful full inhibition of 
DUBs. Previous reports utilising NEM for the inhibition of DUBs used it at a 
concentration of 10mM, however this was only added to the lysis buffer and this 
concentration was found to be toxic when directly added to cells here (Shenoy and 
Lefkowitz, 2002, Hjerpe et al., 2009). Therefore, a lower dose of 2mM NEM was used. 
Alternatively, inhibiting DUBs may result in their counteraction which may mask any 
specific effects on IκBα. The tight network of regulation of NF-κB signalling involves 
multiple DUBs which deubiquitinate different proteins within the NF-κB pathway to both 
upregulate and downregulate NF-κB activation. The effect of inhibiting DUBs which 
reduce IκBα ubiquitination may therefore be masked by inhibiting other DUBs which 
have other effects on other proteins in the NF-κB pathway. Confirmation of DUB 
inhibition with NEM at the concentration used would be needed to determine whether 
this is the case. 
As MG132 allowed visualisation of IκBα, the effect of specifically targeting USP4 
depletion was then studied: the IL-1-induced bands of ubiquitinated IκBα were less 
abundant when USP4 was depleted. This corresponded with higher levels of the protein 
observed with USP4 depletion; the two experiments overall representing reduced or 
slower degradation of IκBα.  
In addition to genes including MMP13 and cytokines IL-6 and IL-8, the translocation of 
NF-κB to the nucleus upon IκB degradation activates the transcription of other genes, 
including IκBα itself. This allows a negative feedback mechanism for the temporal 
control of NF-κB activation (Hoffmann et al., 2002a). Reduced IκBα gene expression 
observed with USP4 depletion also implied downregulation of the pathway, differing to 
Fan et al. (2011b) who reported enhanced IκBα expression in USP4 knockdown cells. 
However, this was with TNFα stimulation and IκBα expression was not measured with 
IL-1 stimulation in this published study. 
There is no evidence to suggest that USP4, as a deubiquitinase, directly acts on IκBα as 
ubiquitination appears decreased in absence of USP4, rather more it hypothesises that 
USP4 functions upstream of IκBα. For IκBα to be recognised by the specific E3 ligase 
SCFβ-TrCP and K48-linked polyubiquitinated for degradation, it is first phosphorylated by 
the IKK complex  (Spencer et al., 1999). IKK is itself activated through TAK1-mediated 
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phosphorylation of the IKKβ subunit at two serine residues within the activation loop. As 
NF-κB activation and IκBα degradation were affected by USP4 depletion, the effect on 
the phosphorylation of the IKK complex was studied to determine whether USP4 may act 
upstream of IκBα. Phosphorylation of IKKα/β was dramatically reduced with USP4 
depletion, indicating there was less phosphorylation of IKK by TAK1 upon IL-1 
stimulation in these cells, and again tying in with downregulation of NF-κB activation. 
Zhou et al. (2012) reported a decrease in IL-1β-induced IκBα levels, again in opposition 
to data in this chapter, however, no study reported on IL-1-induced levels of either P-p65 
or P-IKKα/β. Published data on the effects of IL-1 induction on the level of IκBα also 
utilised a lentivirus-mediated shRNA knockdown of USP4 in HeLa cells, rather than the 
siRNA-mediated depletion of USP4 in SW1353 cells here. Differences in experimental 
methods and cell lines used could therefore account for these conflicting data. Protein 
level experiments were all performed at least three times for reproducibility and 
densitometry combined from these experiments were performed to confirm the 
consistency of any observations and to allow analysis of statistically significant 
differences. As a good antibody against USP4 has been lacking, it is possible the 
antibodies may recognise USP15, which shares significant sequence homology with 
USP4 and so in some initial experiments, the depletion of USP4 was not definitively 
confirmed. The antibody chosen did demonstrate depletion of USP4 with an siRNA 
targeting USP4 and was used to confirm USP4 depletion in most protein analysis 
experiments. Therefore, use of a more accurate USP4 antibody would be helpful.   
Results presented in this chapter consistently pointed towards involvement of USP4 in 
the upregulation of NF-κB activation, in direct contrast to reports in the literature. The 
differences in levels of key adaptor proteins involved in IL-1-induced NF-κB signalling 
were remarkable, particularly the change in the amount of phosphorylated IKKα/β.  
However, previous reports mostly focussed on TNFα-induced NF-κB signalling and here 
the focus was on IL-1 induction. To determine if the differences are due to this, levels of 
key adaptor proteins altered with IL-1 stimulation in USP4 depleted SW1353 cells were 
also examined with TNFα stimulation. Although there may be small differences, the 
effects were not as clear as with IL-1 stimulation. As well as conflicts in data potentially 
arising from differences in cell lines used and methodology, USP4 may function 
differently with different stimuli. Further experimentation is needed to determine where 
USP4 may function to positively regulate IL-1-induced NF-κB signalling. As multiple 
Chapter 4: The Effect of USP4 Depletion on NF-κB Signalling 
 
  
140 
  
proteins are regulated by their ubiquitination in NF-κB signalling, as will be discussed 
further, potential USP4 deubiquitination targets will be examined further in the next 
chapter. 
 IL-1-induced phosphorylation of JNK was reduced with USP4 
depletion 
The particularly significant effect of USP4 depletion on IL-1-induced IKKα/β 
phosphorylation alludes to a role for USP4 acting upstream of the IKK complex. 
Although reports have been inconsistent with the findings in this chapter they have found 
a function for USP4 as a deubiquitinase for TAK1, a kinase which acts upstream of the 
IKK complex and activates IKKβ by phosphorylation (Wang et al., 2001, Fan et al., 
2011b). The K63-linked polyubiquitination of TAK1 is essential for this kinase activation 
and downstream signalling effects in transduction pathways (Fan et al., 2010). In addition 
to acting as an IKK kinase in NF-κB signalling, TAK1 can act as a MAPKKK in 
activating MAPK pathways including p38 and JNK (Moriguchi et al., 1996, Ninomiya-
Tsuji et al., 1999, Shirakabe et al., 1997). Other NF-κB signalling proteins that are crucial 
for the activation of the IKK complex also feature in MAPK activation to mediate 
crosstalk between parallel signalling pathways. As an E3 ligase, TRAF6 ubiquitinates 
IRAK1, TAK1 and self-ubiquitinates with K63-linked polyubiquitination, critical for the 
proximal recruitment of TAK1 and IKK for downstream NF-κB signal transduction in 
IL-1-mediated signalling (Conze et al., 2008, Fan et al., 2010, Lamothe et al., 2007).  
Another member of the TRAF family, TRAF2 is involved in the recruitment of cIAP1/2 
to the TNFR1 complex for TNFα-mediated NF-κB activation (Vince et al., 2009). TRAFs 
can also function as a divergent platform in signal transduction pathways: the activation 
of TRAF6 in IL-1-mediated signalling mediates the activation of TAK1 that can lead to 
activation of not only the NF-κB but also the MAPK pathway. Alternatively, TRAF2, as 
well as activating NF-κB, can associate with several MAPKs for activation of MAPK 
pathways in response to TNFα (Chung et al., 2002). TRAF6 and TRAF2, as well as 
TAK1, are reported substrates for USP4 deubiquitination (Xiao et al., 2012, Zhou et al., 
2012). That data in this thesis alluded to a potential function for USP4 upstream of the 
IKK complex, and that these proteins can also regulate MAPK pathways, led to 
examination of the effects of USP4 depletion on the phosphorylation of MAPKs JNK, 
p38 and ERK. 
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USP4 depletion with IL-1 stimulation in SW1353 cells, and with both IL-1 and TNFα 
stimulation in HeLa cells, abrogated the phosphorylation of JNK, indicative of a reduction 
in activation of the JNK MAPK pathway.  However, it should be noted that JNK total 
protein levels were not measured. In line with reduced JNK phosphorylation, in Chapter 
3 a multi-pathway reporter assay demonstrated an increase in MAPK/JNK activity with 
USP4 wild-type overexpression, but not catalytically inactive USP4 overexpression. It 
has not been reported previously as to whether USP4 is involved in the IL-1-induced 
regulation of JNK phosphorylation and activation. However, conflicting with these data, 
Zhou et al. (2012) reported reductions in the TRAF6- and bacterial lipopolysaccharide 
(LPS)-induced activity of AP-1, a transcription factor which is activated upon activation 
of MAPK pathways, with overexpression of USP4. It would be of interest to determine 
whether depletion of USP4 affects the IL-1-induced activity of AP-1 by performing an 
AP-1-dependent luciferase reporter assay.  
Previously in this chapter, the effect of USP4 on the expression of NF-κB-regulated genes 
were examined with reductions in IL-6 and MMP13 with the depletion of USP4. As well 
as NF-κB, IL-1 induces other signalling pathways through its IL-1R including MAPK 
pathways p38, ERK and JNK. Along with requiring NF-κB translocation for its induction 
MMP13 also requires JNK activation for IL-1-induction of MMP13 in some systems 
(Mengshol et al., 2000). The reduction in the phosphorylation of JNK and the reduction 
in this NF-κB- and JNK-regulated IL-1-induced gene with USP4 depletion, further 
indicates possible crossover between NF-κB and MAPK pathways or USP4 functioning 
upstream of the IKK complex, possibly acting on TAK1 or TRAF6 and thereby having 
more widespread effects than on NF-κB signalling.  
Many of the proteins involved in NF-κB and MAPK signalling pathways are 
ubiquitinated for their regulation, stability and recruitment of proteins for downstream 
signal transduction, leading to the possibility that USP4 functions upstream of the IKK 
complex to positively regulate NF-κB signalling through the deubiquitination of these 
proteins. In IL-1-induced NF-κB signalling, K63-linked polyubiquitin chains act as a 
scaffold for the recruitment of proteins and are crucial for NF-κB activation (Xu et al., 
2009b). TRAF6 both self-ubiquitinates and ubiquitinates TAK1 and IRAK1 with K63-
linked polyubiquitin chains to mediate recruitment and activation of the IKK complex in 
IL-1 signalling (Lamothe et al., 2007, Fan et al., 2010, Conze et al., 2008). Further, 
TRAF6, TAK1 and IRAK1 can also be ubiquitinated with K48-linked polyubiquitin 
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chains to target them for degradation in the regulation of NF-κB signalling (Zhou et al., 
2010, Fan et al., 2012, Cui et al., 2012). Many DUBs which have been identified to 
function in the NF-κB signalling pathway do so by the removal of polyubiquitin chains 
on key adaptor proteins such as these to maintain tight functioning of NF-κB activation 
(Harhaj and Dixit, 2012). As USP4 has been demonstrated to function in the NF-κB 
pathway herein this chapter, potentially by acting upstream of the IKK complex, this gives 
rise to the possibility that USP4 may function by deubiquitinating substrates such as 
TRAF6, TAK1 or IRAK1. Literature reports TRAF6 and TAK1 as targets of USP4 
deubiquitination of K63-linked polyubiquitination (Xiao et al., 2012, Fan et al., 2011b). 
However, these reports were largely conflicting with data in this thesis. Further, Zhou et 
al. (2012) reported that USP4 mediated the removal of TRAF6 K48-linked polyubiquitin 
chains indicating that the mechanism of function of USP4 in NF-κB signalling may be 
complex, with multiple substrates of USP4. To gain further insight into the role of USP4 
within NF-κB signalling, identifying potential substrates and determining whether USP4 
affects the polyubiquitination of these will therefore be further explored in the next 
chapter.  
 Altered levels of IL-1- and TNFα-induced NF-κB adaptor proteins 
were not cell-specific 
This study utilised the chondrosarcoma SW1353 cell line whereas other studies were 
carried out using other cell lines including HEK 293T and cervical adenocarcinoma 
HeLas. To determine whether the effects observed were specific to SW1353 cells, the 
levels of these key adaptor proteins were also examined in HeLa cells. Similarly to in 
SW1353 cells, there appeared to be slightly lower levels of IL-1-induced phosphorylated 
p65, indicating less NF-κB activation in USP4 depleted HeLa cells, and again a markedly 
reduced amount of phosphorylated IKKα/β thereby verifying effects seen in this study. 
Additionally, there was less TNFα-induced IκBα degradation and less phosphorylation of 
IKKα/β. These effects were much clearer in the HeLa cells than in SW1353 cells 
suggesting that USP4 depletion may have stronger, or different, effects in some cell lines 
than others.   
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 IL-1-induced NF-κB activity and NF-κB-regulated gene expression 
were reduced in Usp4-/- MEFs 
Further to this, NF-κB activity and NF-κB gene regulation were measured in Usp4+/+ 
and Usp4-/- MEFs. Null MEFs are a powerful biological tool for exploring the effects of 
USP4, the loss of which was confirmed by measuring Usp4 gene expression alongside all 
gene expression experiments by real-time qRT-PCR. Exactly the same as in USP4 
depleted SW1353 cells, IL-1-induced Il-6 and Mmp13 were significantly reduced in 
Usp4-/- MEFs whereas there may have been a small but insignificant reduction in Cxcl1 
(IL-8 mouse homologue) after 6 hours stimulation. These data also tie in with data in the 
previous chapter which identified reductions in Il-6 and Cxcl1 in the serum of Usp4-/- 
mice using a cytokine array. Differing to this, Zhou et al. (2012) reported an increase IL-
6 expression in Usp4-/- MEFs, however this was in response to stimulation with LPS 
which signals through toll-like receptors (TLRs) to activate NF-κB. Whereas TLRs 
recognise microbial patterns, such as LPS, IL-1Rs bind IL-1-related cytokines. Both TLR 
and IL-1 signalling share many of the same mechanisms, and both the TLRs and the IL-
1R are characterised by an intracellular toll/IL-1 receptor domain (TIR). Similarly to IL-
1-mediated NF-κB activation through the IL-1R, LPS-mediated NF-κB activation 
through TLR-4 involves the recruitment of MyD88, IRAK4 and IRAK1 for IRAK4-
mediated phosphorylation, recruitment of TRAF6 and similar downstream signal 
transduction. However, whereas binding of IL-1 to the IL-1R leads to the formation of a 
receptor complex with IL-1RAcP and recruitment of MyD88 through TIR domains, LPS-
induced recruitment of MyD88 to TLR-4 requires a TIR domain-containing adaptor 
protein (TIRAP).  Moreover, LPS-induced NF-κB signalling through TLR-4 can occur 
independently of MyD88, involving TRIF-related adaptor molecule (TRAM), which 
associates with TRAF6 and RIP1 to induce NF-κB activation (Verstrepen et al., 2008). 
The differences in IL-6 expression in Usp4-/- MEFs as reported with LPS induction, and 
as observed here with IL-1 induction could therefore be due to differences in the signal 
transduction between TLR- and IL-1-mediated signalling. 
In addition to reductions in NF-κB-regulated gene expression, IL-1-induced NF-κB 
activation was reduced in Usp4-/- MEFs in a lentiviral NF-κB reporter assay, confirming 
data observed in SW1353 cells with siRNA-mediated depletion of USP4.  
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 Summary 
The aims of this chapter were to further elucidate a role for USP4 in NF-κB signalling 
through examination of the effects of siRNA-mediated USP4 depletion on NF-κB 
activation, NF-κB-regulated gene expression and on the stability, phosphorylation or 
ubiquitination of key NF-κB adaptor proteins. Studies in this chapter have demonstrated 
a role for USP4 in positively regulating NF-κB activation: IL-1-induced NF-κB activity 
and the expression of NF-κB-regulated genes were reduced in siRNA-mediated USP4 
depleted SW1353 cells and in Usp4-/- MEFs. In addition, there was diminished 
phosphorylation of proteins within the pathway, and reduced IκBα ubiquitination and 
degradation with USP4 depletion. Taken together, the data in this thesis chapter indicated 
that loss of USP4 downregulated IL-1-induced NF-κB signalling. 
Conclusions on the role of USP4 in TNFα-induced NF-κB signalling were not as 
straightforward. Where TNFα-induced NF-κB activity was reduced, opposing data on the 
effect of TNFα-induced NF-κB-regulated gene expression was observed.  
Data in this chapter is opposing to previous reports on the function of USP4 in NF-κB 
signalling. Although the reason for this remains unclear, differences in cell lines used and 
the type and duration of stimulations could possibly account for this. SW1353 cells were 
predominantly used in these experiments but to determine if effects were cell-specific, 
the levels of some proteins altered by the loss of USP4 were also examined in HeLa cells. 
Although, similarly to in SW1353 cells, there were reductions in the IL-1-induced 
phosphorylation of p65 and IKKα/β, IκBα was not degraded. Additionally, effects on 
TNFα-induced protein levels were more dramatic in HeLa cells than in SW1353 cells, 
indicating that there may be differences in the mechanism of NF-κB signalling between 
cell lines and therefore differences with USP4 depletion. The increased NF-κB activity 
observed with overexpression of Usp4 in the previous chapter conflicted with published 
data, possibly due to mouse Usp4 rather than human USP4 being overexpressed. However, 
experiments in this chapter used an RNAi approach to deplete endogenous USP4 in 
human SW1353 cells and a reduction in NF-κB activity was observed, in line with the 
increase in NF-κB activity with mouse Usp4. Additionally, reductions in IL-1-induced 
NF-κB activity and NF-κB-regulated gene expression in USP4 depleted cells were 
mimicked in Usp4-/- MEFs. 
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Due to more significant and consistent results, focus was given to the role of USP4 in IL-
1-induced NF-κB signalling, whereas the literature mainly focuses on TNFα-induced or 
LPS-induced NF-κB signalling. The mechanism of NF-κB activation differs downstream 
of IL-1Rs, TNFRs and TLRs as discussed, meaning that USP4 could have different 
functions in each of these pathways. Thorough examination of the effects of USP4 
depletion on aspects of NF-κB signalling was performed with validation of results by 
replication of experiments and regular confirmation of the depletion of USP4 which 
consistently alluded to a role for USP4 as a positive regulator of IL-1-induced NF-κB 
signalling.  
As IL-1 induced USP4 effects appeared to be the most significant in identifying a possible 
mechanism for the function of USP4 in NF-κB signalling, further elucidating how USP4 
may function to positively regulate IL-1-induced NF-κB activation would be interesting 
and as yet remained undefined. Data in this chapter has indicated USP4 could act 
upstream of the IKK complex. There are many NF-κB adaptor proteins upstream of IKK, 
including IRAK1, TAK1 and TRAF6, which rely on ubiquitination, mainly K63-linked 
polyubiquitination, for the activation and recruitment of proteins crucial for the activation 
of the pathway. Additionally, the K48-linked polyubiquitination and degradation of 
proteins is important in regulating NF-κB, often by preventing persistent activation of the 
pathway. The next chapter will try to identify potential substrates of USP4 and elucidate 
whether USP4, as a DUB, affects the polyubiquitination of these potential targets 
upstream of IKK in the pathway. 
 Conclusions 
USP4 depletion in SW1353 cells: 
 Reduced IL-1- and TNFα-induced NF-κB activity 
 Reduced IL-1-induced NF-κB-regulated gene expression and in some cases 
TNFα-induced NF-κB-regulated gene expression 
 Reduced the IL-1 ubiquitination of IκBα and correspondingly reduced the 
degradation of IκBα in SW1353 cells and HeLa cells 
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 Non-significantly reduced the IL-1-induced phosphorylation of p65 and 
significantly reduced the phosphorylation of IKKα/β and JNK in SW1353 cells 
and HeLa cells 
 Reduced the TNFα-induced degradation of IκBα and the phosphorylation of 
IKKα/β and JNK in HeLa cells 
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Chapter 5 : Target(s) of USP4 within the NF-κB Pathway 
 Introduction 
The previous chapter demonstrated IL-1-induced effects on the levels and 
phosphorylation of specific NF-κB adaptor proteins and effects on the expression of NF-
κB-regulated genes with loss of USP4. Together, data alluded to a potential role for USP4 
upstream of the IKK complex which will be explored further in this chapter. 
Upon binding of IL-1 to the IL-1R, a series of adaptor proteins are recruited for the 
cascade of signalling events required for the activation of the IKK complex and 
downstream NF-κB activation. Many of these events are ubiquitin-dependent and rely on 
different types of polyubiquitin chains for the recognition and activation of key adaptor 
proteins (Iwai, 2014). Amongst others, K63-linked polyubiquitin chains feature in the 
NF-κB signalling pathway, functioning as scaffolds for the recruitment of a multitude of 
proteins upstream of the IKK complex. IL-1 induction leads to the phosphorylation of 
IRAK1 and subsequent recruitment of TRAF6 followed by the TRAF6-mediated K63-
linked polyubiquitination of IRAK1, at Lys134/Lys180, and K63-linked self-
polyubiquitination of TRAF6, at Lys124, in conjunction with E2 enzyme Ubc13/Uev1A 
(Lamothe et al., 2007, Conze et al., 2008). These K63 polyubiquitin chains serve to recruit 
the IKK complex via the NEMO subunit to ubiquitinated IRAK1, and to recruit TAK1 
via TAB2 and TAB3 UBDs to ubiquitinated TRAF6 for its activation of TAK1 and the 
downstream activation of IKK. Furthermore, NEMO also binds to K63-linked 
polyubiquitin chains on TAK1, the ubiquitination of which is mediated again by TRAF6 
upon IL-1 induction for the activation of TAK1 and occurs at Lys158 on TAK1 (Fan et 
al., 2010). These K63-linked polyubiquitin chains together serve as a platform for 
recruiting the IKK complex proximally to the activated TAK1, required for the activation 
of NF-κB. Equally, these polyubiquitin chains can be specifically removed by a number 
of DUBs for the negative regulation of NF-κB and prevention of uncontrolled NF-κB 
activity (Harhaj and Dixit, 2011). Two well-studied DUBs with functions in the NF-κB 
pathway, A20 and CYLD, deubiquitinate substrates including the K63-linked 
polyubiquitin chains on TRAF6 for the downregulation of NF-κB signalling (Heyninck 
and Beyart, 1999, Trompouki et al., 2003). CYLD has also been shown to remove TAK1 
K63-linked polyubiquitin chains for the downregulation of NF-κB (Reiley et al., 2007). 
Both A20- and CYLD-deficient mice show enhanced susceptibility to induced 
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inflammation, highlighting the importance of DUBs in the regulation of NF-κB signalling 
(Lee et al., 2000, Zhang et al., 2006). The full spectrum of DUBs involved in the 
regulation of NF-κB signalling is not yet fully understood, for example there are no 
known reports to identify the DUB(s) responsible for the removal of K63-linked 
polyubiquitin chains on IRAK1. 
In addition to the integral step in NF-κB signalling; the K48-linked polyubiquitination 
and degradation of IκBα, degradative K48-linked chains are crucial in the regulation of 
the pathway at other signalling nodes. The key adaptor protein IRAK1 undergoes IL-1 
induced phosphorylation, followed by SCFβ-TrCP-mediated K48-linked 
polyubiquitination, at Lys134, and is subsequently degraded (Cui et al., 2012). Equally, 
TRAF6 is subjected to K48-linked polyubiquitination and subsequent degradation, 
reportedly through interactions with NUMBL (Zhou et al., 2010). Similarly, TAK1 is 
subject to K48-linked polyubiquitination, at Lys72, for its degradation (Fan et al., 2012). 
The degradation of TRAF6 or TAK1 leads to inhibition of NF-κB activation to suppress 
the pathway, indicating that the negative regulation of TRAF6 and TAK1 can either occur 
through the removal of K63-linked polyubiquitin chains by DUBs or through the K48-
linked polyubiquitination and degradation of TRAF6 and TAK1. There are few studies 
on the importance of the K48-linked polyubiquitination of some of these key adaptor 
proteins in the regulation of NF-κB signalling and, again, limited knowledge on potential 
DUBs that may remove these K48-linked polyubiquitin chains, furthering the regulation 
of NF-κB. 
Although K63- and K48-linked polyubiquitin chains are the most well studied chain 
topologies, others have also been identified in the NF-κB pathway (Iwai, 2014). The IL-
1-induced K63-linked polyubiquitination of IRAK1 induces the formation and covalent 
attachment of linear chains to the K63 chains by the LUBAC complex. This again serves 
as a platform for recruitment of the NEMO subunit of the IKK complex which binds to 
the linear chains (Emmerich et al., 2013). 
As a DUB involved in NF-κB activity, USP4 has been reported to supress IL-1-induced 
NF-κB activity through the deubiquitination of K63-linked polyubiquitin chains of both 
TAK1 and TRAF6 (Fan et al., 2011b, Xiao et al., 2012). However, data in the previous 
chapter have alluded to a role for USP4 in positively regulating NF-κB rather than 
suppressing its activation and there are currently no known reports to identify substrates 
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for which USP4 may deubiquitinate for this positive regulation. As data in the previous 
chapter indicated USP4 may function upstream of the IKK complex, further examination 
of the effect of USP4 on the ubiquitination of some of these key proteins in the IL-1-
induced NF-κB pathway needs to be explored. Computational modelling was utilised as 
a predictor of USP4 substrates in IL-1 NF-κB signalling. Additionally, an RNAi approach 
to deplete USP4 and examine the functional consequences on the K48- and K63-linked 
polyubiquitination of TAK1 and TRAF6, through immunoprecipitation and 
immunoblotting procedures, were also performed. 
 Aims 
 Use computer modelling to identify potential deubiquitination substrates of USP4 
in the positive regulation of the NF-κB pathway 
 Confirm the ubiquitination of TAK1 and TRAF6 
 Determine the effect of depleting USP4 on the IL-1-induced K48- and K63-linked 
polyubiquitination of TAK1 and TRAF6 
 Results 
 Computational modelling of USP4 in the IL-1-induced NF-κB 
signalling pathway 
Data in the previous chapter indicated that USP4 acts as a positive regulator of NF-κB 
signalling, potentially upstream of the IKK complex. Therefore, a computational 
modelling approach was utilised to investigate potential substrates of USP4 in NF-κB 
signalling. The majority of DUBs with identified roles in NF-κB signalling act as negative 
regulators through the removal of K63-linked polyubiquitin chains (Harhaj and Dixit, 
2012). However, the stability of proteins can be mediated through their K48-linked 
polyubiquitination for proteasomal degradation. Upstream of the IKK complex, key 
mediators, TAK1, TRAF6 and IRAK1 have all been reported to be subjected to K48-
linked polyubiquitination (Fan et al., 2012, Zhou et al., 2010, Cui et al., 2012). Therefore, 
the removal of these K48-linked polyubiquitin chains on TAK1, TRAF6 or IRAK1 by 
USP4 were factored into the NF-κB pathway computer model, as three separate models, 
and the output of stochastic simulations for each observed.  Additionally, as USP4 is 
reported in the literature to remove TAK1 and TRAF6 K63-linked polyubiquitin chains, 
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the USP4-mediated removal of these chains was factored into a fourth model. All 
components and reactions in the model are displayed in Appendix Table 1 and Appendix 
Table 2. 
5.2.1.1 Model assumptions 
Under normal conditions, NF-κB is in complex with IκB which prevents activation of 
NF-κB. IL-1 signalling by the binding of IL-1 to the IL-1R, activates MyD88 and IRAK4 
(Martin and Wesche, 2002). Activated IRAK4 enables phosphorylation of IRAK1 and 
subsequent activation of TRAF6 for TRAF6 K63-linked polyubiquitination and TRAF6-
mediated TAK1 K63-linked polyubiquitination (Lamothe et al., 2007). The K63-linked 
polyubiquitination of TAK1 enables the phosphorylation of IKK, leading to the 
phosphorylation and degradation of IκB to release NF-κB (Fan et al., 2010). NF-κB is 
then phosphorylated to activate its transcriptional activity (Sakurai et al., 2003). Included 
are the transcription and translation of NF-κB target genes IL-6, IL-8, MMP13 and IκB. 
Also included are the K48-linked polyubiquitination of IRAK1, TAK1 or TRAF6, in 
three separate models, to mediate their degradation (Fan et al., 2012, Zhou et al., 2010). 
These polyubiquitin chains can be removed by a DUB. For each of the 3 models, the 
specified DUB was USP4 for IRAK1, TAK1 or TRAF6. In a fourth model, USP4 was 
the specified DUB for removal of K63-linked polyubiquitin chains on TAK1 and TRAF6 
(Fan et al., 2011b, Xiao et al., 2012). A simplified diagram of the model components and 
reactions is displayed in Figure 5.1. For all four models, simulations were performed with 
USP4 at control and depleted levels (USP4=100 or USP4=5, respectively). 
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Figure 5.1. IL-1-induced NF-κB signalling pathway model diagram. For each of the three models, 
DUB was replaced with USP4 for removal of K48-linked polyubiquitin chains on IRAK1, TAK1 or 
TRAF6. In a fourth model, USP4 was added for the removal of TAK1 and TRAF6 K63-linked 
polyubiquitin chains. Sink refers to the degradation of a protein. Full details of all reactions are 
displayed in Appendix Table 2. 
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5.2.1.2 USP4 in the computational model 
In the first model, where USP4 was hypothesised to deubiquitinate K48-linked 
polyubiquitin chains on IRAK1, the phosphorylation of IKK was reduced when the level 
of USP4 was reduced, and there were small reductions in the phosphorylation of NF-κB 
(Figure 5.2A and Figure 5.2B).  Additionally, there were reduced levels of IL-6, IL-8 and 
MMP13 (Figure 5.2C, Figure 5.2D and Figure 5.2E). This closely matches the levels of 
phosphorylated IKK and p65 proteins observed in Figure 4.9 and Figure 4.10, and the 
reductions in NF-κB regulated gene expression with USP4 depletion as observed in 
Figure 4.5. 
Similarly, in the second model, where USP4 was hypothesised to deubiquitinate K48-
linked polyubiquitination on TAK1, the phosphorylation of IKK was reduced when the 
level of USP4 was reduced, particularly at early time points (Figure 5.3A).  There were 
also small reductions in the level of phosphorylated NF-κB and reductions in IL-6, IL-8 
and MMP13 (Figure 5.3B, Figure 5.3C, Figure 5.3D and Figure 5.3E). Again, this closely 
matches observations on protein levels and NF-κB-regulated gene expression observed 
with USP4 depletion in Chapter 4. 
In the third model, where USP4 was hypothesised to deubiquitinate K48-linked 
polyubiquitination on TRAF6, IL-6, IL-8 and MMP13 were also reduced when reducing 
the level of USP4 (Figure 5.4C, Figure 5.4D and Figure 5.4E). However, there were no 
discernible differences in the levels of phosphorylated IKK or NF-κB (Figure 5.4A and 
Figure 5.4B).  
In the fourth model, where USP4 was hypothesised to deubiquitinate K63-linked 
polyubiquitination on TAK1 and TRAF6,  there were no differences in the levels of 
phosphorylated IKK or NF-κB with loss of USP4 (Figure 5.5A and Figure 5.5B). There 
were moderate increases in IL-6, IL-8 and MMP13 when the level of USP4 was reduced 
(Figure 5.5C, Figure 5.5D and Figure 5.5E). Although USP4 has been reported to 
deubiquitinate TAK1 and TRAF6 K63-linked polyubiquitin chains, there was very little 
impact of USP4 on NF-κB signalling in this model, and outputs did not match data in this 
thesis, contrasting with published data (Fan et al., 2011b, Xiao et al., 2012).
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Figure 5.2. Simulation when USP4 deubiquitinates K48-linked polyubiquitinated IRAK1. Simulation output from one stochastic simulation showing changes in A) 
phosphorylated IKK (P-IKK), B) phosphorylated NF-kB (P-NF-kB), C) IL-6, D) IL-8 and E) MMP13 particle numbers. Particle number was plotted over time (seconds, s).
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Figure 5.3. Simulation when USP4 deubiquitinates K48-linked polyubiquitinated TAK1. Simulation output from one stochastic simulation showing changes in A) 
phosphorylated IKK (P-IKK), B) phosphorylated NF-kB (P-NF-kB), C) IL-6, D) IL-8 and E) MMP13 particle numbers. Particle number was plotted over time (seconds, s).
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Figure 5.4. Simulation when USP4 deubiquitinates K48-linked polyubiquitinated TRAF6. Simulation output from one stochastic simulation showing changes in A) 
phosphorylated IKK (P-IKK), B) phosphorylated NF-kB (P-NF-kB), C) IL-6, D) IL-8 and E) MMP13 particle numbers. Particle number was plotted over time (seconds, s). 
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Figure 5.5. Simulation when USP4 deubiquitinates K63-linked polyubiquitinated TAK1 and TRAF6. Simulation output from one stochastic simulation showing changes in 
A) phosphorylated IKK (P-IKK), B) phosphorylated NF-kB (P-NF-kB), C) IL-6, D) IL-8 and E) MMP13 particle numbers. Particle number was plotted over time (seconds, 
s). 
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 IL-1-induced TAK1 and TRAF6 ubiquitination, K48- and K63-
linked polyubiquitination 
Computational modelling indicated that if TAK1 was a target of USP4, this could result 
in reduced NF-κB-regulated genes, and reduced phosphorylation of IKK and NF-κB with 
USP4 depletion, as observed in the previous chapter. Additionally, if TRAF6 was a target 
of USP4, this could result in reduced levels of NF-κB-regulated genes. Therefore, as 
potential USP4 substrates, the IL-1-induced polyubiquitination of TAK1 and TRAF6 
with USP4 depletion was examined. 
5.2.2.1 TAK1 and TRAF6 are polyubiquitinated 
There are many reports on the polyubiquitination of TAK1 and TRAF6 in NF-κB 
signalling (Iwai, 2014, Fan et al., 2010, Liang et al., 2013, Conze et al., 2008, Zhou et al., 
2010). To confirm that TAK1 and TRAF6 are polyubiquitinated with both K48- and K63-
linked polyubiquitin chains and that this could be visualised by the chosen method in this 
thesis, HEK 293T cells were transfected with either FLAG-TAK1 or FLAG-TRAF6 and 
either HA-tagged wild-type ubiquitin (HA-Ub WT), a ubiquitin mutant with only K48 
(HA-Ub K48) or a ubiquitin mutant with only K63 (HA-Ub K63). All other Lys residues 
in the ubiquitin mutants had been mutated to arginine. Immunoprecipitation using an anti-
FLAG antibody was performed (as optimised and described in section 2.2.7), followed 
by immunoblotting with the relevant antibodies. FLAG immunoprecipitates, when 
transfected with either FLAG-TAK1 or FLAG-TRAF6, showed smeared bands with all 
HA-tagged wild-type and mutant ubiquitin, indicative that FLAG immunoprecipitates, 
presumably TAK1 and TRAF6, were polyubiquitinated with wild-type ubiquitin and K48 
and K63 polyubiquitin chains following IL-1 stimulation (Figure 5.6). 
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Figure 5.6. FLAG immunoprecipitates were polyubiquitinated following IL-1 induction. HEK 293T 
cells were transfected with HA-Ub WT, HA-Ub K48 or HA-Ub K63, and either A) FLAG-TAK1 or 
B) FLAG-TRAF6. At 24 hours post-transfection cells were stimulated with IL-1α (0.5ng/ml) for 15 
minutes before lysis. NEM (20mM) and MG132 (10µM) were added to the cell extracts. Total proteins 
were extracted, resolved by SDS-PAGE and immunoblotted with an anti-FLAG antibody to confirm 
transfection in whole cell lysates (WCL). GAPDH was used for matching transfection efficiency. 
Immunoprecipitation (IP) was performed with an anti-FLAG antibody and immunoblotting (IB) 
with an anti-HA antibody. Molecular weights (MW) (kDa) are indicated.  
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5.2.2.2  The effect of USP4 depletion on the IL-1-induced polyubiquitination of 
TAK1 
To determine whether USP4 affects the wild-type ubiquitination and both K48- and K63-
linked polyubiquitination of TAK1, USP4 was depleted in HEK 293T cells followed by 
transfection with FLAG-TAK1 and either wild-type or mutant versions of ubiquitin 
before stimulating with IL-1 and performing immunoprecipitation and immunoblotting 
experiments.  
Initially, the wild-type ubiquitination of TAK1 with USP4 depletion was examined. The 
ubiquitination of FLAG immunoprecipitates, presumably TAK1, was reduced with USP4 
depletion compared to the control. This was particularly evident before stimulation with 
IL-1 (Figure 5.7A). However, these data were not definitively confirmed upon replication 
of the experiment. 
Next, the effect of USP4 depletion specifically on the K48-linked polyubiquitination of 
TAK1 was examined. There was no effect on the K48-linked polyubiquitination of FLAG 
immunoprecipitates with IL-1 induction, neither did the depletion of USP4 have any 
effect (Figure 5.7B). 
Additionally, the effect of USP4 depletion specifically on the K63-linked 
polyubiquitination of TAK1 was examined. Although, as with K48-linked 
polyubiquitination, there was no change in the level of K63-linked polyubiquitination of 
FLAG immunoprecipitates with IL-1 induction, there was less IL-1-induced K63-linked 
polyubiquitination with depletion of USP4. This indicates that USP4 may be involved in 
the ubiquitination status of K63-linked polyubiquitination of TAK1 (Figure 5.7C).  
Initial experiments included a negative control for which immunoprecipitation was 
performed using an IgG antibody. As expected, no FLAG or HA was detected when 
immunoblotting with an anti-FLAG or anti-HA antibodies, respectively (data not shown).  
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Figure 5.7. IL-1-induced TAK1 ubiquitination with USP4 depletion. HEK 293T cells were transfected 
with siCon or siUSP4 24 hours before transfection with FLAG-TAK1 and A) HA-Ub WT, B) HA-Ub 
K48 or C) HA-Ub K63. At 24 hours post-transfection, cells were left unstimulated or stimulated with 
IL-1α (0.5ng/ml) for 15 minutes before lysis. Total protein was extracted, resolved by SDS-PAGE 
and immunoblotted (IB) with anti-FLAG, anti-TAK1, anti-USP4 antibodies to confirm transfection 
and USP4 depletion in whole cell lysates (WCL). Immunoprecipitation (IP) was then performed using 
an anti-FLAG antibody and immunoblotting with anti-HA, anti-FLAG and anti-TAK1 antibodies. 
Figure is representative of three independent experiments for each ubiquitin mutant. 
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5.2.2.3  The effect of USP4 depletion on the IL-1-induced polyubiquitination of 
TRAF6 
As another key protein which is ubiquitinated in NF-κB signalling, the polyubiquitination 
of TRAF6 with USP4 depletion was next examined. Similarly to the examination of 
TAK1, HEK 293T cells were transfected with FLAG-TRAF6 and HA-tagged wild-type 
or mutant versions of ubiquitin before stimulating with IL-1 and performing 
immunoprecipitation and immunoblotting experiments.  
First, the wild-type ubiquitination of TRAF6 was examined. The ubiquitination of FLAG 
immunoprecipitates, presumably TRAF6, was not affected by stimulation with IL-1, nor 
did depleting USP4 have any effect (Figure 5.8A).  
The K48- and K63-linked polyubiquitination of FLAG immunoprecipitates were not 
affected by stimulation with IL-1 for the control. There was, however, a reduction in the 
IL-1-induced K48-linked polyubiquitination of FLAG immunoprecipitates with USP4 
depletion (Figure 5.8B). The IL-1-induced K63-linked polyubiquitination was also 
slightly reduced with USP4 depletion (Figure 5.8C). 
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Figure 5.8. IL-1-induced TRAF6 ubiquitination with USP4 depletion. HEK 293T cells were 
transfected with siCon or siUSP4 24 hours before transfection with FLAG-TRAF6 and A) HA-Ub 
WT, B) HA-Ub K48 or C) HA-Ub K63. At 24 hours post-transfection, cells were left unstimulated or 
stimulated with IL-1α (0.5ng/ml) for 15 minutes before lysis. Total protein was extracted, resolved 
by SDS-PAGE and immunoblotted (IB) with anti-FLAG or anti-USP4 antibodies to confirm 
transfection and USP4 depletion in whole cell lysates (WCL). GAPDH was used as a loading control. 
Immunoprecipitation (IP) was then performed using an anti-FLAG antibody and immunoblotting 
with anti-HA or anti-FLAG antibodies. Figure is representative of two independent experiments for 
each ubiquitin mutant. 
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5.2.2.4  The effect of USP4 depletion on IL-1-induced levels of key NF-κB adaptor 
proteins in HEK 293T cells 
In this chapter, HEK 293T cells were selected for all immunoprecipitation experiments 
due to the high transfection efficiency of this cell line. Optimisation experiments, in 
section 2.2.7.1, demonstrated higher transfection of FLAG-tagged expression plasmids in 
HEK 293T cells compared to SW1353 cells. However, the data from the previous chapter 
was from experiments in SW1353 cells. There were some dramatic changes in the levels 
of key NF-κB adaptor proteins with USP4 depletion in SW1353 cells and so to determine 
whether the same effects could be observed in HEK 293T cells, the levels of these key 
adaptor proteins were also examined in this cell line. After USP4 depletion, HEK 293T 
cells were treated with IL-1 for the indicated time points, lysed, total protein extracted 
and resolved by electrophoresis before immunoblotting with the relevant antibodies. 
The phosphorylation of p65 was not induced in USP4 depleted cells as strongly as in the 
control. However, the level of phosphorylation was less after 15, 30 and 60 minutes IL-1 
induction with USP4 depletion, similar to observations in SW1353 cells (Figure 5.9). 
There were no changes in the levels of IκBα with IL-1 treatment, an observation matching 
IκBα levels in HeLa cells in the previous chapter. Again though, both the IL-1-induced 
phosphorylation of IKKα/β and JNK were reduced with USP4 depletion, however, these 
effects were not as clear as in SW1353 cells and HeLa cells. 
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Figure 5.9. The effect of USP4 depletion on levels of NF-κB adaptor proteins in HEK 293T cells. HEK 
293T cells were transfected with siCon or siUSP4 for 24 hours, serum-starved overnight and 
stimulated with IL-1α (0.5ng/ml) for the indicated times (minutes). Total protein was extracted, 
resolved by SDS-PAGE and immunoblotted with anti-IκBα, anti-P-p65, anti-P-IKKα/β, anti-P-JNK 
and anti-USP4 antibodies. GAPDH was used as a loading control. 
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5.2.2.5  The effect on the IL-1-induced polyubiquitination of TAK1 with USP4 
depletion in SW1353 cells 
As the effects of USP4 depletion on IL-1-induced NF-κB protein and phosphorylation 
levels in HEK 293T cells were not as clear as in SW1353 cells in the previous chapter, 
the effect of USP4 depletion on the IL-1-induced polyubiquitination of TAK1 was next 
examined in SW1353 cells. SW1353 cells were transfected with FLAG-TAK1 and either 
wild-type or mutant versions of ubiquitin before stimulating with IL-1 and performing 
immunoprecipitation and immunoblotting experiments. 
Unlike in HEK 293T cells, the overall ubiquitination of FLAG immunoprecipitates, 
presumably TAK1, was slightly increased with depletion of USP4 but again IL-1 
treatment did not affect the polyubiquitination of TAK1 (Figure 5.10A). 
Whereas there were no effects of USP4 depletion on the K48-linked polyubiquitination 
of FLAG immunoprecipitates in HEK 293T cells, USP4 depletion reduced the K48-
linked polyubiquitination in SW1353 cells both with and without IL-1 induction (Figure 
5.10B).  
Again, IL-1 treatment did not alter the K63-linked polyubiquitination of FLAG 
immunoprecipitates in SW1353 cells. There was a strong band of K63-linked 
polyubiquitination in control cells stimulated with IL-1 that was reduced with USP4 
depletion (Figure 5.10C). Overall this was indicative that the IL-1-induced K63-linked 
polyubiquitination of TAK1 was reduced with depletion of USP4 in HEK 293T cells and 
SW1353 cells.  
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Figure 5.10. IL-1-induced TAK1 ubiquitination with USP4 depletion in SW1353 cells. SW1353 cells 
were transfected with siCon or siUSP4 24 hours before transfection with FLAG-TAK1 and A) HA-
Ub WT, B) HA-Ub K48 or C) HA-Ub K63. At 24 hours post-transfection, cells were left unstimulated 
or stimulated with IL-1α (0.5ng/ml) for 15 minutes before lysis. Total protein was extracted, resolved 
by SDS-PAGE and immunoblotted (IB) with anti-FLAG, anti-TAK1, anti-USP4 antibodies to 
confirm transfection and USP4 depletion in whole cell lysates (WCL). GAPDH was used as a loading 
control. Immunoprecipitation (IP) was then performed using an anti-FLAG antibody and 
immunoblotting with anti-HA and anti-FLAG antibodies. 
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 The effect of USP4 depletion on the IL-1-induced levels of 
proteins upstream of the IKK complex 
The depletion of USP4 potentially affected the K48-linked polyubiquitination of TAK1 
and TRAF6. As this ubiquitin linkage type is associated with targeting proteins for 
proteasomal degradation, the effect of USP4 depletion on the levels of these (and other 
NF-κB adaptor proteins upstream of the IKK complex not previously examined) were 
next observed. The depletion of USP4 did not affect protein levels of TAK1, TRAF2, 
TRAF6 or IRAK1, indicating that USP4 did not affect the stability of these proteins 
(Figure 5.11). 
 
Figure 5.11. The effect of USP4 depletion on levels of NF-κB adaptor proteins upstream of IKK. 
SW1353 cells were transfected with siCon or siUSP4 for 24 hours, serum-starved overnight and 
stimulated with IL-1α (0.5ng/ml) for the indicated times (minutes). Total protein was extracted, 
resolved by SDS-PAGE and immunoblotted with anti-TAK1, anti-TRAF2, anti-TRAF6, anti-IRAK1 
and anti-USP4 antibodies. GAPDH was used as a loading control. 
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 Discussion 
The aims of this chapter were to examine potential substrates of USP4 through use of 
computational modelling and to examine the ubiquitination of these potential substrates 
with loss of USP4. 
 Computational modelling to determine potential USP4 
substrate(s) 
Computational modelling is a useful tool for the prediction of interactions with cell 
signalling networks and was utilised to identify potential targets of USP4 within the NF-
κB signalling pathway. Data within this thesis indicated that USP4 functions upstream of 
the IKK complex and so the potential effects of USP4 in deubiquitinating proteins in this 
part of the pathway was examined by hypothesising that USP4 may deubiquitinate K48-
linked polyubiquitin chains on TAK1, TRAF6 and IRAK1 to mediate proteasomal 
degradation. Outputs from stochastic simulations of the model demonstrated a reduction 
in phosphorylated IKK, phosphorylated NF-κB and levels of IL-6, IL-8 and MMP13 with 
reduced USP4 levels when USP4 was hypothesised to deubiquitinate K48-linked 
polyubiquitination chains on TAK1 and IRAK1. This is consistent with experimental data 
where USP4 depletion reduced levels of phosphorylated IKK and p65, and expression of 
IL-6, IL-8 and MMP13 (Chapter 4). Simulations also demonstrated a reduction in levels 
of IL-6, IL-8 and MMP13 when USP4 was hypothesised to deubiquitinate TRAF6, but 
there were no obvious differences in phosphorylated IKK or NF-κB. USP4 has been 
reported to interact with both TAK1 and TRAF6 in the NF-κB signalling pathway and so 
perhaps further differences would have been observed if USP4 was set to deubiquitinate 
multiple adaptors in the same model (Xiao et al., 2012, Fan et al., 2011b).  
USP4 has been reported to deubiquitinate K63-linked polyubiquitinated substrates TAK1 
and TRAF6 to downregulate NF-κB (Fan et al., 2011b, Xiao et al., 2012). Given this, a 
fourth model was designed which incorporated USP4-mediated removal of K63 
polyubiquitin chains on TAK1 and TRAF6. Data in previous chapters were conflicting 
with reports that USP4 acts as a negative regulator of NF-κB signalling, and outputs from 
stochastic simulations indicated moderate increases in IL-6, IL-8 and MMP13 with 
reduced USP4, again conflicting with data herein this thesis. Together, data in the 
previous chapter and model outputs in this chapter indicated that it is unlikely that USP4 
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targets TAK1 and TRAF6 for K63-linked deubiquitination for the positive regulation of 
NF-κB.   
Within the IL-1 NF-κB signalling pathway, phosphorylated IRAK1 undergoes SCFβ-TrCP-
mediated K48-linked polyubiquitination and degradation to allow dissociation of 
TRAF6-TAK1 from the complex with IRAK1 for downstream activation (Cui et al., 
2012). This indicates that the degradation of IRAK1 is important to transduce the signal 
down the pathway for NF-κB activation. The TRAF6-TAK1 dissociation from IRAK1 
was not incorporated into the model utilised in this thesis, and as the degradation of 
IRAK1 is reported to enhance rather than suppress NF-κB activation, it seems unlikely 
that USP4 mediates the removal of these ubiquitin chains as USP4 was demonstrated to 
positively regulate NF-κB signalling in the previous chapter. Both TAK1 and TRAF6 
have been reported to be polyubiquitinated with K48-linked polyubiquitin chains for 
proteasomal degradation and the prevention of persistent NF-κB activation (Fan et al., 
2012, Zhou et al., 2010). Outputs from the models hypothesising that USP4 
deubiquitinates K48-linked polyubiquitination of TAK1 or TRAF6 fitted with the 
reduced expression of NF-κB-regulated genes observed with USP4 depletion. Therefore, 
it was decided that TAK1 and TRAF6 are more likely targets for deubiquitination by 
USP4 than IRAK1 and experiments to observe the effects of USP4 depletion on the 
polyubiquitination of these proteins were performed. 
 The effect of USP4 depletion on the IL-1-induced ubiquitination of 
TAK1 and TRAF6 
5.3.2.1 TAK1 polyubiquitination 
In signalling pathways, K63-linked polyubiquitin chains can serve as a platform for the 
assembly of protein complexes. It is well documented that TAK1 is polyubiquitinated 
with K63-linked polyubiquitin chains upon activation of the NF-κB pathway as a key step 
for downstream NF-κB activation (Fan et al., 2010, Liang et al., 2013, Li et al., 2011, Fan 
et al., 2011a). IL-1-induced K63-linked polyubiquitination of TAK1 by TRAF6 at Lys158 
mediates activation of TAK1 and recruitment of the IKK complex for the TAK1-mediated 
phosphorylation of IKKβ required for NF-κB activation (Fan et al., 2010). Further, NF-
κB can later be downregulated at the level of TAK1 through the K48-linked 
polyubiquitination of TAK1 and subsequent degradation (Fan et al., 2012). TNFα-
induced K48-linked polyubiquitination of TAK1 at Lys72 was reported to occur at a later 
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time point than the K63-linked polyubiquitination of TAK1 to mediate TAK1 degradation 
and prevent persistent activation of NF-κB. There are no known reports to have 
specifically identified IL-1-induced K48-linked polyubiquitination of TAK1.  
As the K63- and K48-linked polyubiquitination of TAK1 play important roles in the 
activation and downregulation of NF-κB, respectively, and as USP4 was demonstrated to 
act as a potential positive regulator of NF-κB in previous chapters in this thesis, TAK1 
was examined as a potential USP4 substrate for deubiquitination. Mutant versions of 
ubiquitin, for which the only Lys present was K48 or K63, allowed visualisation of these 
specific ubiquitin topologies. It was first confirmed that, as according to reports, FLAG 
immunoprecipitates can be polyubiquitinated with K63-linked polyubiquitin chains upon 
IL-1 stimulation. Additionally, FLAG immunoprecipitates, presumably TAK1, were also 
polyubiquitinated with K48-linked polyubiquitin chains with IL-1 stimulation, as 
identified previously with TNFα stimulation (Fan et al., 2012). This is presumably TAK1 
polyubiquitination, although other proteins could have been co-immunoprecipitated with 
TAK1 which are immunoblotted with HA. Therefore, although it can be assumed that the 
polyubiquitination in these experiments represents the polyubiquitination of TAK1 (or 
TRAF6 in later experiments) it has not been directly confirmed to be specifically 
polyubiquitination of TAK1. 
Next, the effect of USP4 depletion on the polyubiquitination of TAK1 was examined, 
initially in HEK 293T cells. FLAG immunoprecipitates were polyubiquitinated with 
wild-type ubiquitin and K48- and K63-linked polyubiquitin with and without the presence 
of IL-1. This observation was surprising considering that TAK1 has been documented to 
be polyubiquitinated upon stimulation of the NF-κB pathway (Fan et al., 2010, Fan et al., 
2012). It would be expected that the ubiquitination should be increased with induction, 
something not observed here in control cells. The same concentration of IL-1 was used 
in these experiments as in SW1353 cells in previous experiments, for which elements of 
the NF-κB signalling pathway were induced (Chapter 4). HEK 293T cells are smaller in 
size than SW1353 cells. As such, more cells were seeded onto plates meaning that perhaps 
a higher concentration of IL-1 needed to be used. However, there was also no effect on 
the polyubiquitination with IL-1 induction when the experiment was repeated in control 
SW1353 cells. The observed ubiquitination with no IL-1 induction suggests that 
overexpressing TAK1 was enough to induce the pathway and its ubiquitination. 
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Additionally, some differences were observed in USP4 depleted cells with IL-1 induction 
suggesting that IL-1 induction was successful. 
When examining the effects of USP4 depletion on the levels and phosphorylation of NF-
κB adaptor proteins, experiments were performed over a time course. The most apparent 
differences with USP4 depletion on the levels of proteins, for example IκBα and 
phosphorylated p65 and IKKα/β, were observed after 15 minutes of stimulation. This was 
therefore the time point chosen for IL-1 stimulation in these experiments. As the 
degradation of IκBα and the phosphorylation of IKKα/β and p65 occur downstream of 
TAK1 K63-linked polyubiquitination, it is possible that an earlier time point may have 
demonstrated more differences. Furthermore, many DUBs counteract the action of E3 
ligases by deubiquitinating K63-linked polyubiquitinated proteins to prevent persistent 
activation of NF-κB (Harhaj and Dixit, 2012). It is possible that no differences were 
observed in the polyubiquitination of FLAG immunoprecipitates with IL-1 induction after 
15 minutes as the action of DUBs may have resulted in a balanced level of ubiquitination 
at this time point in control cells. This would also explain why depleting USP4 
demonstrated differences with IL-1 induction but not control; depleting USP4 may have 
disrupted the balance between ubiquitination/deubiquitination within the NF-κB 
pathway. It would have been interesting to have been able to perform these experiments 
over a time course of IL-1 induction to observe whether TAK1 polyubiquitination is 
altered at different times after induction. The K48-linked polyubiquitination of TAK1 
was reported with TNFα induction at a later time point than the K63-linked 
polyubiquitination of TAK1 (after one hour TNFα stimulation) (Fan et al., 2012). It would 
therefore be interesting to see if this is the same with IL-1 induction by performing a time 
course experiment with longer stimulation times. 
Overall, loss of USP4 reduced the polyubiquitination of FLAG immunoprecipitates, 
presumably TAK1, particularly with IL-1 induction. Specifically, K63-linked 
polyubiquitination was reduced with USP4 depletion and IL-1 induction. This concurs 
with data in Chapter 4 of this thesis where IL-1-induced NF-κB signalling was suppressed 
with depletion of USP4. Previously, it has been reported that USP4 deubiquitinates TAK1 
for the downregulation of NF-κB (Fan et al., 2011b). However, the reported data conflict 
with data in this thesis which have indicated USP4 positively regulates NF-κB. Fan et al. 
(2011b) reported that USP4 interacted with TAK1 and that TNFα-induced 
polyubiquitination of TAK1 was enhanced with depletion of USP4 and reduced with 
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overexpression of wild-type, but not catalytically inactive, USP4. Whether these reported 
changes in TAK1 ubiquitination were due to USP4 deubiquitinating K63- or K48-linked 
polyubiquitin chains was not determined. The published data are again in contrast with 
observations in this chapter where USP4 depletion reduced the IL-1-induced overall, and 
specifically K63-linked, polyubiquitination of FLAG immunoprecipitates, presumably 
TAK1. TNFα-induced TAK1 polyubiquitination was not examined in this chapter, 
potentially the differences could be due to the difference between IL-1- and TNFα-
induced NF-κB signalling. However, the previous chapter demonstrated TNFα-induced 
NF-κB activity, NF-κB-regulated gene expression and levels of NF-κB adaptor proteins, 
in some cases, were consistent with IL-1, upon USP4 depletion. Additionally, Fan et al. 
(2011b) reported inhibition of IL-1-induced NF-κB activity with overexpression of USP4, 
again inconsistent with data in this thesis.  
Given that optimisation of transfection revealed higher transfection efficiency in HEK 
293T cells than SW1353 cells, it was the original chosen cell line for immunoprecipitation 
experiments. Considering previous experiments were predominantly performed in 
SW1353 cells rather than HEK 293T cells, the effect of USP4 depletion on the IL-1-
induced levels of key proteins which were altered in SW1353 cells were examined in 
HEK 293T cells. Similar to SW1353 cells, extracts from HEK 293T cells demonstrated 
lower levels of p65 and IKKα/β phosphorylation with loss of USP4, although these effects 
were not as clear. Therefore, examination of the IL-1-induced polyubiquitination of 
TAK1 with USP4 depletion was also performed in SW1353 cells via 
immunoprecipitation. In contrast to HEK 293T cells, the wild-type ubiquitination of 
FLAG immunoprecipitates, presumably TAK1, was increased with depletion of USP4, 
suggesting that USP4 may deubiquitinate TAK1 polyubiquitin chains. To determine 
whether USP4 may be involved in the deubiquitination of specifically K48 or K63 
polyubiquitin chains, the K48- and K63-linked polyubiquitination of TAK1 were also 
examined. Loss of USP4 resulted in a reduction of both IL-1-induced K48- and K63-
linked polyubiquitination, indicating that USP4 does not deubiquitinate these TAK1 
polyubiquitin chains. The reduction in K63-linked polyubiquitination is in line with the 
downregulation of IL-1-induced NF-κB signalling observed in the previous chapter. As 
the wild-type ubiquitination was enhanced with USP4 depletion, this could point to USP4 
deubiquitinating a different TAK1 ubiquitin chain topology. The importance of 
polyubiquitin chains other than K48- and K63-linked in NF-κB signalling is only just 
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beginning to emerge (Iwai, 2014). Similarly to K63-linked chains, linear chains have been 
reported to serve as a platform for the recruitment of the IKK complex for the activation 
of NF-κB. With IL-1 induction, the LUBAC complex attaches linear ubiquitin chains to 
K63-linked polyubiquitinated IRAK1 which NEMO of the IKK complex binds to, 
indicating that different ubiquitin topologies can interact for further regulation of NF-κB 
signalling (Emmerich et al., 2013). In addition, in TNFα-mediated NF-κB signalling, 
RIP1 can be polyubiquitinated with K11 chains by cIAP ligases (Dynek et al., 2010). 
Although different chain linkages have been reported to be involved in NF-κB activation, 
the exact roles played by these and the substrate targets for these ubiquitin chains have 
not been fully identified. Therefore, USP4 may be involved in the removal of linear, or 
other ubiquitin chains on TAK1 that have not yet been reported. If TAK1 is ubiquitinated 
with an unidentified type of polyubiquitin chain, the removal of these may be required 
before TAK1 can become K63 polyubiquitinated for the downstream activation of NF-
κB. By depleting USP4, the removal of these unknown polyubiquitin chains may be 
prevented, thus preventing full K63-linked polyubiquitination of TAK1 and K48-linked 
polyubiquitination of TAK1. Hence reduced polyubiquitin levels would be observed and, 
further, the suppression of NF-κB activation. Similar to the immunoprecipitation 
experiments performed here, it would be interesting to determine whether TAK1 is 
subject to ubiquitination via other linkage topologies and whether the depletion of USP4 
affects this. 
Moreover, through replacement of ubiquitin with a K63 mutant ubiquitin, it has been 
demonstrated that K63 polyubiquitination is required for IL-1-induced IKK activation, 
but not TNFα (Xu et al., 2009b). In the previous chapter, there were clearer effects on IL-
1-induced NF-κB signalling than TNFα-induced NF-κB signalling with USP4 depletion. 
If USP4 is involved in enabling K63-linked polyubiquitination of substrates involved in 
NF-κB, this may not be a requirement for TNFα-mediated signalling and could somewhat 
explain the differences in effects between TNFα- and IL-1-induced NF-κB signalling.  
Another possibility for the reduction of K63- and K48-linked polyubiquitination could be 
due to interactions of USP4 with another protein upstream of TAK1, rather than direct 
interaction with TAK1. Other reported TNFα-induced protein-protein interactions 
include IKKβ and TRAF6 with USP4, and so it may be that changes in the 
polyubiquitination of TAK1 with USP4 depletion is a result of interaction with a different 
protein within the NF-κB pathway (Fan et al., 2011b). Alternatively, many E3 ligases 
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exist in complexes with DUBs for the tight control of the ubiquitination/deubiquitination 
of proteins. For example, USP7 binds to p53 ligase Mdm2 for the tight control of p53 
stability (Li et al., 2004). USP4 could therefore be interacting with a TAK1 E3 ligase for 
the regulation of its polyubiquitination. Upstream of TAK1 is TRAF6 which is itself 
polyubiquitinated and also acts as a TAK1 E3 ligase. As such, TRAF6 could be a potential 
substrate of USP4. 
Co-immunoprecipitation experiments to determine whether IL-1 induces a specific 
interaction of USP4 with TAK1, as was reported with TNFα induction previously, or 
other known NF-κB adaptor proteins upstream of the IKK complex, would be 
informative. Immunoprecipitating USP4 would allow examination of potential 
interactions with proteins upstream of the IKK complex and/or E3 ligases which USP4 
may potential form a complex with to mediate effects on the IL-1-induced 
polyubiquitination of proteins.  
5.3.2.2 TRAF6 polyubiquitination 
TRAF6 is a key adaptor protein in the NF-κB signalling pathway, for which its 
ubiquitination is essential for the regulation of this pathway. IL-1-induced self-
ubiquitination of TRAF6 with K63-linked polyubiquitin chains serves as a platform for 
the recruitment of TAK1 via the UBDs of TAB2 and TAB3 (Xia et al., 2009, Lamothe et 
al., 2007). DUBs have been identified which can remove this K63 polyubiquitination of 
TRAF6 for downregulation of the NF-κB pathway including CYLD (Trompouki et al., 
2003). Additionally, the NF-κB pathway can be downregulated by the K48-linked 
polyubiquitination and degradation of TRAF6 (Zhou et al., 2010). Moreover, TRAF6 acts 
as an E3 ligase for self-ubiquitination and the K63-linked polyubiquitination of TAK1 
(Lamothe et al., 2007, Fan et al., 2010). Due to the importance of TRAF6 in ubiquitin 
signalling in the NF-κB pathway, and given that TRAF6 has been shown to directly 
associate with USP4, the effect of IL-1-induced polyubiquitination of TRAF6 with USP4 
depletion was also examined (Xiao et al., 2012).  
It was first confirmed that FLAG immunoprecipitates, presumably TRAF6, can be 
polyubiquitinated with K48- and K63-linked polyubiquitin chains upon IL-1 stimulation. 
Next, examination of whether USP4 affects this polyubiquitination revealed that the IL-
1-induced wild-type ubiquitination was not affected by the loss of USP4 but both IL-1-
induced K48- and K63-linked polyubiquitination were reduced with loss of USP4. This 
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is in contrast with reports than USP4 directly deubiquitinates K48- and K63-linked 
polyubiquitinated TRAF6 (Xiao et al., 2012, Zhou et al., 2012). Xiao et al. (2012) 
reported that overexpression of USP4, but not catalytically inactive USP4, reduced the 
ubiquitination of TRAF6 in HEK 293T cells under basal conditions and, equally, the 
siRNA-mediated depletion of USP4 enhanced the ubiquitination of TRAF6. This is not 
in line with data in this chapter for which the ubiquitination of FLAG immunoprecipitates, 
presumably TRAF6, was unaffected with USP4 depletion at basal levels in HEK 293T 
cells. Zhao et al. (2012a) reported that overexpression of USP4, but not catalytically 
inactive USP4, reduced the wild-type, K48- and K63-linked polyubiquitination of TRAF6 
in HEK 293T cells using K48 and K63 ubiquitin mutants. They also reported that USP4, 
but not catalytically inactive USP4, reduced the IL-1-induced TRAF6 K63-linked 
polyubiquitination in HeLa cells, and that shRNA-mediated depletion of USP4 enhanced 
the basal and IL-1-induced TRAF6 K63-linked polyubiquitination in HeLa cells and 
macrophages. Again, this is in contrast with data here, where IL-1-induced K63-linked 
polyubiquitination was reduced with USP4 depletion. It would have been interesting to 
examine here whether overexpression of wild-type and catalytically inactive Usp4 would 
affect polyubiquitination and whether this would also have been contradictory to the 
literature. Given that experiments were previously predominantly performed in SW1353 
cells, if time allowed it would have been potentially beneficial to also examine the effects 
of IL-1-induced TRAF6 polyubiquitination with USP4 depletion in this cell line, in 
addition to HEK 293T cells. 
As with reductions observed herein this chapter in the K63-linked polyubiquitination of 
FLAG immunoprecipitates, presumably TAK1, with USP4 depletion, the reduction in the 
K63-linked polyubiquitination of FLAG immunoprecipitates, presumably TRAF6, also 
concurs with the downregulation in NF-κB signalling as observed in Chapter 4. Again, 
this could potentially be due to interactions with either a protein upstream of TRAF6 or 
due to interactions with an E3 ligase responsible for the ubiquitination of TRAF6.  
5.3.2.3 Other potential substrates of USP4 
Computational modelling indicated that if USP4 removes K48-linked polyubiquitin 
chains from IRAK1, this could result in outputs matching data to implicate USP4 is 
involved in positively regulating NF-κB signalling. As literature have reported that the 
K48-linked polyubiquitination and degradation of IRAK1 allows TAK1-TRAF6 to 
dissociate from IRAK1 and further the signal for activating NF-κB, it was decided that 
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this was an unlikely target for USP4 (Cui et al., 2012). As the ubiquitination of TRAF6 
and TAK1 was potentially affected by USP4 depletion, but not indicative that USP4 
directly deubiquitinated either of these proteins, it is possible that USP4 acts upstream of 
this part of the pathway. As IRAK1 is known to be not only K63- and K48-
polyubiquitinated but also linearly ubiquitinated, it would be interesting to observe 
whether USP4 affects any of these types of ubiquitination (Conze et al., 2008, Cui et al., 
2012, Emmerich et al., 2013). 
Although TRAF6 is reported to self-ubiquitinate with K63 polyubiquitin chains, other 
ligases able to catalyse TRAF6 K63-linked polyubiquitination include; the U-box E3 
ligase, Act1, within IL-17-mediated signalling pathways, including NF-κB, and the RING 
E3 ligase, tripartite motif (TRIM) 38 (Liu et al., 2009, Zhao et al., 2012b). This gives rise 
to the possibility that, in addition to self-ubiquitination, other E3 ligases may be 
responsible for the K63-linked polyubiquitination of TRAF6. Equally, some E3 ligases 
which mediate the K48-linked polyubiquitination for the proteasomal degradation of 
TRAF6 have been identified including; WW domain containing E3 ubiquitin protein 
ligase 1 (WWP1) and TRIM38 in TLR signalling, and NUMBL (Lin et al., 2013, Zhao et 
al., 2012b, Zhou et al., 2010). As mentioned, E3 ligases can exist in complex with DUBs, 
presumably for controlled regulation of the ubiquitination/deubiquitination of proteins. 
Within the NF-κB signalling pathway, the DUB CYLD has been documented to 
downregulate NF-κB activation through the deubiquitination of K63-linked polyubiquitin 
chains (Trompouki et al., 2003). Additionally, CYLD can interact with the E3 ligase Itch 
and form a ubiquitin-editing complex for the removal of Tak1 K63-linked ubiquitination 
and catalysis of Tak1 K48-linked ubiquitination for proteasomal degradation (Ahmed et 
al., 2011). Similarly, USP4 may form a complex with an E3 ligase, perhaps TRAF6 itself, 
to tightly regulate the ubiquitination/deubiquitination of TRAF6.  
Ro52 (also known as TRIM21) is a RING E3 ligase able to monoubiquitinate 
phosphorylated IKKβ for the downregulation of NF-κB signalling (Wada et al., 2009). 
Interestingly, USP4 and Ro52 interact to form a transregulatory protein complex in which 
USP4 is able to deubiquitinate self-ubiquitinated Ro52, and Ro52 is able to 
monoubiquitinate USP4 and USP4 potentially removes this Ro52-mediated 
ubiquitination (Wada et al., 2006, Wada and Kamitani, 2006b). Given that Ro52 is 
involved in the regulation of the NF-κB pathway, it would be interesting to investigate 
further whether the function of USP4 in the positive regulation of NF-κB is mediated by 
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interactions with Ro52 and whether this ubiquitinating/deubiquitinating complex is 
important in the regulation of the NF-κB signalling pathway.  
As discussed, although it was presumed that the polyubiquitination observed in these 
experiments was of TAK1 or TRAF6, other proteins may have been co-
immunoprecipitated with TAK1 or TRAF6. The polyubiquitination observed may 
therefore also represent polyubiquitination of other proteins which were co-
immunoprecipitated. This further indicates the importance of determining protein-protein 
interactions upstream of the IKK complex for USP4 and also for TAK1 and TRAF6 
through co-immunoprecipitation experiments.  
5.3.2.4 The effect of USP4 depletion on the levels of NF-κB adaptor proteins 
upstream of the IKK complex 
Although the substrate(s) of USP4 within the NF-κB signalling pathway have not been 
fully determined from data here, there were potential effects on the IL-1-induced K48-
linked polyubiquitination of TAK1 and TRAF6 with USP4 depletion. Therefore, the 
levels of proteins upstream of the IKK complex, including TAK1 and TRAF6, were 
examined to determine any effects of USP4 depletion on the stability of these proteins. 
Neither the levels of TAK1, TRAF2, TRAF6 nor IRAK1 were altered with loss of USP4 
across a time-course of IL-1-induction. This indicates that USP4 does not affect the 
stability of these proteins. However, timepoints chosen were based on those from 
experiments performed in Chapter 4. Studies reporting the proteasomal degradation of 
TAK1 and TRAF6 have indicated that the K48-linked polyubiquitination and subsequent 
degradation of these proteins occurs after their K63-linked polyubiquitination as a 
measure of downregulating the pathway to prevent persistent activation. For example, 
TNFα-induced degradation of TAK1 occurred after one hour of treatment (Fan et al., 
2012). Therefore, examination of protein levels at later time points may be more 
beneficial in determining potential effects of USP4 on the stability of these proteins. 
Additionally, the deubiquitination of these adaptor proteins could alter their cellular 
distribution. As such, it would be interesting to examine the levels of these proteins in 
nuclear and cytoplasmic extracts in addition to the whole cell extracts examined here.  
 Summary 
Ubiquitin signalling is crucial in the regulation of the NF-κB signalling pathway. As 
USP4 is a DUB with a role in the positive regulation of IL-1-induced NF-κB signalling, 
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as demonstrated in this thesis, potential substrates within this pathway were explored in 
this chapter. As the majority of DUBs with known roles in NF-κB signalling function to 
negatively regulate the pathway through the removal of K63-linked polyubiquitin chains, 
it was difficult to determine how USP4 may function to positively regulate NF-κB 
signalling. Computational modelling predicted that if USP4 was deubiquitinating K48-
linked chains, rather than K63-linked chains, on TAK1 and TRAF6, outputs consistent 
with suppression of NF-κB signalling with USP4 depletion could be observed. Upon 
examination of the ubiquitination of TAK1 and TRAF6, it was demonstrated that loss of 
USP4 led to potentially reduced IL-1-induced K48- and K63-linked polyubiquitination 
of TAK1 and TRAF6. Although not indicative of direct deubiquitination of these proteins, 
but rather indicative of enhanced ubiquitination or reduced deubiquitination, it is possible 
that USP4 may interact with another protein upstream of TAK1 and TRAF6 or may 
regulate an E3 ligase responsible for ubiquitinating them. Alternatively, USP4 may 
deubiquitinate a different type of ubiquitin chain, as yet unidentified. USP4 has been 
shown previously to have a higher specificity for the removal of linear ubiquitin chains, 
than either K48- or K63-linked chains (McGouran et al., 2013). Linear chains have known 
involvement in the regulation of IL-1-induced NF-κB signalling, and so it is possible that 
USP4 may target this type of chain. Further examination to determine the substrate(s) of 
USP4, and of the effect of USP4 depletion on chains other than K48- and K63-linked 
chains would provide further insight into where and how USP4 functions to positively 
regulate IL-1-induced NF-κB signalling.  
 Conclusions 
 Computational modelling predicted that removal of TAK1 or TRAF6 K48-linked 
polyubiquitin chains by USP4 could produce outputs consistent with USP4 as a 
positive regulator of IL-1-induced NF-κB signalling 
 FLAG immunoprecipitates, presumably TAK1 and TRAF6, were ubiquitinated 
with both K48- and K63-linked polyubiquitin chains 
 Depleting USP4 potentially reduced the IL-1-induced K48- and K63-linked 
polyubiquitination of TAK1 and TRAF6 
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Chapter 6 : USP4 Phosphorylation and NF-κB Signalling 
 Introduction 
USP4 has many known substrates, including PDK1, A2A adenosine receptor and 
spliceosome components (Uras et al., 2012, Milojević et al., 2006, Song et al., 2010). It 
is also involved in the regulation of many cell signalling pathways, including p53, TGF-
β, NF-κB pathways, and in cellular processes including neuronal morphogenesis (Zhang 
et al., 2011, Zhang et al., 2012, Fan et al., 2011b, Anckar and Bonni, 2015). However, the 
mechanisms by which USP4 is regulated itself are largely unknown. 
PTMs regulate the function of a wide array of proteins. The phosphorylation of proteins 
is one of the most well-studied PTMs and plays a critical role in the regulation of many 
cell signalling pathways: MAPK pathways are based on signalling through a series of 
phosphorylation events: ERK, p38 and JNK MAPKs require activation by a series of 
other kinases leading to a cascade of phosphorylations and the transcriptional activation 
of target genes (Kim and Choi, 2010). Additionally, NF-κB signalling is regulated by 
phosphorylation events: the key step in the activation of NF-κB relies on the 
phosphorylation of IκB to mediate its ubiquitination and degradation for NF-κB release.  
As well as regulating protein activity and stability, PTMs can regulate protein-protein 
interactions and the subcellular localisation of proteins and many DUBs are regulated in 
this way. The phosphorylation of USP1 facilitates the protein interaction with UAF1 to 
mediate its catalytic activity, and the phosphorylation of USP10 facilitates its 
translocation to the nucleus to allow for the deubiquitination of nuclear p53 (Villamil et 
al., 2012, Yuan et al., 2010). 
When this project first began there were no reports on how PTMs may regulate the 
function of USP4. Recently, it was revealed that the AKT-mediated phosphorylation of 
USP4 at Ser445 results in its translocation from the nucleus to the cytoplasm and plasma 
membrane. This allows USP4 to interact with TβR-I at the plasma membrane resulting in 
the deubiquitination and stabilisation of the receptor for the downstream activation of the 
TGF-β pathway (Zhang et al., 2012). This mechanism regulates the subcellular 
localisation of USP4 in the TGF-β signalling pathway, but how USP4 might be regulated 
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by PTMs for other functions of USP4 and in other cell signalling pathways has still not 
been reported. 
In addition to phosphorylation at Ser445, other residues which can be modified by PTMs 
have been mapped in high-throughput and proteomic studies which may also regulate the 
function of USP4 (PhosphoSitePlus™: www.phosphosite.org). These phosphorylation 
sites and other USP4 modifications are depicted in Figure 6.1. Thin-layer 
chromatography of isotope-labelled USP4 identified USP4 was serine phosphorylated. 
This was mapped to two serines located at Ser675 and Ser680 by proteomics by Dr Doug 
Gray in collaboration with the Ottawa Institute for Systems Biology (Figure 6.1). In 
parallel to experiments to examine the functional consequences of USP4 depletion on 
NF-κB signalling in the previous chapters, the function of the phosphorylation of USP4 
at these two sites was examined, with particular focus on NF-κB signalling.  
 
Figure 6.1. USP4 modification sites. Diagram indicating the PTMs of human USP4. Serines 675 and 
680 are highlighted in blue. Adapted from PhosphoSitePlusTM: www.phosphosite.org. 
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First, a readout of function of USP4 was needed to study these PTMs. Previous chapters 
in this thesis identified a function for USP4 in the NF-κB signalling pathway allowing the 
effect of Usp4 phosphorylation in NF-κB signalling to next be examined. To establish a 
useful method for addressing the effects of Usp4 PTMs at Ser675/Ser680, a range of 
phosphorylation and phosphomimetic mutants were generated to enable examination of 
Usp4 phosphorylation on its subcellular localisation and effects on the activity of cell 
signalling pathways, specifically the NF-κB pathway. Additionally, RNAi knockdown of 
an identified kinase for USP4 allowed examination on the effect of this in NF-κB 
signalling. 
 Aims 
 Determine the effect of overexpressing a non-phosphorylatable version of Usp4 
on its subcellular localisation  
 Determine whether Usp4 phosphorylation is involved in regulating cell signalling 
pathways 
 Confirm the phosphorylation status of Usp4 phosphorylation variants 
 Determine the effect of overexpressing a non-phosphorylatable version of Usp4 
on IL-1-induced NF-κB activation 
 Generate a range of phosphorylation variants and lentiviral phosphorylation 
variants 
 Examine the effect of Usp4 PTMon the IL-1-induced NF-κB activation in 
SW1353 cells and MEFs 
 Examine the effect of siRNA-mediated depletion of the kinase GRK2 on NF-κB 
signalling 
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 Results 
 Usp4 phosphorylation at Ser675/Ser680 does not affect 
subcellular localisation 
USP4 has been located in both the nucleus and the cytoplasm, displaying 
nucleocytoplasmic shuttling properties (Soboleva et al., 2005). Both NLS and NES motifs 
have also been identified. The localisation of USP4 differs between cell types and the 
regulation of its subcellular localisation may be crucial to its function. Therefore, this 
chapter aimed to explore effects of these PTMs and the effect on the subcellular 
localisation of USP4 was first examined. After experiments to examine the effects of 
modification at Ser675/Ser680 were performed in this thesis, Zhang et al. (2012) reported 
that the phosphorylation of USP4 at Ser445 is important for its translocation as part of its 
function within the TGF-β signalling pathway. When beginning this thesis, two Ser 
residues at 675 and 680 were novel phosphorylation sites.  
Mouse NIH3T3 fibroblasts were transfected with GFP-tagged Usp4 wild-type (Usp4 
WT), a mutant version of Usp4 for which Ser675 and Ser680 were mutated to alanine 
(Ala) rendering it non-phosphorylatable at these sites (Usp4 S675A/S680A), or a 
catalytically inactive version of Usp4 (C311A).  Cells were fixed and mounted for 
visualisation by confocal fluorescent microscopy and analysed by scoring GFP 
fluorescence (and so Usp4) as being predominantly nuclear, both nuclear and cytoplasmic 
or predominantly cytoplasmic (Figure 6.2A).  
In NIH3T3 cells, Usp4 WT was predominantly cytoplasmic in approximately 65% of 
cells, predominantly nuclear in approximately 15% of cells and was observed throughout 
the cell in approximately 20% cells (Figure 6.2B). There were no significant differences 
between the localisation of Usp4 WT, Usp4 C311A or Usp4 S675A/S680A, indicating 
that neither the catalytic activity of Usp4 nor the phosphorylation at Ser675/680 regulates 
the subcellular localisation of Usp4 under the conditions investigated.  
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Figure 6.2. The subcellular localisation of Usp4 in NIH3T3 cells. NIH3T3 cells were transfected with 
GFP-tagged Usp4 wild-type (Usp4 WT), a non-phosphorylatable version of Usp4 (Usp4 
S675A/S680A), or a catalytically inactive version of Usp4 (Usp4 C311A). At 24 hours post-
transfection, cells were fixed in 4% PFA, mounted and stained with DAPI for nuclei staining before 
visualisation on a confocal fluorescent microscope. A) Example image of a cell in which Usp4 was 
scored as predominantly cytoplasmic. Region of interest (ROI) was drawn through the cell and 
represented as a graph of fluorescent intensity for determining the localisation. Usp4 was scored as 
being predominantly nuclear (nucleus) when fluorescent intensity increased at the nucleus, 
predominantly cytoplasmic (cytoplasm) when fluorescent intensity decreased at the nucleus, or 
throughout the cell (nucleus/cytoplasm) when there were no changes in fluorescent intensity. Channel 
1= DAPI, Channel 2= GFP. B) Percentage of cells for which Usp4 was predominantly nuclear, 
cytoplasmic or throughout the cell. Data are presented as a percentage of total cells analysed and are 
combined from 3 independent experiments. Statistical analysis was performed using two-way 
ANOVA with posthoc Bonferroni analysis.  
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 The effect of Usp4 phosphorylation at Ser675/Ser680 on cell 
signalling pathways 
As the prevention of the phosphorylation of Usp4 at Ser675/Ser680 did not affect the 
subcellular localisation of Usp4, the effect of overexpressing the non-phosphorylatable 
version of Usp4 on the activity of cell signalling pathways was next explored. 
6.2.2.1  Overexpression of non-phosphorylatable Usp4 at Ser675/Ser680 affects 
cell signalling pathways 
To examine the potential effect of the phosphorylation of Usp4 on cell signalling 
pathways, the effect of overexpressing a mutant phosphorylation version of Usp4 using a 
multi-reporter array was performed. Osteosarcoma U2OS cells were seeded onto the 
reporter array containing constructs for 10 pathways with either Usp4 WT, Usp4 
S675A/S680A or a control vector (pCMV6-AN-mGFP) and a luciferase assay was 
performed as described in section 2.2.5.2.  
As seen previously in section 3.3.1, the reporter array determined that overexpression of 
Usp4 significantly increased the activity of p53, NF-κB, MAPK/ERK and MAPK/JNK 
pathways (Figure 6.2). Overexpression of the version of Usp4 which is non-
phosphorylatable at Ser675/S680 ablated the ability of Usp4 to enhance these pathways, 
restoring levels to those containing the empty vector (Figure 6.3). 
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Figure 6.3. Overexpression of Usp4 affects the activity of cell signalling pathways, potentially 
regulated by the phosphorylation of Usp4. A Renilla reporter vector and either p-CMV6-AN-mGFP 
control vector (Control), wild-type Usp4 expression plasmid (WT) or non-phosphorylatable Usp4 
expression plasmid (S675A/S680A) were added to wells of a multi-pathway reporter array plate 
containing reporter constructs for 10 different pathways. After transfection reagent/DNA complex 
formation, U2OS cells were seeded onto the plates. At 24 hours post-transfection a luciferase assay 
was performed. Data were normalised to Renilla and to positive control values and are displayed as 
normalised relative light units (RLU). Figure is from one experiment ±SEM (n=4/experiment). For 
statistical analysis, one way ANOVA with a post-hoc Tukey comparison test was performed on data 
from each pathway separately. * p≤0.05, **p≤0.01, *** p≤0.001. 
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6.2.2.2  Overexpression of non-phosphorylatable Usp4 at Ser675/Ser680 affects 
IL-1- and TNFα-induced NF-κB activity 
As overexpression of Usp4, non-phosphorylatable at Ser675/S680, reduced the increase 
in NF-κB activity that was observed with overexpression of wild-type Usp4, its effect on 
IL-1- and TNFα-induced NF-κB activity was next examined by performing an NF-κB 
pathway reporter assay. SW1353 cells were co-transfected with NF-κB responsive firefly 
luciferase reporter and constitutive Renilla expression vectors alongside control, Usp4 
WT, Usp4 C311A or Usp4 S675A/S680A expression vectors. After stimulation with 
either IL-1 or TNFα, luciferase activity was measured and normalised to Renilla. 
Additionally, the expression of Usp4-GFP was confirmed by transfection of the Usp4 
expression vectors into SW1353. Cells were then lysed, total protein extracted, resolved 
by electrophoresis and immunoblotted with an anti-GFP antibody. Wild-type and mutant 
versions of Usp4 were expressed at similar levels (Figure 6.4A).  
The reporter assay demonstrated a significant increase in both IL-1- and TNFα-induced 
NF-κB activity with overexpression of wild-type Usp4 compared to the control. The 
increase was attenuated with overexpression of catalytically inactive Usp4, indicating that 
the increase in IL-1- and TNFα-induced NF-κB activity is due to the deubiquitinase 
activity of Usp4 (Figure 6.4B and Figure 6.4C). Further, the overexpression of non-
phosphorylatable Usp4 at Ser675/Ser680 significantly reduced the activity of NF-κB 
compared to overexpression of wild-type Usp4. This significant reduction led to restored 
control NF-κB activity levels with IL-1 stimulation and significantly reduced NF-κB 
activity to levels below that of the control with TNFα stimulation, indicating that the 
phosphorylation of Usp4 may be involved in the regulation of its function within the NF-
κB signalling pathway (Figure 6.4B and Figure 6.4C).  
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Figure 6.4. Overexpression of Usp4 and Usp4 variants affected NF-κB activity. A) SW1353 cells were 
transfected with control, Usp4 WT, Usp4 C311A or Usp4 S675A/S680A vectors for 24 hours before 
being lysed. Total protein was extracted, resolved by SDS-PAGE and immunoblotted with an anti-
GFP antibody. GAPDH was used as a loading control. B) and C) NF-κB responsive firefly luciferase 
and Renilla reporter vectors were co-transfected into SW1353 cells with either control (pCMV6-AN-
mGFP), wild-type Usp4 (Usp4 WT), catalytically inactive Usp4 (Usp4 C311A) or non-
phosphorylatable Usp4 (Usp4 S675A/S680A) vectors. At 24 hours post-transfection, cell were serum-
starved overnight before a 6 hour stimulation with the relevant stimulus. B) Cells were stimulated 
with IL-1α (0.5ng/ml). Data are combined from 2 independent experiments ±SEM (n=4/experiment). 
* p≤0.05, *** p≤0.001. C) Cells were stimulated with TNFα (10µg/ml). Data are combined from 3 
independent experiments ±SEM (n=4/experiment). * p≤0.05, *** p≤0.001.  
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  The generation of Usp4 phosphorylation variants 
6.2.3.1 Usp4 phosphorylation variant generation 
The data presented in this chapter to date have utilised a phosphorylation variant of Usp4 
for which both of two closely located phosphorylation sites, Ser675 and Ser680 were 
mutated to Ala residues to prevent phosphorylation of Usp4 at these sites. Alternatively, 
these sites could be mutated to aspartic acid (Asp) residues which has been shown to 
mimic phosphorylation (Léger et al., 1997, Zhang et al., 2012). To further explore the 
function of Usp4 phosphorylation, a range of different Usp4 phosphorylation variants 
were generated which incorporate mutations at one or both sites to prevent or mimic the 
phosphorylation of Usp4.  
Site-directed mutagenesis of the pCMV6-AN-Usp4-mGFP vector was performed to 
generate a series of phosphorylation variants. For some variants, one or both of the Ser 
sites were mutated to Ala, referred to herein as non-phosphorylatable. For other variants, 
one or both of the Ser sites were also mutated to Asp, referred to herein as 
phosphomimetic. Presence of the correct mutations were confirmed by sequencing and 
are displayed in Table 6.1. 
 
  
 
 
1
8
9
 
Table 6.1. Usp4 phosphorylation variants generated by mutagenesis. Mutations at sites 675 and 680 are highlighted in red, wild-type sites are highlighted in green. 
Usp4 Variant Sequence Non-phosphorylatable/ 
phosphomimetic? 
Usp4 WT GGAAAAGAGCAGCTTTCCGAAGTGGAAGGCAGTGGTGAGGACGATCAG N/A 
Usp4 S675A GGAAAAGAGCAGCTTGCGGAAGTGGAAGGCAGTGGTGAGGACGATCAG Non-phosphorylatable 
Usp4 S680A GGAAAAGAGCAGCTTTCCGAAGTGGAAGGCGCGGGTGAGGACGATCAG Non-phosphorylatable 
Usp4 S675A/S680A GGAAAAGAGCAGCTTGCCGAAGTGGAAGGCGCCGGTGAGGACGATCAG Non-phosphorylatable 
Usp4 S675D GGAAAAGAGCAGCTTGACGAAGTGGAAGGCAGTGGTGAGGACGATCAG Phosphomimetic 
Usp4 S680D GGAAAAGAGCAGCTTTCCGAAGTGGAAGGCGATGGTGAGGACGATCAG Phosphomimetic 
Usp4 S675D/S680D GGAAAAGAGCAGCTTGACGAAGTGGAAGGCGATGGTGAGGACGATCAG Phosphomimetic 
Usp4 S675A/S680D GGAAAAGAGCAGCTTGCGGAAGTGGAAGGCGATGGTGAGGACGATCAG Non-phosphorylatable/ Phosphomimetic 
Usp4 S675D/S675A GGAAAAGAGCAGCTTGACGAAGTGGAAGGCGCGGGTGAGGACGATCAG Non-phosphorylatable/ Phosphomimetic 
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6.2.3.2  Identification of the phosphorylation status of Usp4 
To determine the phosphorylation status of wild-type Usp4 (Usp4 WT), non-
phosphorylatable Usp4 (Usp4 S675A/S680A) and phosphomimetic Usp4 (Usp4 
S657D/S680D), the GFP-tagged expression vectors and a control vector (pCMV-AN-
mGFP) were transfected into HEK 293T cells, immunoprecipitated with an anti-GFP 
antibody, resolved by electrophoresis and immunoblotted with an anti-phosphoserine 
antibody.  
Usp4 WT, Usp4 S675A/S680A and Usp4 S675D/S680D were all immunoprecipitated 
successfully as demonstrated by the presence of GFP and Usp4, but not in the control 
(Figure 6.5). All variants of Usp4 were serine phosphorylated, with less phosphorylation 
of the Usp4 S675A/S680A variant than Usp4 S675D/S680D, indicating that the non-
phosphorylatable Usp4 at sites Ser675 and Ser680 was less phosphorylated than the 
phosphomimetic Usp4 variant. 
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Figure 6.5. Usp4 is serine phosphorylated. HEK 293T cells were transfected with a control vector 
(pCMV-AN-mGFP) or Usp4 wild-type (Usp4 WT) or phosphorylation variants (Usp4 S675A/S680A 
or Usp4 S675D/S680D). At 24 hours post-transfection, cells were lysed, total protein extracted, 
resolved by SDS-PAGE and immunoblotted (IB) with anti-GFP and anti-Usp4 antibodies to confirm 
successful transfection in whole cell lysates (WCL). GAPDH was used as a loading control. Extracts 
were pre-cleared with rabbit IgG before immunoprecipitation (IP) with an anti-GFP antibody 
overnight, resolved by SDS-PAGE and immunoblotted (IB) with anti-phosphoserine (P-Ser), anti-
GFP and anti-USP4 antibodies. Figure is representative of 3 independent experiments. 
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6.2.3.3  The effect of overexpressing Usp4 phosphorylation variants on NF-κB 
activity 
As overexpression of the non-phosphorylatable Usp4 variant, Usp4 S675A/S680A, 
restored the level of IL-1-induced NF-κB activity to control levels in comparison to the 
overexpression of Usp4 WT, the effect of the overexpression of the other variants was 
next examined. SW1353 cells were co-transfected with NF-κB responsive firefly 
luciferase reporter and constitutive Renilla expression vectors alongside control, Usp4 
WT and Usp4 phosphorylation variant expression vectors. After stimulation with IL-1, 
luciferase activity was measured and normalised to Renilla. 
An example of one experiment is shown in Figure 6.6. All phosphorylation mutants 
significantly reduced IL-1-induced NF-κB activity, compared to wild-type Usp4, in this 
experiment. However, data from replicative experiments were very variable and not 
reproducible, therefore no conclusive effects could be observed. For this reason it was 
decided a new approach to introduce the Usp4 phosphorylation variants into cells would 
be utilised. 
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Figure 6.6. Overexpression of Usp4 and Usp4 phosphorylation variants on IL-1-induced NF-κB 
activity. SW1353 cells were co-transfected with NF-κB-dependent firefly luciferase and Renilla 
expression vectors along with either empty vector (Control), wild-type Usp4 (Usp4 WT) or Usp4 
phosphorylation variants. At 24 hours post-transfection, cells were serum-starved overnight before 
being left unstimulated (Unstim) or stimulated with IL-1α (0.5ng/ml) for 6 hours (IL-1). Data is an 
example of one experiment (n=4). Data are plotted as mean ±SEM. Two way ANOVA with post-hoc 
Bonferroni comparison test was performed as statistical analysis. ** p≤0.01, *** p≤0.001. 
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6.2.3.4  Lentiviral generation 
To overcome difficulties in the reproducibility of data from NF-κB responsive luciferase 
assays with overexpression of Usp4 WT and phosphorylation variants, a lentiviral-
mediated delivery approach was developed. 
Initially, a doxycycline-inducible expression system was utilised. Usp4 WT and variants, 
with the GFP, were cloned into a response vector, pLVX-Tight-Puro, and transfected into 
cells with lentiviral packaging vectors to produce response lentiviral supernatants. 
Additionally, a regulator vector, pLVX-Tet-On Advanced, was transfected into HEK 
293T cells with lentiviral packaging vectors to produce regulator lentiviral supernatants. 
Transduction of both regulator and response lentiviral supernatants into cells should 
activate transgene expression upon doxycycline induction. Various conditions to optimise 
the production of lentivirus in HEK 293T cells and transduction into SW1353 cells were 
tested as described in section 2.2.14. As the lentiviral particles should express a GFP 
protein if successfully transduced, cells were visualised on a fluorescent microscope, 
however no GFP was observed indicating unsuccessful lentiviral production or 
transduction. 
The next approach was to utilise a different lentiviral expression system more commonly 
used in our laboratory, a second generation packaging and envelope plasmid system.  
Usp4 WT, Usp4 C311A and all Usp4 phosphorylation variants were first cloned into the 
lentiviral expression vector, pCDH-EF1-MCS-IRES-GFP. Lentiviral supernatants were 
produced by transfection of the lentiviral constructs, or control vector, pCDH-EF1-MCS-
IRES-GFP, a packaging vector and an envelope vector into HEK 293T cells before 
harvesting. Successful transduction into SW1353 cells was confirmed by visualisation of 
GFP expression on a fluorescent microscope. 
 The effect of Usp4 phosphorylation on IL-1-induced NF-κB 
activity 
6.2.4.1  Lentiviral-mediated overexpression of Usp4 phosphorylation variants 
on IL-1-induced NF-κB activity in SW1353 cells using viral titre normalisation 
To ensure cells were transduced with equal viral particles across all lentiviral supernatants 
used, the viral RNA genome was measured by titration, as described in section 2.2.14.3, 
and normalised for all of the Usp4 variants and control to the lowest viral RNA copy 
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number. To determine the effect of Usp4 phosphorylation on NF-κB activity, an NF-κB 
responsive luciferase assay was performed using lentiviral preparations for control, wild-
type Usp4, catalytically inactive Usp4 and non-phosphorylatable and phosphomimetic 
Usp4. SW1353 cells were co-transduced with the lentiviral preparations and NF-κB 
luciferase lentiviral preparations, followed later by stimulation with IL-1 and lysis for use 
in a luciferase assay. Successful transduction of NF-κB luciferase reporter, pHAGE-NF-
κB-TA-LUC-GFP-W, was previously verified (Figure 4.14).  
There was no difference in IL-1-induced NF-κB activity with overexpression of Usp4 
WT compared to the control, in contrast with data in Figure 6.4. Overexpression of Usp4 
C311A increased IL-1-induced NF-κB activity compared to overexpression of Usp4 WT, 
again in contrast to data in Figure 6.4. In line with data in Figure 6.4, overexpression of 
the non-phosphorylatable Usp4, Usp4 S675A/S680A, reduced IL-1-induced NF-κB 
activity compared to the overexpression of Usp4 WT. IL-1-induced NF-κB activity was 
also reduced with overexpression of a variant with a single phosphorylation mutant, Usp4 
S675A, and in both single phosphomimetic variants, Usp4 S675D and Usp4 S680D, in 
addition to a variant in which one site is non-phosphorylatable and one phosphomimetic, 
Usp4 S675D/S680D. The only Usp4 phosphorylation variant to increase the activity of 
NF-κB compared to the Usp4 WT was a variant with the second phosphorylation site 
mutated to non-phosphorylatable, S680A (Figure 6.7).  
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Figure 6.7. Lentiviral-mediated expression of Usp4 and Usp4 phosphorylation mutants on IL-1-
induced NF-κB activity in SW1353 cells with normalised amounts of viral preparations. SW1353 cells 
were transduced with lentiviral preparations for an NF-κB responsive firefly luciferase expression 
vector (pHAGE-NF-κB-TA-LUC-UBC-GFP-W) and either lentiviral preparations for a control 
(pCDH-EF1–MCS-IRES-GFP), wild-type Usp4 (Usp4 WT), catalytically inactive Usp4 (Usp4 
C311A) or Usp4 phosphorylation variants, and treated with polybrene (8µg/ml). After 48 hours, cells 
were stimulated with IL-1α (0.5ng/ml) for 6 hours, or left unstimulated, before cell lysis and 
luminescence was measured. Data are displayed in relative light units (RLU) ± SEM (n=4). Two way 
ANOVA with post-hoc Bonferroni comparison test was performed as statistical analysis. * p ≤0.05, 
*** p≤0.001. 
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6.2.4.2  Expression of Usp4 with lentiviral-mediated overexpression of Usp4 
phosphorylation variants 
As the data in Figure 6.7 is conflicting with previous data in this thesis, the expression of 
Usp4 was examined for each of the Usp4 phosphorylation variants when transducing cells 
with equal viral particles, as determined by viral titre. SW1353 cells were transduced with 
lentiviral preparations for all Usp4 variants, cells were lysed, resolved by electrophoresis 
and immunoblotted with an anti-USP4 antibody.  
Expression of Usp4 was observed for all Usp4 phosphorylation variants, however, the 
levels of Usp4 expression varied between the different lentiviral preparations, possibly 
indicating there was unequal transduction (Figure 6.8). 
 
Figure 6.8.  USP4 expression with lentiviral Usp4 and Usp4 phosphorylation variants. SW1353 cells 
were transduced with Usp4 WT, Usp4 C311A or Usp4 phosphorylation variants and treated with 
polybrene (8µg/ml), or treated with polybrene only (8µg/ml) (Polybrene only). After 48 hours, cells 
were lysed, resolved by SDS-PAGE and immunoblotted with an anti-USP4 antibody. GAPDH was 
used as a loading control. 
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6.2.4.3  Lentiviral-mediated overexpression of Usp4 phosphorylation variants 
on IL-1-induced NF-κB activity in SW1353 cells with equal viral preparation 
volume 
As the expression of Usp4 was unequal between the different Usp4 phosphorylation 
variants when normalising the volume of viral preparations used according to viral titre, 
and the NF-κB responsive reporter assay produced data conflicting to other data in this 
thesis, the IL-1-induced NF-κB activity was next examined using equal volumes of viral 
preparations with an assumption that viral preparations contain similar amounts of viral 
particles. The lentiviral particles generated were produced using the exact same procedure 
and the same lentiviral expression vector, therefore it would be expected that the amounts 
of viral particles produced would be similar across all preparations. Again, SW1353 cells 
were co-transduced with the lentiviral preparations and NF-κB luciferase lentiviral 
preparations, followed later by stimulation with IL-1 and lysis for use in a luciferase 
assay. 
Consistent with the effects on NF-κB activity in Figure 6.4, lentiviral-mediated 
overexpression of wild-type Usp4 significantly increased IL-1-induced NF-κB activity 
compared to the control. This was restored to control levels with lentiviral-mediated 
overexpression of catalytically inactive Usp4 and the non-phosphorylatable Usp4 variant, 
S675A/S680A. All other phosphorylation variants also significantly reduced the IL-1-
induced NF-κB activity compared to wild-type Usp4 (Figure 6.9). 
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Figure 6.9. Lentiviral-mediated expression of Usp4 and Usp4 phosphorylation mutants on IL-1-
induced NF-κB activity in SW1353 cells with equal volumes of preparations. SW1353 cells were 
transduced with equal volumes of lentiviral preparations for an NF-κB responsive firefly luciferase 
expression vector (pHAGE-NF-κB-TA-LUC-UBC-GFP-W) and equal volumes of either lentiviral 
preparations for a control (pCDH-EF1–MCS-IRES-GFP), wild-type Usp4 (Usp4 WT), catalytically 
inactive Usp4 (Usp4 C311A) or Usp4 phosphorylation variants and treated with polybrene (8µg/ml). 
After 48 hours, cells were stimulated with IL-1α (0.5ng/ml), or left unstimulated, for 6 hours before 
cell lysis and luminescence measured. Data are displayed in relative light units (RLU) ± SEM (n=4). 
Two way ANOVA with post-hoc Bonferroni comparison test was performed as statistical analysis. 
*** p≤0.001. 
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6.2.4.4  Lentiviral-mediated overexpression of Usp4 phosphorylation variants 
on IL-1-induced NF-κB activity in Usp4 -/- MEFs 
Lentiviral expression vectors are also an effective way for gene delivery into cells which 
can be difficult to transfect ordinarily, such as MEFs. Therefore, this method was also 
utilised to examine the effect of Usp4 phosphorylation in Usp4-/- MEFs. This allowed a 
model for which no endogenous Usp4 would be present, only the Usp4 variant introduced 
into the cell via lentiviral transduction would be present in the cells, eliminating any 
masking of effects by endogenous Usp4. The Usp4-/- MEFs were transduced with equal 
volumes of control or Usp4 lentiviral preparations, and with NF-κB luciferase lentiviral 
preparations, followed later by stimulation with IL-1 and lysis for use in a luciferase 
assay. 
As in SW1353 cells (Figure 6.9), IL-1-induced NF-κB activity was increased with 
overexpression of wild-type Usp4 compared to the control, and restored to control levels 
with overexpression of catalytically inactive Usp4. Overexpression of the single and 
double non-phosphorylatable variants, Usp4 S675A and Usp4 S675A/S680A, also 
significantly reduced IL-1-induced NF-κB activity compared to wild-type, as did all of 
the phosphomimetic variants, Usp4 S675D, Usp4 S680D and Usp4 S675D/S680D. No 
differences in the IL-1-induced NF-κB activity were observed with the single non-
phosphorylatable variant, Usp4 S680A, or either of the combined variants, S675A/S680D 
and S675D/S680D (Figure 6.10).  
Chapter 6: USP4 Phosphorylation and NF-κB Signalling 
 
  
201 
 
 
Figure 6.10. Lentiviral-mediated expression of Usp4 and Usp4 phosphorylation mutants on IL-1α-
induced NF-κB activity in Usp4-/- MEFs. Usp4-/- MEFs were transduced with lentiviral preparations 
for an NF-κB responsive firefly luciferase expression vector (pHAGE-NF-κB-TA-LUC-UBC-GFP-
W) and equal volumes of either lentiviral preparations for a control (pCDH-EF1–MCS-IRES-GFP), 
wild-type Usp4 (Usp4 WT), catalytically inactive Usp4 (Usp4 C311A) or Usp4 phosphorylation 
variants and treated with polybrene (8µg/ml). After 48 hours, cells were stimulated with IL-1α 
(0.5ng/ml), or left unstimulated, for 6 hours before cell lysis and luminescence measured. Data are 
displayed in relative light units (RLU) ± SEM (n=4). Two way ANOVA with post-hoc Bonferroni 
comparison test was performed as statistical analysis. * p≤0.05, *** p≤0.001.
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 The effect of depleting a USP4 kinase on NF-κB signalling 
6.2.5.1  Identification of USP4 protein kinases 
To identify the protein kinases that phosphorylate the Ser675 and Ser680 residues, the 
laboratory of Dr. Robert Screaton in collaboration with Dr. Doug Gray, performed an in 
vitro kinase screen. A fusion of GST and a USP4 fragment, containing the two relevant 
serines, was exposed to a panel of recombinant kinases in the presence of γ-32P-labelled 
ATP. For methodology see report by Jansson et al. (2008).  
Several kinases were identified that could phosphorylate USP4, including G-protein-
coupled receptor kinases (GRKs) 1, 2 and 6 (Figure 6.11).  
 
Figure 6.11. A kinase screen identified GRK1, 2 and 6 as USP4 kinases. A fragment of USP4 
incorporating Ser675 and Ser680 was exposed to a panel of kinases in the presence of γ-32P-labelled 
ATP. A control fragment of myelin basic protein was also included in the screen as a control 
(Control).  Phosphorylated USP4 fragment is indicated (USP4) as is kinase autophosphorylation 
(AutoP). 
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GRKs are a family of Ser/Thr protein kinases known for phosphorylating activated G-
protein-coupled receptors (GPCRs) to mediate their desensitisation as a key mechanism 
of regulation of cell signalling pathways (Ribas et al., 2006). GRK2 is a β-adrenergic 
receptor kinase with substrates including Akt, R-Smads, p38 and A2A adenosine receptor, 
and is involved in cell signalling pathways other that those mediated by GPCRs including 
TGF-β, MAPK and NF-κB pathways (Ribas et al., 2006, Ho et al., 2005, Peregrin et al., 
2006, Robinson and Pitcher, 2013, Patial et al., 2009). Given that USP4 affected the IL-
1-induced activity of NF-κB and that the phosphorylation of Usp4 potentially has a role 
in this, it would be interesting to explore the effect of USP4 kinases on NF-κB signalling. 
As an identified USP4 kinase with some shared substrates of USP4, and involvement in 
the regulation of some of the same pathways as USP4, the effect of GRK2 on NF-κB 
signalling was examined using an RNAi approach to deplete GRK2. 
6.2.5.2 The effect of GRK2 depletion on IL-1-induced NF-κB activity  
To determine the effect of GRK2 depletion on the IL-1-induced activation of NF-κB, an 
NF-κB pathway luciferase reporter assay was performed. SW1353 cells transfected with 
an NF-κB responsive firefly luciferase reporter and a constitutive Renilla expression 
vector were GRK2 depleted by RNAi before stimulation with IL-1 and lysis for the 
luciferase assay. Luciferase activity was normalised to Renilla. 
The reporter assay demonstrated no significant difference in IL-1-induced NF-κB activity 
with depletion of GRK2 compared to the control (Figure 6.12). 
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Figure 6.12. Depletion of GRK2 did not affect IL-1-induced NF-κB activity. NF-κB responsive firefly 
luciferase and Renilla reporter vectors were transfected into SW1353 cell followed by transfection 
with siCon or siGRK2 after 6-8 hours. At 24 hours post-transfection, cells were serum-starved 
overnight before a 6 hour stimulation with IL-1α (0.5ng/ml), cell lysis and measurement of relative 
luciferase activity. Data were normalised to Renilla and to siCon IL-1=100% and are displayed as 
normalised relative light units (RLU). Figure is combined of three experiments ±SEM 
(n=4/experiment). One-way ANOVA with a post-hoc Tukey test was performed as statistical analysis. 
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6.2.5.3 The effect of GRK2 depletion on IL-1-induced NF-κB-regulated gene 
expression  
As the depletion of USP4 reduced IL-1-induced expression of some NF-κB-regulated 
genes, the effect of GRK2 depletion on the expression of IL-6, IL-8 and MMP13 were 
next examined.  SW1353 cells were transfected with siCon, siUSP4 or siGRK2, total 
RNAs extracted and real-time RT-PCR performed.  
GRK2 depletion with transfection of an siRNA targeting GRK2 (siGRK2) was confirmed 
(Figure 6.13E). Similarly to USP4 depletion, GRK2 depletion significantly reduced the 
IL-1-induced expression of IL-6 and MMP13 but there was no effect with GRK2 
depletion on the IL-1-induced expression of IL-8 (Figure 6.13A, Figure 6.13B and Figure 
6.13C). 
  
  
 
2
0
6
 
 
Figure 6.13. GRK2 depletion reduced IL-1-induced expression of NF-κB-regulated genes. SW1353 cells were transfected with siCon, siUSP4 or siGRK2 for 24 hours. After 
overnight serum-starvation, cells were stimulated with IL-1α (0.5ng/ml) for 6 hours before total RNA was extracted, reverse transcribed to cDNA and analysed by real-time 
RT-PCR. Relative gene expression of A) IL-6, B) IL-8, C) MMP13, D) USP4 and E) GRK2 were measured. Data are normalised to 18S and are plotted as mean ±SEM (n=6). 
Two-way ANOVA with post hoc test Bonferroni was performed as statistical analysis. * p≤0.05, *** p≤0.001
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6.2.5.4 The effect of GRK2 depletion on the levels of NF-κB adaptor proteins 
Next, the effect of depleting GRK2 on the levels of key proteins involved in NF-κB 
signalling, for which depleting USP4 affected, were examined by immunoblotting total 
protein extracts from control, USP4 depleted and GRK2 depleted SW1353 cells with the 
relevant antibodies. 
Whereas USP4 depletion reduced the levels of phosphorylated IKKα/β and 
phosphorylated JNK and reduced the degradation of IκBα, the depletion of GRK2 had no 
effect on the levels of any of these proteins compared to the control (Figure 6.14).  
 
Figure 6.14. The effect of GRK2 depletion on levels of NF-κB pathway proteins. SW1353 cells were 
transfected with siCon, siUSP4 or siGRK2 for 24 hours, serum-starved overnight and treated with 
IL-1α (0.5ng/ml) for the indicated time (minutes). Total protein was extracted, resolved by SDS-
PAGE and immunoblotted with anti-IκBα, anti-P-IKKα/β, anti-P-JNK and anti-USP4 antibodies. 
GAPDH was used as a loading control. 
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 Discussion 
The aim of this chapter was to explore how the PTM of USP4 could affect its function. A 
series of phosphorylation mutants were generated to examine the functional consequences 
of their overexpression on the subcellular localisation of Usp4 and on cell signalling 
pathways. Experiments were performed in parallel with experiments to determine the role 
of USP4 on the NF-κB signalling pathway, as discussed in previous chapters in this thesis. 
Given that data demonstrated that USP4 functions in the NF-κB signalling pathway, the 
main focus was to examine effects of its phosphorylation on the activity of NF-κB. 
Additionally, a potential USP4 kinase, GRK2, was also examined in relation to NF-κB 
signalling. 
It should be noted that although the Ser residues 675 and 680 were shown to be 
phosphorylated, other PTMs can modify Ser residues, including acetylation and O-
glycosylation, thereby further diversifying regulation of the protein (Mukherjee et al., 
2007, Huber and Hardin, 2004). A series of phosphorylation mutants were generated to 
examine the function of the phosphorylation at Ser675/Ser680, however, there is a 
possibility that this may affect other PTMs at these sites which should be kept in mind. 
 Overexpression of a non-phosphorylatable Usp4 variant, at 
Ser675 and Ser680, did not affect the subcellular localisation of Usp4 
The phosphorylation of DUBs has been demonstrated to regulate their translocation 
between subcellular locations (Yuan et al., 2010, Zhang et al., 2012, Kessler and 
Edelmann, 2011). The effect of USP4 phosphorylation on its subcellular localisation was 
therefore examined by overexpression of a Usp4 phosphorylation variant which has two 
phosphorylation sites, Ser 675 and Ser680, mutated to Ala to prevent phosphorylation at 
these sites. Both overexpression of wild-type Usp4 and the Usp4 phosphorylation variant 
of Usp4 were localised mainly in the cytoplasm of NIH3T3 cells with no differences 
observed in the localisation between either version of Usp4, indicating that the 
phosphorylation status at these sites does not regulate its subcellular localisation. 
Although performed without stimulation of the cells, differences in the distribution of 
Usp4 between cells could be due to the presence of cytokines in the serum which mean 
the cells are in different phases. 
Chapter 6: USP4 Phosphorylation and NF-κB Signalling 
 
  
209 
 
USP4 is known to regulate many pathways, including p53, Wnt, RIG-I, TGF-β and NF-
κB pathways (Zhang et al., 2011, Zhao et al., 2009, Wang et al., 2013, Zhang et al., 2012, 
Fan et al., 2011b). The mechanism of the regulation of USP4 in TGF-β signalling is 
through the AKT-mediated phosphorylation of USP4 at Ser445 which facilitates its 
translocation from the nucleus to the cytoplasm and plasma membrane to spatially locate 
it to the TβR-I, required for its function in this pathway (Zhang et al., 2012). The reported 
data on the regulation of USP4 by its phosphorylation at Ser445 was published after 
experiments to evaluate Usp4 PTM at Ser675/Ser680. The mechanism of USP4 
regulation in other pathways is largely unexplored but it is possible that regulation of its 
subcellular localisation is important for its function. Although, under conditions tested 
here, the PTM of Usp4 at Ser675/Ser680 did not regulate its subcellular localisation, it 
would be interesting to examine whether stimulating with IL-1 affects this, as this was 
shown to be regulated by phosphorylation of Usp4. Further, expressing or inhibiting 
known Usp4 kinases or expressing phosphomimetic Usp4 variants, as generated later in 
these studies, may give further insight into the effect of Usp4 PTM on its subcellular 
localisation.  
 Usp4 PTM at Ser675/Ser680: effects on cell signalling pathways 
It was demonstrated in Chapter 3 that Usp4 affected cell signalling pathways in a multi-
pathway reporter array, including p53, NF-κB, MAPK/ERK and MAPK/JNK pathways. 
This was potentially through the deubiquitinase activity of Usp4 as a catalytically inactive 
Usp4 partially or fully attenuated the ability of Usp4 to enhance NF-κB activity, restoring 
activity to control levels. In parallel, the effect of Usp4 phosphorylation on cell signalling 
pathways was examined, by overexpression of non-phosphorylatable Usp4 at 
Ser675/Ser680, and was demonstrated to attenuate the ability of Usp4 to enhance activity 
of pathways p53, NF-κB, MAPK/ERK and MAPK/JNK, restoring activity to control 
levels. As wild-type Usp4 was demonstrated to increase the activity of these pathways, it 
suggests that PTM of Usp4 at one or both of these serines is required for the function of 
Usp4 within these pathways.  
The multi-pathway reporter array was performed without stimulation, and as no effect on 
the subcellular localisation was observed under the same conditions, it seems likely that 
the subcellular localisation of Usp4 is not regulated by phosphorylation at Ser675/Ser680 
for its function in these pathways. Instead, its phosphorylation may facilitate protein-
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protein interactions or alter the stability or activity of Usp4 to allow it to function in these 
pathways. However, as mentioned previously, the reporter array was performed with 
serum present in the media meaning that these pathways could have been induced by low 
levels of cytokines present in the serum. Again, it would be interesting to individually 
induce the pathways in the multi-pathway reporter array to further examine effects on 
pathway activity. 
 The effect of Usp4 PTM on IL-1-induced NF-κB activity 
The previous chapters in this thesis demonstrated a role for USP4 in TNFα- and 
particularly IL-1-induced NF-κB signalling. The multi-pathway reporter array also 
demonstrated differences in NF-κB activity with a phosphorylation variant of Usp4, 
compared to the wild-type, indicating that Usp4 phosphorylation may be involved in 
regulating Usp4 for its role in NF-κB signalling. Initially, an NF-κB responsive luciferase 
reporter assay was performed for wild-type, catalytically inactive Usp4 and the 
phosphorylation variant of Usp4. Consistent with data from RNAi experiments in which 
USP4 depletion reduced NF-κB activity, overexpression of wild-type Usp4 significantly 
enhanced NF-κB activity, but not overexpression of catalytically inactive Usp4. This 
suggests Usp4 enhanced NF-κB activity due to its deubiquitinase activity. In line with the 
multi-reporter array, the increase in IL-1-induced NF-κB activity was attenuated when 
phosphorylation at Ser675/Ser680 was prevented. TNFα-induced NF-κB activity was 
actually reduced to below control levels of activity when phosphorylation was prevented, 
indicating that the PTM of Usp4 may alter the function of Usp4 in TNFα-mediated NF-
κB signalling. Overall, it suggested that the phosphorylation of Usp4 at one or both of 
these serines is important in the IL-1- and TNFα-induced activation of NF-κB. 
Protein levels of Usp4 were also examined for wild-type and both Usp4 variants. 
Phosphorylation and ubiquitination can crosstalk, adding to the complexity of regulation 
of proteins. The presence of a phosphodegron or phosphorylation of a protein can serve 
as a prerequisite for the ubiquitination and subsequent degradation of proteins, as occurs 
in NF-κB signalling where IκBα is phosphorylated by the IKK complex for recognition 
by the E3 ligase SCF-β-TrCP (Spencer et al., 1999). This is also potentially a mechanism by 
which DUBs may be regulated. Phosphorylation of USP25 by a tyrosine kinase led to a 
decrease in USP25 protein levels in the cell indicating that its phosphorylation may affect 
the stability of the protein (Cholay et al., 2010). Examination of protein levels revealed 
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there were similar levels of GFP-tagged Usp4 with expression of both Usp4 variants and 
wild-type Usp4, suggesting that neither the phosphorylation of Usp4 at these sites, nor its 
catalytic activity, regulate its stability.  
Although preliminary experiments demonstrated that overexpression of the non-
phosphorylatable Usp4 at Ser675/Ser680 attenuated NF-κB activity compared to wild-
type Usp4, it did not give indications as to which phosphorylation site(s) may be involved. 
To further explore Usp4 phosphorylation, a series of Usp4 phosphorylation variants were 
generated next.  
6.3.3.1 Generation of Usp4 phosphorylation variants 
Overexpression of proteins is an important molecular biological technique for observing 
the effects of a protein on a particular system. It also allows manipulated versions of the 
protein to be introduced into cells to allow observation of effects on these systems. It was 
therefore decided that a series of Usp4 phosphorylation variants would be generated to 
allow observations of effects on NF-κB activity with modifications to the phosphorylation 
status of Usp4.  
Initially, Usp4 phosphorylation variants generated by site-directed mutagenesis were used 
in NF-κB responsive luciferase assays, as for the non-phosphorylatable Usp4 
S675A/S680A variant. The lack of reproducibility of the data in these experiments led to 
a different, lentiviral-mediated approach as a more stable vehicle for the delivery of the 
Usp4 variants into cells. One limitation of overexpressing Usp4 in cells is that 
endogenous USP4 is still present which could affect observations made in these 
experiments. The overall aim of generating lentiviral preparations for the delivery of 
variants of Usp4 was for use in Usp4-/- MEFs, where the only Usp4 present would be the 
mutant variant transduced in the cells. Lentiviral-mediated gene expression has many 
advantages over transient transfection of expression vectors. Primary cells are notoriously 
difficult to transfect, and transient transfection of MEFs with a lentiviral NF-κB 
expression vector previously in this thesis proved unsuccessful. Lentiviral expression 
vectors are effective vehicles for the efficient delivery and stable expression of genes into 
primary cells (Stewart et al., 2003). As such, it was decided that lentiviral-mediated gene 
expression would be used.  
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The first method approached was a tetracycline-inducible lentiviral expression system. 
This system required production of lentiviral particles for a response vector, containing 
an inducible promoter, PTight, and Usp4 variant, and lentiviral particles for a regulator 
vector, containing a tetracycline-controlled transactivator, rtTA-Advanced. When 
transduced into cells, induction with doxycycline should enable rtTA-Advanced to bind 
to the PTight promoter to activate transcription of Usp4. After lentiviral production, 
different conditions including varying the ratio of regulator:response lentiviral 
preparations and varying the concentration of doxycycline added were tested to try and 
optimise transduction in SW1353 cells. However, no transduction occurred, as 
determined by the absence of any expression of GFP (which would be fused to Usp4) 
when visualised on a fluorescent microscope. Doxycycline concentrations and lentiviral 
volumes tested were within manufacturer recommended amounts. Viral RNA genome 
was measured which confirmed the presence of viral particles in both the regulator and 
response lentiviral preparations although this does not confirm the presence of Usp4. 
Whether the unsuccessful transductions were due to production of the lentiviral 
preparations or unsuccessful doxycycline induction were not determined. After several 
efforts, it was decided to use a different system for lentiviral delivery of Usp4.   
The second method approached was a second generation lentiviral expression system. 
This method uses a constitutive promoter for the expression of the gene and required the 
production of only one lentiviral preparation for each of the Usp4 variants. As such it was 
deemed a more appropriate system for these experiments. All 10 Usp4 variants, 
previously generated by site-directed mutagenesis of the pCMV-AN-Usp4-mGFP vector, 
were cloned into the lentiviral expression vector, ensuring that Usp4 contained a KOZAK 
sequence for efficient translation initiation. The Usp4 endogenous stop codon was re-
introduced to ensure the GFP fusion was not cloned into the vectors as the lentiviral 
expression vector contains an IRES GFP. Steps were taken to confirm successful 
lentiviral preparation and transduction: the presence of the Usp4 insert into the lentiviral 
expression vectors were confirmed by sequencing, transduction in SW1353 cells was 
confirmed by the presence of GFP, and to confirm the presence of viral particles in the 
lentiviral preparations (and to control for equal amounts of viral particles across the series 
of Usp4 variants) viral titration was performed. The time spent cloning all the Usp4 
variants into the expression vectors and confirming successful cloning and the presence 
of viral particles in the lentiviral preparations allowed confidence in an effective system 
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for introducing these mutants into cells for examination of Usp4 phosphorylation at the 
two Ser residues. 
6.3.3.2 The effect of Usp4 PTM at Ser675/Ser680 on IL-1-induced NF-κB activity 
in SW1353 cells and Usp4-/- MEFs 
In conflict to overexpression of wild-type Usp4 by transient transfection, lentiviral-
mediated expression of wild-type Usp4 did not significantly increase IL-1-induced NF-
κB activity and catalytically inactive Usp4 significantly increased IL-1-induced NF-κB 
activity compared to wild-type Usp4. Similarly to previously, the non-phosphorylatable 
Usp4 at Ser675/Ser680 significantly decreased NF-κB activity compared to the wild-type, 
as did the phosphomimetic Usp4 variants and the single non-phosphorylatable variant at 
Ser675. The surprising conflict in data was examined by determining the expression of 
Usp4 with all of the lentiviral Usp4 variants. Many of the Usp4 phosphorylation variants 
were expressed at much lower levels than wild-type Usp4, possibly indicating unequal or 
unsuccessful transduction. Another possibility could be that the phosphorylation status of 
Usp4 does affect the stability of this protein, however, levels of Usp4-GFP were 
previously examined for the original non-phosphorylatable Usp4 at Ser675/Ser680 and 
no differences were observed.  
Viral titration allowed measurement of the viral RNA genome in the viral preparations. 
As the same lentiviral expression vector backbone was used for the production of all viral 
particles and the same protocol and conditions performed, it would be expected that viral 
titres would be similar for all preparations. However, viral titres revealed differences 
between viral particles of up to nearly 20 fold in some cases. As the viral titration was 
only performed once, it is possible that these titres are not reliable. Considering this, it 
was decided that the NF-κB responsive luciferase assay should be repeated using equal 
volumes of viral preparations rather than volumes normalised to the determined titre 
values. 
By doing this, data were in line with data from experiments where overexpression of Usp4 
was achieved through transient transfection. Lentiviral-mediated expression of wild-type 
Usp4 significantly enhanced IL-1-induced NF-κB activity compared to the control. 
Again, expression of catalytically inactive Usp4 and non-phosphorylatable Usp4 at both 
serines reduced the IL-1-induced NF-κB activity compared to the wild-type, with the 
lowest levels of NF-κB activity observed with non-phosphorylatable Usp4, at 
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Ser675/Ser680. Additionally, Usp4 variants with non-phosphorylatable sites at either 
Ser675 or Ser680 significantly reduced IL-1-induced activity compared to wild-type 
Usp4. This indicated that the phosphorylation of both of these sites is important for the 
function of Usp4 in NF-κB signalling. Prevention of phosphorylation at one Ser partially 
restored NF-κB activity to control levels, and prevention of phosphorylation at both sites 
reduced NF-κB activity further. If the phosphorylation of Usp4 at both of these Ser 
residues does regulate Usp4 in NF-κB signalling, the phosphorylation of Usp4 at only 
one Ser may partly compensate for the prevention of phosphorylation at the other Ser, 
explaining why levels were further reduced when both Ser residues were mutated. 
Further, altering one or both of the Usp4 Ser sites to the phosphomimetic Asp 
significantly reduced the enhanced IL-1-induced NF-κB activity observed with wild-type 
Usp4. This indicated that the mechanism of regulation of Usp4 by phosphorylation is 
more complex than simply requiring phosphorylation at Ser675 and/or Ser680 to function 
in the NF-κB signalling pathway. Phosphorylation is a dynamic process and the 
regulation of Usp4 may require both the phosphorylation and dephosphorylation at one 
or both sites to function in NF-κB signalling pathway. Indeed the reduction in NF-κB 
activity compared to wild-type Usp4, with variants for which one Ser site was non-
phosphorylatable and one Ser site was phosphomimetic, S675A/S680D or 
S675D/Ser680A, were not as big as reductions in NF-κB activity where both Ser sites 
were either non-phosphorylatable or phosphomimetic, S675A/S680A or S675D/S680D.  
Although data has shown that Usp4 is phosphorylated at these Ser675/Ser680, there is a 
possibility that other modifications, such as acetylation or O-glycosylation, may also 
occur at these sites. These PTMs may be required for the regulation of Usp4 and could 
have been prevented by mutating one or both sites. This could therefore be another 
explanation for the attenuated ability of Usp4 to enhance NF-κB activity observed when 
both sites were mutated to Ala or Asp.  
The endogenous USP4 present in these cells may also be altering or masking effects of 
changing the phosphorylation status of Usp4. Therefore, this experiment was also 
performed in Usp4-/- MEFs where the only Usp4 present was the Usp4 variant lentivirally 
expressed. 
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Similarly to previous data, expression of wild-type Usp4 significantly increased NF-κB 
activity compared to the control. This increase was attenuated with expression of 
catalytically inactive Usp4, or when Usp4 is non-phosphorylatable at Ser675 or both Ser 
sites, Ser675/Ser680, or when Usp4 is phosphomimetic at Ser675, Ser680 or 
Ser675/Ser680. However, when Usp4 was non-phosphorylatable at Ser675 or Ser sites 
were both either non-phosphorylatable or phosphomimetic, S675A/S680D or 
S675D/S680A, IL-1-induced NF-κB activity was similar to wild-type Usp4 levels. This 
again indicates that the phosphorylation/dephosphorylation of Usp4 at these sites is 
important in the role of Usp4 in NF-κB activation, with perhaps phosphorylation of one 
site being able to compensate for the prevention of phosphorylation at the other. How 
Usp4 may be regulated by its phosphorylation may be complex. Although many studies 
have identified PTMs which regulate DUBs, the full spectrum of PTM-mediated 
regulation of DUBs is still not well understood and crosstalk between different PTMs add 
further complexity to the field (Kessler and Edelmann, 2011). Further knowledge of 
USP4 phosphorylation is needed to understand how it may regulate its function. In 
addition, whether these Ser residues are subject to other modifications needs to be 
explored.  
Given that the phosphorylation status of Usp4 affected the IL-1-induced activity of NF-
κB, it would be interesting to explore effects of Usp4 phosphorylation on NF-κB-
regulated gene expression and on the levels and phosphorylation of NF-κB adaptor 
proteins, as was examined with USP4 depletion, but using lentiviral-mediated expression 
of Usp4 and Usp4 phosphorylation variants in Usp4-/- MEFs.   
6.3.3.3 Limitations 
It should be noted that although the lentiviral-mediated expression of Usp4 variants in 
these experiments demonstrated data consistent with previous experiments in this thesis, 
due to time constraints, these assays were only performed once. Reproducibility of these 
data would enable more definite conclusions to be made. Additionally, equal transduction 
needs to be confirmed and the effect of Usp4 phosphorylation on the stability of Usp4 
further examined. Data herein have demonstrated that the PTM of Usp4 at one or both of 
these sites does regulate the ability of Usp4 to enhance IL-1-induced NF-κB activity. It 
would be interesting to uncover the mechanism of regulation of Usp4 phosphorylation 
further. No known studies to date have examined the regulation of USP4 phosphorylation 
at Ser675 and Ser680 and consequently it is not currently known whether phosphorylation 
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at these sites affects the catalytic activity of Usp4 or affects protein-protein interactions 
which may enable Usp4 to function in NF-κB signalling. It was interesting that 
catalytically inactive Usp4 and non-phosphorylatable Usp4 both attenuated the increase 
in NF-κB activity that wild-type Usp4 demonstrated. The phosphorylation of some DUBs 
regulates their catalytic activity (Reiley et al., 2005, Hutti et al., 2007). The USP4 Ser 
sites 675 and 680 are located within the catalytic core of USP4 meaning that 
phosphorylation could regulate its catalytic activity. A DUB assay would allow 
examination of the catalytic activity of wild-type Usp4, catalytically inactive Usp4 and 
all Usp4 phosphorylation variants, with and without IL-1 stimulation, and therefore assess 
whether the phosphorylation of Usp4 regulates its activity with IL-1 induction. This 
would be needed to further assess the regulation of Usp4 by its PTM at these Ser residues. 
6.3.3.4 The phosphorylation status of Usp4 phosphorylation variants 
The serine phosphorylation of Usp4 was examined for Usp4 wild-type and 
phosphorylation variants. This confirmed the serine phosphorylation of wild-type Usp4 
and indicated that this serine phosphorylation was less in the non-phosphorylatable 
variant of Usp4. However, the antibody used detects any serine phosphorylation, not 
specifically at Ser675 and Ser680. The phosphorylation of USP4 at Ser445 regulates its 
function in TGF-β signalling and other Ser sites in USP4 have also been identified, 
including Ser196, Ser 595 and Ser598 amongst others, which could have been detected 
by the phosphoserine antibody (Zhang et al., 2012)(www.phosphosite.org). Design of 
phosphospecific antibodies which specifically recognise phosphorylation at Ser675 and 
Ser680 would allow confirmation of the phosphorylation status of Usp4 and Usp4 
phosphorylation variants. 
 The effect of depletion of a USP4 kinase on NF-κB signalling 
A kinase screen identified GRK family members, especially GRK2, as kinases able to 
phosphorylate USP4 at Ser675 and/or Ser680. As such, further examination of whether 
GRK2 may be the kinase regulating the phosphorylation of USP4, potentially for its role 
in NF-κB signalling was performed. It has been reported that GRK2 enhances TNFα-
induced NF-κB activity in macrophages, possibly through interactions with IκBα (Patial 
et al., 2009). Knockdown of GRK2 in that report resulted in reduced IκBα 
phosphorylation and reduced IκBα but only with TNFα stimulation and basal levels were 
not affected. This indicates that GRK2 acts in the NF-κB signalling pathway only upon 
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stimulation. There are no known studies which have examined GRK2 in IL-1-induced 
NF-κB signalling. In this chapter it was demonstrated, using an RNAi approach, that 
GRK2 depletion did not affect the IL-1-induced activity of NF-κB. It would be interesting 
to examine the effect of GRK2 depletion on TNFα-induced NF-κB signalling. 
To further explore the effects of GRK2 on NF-κB signalling, in comparison to USP4, the 
effect of GRK2 depletion on the expression of NF-κB-regulated genes was also 
examined. Similar to the depletion of USP4, depletion of GRK2 significantly reduced the 
IL-1-induced expression of IL-6 and MMP13. Although the level of IL-1-induced 
expression of IL-8 was significantly reduced with depletion of USP4, no effect was 
observed with depletion of USP4. GRK2 has many identified roles in cell signalling 
pathways, independent of its effects on GPCR signalling including roles in MAPK 
pathways. GRK2 has been reported to act as a RhoA-activated scaffold protein to mediate 
binding to Raf1, MEK1 and ERK2 for ERK MAPK activation, downstream of the 
epidermal growth factor (EGF) receptor (EGFR) (Robinson and Pitcher, 2013). It has also 
been shown to enhance EGF-induced ERK MAPK activation through complex formation 
with the EGFR (Gao et al., 2005). Alternatively, GRK2 is also reported to suppress p38 
MAPK signalling by phosphorylating p38 to prevent phosphorylation and activation by 
MKK6 (Peregrin et al., 2006). Clearly, the function of GRK2 is complex. Although the 
reports mentioned demonstrate effects of GRK2 in EGF-mediated ERK MAPK 
signalling, it is possible it may have a function in regulating other IL-1-induced pathways. 
The expression of genes including IL-6 and MMP13 are regulated by multiple pathways, 
including MAPK (Mengshol et al., 2000, Liu et al., 2015). Given that no effect on NF-
κB activity was observed with GRK2 depletion, the differences in gene expression 
observed here could be due to changes in the GRK2-mediated regulation of pathways 
other than NF-κB. 
The effect of GRK2 depletion on the levels and the phosphorylation of some of the key 
NF-κB proteins that were affected by USP4 depletion was also examined. As previously 
demonstrated in this thesis, IL-1-induced phosphorylation of IKKα/β and degradation of 
IκBα were reduced with depletion of USP4. Depletion of GRK2 had no effect on either 
of these proteins. 
The absence of any effects on IL-1-induced NF-κB activity or levels of key NF-κB 
adaptor proteins, indicated that GRK2 did not directly regulate IL-1 NF-κB signalling. 
Chapter 6: USP4 Phosphorylation and NF-κB Signalling 
 
  
218 
 
Although Usp4 phosphorylation was demonstrated to potentially regulate the function of 
Usp4 in NF-κB signalling, and GRK2 was identified as a kinase of USP4, it is possible 
that GRK2 is not the kinase responsible for this mechanism of regulation in NF-κB 
signalling. Several other kinases were also identified in the kinase screen, including 
GRK1 and GRK6. Alternatively, the effects with GRK2 depletion on NF-κB signalling 
may be masked by the presence of other kinases able to phosphorylate USP4. Further 
study is required to identify which kinase(s) may phosphorylate USP4 at Ser675 and 
Ser680 for its function within the NF-κB signalling pathway. By identifying the kinases 
responsible for USP4 phosphorylation, experiments could be performed using kinase 
inhibitors or siRNA-mediated depletion of the kinase to monitor effects on NF-κB 
signalling, and with Usp4 phosphorylation variants. 
 Summary 
The main aim of this chapter was to further explore Usp4 modification at Ser675/Ser680 
through the generation of a series of Usp4 phosphorylation variants. As previous chapters 
demonstrated a role for USP4 in the NF-κB signalling pathway, the effect of Usp4 
phosphorylation on NF-κB activity was examined. Time was spent to develop a system 
for examining the PTM of Usp4 at these sites through generation of lentiviral expression 
vectors containing all 10 different Usp4 phosphorylation variants for lentiviral-mediated 
delivery into SW1353 cells and Usp4-/- MEFs. Studies in this chapter have identified the 
PTM of Usp4 at Ser675 and Ser680 as a potential mechanism of regulation for Usp4 
within the NF-κB signalling pathway. By altering the phosphorylation status of Usp4 at 
these sites, the enhancement of IL-1-induced NF-κB activity by wild-type Usp4 was 
attenuated. This indicates that the regulation of Usp4 by its phosphorylation is a complex 
process. As phosphorylation is a dynamic process, the interplay between the 
phosphorylation and dephosphorylation at each Ser residue may be crucial to 
understanding how Usp4 is regulated in this pathway. Alternatively, these Ser sites may 
also be modified by other PTMs. Use of phospho-specific antibodies for these Ser sites 
would allow observation of the phosphorylation status of USP4 upon induction with IL-
1 to examine in more depth as to how the phosphorylation/dephosphorylation may 
regulate the function of USP4 in relation to NF-κB. 
Under conditions tested, the subcellular localisation of Usp4 was not affected by 
preventing phosphorylation at Ser675 and Ser680, but stimulation of the pathways 
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activated by Usp4 overexpression would be needed to fully determine if this is how Usp4 
is regulated within these pathways. Additional examination of whether the 
phosphorylation of Usp4 regulates its stability, activity or protein-protein interactions is 
needed to further understanding of how USP4 is regulated in NF-κB signalling and could 
be performed using the lentiviral Usp4 phosphorylation variants generated in this chapter.   
Identifying the kinase responsible for phosphorylation at these sites would also enable 
further examination of Usp4 phosphorylation in NF-κB signalling. GRK2 depletion 
studies did not suggest a specific role for this kinase in NF-κB signalling, but multiple 
USP4 kinases were identified which could potentially phosphorylate USP4 in relation to 
NF-κB signalling.  
 Conclusions 
 Preventing Usp4 phosphorylation at Ser657/Ser680 did not affect the subcellular 
localisation of Usp4 under the conditions assessed 
 Prevention of Usp4 phosphorylation at Ser675/S680 attenuated effects of wild-
type Usp4 on the activity of cell signalling pathways 
 A series of Usp4 phosphorylation variants and lentiviral variants were generated 
 Altering the phosphorylation status of Usp4 altered effects of wild-type Usp4 on 
IL-1-induced NF-κB activity 
 Depletion of the USP4 kinase, GRK2, did not affect IL-1-induced NF-κB activity 
or the levels or phosphorylation of proteins involved in the NF-κB signalling 
pathway 
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Chapter 7 : General Discussion 
Ubiquitin signalling is a tightly regulated process, critical in multiple cellular processes 
and cell signalling pathways for the correct functioning of cells. Detrimental effects from 
aberrations in ubiquitin signalling can lead to the development of diseases and pathologies 
including many cancers and inflammatory disorders, osteoarthritis, and even the normal 
ageing process (Kessler, 2013, Popovic et al., 2014, Löw, 2011). Further insight into the 
regulation of the components of ubiquitin signalling could provide knowledge leading to 
potential new therapeutic targets for these diseases and pathologies. 
USP4 is a member of the ubiquitin-specific protease family of DUBs, responsible for 
reversing the ubiquitination process. USP4 expression is upregulated in human lung, 
urinary and prostate cancers and primary cell lines but has also been reported to be 
reduced in small cell lung carcinoma cell lines (Gray et al., 1995, Frederick et al., 1998, 
Zhang et al., 2011). USP4 increased migration of breast cancer cells, and in a zebrafish 
embryo xenograft invasion-metastasis model increased invasion and metastasis of breast 
cancer cells, indicating that USP4 may possess oncogenic properties and have 
involvement in the progression of cancers (Zhang et al., 2012). Consistent with this, USP4 
stabilises ARF-BP1, an E3 ligase responsible for the ubiquitin and degradation of the p53 
tumour suppressor (Zhang et al., 2011).  
When this thesis was first started, although many substrates of USP4 had been identified, 
including the A2A adenosine receptor, spliceosome U4 component Prp3, PDK1 and the 
S9/Rpn6 subunit of the proteasome, there were limited reports about its involvement in 
cell signalling pathways or about mechanisms of USP4 regulation (Milojević et al., 2006, 
Uras et al., 2012, Song et al., 2010, Zhao et al., 2012a). As ubiquitin signalling is key in 
the tight regulation of many cell signalling pathways, a more comprehensive 
understanding of the functioning of USP4 within cell signalling pathways and the 
mechanism of regulation of USP4 would contribute to research into the role of USP4 and 
in pathologies, including cancers. Further, this could provide understanding which could 
lead to novel therapeutic targets. In view of this, the aim of this thesis was to establish 
cell signalling pathways for which USP4 is involved and begin to determine how it 
functions in these pathways. Moreover, as the regulation of multiple DUBs is dependent 
on PTMs, including phosphorylation, another aim of this thesis was to explore the 
potential mechanism of regulation of USP4 by its PTM at Ser675/Ser680. 
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As this thesis was in progress, reports emerged to implicate functioning of USP4 in cell 
signalling pathways including Wnt/β-catenin, NF-κB, TGF-β and RIG-I (Zhao et al., 
2009, Fan et al., 2011b, Xiao et al., 2012, Zhou et al., 2012, Zhang et al., 2012, Wang et 
al., 2013). Further, preliminary data alluded to a role for USP4 in the positive regulation 
of NF-κB signalling and potential effects on inflammatory and immune responses, 
leading to further focus on the function of USP4 and its regulation in the NF-κB signalling 
pathway. 
 USP4 in cell signalling pathways 
The first aim of this thesis was to establish a role for USP4 in cell signalling pathways. 
Preliminary experiments indicated that Usp4 may function to suppress p53 activity. This 
was in line with Zhang et al. (2011) who reported inhibition of p53 due to the USP4-
mediated deubiquitination and stabilisation of the p53 E3 ligase ARF-BP1. Additionally, 
experiments demonstrated effects of Usp4 on other pathways, including enhanced NF-κB 
activity and enhanced MAPK/ERK and MAPK/JNK activity. Consistent with initial 
observations of enhanced MAPK activity with Usp4 overexpression, it was later 
demonstrated in this thesis that depletion of USP4 suppressed the IL-1-induced 
phosphorylation of JNK. Therefore overall, initial findings in this thesis elucidated 
potential functions for USP4 in p53, MAPK and NF-κB pathways, the latter of which was 
further addressed. 
 Usp4 in immune and inflammatory pathways 
In addition to initial observations suggesting a role for Usp4 in pathways associated with 
inflammation, effects on the circulating levels of specific inflammatory cytokines in 
Usp4-/- mice further implicated a role for the DUB in the immune or inflammatory 
response. MEFs derived from Usp4-/- mice and infected with VSV demonstrated 
increased VSV compared to wild-type MEFs. Consistent with this, there was increased 
VSV staining in the brains of Usp4-/- mice compared to the brains of wild-type mice 
infected with VSV. Given that USP4 positively regulates RIG-I signalling, an antiviral 
immune response pathway, the enhanced levels of virus observed with loss of Usp4 could 
be indicative of dysregulation of antiviral pathways leading to reduced viral clearance 
and increased viral replication (Wang et al., 2013). Alternatively, this could be due to 
dysregulation of anti-inflammatory pathways and an altered inflammatory response. 
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Further examination would be needed to determine the mechanism of increased VSV with 
loss of Usp4.  
 USP4 in NF-κB signalling 
Preliminary experiments to examine Usp4 in cell signalling pathways, and the effects of 
Usp4 phosphorylation at Ser675/Ser680 were initially performed in parallel. This 
examination revealed that overexpression of Usp4 enhanced NF-κB activity and that this 
could be attenuated by overexpression of catalytically inactive or non-phosphorylatable 
Usp4. Therefore, further examination of USP4 in the NF-κB signalling pathway was 
carried out as a prerequisite to examining the mechanism of phosphorylation of USP4 in 
NF-κB signalling later in this thesis.  
During the progression of this thesis studies reported that USP4 negatively regulates NF-
κB signalling (Fan et al., 2011b, Xiao et al., 2012, Zhou et al., 2012). Conversely, 
preliminary results in this thesis indicated that USP4 positively regulated NF-κB activity. 
Further results presented in this thesis confirmed USP4 as a positive regulator of NF-κB 
activity. In addition to enhancing NF-κB activity at basal levels in preliminary 
experiments, the overexpression of Usp4 was also shown to enhance IL-1- and TNFα-
induced NF-κB activity. In all cases, the ability of Usp4 to enhance NF-κB activity was 
attenuated to control levels with overexpression of catalytically inactive Usp4, indicating 
that Usp4 catalytic activity was required to enhance NF-κB. The regulation of NF-κB 
signalling was further evaluated using an RNAi approach to deplete levels of USP4 in 
SW1353 chondrosarcoma cells. Consistent with enhanced NF-κB activity with 
overexpression of Usp4, suppression of IL-1- and TNFα-induced NF-κB activity was 
observed with USP4 depletion. A strength of this work was that the effect of USP4 on 
NF-κB was examined by both depleting USP4 and overexpressing Usp4 and catalytically 
inactive Usp4, and effects were observed in multiple cell lines, with two different stimuli 
and with transient and lentiviral reporters.  
NF-κB activation ultimately leads to the transcriptional activation of a number of target 
genes including proinflammatory cytokines, IL-6 and IL-8, and MMP13 (Shimizu et al., 
1990, Kunsch and Rosen, 1993, Mengshol et al., 2000). These genes were chosen due to 
their transcriptional activation via NF-κB with both TNFα and IL-1 stimulation: IL-8 is a 
classic NF-κB-regulated gene whereas the regulation of MMP13 is more complex, 
requiring NF-κB and MAPK for its delayed induction. Differences observed between 
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these IL-1-induced and TNFα-induced NF-κB-regulated genes with USP4 depletion 
indicated that USP4 may function differently between IL-1 and TNFα NF-κB signalling. 
At varying IL-1 stimulation times over a 24 hour period, USP4 depletion reduced the 
expression of IL-6, IL-8 and MMP13, consistent with suppression of NF-κB. Although 
initially TNFα stimulation reduced IL-6 and MMP13, further analysis revealed only 
reduced MMP13 expression and enhanced IL-6 and IL-8 expression with USP4 depletion 
and TNFα stimulation. Discrepancies between stimulation with TNFα at a single time 
point and over a time course are difficult to explain, considering the experimental 
procedure was controlled and replications performed. Additionally, enhanced NF-κB-
regulated gene expression was not consistent with reduced NF-κB activity observed, 
indicating TNFα-induced NF-κB regulation by USP4 to be complex. The activation of 
many genes which are regulated by NF-κB, can also be activated by co-ordination of 
other IL-1- and TNFα-induced pathways, including IL-6, IL-8 and MMP13 which are also 
activated by MAPK pathways (Hoffmann et al., 2002b, Mengshol et al., 2000, Schmucker 
et al., 2012). Experiments herein also indicated that Usp4 may also function in MAPK 
pathways, including JNK and ERK, therefore, effects observed on the expression of these 
genes could also be due to effects on pathways other than NF-κB or due to crosstalk 
between NF-κB and MAPK signalling pathways. 
To further explore how USP4 regulates NF-κB signalling, the effect of USP4 depletion 
on the IL-1-induced level and phosphorylation of a number of key proteins important for 
signal transduction were assessed. The aim was to elucidate where USP4 may act within 
the NF-κB signalling pathway. As an integral step in the activation of NF-κB, the 
degradation of IκBα was first examined. USP4 depletion enhanced levels of IκBα at 
certain timepoints, suggesting alterations in its degradation. Itself a transcriptional target 
of NF-κB, expression levels of IκBα were reduced with USP4 depletion, indicating that 
enhanced protein levels were due to less or slower degradation of IκBα rather than 
increased expression. In line with less or slower degradation of IκBα, USP4 depletion 
reduced polyubiquitination levels of IκBα. The reduced expression, ubiquitination and 
degradation of IκBα, as a result of reduction of USP4, are all in agreement with 
suppression of NF-κB signalling. Together with effects on IκBα degradation, the 
downstream effects of USP4 depletion on reducing IL-1-induced phosphorylation of p65 
and the upstream effects of USP4 depletion on IL-1 induced phosphorylation of IKKα/β 
all confirm USP4 as a positive regulator of IL-1 induced NF-κB signalling. The 
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phosphorylation of IKK is crucial for downstream IκB phosphorylation and downstream 
signal transduction (Zhang et al., 2014). That USP4 depletion dramatically reduced the 
phosphorylation of IKKα/β indicates that USP4 positively regulates IL-1-induced NF-κB 
signalling by functioning upstream of the IKK complex. 
In contrast, reports have indicated that USP4 negatively regulates NF-κB signalling. In 
opposition to this thesis, it has been reported that overexpression of USP4 inhibited IL-
1- and TNFα-induced NF-κB activity and phosphorylation of IKKα/β, whereas USP4 
knockdown enhanced IL-1- and TNFα-induced NF-κB activity, NF-κB-regulated gene 
expression and phosphorylation and degradation of IκBα (Fan et al., 2011b, Xiao et al., 
2012, Zhou et al., 2012). These published studies used IL-1β for stimulation of the NF-
κB pathway through the IL-1RI, whereas IL-1α was used herein. Both IL-1β and IL-1α 
bind to the IL-1R, followed by recruitment of the IL-1RAcP to initiate the same signal 
and therefore exert their biological activity in a similar way (Dinarello, 2011). However, 
there are differences between IL-1β and IL-1α; for instance both are synthesised as 
precursor forms, but only IL-1β requires cleaving to its mature form before it is able to 
bind to the IL-1R (Contassot et al., 2012). Additionally, the IL-1α precursor form is able 
to activate transcription in the nucleus, as well as binding to the IL-1RI at the cell surface 
(Werman et al., 2004). Whilst the reason for these contradictions are not clear it could be 
due to type of stimulus, stimulation times, method of USP4 knockdown/overexpression, 
or cell type or species.  
The use of an RNAi approach to deplete USP4 in SW1353 cells was a good, useful 
technique for examining effects with loss of USP4.  Alternatively, the use of null MEFs 
are a powerful tool for examining effects with loss of Usp4 and as such, were used for 
observing effects on NF-κB signalling. Usp4-/- MEFs exhibited reductions in IL-1-
induced NF-κB activity and NF-κB-regulated gene expression, mimicking effects 
observed in SW1353 USP4 depleted cells and confirming that Usp4 positively regulates 
IL-1-induced NF-κB signalling, thus we re-introduced Usp4 into MEFs in lentivirus.  
 Targets of USP4 in the NF-κB signalling pathway 
After identifying a role for USP4 upstream of the IKK complex in the IL-1 NF-κB 
signalling pathway, this thesis next aimed to identify possible target substrates for 
deubiquitination by USP4. Multiple proteins within the NF-κB signalling pathway are 
subject to various polyubiquitin chain topologies for their regulation and for the 
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recruitment of downstream signal adaptors (Iwai, 2014). Equally, these polyubiquitin 
chains are subject to removal by DUBs, adding another level of complexity to the 
regulation of NF-κB signalling (Harhaj and Dixit, 2012, Napetschnig and Wu, 2013). 
Given that overexpression of catalytically inactive Usp4 attenuated the increase observed 
in NF-κB with wild-type Usp4, it is likely that USP4 regulates NF-κB signalling through 
its deubiquitinating activity. A number of potential targets upstream of the IKK include 
IRAK1, TAK1 and TRAF6 which have been demonstrated to be polyubiquitinated with 
chains including linear, and/or K48- and K63-linked polyubiquitin chains (Conze et al., 
2008, Cui et al., 2012, Emmerich et al., 2013, Fan et al., 2010, Fan et al., 2012, Lamothe 
et al., 2007, Zhou et al., 2010). Indeed, USP4 has previously been reported to interact 
with and deubiquitinate TAK1 and TRAF6 (Fan et al., 2011b, Xiao et al., 2012). 
However, these reports identified a role for USP4 in downregulating NF-κB, no reports 
exist to elucidate how USP4 may positively regulate NF-κB signalling.  
As likely substrates of USP4 deubiquitination, use of computational modelling to 
hypothesise that USP4 may deubiquitinate the K48-linked polyubiquitination of TAK1 
and TRAF6 gave simulation outputs consistent with results demonstrating positive 
regulation of NF-κB signalling by USP4. Further evaluation of the polyubiquitination of 
these potential substrates was performed by examining the effects with loss of USP4. 
Analysis of the polyubiquitination of FLAG-tagged TAK1 and TRAF6 with USP4 
depletion demonstrated reductions in both the K48- and K63-linked polyubiquitination 
when FLAG was immunoprecipitated after IL-1 stimulation. This was in contrast to 
previously published data which reported enhanced TNFα-induced TAK1 
polyubiquitination of TRAF6 with USP4 depletion and enhanced IL-1-induced TRAF6 
polyubiquitination, and specifically K48- and K63-linked polyubiquitination with USP4 
depletion (Fan et al., 2011b, Xiao et al., 2012, Zhou et al., 2012). As many DUBs are 
reported to negatively regulate NF-κB signalling by the removal of K63-linked 
polyubiquitin chains, thereby preventing the activation or recruitment of proteins required 
for signal transduction, it is difficult to predict how USP4 may be positively regulating 
NF-κB activity. However, the reduced polyubiquitination of TAK1 and TRAF6 were 
consistent with downregulation of IL-1-induced NF-κB signalling, as observed when 
examining effects on the level and phosphorylation of NF-κB adaptor proteins and when 
examining effects on IL-1-induced NF-κB activity and NF-κB-regulated gene expression. 
These alterations in K48- and K63-linked polyubiquitination of immunoprecipitates 
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therefore suggest, rather than targeting these proteins specifically for deubiquitination of 
K48- and K63-linked polyubiquitin chains, USP4 may alternatively be responsible for the 
removal of other, as yet unidentified, polyubiquitin chains. These could be linear chains 
which are known to be involved in the recruitment of the NEMO subunit of the IKK 
complex (Emmerich et al., 2013, Iwai, 2014). Although progress has been made in 
understanding the significance of ubiquitin signalling within cell signalling pathways, and 
many critical ubiquitination events have been identified, there is still limited information 
on how different ubiquitin chain topologies may be involved and the exact ubiquitin 
signalling components involved. Alternatively, the substrate(s) of USP4 may be further 
upstream of TAK1 and TRAF6 or USP4 may interact with another protein, possibly an 
E3 ligase, to mediate effects on the K48- and K63-linked polyubiquitination of these 
proteins. Identification of the substrate(s) which USP4 may specifically target for the 
positive regulation of NF-κB therefore remains to be confirmed. Further examination of 
the polyubiquitination of proteins upstream of the IKK complex and protein-protein 
interactions of USP4 need to be addressed to fully elucidate the mechanism of function 
for USP4 in IL-1-mediated NF-κB signalling.  
 The PTM of Usp4 at Ser675/Ser680 
In addition to further elucidating a role for USP4 in the NF-κB signalling pathway, 
another aim of this thesis was to examine the regulation of Usp4 by its phosphorylation 
at two serine residues in close proximity to each other, Ser675/Ser680. The mechanism 
of regulation of DUBs often involves PTMs which have been demonstrated to regulate 
their stability, activity, protein-protein interactions and subcellular localisation (Kessler 
and Edelmann, 2011). Given this, effects of the PTM of Usp4 at Ser675/Ser680, 
presumably phosphorylation, were assessed. 
The phosphorylation of proteins has been demonstrated to regulate the translocation of 
proteins to and from the nucleus to spatially locate the protein to the correct subcellular 
site for its function. Indeed, whilst this thesis was in progress, the Akt-mediated 
phosphorylation of USP4 at Ser445 was demonstrated to translocate USP4 to the plasma 
membrane for interactions with the TβR-I as part of the activation of the TGF-β signalling 
pathway (Zhang et al., 2012). Unlike its phosphorylation at Ser445, the PTM of Usp4 at 
Ser675/Ser680 did not affect the subcellular localisation. Whilst the Akt-mediated 
phosphorylation of USP4 occurred with activated Akt or induction with TGF-β, 
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subcellular localisation here was only determined at basal levels. Whether the localisation 
of Usp4 by its phosphorylation at Ser675/Ser680 is altered in response to induction, 
perhaps to specifically locate Usp4 only when required for the regulation of a pathway, 
remains to be determined. The Ser445 phosphorylation mutant could also have been 
generated to verify localisation changes with alteration of the phosphorylation status of 
Usp4 at this Ser residue.  
In parallel to examining the effect of Usp4 on the activity of cell signalling pathways, the 
effect of the phosphorylation of Usp4 on the activity of cell signalling pathways was also 
examined. Preventing phosphorylation of Usp4 at Ser675/Ser680 attenuated effects seen 
with wild-type Usp4 on the activity of some pathways, including NF-κB. Given this 
preliminary experiment identified potential regulation of Usp4 by its phosphorylation for 
mediating effects on NF-κB signalling, and that a role for USP4 in NF-κB signalling was 
further elucidated previously in his thesis, establishing a method to further assess this was 
essential. Overexpression of proteins with mutations is a useful way to study the effects 
on cellular processes, and lentiviral-mediated delivery of the mutated gene into cells is a 
stable way to introduce the gene into cells, particularly useful for delivery into cells which 
can be difficult to transiently transfect, such as MEFs. To fully assess the effects of 
phosphorylation at these sites, a series of phosphorylation mutants were generated, with 
one or both Ser sites mutated to Ala or Asp to represent non-phosphorylatable or 
phosphomimetic sites, respectively. Lentiviral preparations of these Usp4 mutant variants 
allowed evaluation of the effects of Usp4 PTM on NF-κB signalling in both SW1353 
cells and Usp4-/- MEFs. The PTM of USP4 at Ser675/Ser680 had not previously been 
studied and was demonstrated here to be a potential mechanism of regulation of Usp4 
within the NF-κB signalling pathway. Altering the phosphorylation status of Usp4 
attenuated IL-1-induced effects of wild-type Usp4 on NF-κB activity. Phosphorylation is 
a dynamic process, potentially requiring interplay between the phosphorylation and 
dephosphorylation of Usp4 at Ser675/Ser680 to regulate its function in the IL-1-induced 
NF-κB pathway. Further examination of whether these may regulate Usp4 subcellular 
localisation when induced with IL-1, or whether they regulate the catalytic activity or 
protein-protein interactions is needed to fully understand the mechanism of regulation of 
Usp4 at these Ser sites with relation to NF-κB signalling.  
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 Future work 
The work presented in this thesis has furthered understanding of USP4 by establishing a 
role for USP4 in the positive regulation of NF-κB signalling, potentially regulated by its 
phosphorylation at two serine residues. Discussion of this work highlighted a number of 
potential mechanisms by which USP4 could regulate NF-κB signalling and itself be 
regulated through its PTMs. Therefore, future work would be required to address these 
and confirm some of the findings in this thesis, including: 
 Overexpression of Usp4 affected the activity of some cell signalling pathways 
under basal conditions in a multi-pathway reporter array. To further assess the 
pathways that Usp4 may be regulating, these arrays could be repeated with 
induction of the pathways. 
 Usp4-/- mice demonstrated potentially reduced levels of some cytokines, 
indicating changes in the inflammatory response in these mice. Although the 
model used identified alterations in the replication of viral infection in the Usp4-
/- mice, indicative of compromised immune responses, use of an inflammatory 
model would be more suitable to evaluate the involvement of Usp4 in the 
inflammatory response. Mice could be injected with LPS to induce an 
inflammatory response as LPS mimics infection, and effects, such as effects on 
cytokine levels, between Usp4+/+ and Usp4-/- mice examined. 
 To confirm effects on NF-κB signalling observed with USP4 depletion, 
overexpression of wild-type and catalytically inactive Usp4 would allow effects 
examination of the effects of Usp4 on NF-κB-regulated gene expression and the 
levels and phosphorylation of NF-κB adaptor proteins. 
 Further examination of the involvement of USP4 in TNFα-mediated NF-κB 
signalling could be performed to attempt to elucidate the contradictory 
observations made in this thesis. 
 To further evaluate potential targets of USP4 deubiquitination in the IL-1-induced 
NF-κB pathway, USP4 protein-protein interactions could be examined. USP4 
could be immunoprecipitated and probed with antibodies for proteins which 
function upstream of the IKK complex in NF-κB signalling, including TAK1, 
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TRAF6 and IRAK1. This would be important in determining where USP4 
interacts with the NF-κB signalling pathway. In addition, other types of 
polyubiquitination of these proteins, such as linear, could be examined, similarly 
to K48- and K63-linked polyubiquitination. 
 A quantitative proteomics approach could be used to identify USP4 substrates. 
Tandem-repeated ubiquitin-binding entities (TUBEs) recognise tetra-ubiquitin 
and allow enrichment of polyubiquitinated substrates from cell extracts. TUBEs 
could be used to enrich polyubiquitinated substrates in the presence and absence 
of USP4 with IL-1 stimulation, and identified by mass spectrometric analysis. 
Alternatively, a stable isotope labelling by amino acids in cell culture (SILAC) 
strategy could be employed to compare proteomic expression profiles in the 
presence and absence of USP4 with IL-1 stimulation. 
 Altering the phosphorylation status, through mutations, attenuated the enhanced 
NF-κB activity observed with Usp4. The phosphorylation status of these mutants 
needs to be confirmed through use of phospho-specific antibodies. 
 Effects of lentiviral-mediated expression of Usp4 and the phosphorylation variants 
of Usp4 need to be confirmed by confirming equal transduction of cells. Once this 
has been completed, use of these lentiviral preparations in Usp4-/- MEFs would 
allow further validation of the effects on NF-κB activity and could be used to 
examine effects of Usp4 phosphorylation on NF-κB-regulated gene expression 
and the levels and phosphorylation of NF-κB adaptor proteins.  
 Importantly, a DUB assay could be performed, using the Usp4 phosphorylation 
variants, to examine whether the phosphorylation of Usp4 regulates its catalytic 
activity. To examine whether the PTM of Usp4 at Ser 675 and Ser680 regulates 
the catalytic activity of Usp4, and whether this is further regulated by IL-1 
induction, wild-type Usp4, the C311A Usp4 mutant, and all Usp4 phosphorylation 
variants would need to be purified from transfected cells which have been 
stimulated with IL-1 (or left unstimulated). These could then be incubated with a 
fluorogenic substrate, e.g. ubiquitin-7-amido-4-methylcoumarin (AMC) (Boston 
Biochem), the cleavage of which can be monitored fluorometrically to determine 
the deubiquitinase activity of each of the Usp4 variants. 
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 As specifically depleting the identified USP4 kinase, GRK2, indicated no effect 
on NF-κB signalling, use of kinase inhibitors may give more clues as to the 
regulation of USP4 by its phosphorylation. The phosphorylation of USP4 in the 
presence of a kinase inhibitor and upon stimulation with IL-1 could be examined 
by immunoprecipitating USP4 and using phospho-specific antibodies.  
 Summary 
In summary of the findings in this thesis, it has been demonstrated that USP4 functions 
in cell signalling pathways, including NF-κB signalling. Further evaluation revealed 
involvement of USP4 in the regulation of NF-κB-regulated gene expression, the 
ubiquitination and degradation of IκBα and the phosphorylation of p65 and IKKα/β. 
Overall, data have shown USP4 to positively regulate IL-1-induced NF-κB signalling, not 
previously reported. Data alluded to a role for USP4 upstream of the IKK complex, and 
indeed further evaluation revealed differences in the K48- and K63-linked 
polyubiquitination of immunoprecipitated proteins, presumably TAK1 and TRAF6, 
consistent with USP4 as a positive regulator of IL-1-induced NF-κB signalling.  
Additionally, a series of Usp4 phosphorylation variants were generated, and a series of 
lentiviral phosphorylation variants, to examine effects of altering two Ser residues, 
Ser675/Ser680, on NF-κB signalling. Altering the phosphorylation status of Usp4 
attenuated effects of Usp4 on NF-κB activity, indicating that the PTM at these Ser 
residues, presumably phosphorylation, is involved in regulating the mechanism of 
function of Usp4 within the NF-κB signalling pathway.  
These findings have furthered understanding of USP4 and how it may be regulated, 
contributing to the growing research of ubiquitin signalling, the importance of this in 
regulating cell signalling pathways, and how components of ubiquitin signalling are 
themselves regulated. Given the importance of tight regulation of NF-κB signalling in 
preventing persistent activation, which can lead to chronic inflammation and cancers, this 
research will aid understanding in how USP4 may contribute to this regulation.  
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Appendix 
Appendix Table 1. List of model species in the NF-κB computational model. 
Species name Description Initial 
value 
DUB Generic DUB 100 
IkB Inhibitor of κB 10 
IkB_mRNA IκB messenger RNA 0 
IkB_P Phosphorylated IκB 0 
IkB_NFkB Complex of IκB and NF-κB 100 
IκB_P_NFkB Complex of phosphorylated IκB and NF-
κB 
0 
IKK IκB kinase 100 
IKK_P Phosphorylated IKK 0 
IL1 Cytokine interleukin-1 100 
IL1_IL1R IL-1 bound to IL-1 receptor 0 
IL6 Cytokine interleukin-6 0 
IL6_mRNA IL-6 messenger RNA 0 
IL8 Cytokine IL-8 0 
IL8_mRNA IL-8 messenger RNA 0 
ILR1 IL-1 receptor 1 100 
IRAK1 IL-1R associated kinase 1 100 
IRAK1_P Phosphorylated IRAK1 0 
IRAK1_P_K48Ub[x] Phosphorylated IRAK1 ubiquitinated with 
x K48-linked ubiquitins 
0 
IRAK1_A Active IRAK1 0 
IRAK1_I Inactive IRAK1 100 
MMP13 Matrix metalloproteinase 13 0 
MMP13_mRNA MMP13 messenger RNA 0 
MyD88_A Active myeloid differentiation factor 0 
MyD88_I Inactive MyD88 100 
NKkB Nuclear factor of κB 0 
NFkB_P Phosphorylated NF-κB (active) 0 
MAPK Mitogen-activated protein kinase 100 
MAPK_P Phosphorylated MAPK 0 
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PP2A MAPK phosphatase 0 
ROS Reactive oxygen species 0 
Sink Protein degraded 0 
Source Protein synthesised 1 
Tak1 Transforming growth factor-β-kinase 1 100 
Tak1_K48Ub[x] Tak1 ubiquitinated with x K48-linked 
ubiquitins 
0 
Tak1_K63Ub[x] Tak1 ubiquitinated with x K63-linked 
ubiquitins 
0 
Tak1_Traf6_A_K63Ub6 Complex of Tak1 with active, K63 
polyubiquitinated TNFα receptor-
associated factor 6 
0 
Tak1_Ub[x]_Traf6_A_K63Ub6 Complex of Tak1 ubiquitinated with x 
K63-linked ubiquitins and active, K63 
polyubiquitinated TRAF6 
0 
Traf6_A Active TRAF6 0 
Traf6_A_K48Ub[x] Active TRAF6 ubiquitinated with x K48-
linked ubiquitins 
0 
Traf6_A_K63Ub[x] Active TRAF6 ubiquitinated with x K63-
linked ubiquitins 
0 
Traf6_I Inactive TRAF6 100 
Ub Ubiquitin 1500 
Usp4 Ubiquitin-specific protease 4 5, 100 
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Appendix Table 2. Reactions for the NF-κB computational model. 
Reaction name Reaction Parameter 
name 
Value 
IκB_degradation IkB_P_NFkB → NFkB kdegIkB 5e-3 s-1 
IκB_NFkB_binding IkB + NFkB → 
IkB_NFkB 
kbinIkBNFkB 0.1 mol-1 s-1 
IκB_NFkB_P_binding IkB + NFkB_P → 
IkB_NFkB 
kbinIkBNFkBnuc 1e-5 mol-1 s-1 
IκB_NFkB_release IkB_NFkB → IkB + 
NFkB 
krelIkBNFkB 0.001 s-1 
IκB_phosphorylation IkB_NFkB + IKK_P → 
IkB_P_NFkB + IKK_P 
kphosIkB 1e-5 mol-1 s-1 
IκB_transcription NFkB_P → IkB_mRNA 
+ NFkB_P 
ksynIkBmRNA 0.004 s-1 
IκB_translation IkB_mRNA → 
IkB_mRNA + IkB 
ksynIkB 0.001 s-1 
IkBmRNA_degradation IkB_mRNA → Sink kdegIkBmRNA 0.002 s-1 
IKK_dephosphorylation IKK_P → IKK kdephosIKK 0.1 s-1 
IKK_phosphorylation Tak1_K63Ub6_Traf6_A
_K63Ub6 + IKK → 
Tak1_K63Ub6_Traf6_A
_K63Ub6 + IKK_P 
kphosIKK 5e-4 mol-1 s-1 
IL1_degradation IL1 → Sink kdegIL1 2e-5 s-1 
IL1_ILR1_binding IL1 + ILR1 → IL1_ILR1 kbinIL1ILR1 1e-5 mol-1 s-1 
IL1_ILR1_release IL1_ILR1 → IL1 + ILR1 krelIL1ILR1 0.001 s-1 
IL1_synthesis NFkB_P → IL1 + 
NFkB_P 
ksynIL1 1e-4 s-1 
IL6_degradation IL6 → Sink kdegIL6 2e-5 s-1 
IL6_transcription NFkB_P → IL6_mRNA 
+ NFkB_P 
ksynIL6mRNA 0.001 s-1 
IL6_translation IL6_mRNA → 
IL6_mRNA + IL6 
ksynIL6 1e-4 s-1 
IL6_mRNA_degradation IL6_mRNA → Sink kdegIL6mRNA 1e-4 s-1 
IL8_degradation IL8 → Sink kdegIL8 2e-5 s-1 
IL8_transcription NFkB_P → IL8_mRNA 
+ NFkB_P 
ksynIL8mRNA 0.001 s-1 
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IL8_translation IL8_mRNA → 
IL8_mRNA + IL8 
ksynIL8 1e-4 s-1 
IL8_mRNA_degradation IL8_mRNA → Sink kdegIL8mRNA 1e-4 s-1 
IRAK1_degradation IRAK1_P_K48Ub4 → 4 
* Ub 
kdegIRAK1 0.01 s-1 
IRAK1_dephosphorylation IRAK1_P → IRAK1 kdephosIRAK1 0.1 s-1 
IRAK1_K48Deubiquitination[x] IRAK1_P_K48Ub[x] + 
DUB → 
IRAK1_P_K48Ub[x-1] + 
Ub + DUB 
kdeubK48IRAK1 0.01 mol-1 s-1 
IRAK1_K48Ubiquitination[x] IRAK1_P + Ub → 
IRAK1_P_K48Ub[x] 
kubK48IRAK1 1e-4 mol-1 s-1 
IRAK1_phosphorylation IRAK1 + IRAK4_A → 
IRAK1_P + IRAK4_A 
kphosIRAK1 0.001 mol-1 s-1 
IRAK1_synthesis Source → IRAK1 ksynIRAK1 0.001 mol s-1 
IRAK4_activation IRAK4_I + MyD88_A 
→ IRAK4_A + 
MyD88_A 
kactIRAK4 1e-4 mol-1 s-1 
IRAK4_inactivation IRAK4_A → IRAK4_I kinactIRAK4 0.01 s-1 
MMP13_degradation MMP13 → Sink kdegMMP13 2e-5 s-1 
MMP13_transcription NFkB_P → NFkB_P + 
MMP13_mRNA 
ksynMMP13mRN
A 
3e-5 s-1 
MMP13_transcription_by_MAPK MAPK_P → MAPK_P + 
MMP13_mRNA 
KsynMMP13mR
NAbyMAPK 
3e-5 s-1 
MMP13_translation MMP13_mRNA → 
MMP13_mRNA + 
MMP13 
ksynMMP13 1e-4 s-1 
MMP13mRNA_degradation MMP13_mRNA → Sink kdegMMP13mR
NA 
6.4e6 s-1 
MyD88_activation MyD88_I + IL1_ILR1 
→ MyD88_A + 
IL1_ILR1 
kactMyD88 1e-4 mol-1 s-1 
MyD88_inactivation MyD88_A → MyD88_I kinactMyD88 0.01 s-1 
NFkB_activation NFkB + MAPK_P → 
NFkB_P + MAPK_P 
kactNfkb 0.001 mol-1 s-1 
MAPK_dephosphorylation MAPK_P → MAPK kdephosMAPK 0.001 s-1 
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MAPK_dephosphorylation_PP2A MAPK_P + PP2A → 
MAPK + PP2A 
kdephosMAPKPP
2A 
0.01 mol-1 s-1 
MAPK_phosphorylation_by_ROS MAPK + ROS → 
MAPK_P + ROS 
kphospMAPK 1e-4 mol-1 s-1 
MAPK_phosphorylation_by_IL1 MAPK + IL1_ILR1 → 
MAPK + IL1_ILR1 
kphosMAPK 1e-4 mol-1 s-1 
PP2A_degradation PP2A → Sink kdegPP2A 1e-4 s-1 
PP2A_synthesis NFkB_P → PP2A + 
NFkB_P 
ksynPP2A 0.001 s-1 
ROS_basal_generation Source → ROS kbasalROS 1e-5 mol s-1 
ROS_generation_by_IL6 IL6 → IL6 + ROS kgenROSIL6 1e-5 s-1 
ROS_removal ROS → Sink kremROS 1e-4 s-1 
Tak1_binding_to_Traf6 Tak1 + 
Traf6_A_K63Ub6 → 
Tak1_Traf6_A_K63Ub6 
kbinTak1Traf6 1e-4 mol-1 s-1 
Tak1_degradation Tak1_K48Ub4 → 4 * Ub kdegTak1 1e-5 s-1 
Tak1_K63Deubiquitination[x] Tak1_K63Ub[x]_Traf6_
A_K63Ub6 → 
Tak1_K63Ub[x-
1]_Traf6_A_K63Ub6 + 
Ub 
kdubTak1 1e-7 s-1 
Tak1_K48Deubiquitination[x] Tak1_K48Ub[x] + DUB 
→ Tak1_K48Ub[x-1] + 
Ub + DUB 
kdeubK48Tak1 0.01 mol-1 s-1 
Tak1_K48Ubiquitination[x] Tak1 + Ub → 
Tak1_K48Ub[x] 
kubK48Tak1 1e-4 mol-1 s-1 
Tak1_K63Ubiquitination[x] Tak1_Traf6_A_K63Ub6 
+ Ub → 
Tak1_K63Ub[x]_Traf6_
A_K63Ub6 
kubTak1 5e-6 mol-1 s-1 
Tak1_release_from_Traf6 Tak1_Traf6_A_K63Ub6 
→ Tak1 + 
Traf6_A_K63Ub6 
krelTak1Traf6 0.001 s-1 
Tak1_synthesis Source → Tak1 ksynTak1 0.001 mol s-1 
Traf6_activation Traf6_I + IRAK1_P → 
Traf6_A + IRAK1_P 
kactTraf6 0.001 mol-1 s-1 
Traf6_degradation Traf6_A_K48Ub4 → 4 * 
Ub 
kdegTraf6 1e-5 s-1 
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Traf6_inhibition Traf6_A → Traf6_I kinactTraf6 0.01 s-1 
Traf6_K48Deubiquitination[x] Traf6_A_K48Ub[x] + 
DUB → 
Traf6_A_K48Ub[x-1] + 
Ub + DUB 
kdeubK48Traf6 0.01 mol-1 s-1 
Traf6_K48Ubiquitination[x] Traf6_A + Ub → 
Traf6_A_K48Ub[x] 
kubK48Traf6 1e-4 mol-1 s-1 
Traf6_K63Deubiquitination[x] Traf6_A_K63Ub[x] → 
Traf6_A_K63Ub[x-1] + 
Ub 
kdeubTraf6 0.01 s-1 
Traf6_K63Ubiquitination[x] Traf6_A + Ub → 
Traf6_A_K63Ub[x] 
kubK63Traf6 1e-4 mol-1 s-1 
Traf6_synthesis Source → Traf6_I ksynTraf6 0.001 mol s-1 
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Appendix Figure 1. Full length blots of antibodies used in Chapter 4.  SW1353 cells were seeded, serum-starved overnight and stimulated with IL-1 (0.5ng/ml) for 15 minutes 
(min), or left unstimulated, before lysis. Total protein was extracted, resolved by SDS-PAGE and immunoblotted with the relevant antibodies. Red arrows indicate the 
protein of interest. 
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